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Abstract  
 Recent reports have shown that HIV-1 Gag can directly affect susceptibility to 
protease inhibitors (PIs) in the absence of known resistance mutations in 
protease.  Inclusion of co-evolved Gag alongside protease in phenotypic drug 
susceptibility assays can alter PI susceptibility in comparison to protease with a 
wild-type Gag.    
Using a single replication-cycle assay encompassing full-length Gag together 
with protease, we demonstrate significant variation in PI susceptibility between 
a number of PI-naïve subtype B viruses.  Six publicly available subtype B 
molecular clones, namely HXB2, NL4-3, SF2, YU2, JRFL and 89.6, displayed 
up to 9-fold reduction in PI susceptibility.  For two molecular clones, YU2 and 
JRFL, Gag contributed solely to the observed reduction in susceptibility.  Gag 
and protease from treatment-naïve, patient-derived viruses also demonstrated 
significant variation in susceptibility, with up to a 17-fold reduction to atazanavir.  
In contrast to the molecular clones, protease was the main determinant of the 
reduced susceptibility.  Common polymorphisms in protease including I13V, 
L63P and A71T were shown to contribute to this reduction in PI susceptibility, in 
the absence of major resistance mutations.    
The role of variation in PI susceptibility on LPV/r monotherapy treatment failure 
was investigated.  The contribution of suboptimal adherence to treatment failure 
was shown and the development of reduced PI susceptibility during treatment 
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observed.  In addition, reduced PI susceptibility and single-round infectivity 
were associated with subsequent treatment failure.  
This study demonstrates significant variation in PI susceptibility of treatment-
naïve patient viruses and provides further evidence of the independent role of 
Gag, the protease substrate, and in particular the amino terminus of Gag in PI 
susceptibility.  It also highlights the importance of considering co-evolved Gag 
and protease when assessing PI susceptibility.  These data indicate that 
reduced PI susceptibility at baseline may contribute to treatment failure on PI 
monotherapy.  
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1 Introduction  
1.1 HIV and the AIDS epidemic 
In 1981, acquired immunodeficiency syndrome (AIDS) was first identified 
following the presentation of a collection of patients with unusual opportunistic 
infections such as Kaposi’s sarcoma and Pneumocystis carinii pneumonia 
(PCP), and reduced levels of T helper lymphocytes. In 1983, human 
immunodeficiency virus (HIV) was identified as the causative agent, although 
the virus was named lymphadenopathyassociated virus (LAV) and Human T-
cell Lymphotropic virus type 3 (HTLV-III) until 1986 (Barre-Sinoussi et al., 
1983). HIV is a lentivirus from the family Retroviridae. HIV predominantly infects 
the CD4+ T cells of the human immune system and over the course of infection 
the number of CD4+ T cells falls below the threshold for adequate function of 
the immune system, leading to the emergence of opportunistic infections that 
are eventually fatal. HIV first infected humans after a number of zoonosis 
events of simian immunodeficiency virus (SIV) from various primates into 
humans. To date there are two HIV ‘types’ – HIV-1 and HIV-2, both of which 
occurred from separate transmission events from different primates. In addition, 
there are four groups of HIV-1 virus, again each of which is predicted to have 
derived from separate zoonotic transmission events. Molecular phylogenetic 
methods have suggested that the initial jump into humans occurred in the early 
20th century (Korber et al., 2000).   
1.1.1 Global and national burden of HIV/AIDS 
Since its discovery in 1981, the global burden of HIV has expanded 
exponentially and the demographic of those infected has also shifted. In 2010, 
an estimated 35.3 million individuals were infected with HIV across the world, 
with approximately 25 million of these individuals living in Sub-Saharan Africa 
(WHO, 2013).   
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Figure 1.1. The global prevalence of HIV infection. The total estimated number of HIV positive individuals, both adults and children, 
per region is shown for 2012, with the vast majority of infections occur in Sub-Saharan Africa. This figure is taken from the WHO, 2013. 
Total: 35.3 million [32.2 million – 38.8 million] 
 
  
         
Western &  
Central Europe 
860 000 
[800 000 – 930 000] 
Middle East & North Africa 
260 000 
[200 000 – 380 000] 
Sub-Saharan Africa 
25.0 million 
[23.5 million – 26.6 million] 
Eastern Europe  
& Central Asia 
1.3 million  
[1.0 million – 1.7 million] 
South & South-East Asia 
 3.9 million 
 [2.9 million – 5.2 million] 
Oceania 
51 000 
[43 000 – 59 000] 
North America 
1.3 million 
[980 000 – 1.9 million] 
Latin America 
1.5 million 
[1.2 million – 1.9 million] 
East Asia 
880 000 
[650 000 – 1.2 million] 
Caribbean 
250 000 
[220 000 – 280 000] 
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The global distribution of individuals infected with HIV in 2012 is shown in figure 
1.1. Of those infected with HIV in 2010, 3.3 million were children under 15.  
There are a significant number of AIDS related deaths annually, with 1.6 million 
reported in 2012 (WHO, 2013). In addition to the direct morbidity and mortality 
caused by the virus, HIV has a significant economic impact globally and it has 
been estimated to reduce the GDP in high prevalence countries, with up to an 
8% decrease estimated in South Africa (Dixon et al., 2013). The significant 
financial cost of treatment and research contribute to its impact, with some 
countries spending up to 20% of their annual health budgets on HIV treatment 
(Amico et al., 2010).   
Within the UK 96,000 individuals are estimated to be HIV positive, but around a 
quarter of these individuals are unaware of their infection (Health Protection 
Agency, 2012). The UK epidemic continues to expand, with an estimated 6,280 
new infections in 2011. At present, the UK-wide prevalence of HIV is 
approximately 0.14%, although in some inner city areas this rate rises above 
0.2%. It has been estimated that each HIV positive patient will cost £250,000 to 
treat over their lifetime, providing a significant burden to the National Health 
Service, NHS (Health Protection Agency, 2012).   
1.1.2 HIV diversity and geographical distribution 
Globally the majority of HIV infections are with HIV-1, with just a small fraction 
caused by HIV-2 viruses. Currently, four groups of HIV-1 viruses have been 
described M ‘major’, N ‘non-M and non-O’, O ‘outlier’ and P with the vast 
majority of infections worldwide caused by HIV-1 group M viruses. Each of the 
four HIV-1 groups are thought to have arisen from separate transmission events 
into humans, with groups M and N originating from SIV infecting chimpanzees 
(Pan troglodytes troglodytes) and O and P from SIV infecting wild gorillas 
(Plantier et al., 2009; Van Heuverswyn et al., 2006). Viruses from groups N and 
P, the most recently described group, have been reported in small numbers of 
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individuals in Cameroon (Plantier et al., 2009; Vallari et al., 2010; Vallari et al., 
2011). Group O viruses have also been identified in Cameroon, although at a 
higher frequency than groups N and P, causing a reported 2% of infections 
nationwide (Brennan et al., 2008). 
Group M viruses can be divided into phylogenetically distinct subtypes: A1, A2, 
B, C, D, F1, F2, G, H, J and K, although A1, A2, F1 and F2 are sometimes 
considered sub-subtypes. In addition, in patients dually-infected with two 
subtypes, recombination between these viruses can occur resulting in the 
production of unique recombinant forms (URFs). URFs are designated as 
circulating recombinant forms (CRFs) when reported in at least three 
epidemiologically distinct individuals, and numbered according to the order of 
their discovery. Viruses initially identified as subtype E are now widely 
recognised as CRF01_AE as they comprise predominantly subtype A genomes 
with a subtype E env gene.  
The global distribution of HIV-1 subtypes is not uniform, and is shown in figure 
1.2. The most predominant subtypes globally are: subtype C (52%), A1 (12%) 
and B (10%) (Arien et al., 2007). In Southern Africa, the Horn of Africa and 
Central Asia, subtype C viruses predominate whereas in the Americas and 
Europe, subtype B viruses cause the majority of infections.  CRF01_AE (3.1%) 
and CRF02_AG (6.7%) are the most predominant CRFs globally, with 
CRF01_AE being the predominant subtype in South Asia and CRF02_AG 
causing a significant proportion of infections in West Africa. 
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Figure 1.2. The global distribution of HIV-1 subtypes. The frequency of each subtype in each region was estimated and is depicted in the pie-
charts, with the colour of the countries representing the predominant subtype in the region. The pie chart on the left represents the global frequency of 
each subtype and major CRF. Subtype B is the most prevalent in Western Europe and the Americas, whilst subtypes A1, C and CRF02_AG are the 
most frequent in Africa. Figure taken from Arien et al. 2007.
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The HIV-1 subtypes present in the UK are diverse, as a result of a number of 
separate transmission routes within the UK and migration events into the 
country. Between 2002 and 2010, the prevalence of subtypes in the UK was as 
follows: B (39.9%), C (34.3%), A (5%), novel recombinants (9.9%), D (2.5%), G 
(2.7%) and CRF01_AE (2%) (Dolling et al., 2013a). During this period, men who 
have sex with men (MSMs) were predominantly infected with subtype B viruses 
(88.4%), although the percentage of infections with non-B and non-C viruses in 
MSMs has increased from 4.8% in 2002 to 12.4% in 2010. A different subtype 
distribution is present in individuals infected through heterosexual contact in the 
UK, with subtype C viruses the most frequent causing 46.7% of infections in 
men and 55% in women (Dolling et al. 2013).      
HIV-2 was first described in 1986 and has been shown to be most closely 
related to SIV viruses isolated from sooty mangabeys. HIV-2 infection has 
primarily been found in West Africa including Guinea Bissau and Senegal, with 
a few cases reported in western Europe and America (as reviewed by Sharp 
and Hahn, 2011). HIV-2 viruses are not classified into subtypes, but into groups 
as the diversity between groups of HIV-2 viruses is similar to that between the 
HIV-1 virus groups. Unlike HIV-1, HIV-2 recombinants between groups are rare 
although they have been described (Ibe et al., 2010). HIV-2 has been shown to 
be less infectious via the mother-to-child transmission route than HIV-1 and 
most individuals have a lower viral load in comparison with those infected with 
HIV-1 (as reviewed by Sharp and Hahn, 2011).  
 
 
 
 
 
  
27 
 
 
1.1.3 Natural course of HIV-1 infection  
Transmission of HIV between individuals occurs primarily through direct sexual 
contact, either heterosexual or homosexual. However, a small proportion of 
infections occur via direct inoculation of the blood through the use of 
contaminated needles or blood products. Infection can also occur via the 
mother-to-child transmission route during gestation, birth or breastfeeding. In 
the absence of interventions in HIV positive pregnant women, transmission to 
the baby occurs in approximately 25% of cases (Coutsoudis et al., 1999).  
However, the use of appropriate prevention strategies has resulted in this rate 
dropping to around 1% in developed countries such as the UK (Bailey et al., 
2011). In the UK in 2009, 95% of pregnant women received an HIV test during 
pregnancy, which enabled the targeting of appropriate prevention methods to 
reduce mother-to-child transmission. In 2009, of those HIV positive individuals 
who were aware of their status and accessing care in the UK, 51% were 
infected heterosexually, 43% were MSMs, 2% were infected through injecting 
drug use and 2% by mother-to-child transmission (Health Protection Agency, 
2012).    
The course of natural HIV-1 infection, without treatment intervention, can be 
seen in figure 1.3. Following primary infection, approximately 50% of individuals 
experience flu-like symptoms with the remaining 50% being asymptomatic.  
During the first phase of infection, the acute phase, high levels of viral 
replication take place resulting in a viral load reaching 106 or 107 copies/ml in 
the blood and cerebral spinal fluid (Cohen et al., 2012). At this stage, infection 
can be detected reliably using qPCR methods to detect viral RNA. This is 
followed by the clinical latency phase characterised by a reduced viral load that 
stabilises at the viral load set point, which has been  associated with  
progression to AIDS (Hodcroft et al., 2014). The clinical latency phase is also 
characterised by a gradual reduction in CD4+ T cell count, although relatively 
few clinical symptoms, if any, are observed. The final phase of infection is 
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characterised by a drop in CD4+ T cell count below levels able to maintain a 
normal immune response, often at between 250-300 cells/μl. An increase in 
viral load occurs and clinical symptoms become apparent in the form of 
opportunistic infections. The time taken for the progression after initial infection 
to AIDS varies between individuals, but can be a few years to decades   
(Hodcroft et al., 2014).    
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3. The natural course of HIV infection in the absence of ART 
therapy. Acute infection is associated with a high viral load and rapid decline in 
CD4+ T cell count. Viral load stabilises at a set point which is maintained during 
clinical latency. Gradual decline in CD4+ T cell count eventually compromises 
immune function, leading to increased viral load and onset of AIDS. Figure 
taken from Coffin et al., 1997. 
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1.2 HIV life cycle 
An overview of the HIV life cycle is displayed in figure 1.4.   
 
Figure 1.4. The HIV-1 life cycle and involvement of host proteins. The first stage of 
infection involves the interaction of the Env glycoproteins with CD4 and the CCR5 co-
receptor, leading to membrane fusion and entry. Then reverse transcription and 
uncoating of the viral nucleic acids occurs, although the timing of these two processes 
in relation to each other remains controversial. The pre-integration complex is imported 
into the nucleus and cDNA is integrated into the host genome. Transcription of the viral 
genes takes place and viral mRNAs are exported from the nucleus at different times, 
depending on the degree of splicing and the action of accessory protein Rev. Assembly 
of the virus occurs at the plasma membrane and is driven by the Gag polyprotein. The 
virus buds from the cell and is released, before undergoing protease-dependent 
maturation. Figure from Engelman and Cherepenov, 2012.  
  
30 
 
 
1.2.1 HIV-1 genome 
In common with all retroviruses, HIV possesses two copies of a single stranded 
RNA genome, which must be converted to a double stranded DNA intermediate 
and integrated into the host genome before viral replication can take place. The 
HIV-1 genome is 9.8 kb long and encodes 3 essential genes found in all 
retroviruses (gag, pol and env) and a number of accessory and regulatory 
genes unique to HIV (vif, vpr, vpu, tat, rev and nef). A schematic representation 
of the HIV-1 genome can be seen in figure 1.5. The gag gene encodes the 
structural proteins necessary for viral particle formation, pol encodes the 
enzymes required for the HIV-1 life cycle and env encodes envelope 
glycoproteins necessary for binding of the virus to host cells. The accessory and 
regulatory genes perform a variety of functions which increase viral transcription 
and fitness. Tat is involved in transcription activation whilst rev regulates export 
of transcribed genomic RNA from the nucleus (Karn and Stoltzfus, 2012). Vif 
has been shown to affect the infectivity of viral particles in part by counteracting 
APOBEC proteins (apolipoprotein B mRNA-editing enzyme-catalytic peptide-
like) (Malim et al., 2012). Nef is involved in infectivity and pathogenicity and has 
been shown to downregulate the expression of cell surface receptors including 
CD4 (Landi et al., 2011). Vpr has a number of roles including the induction of 
cell cycle arrest (Guenzel et al., 2014). Finally, vpu is an integral membrane 
protein that counteracts innate restriction by host tetherin (Neil et al., 2008).  
The viral genome is flanked by long terminal repeats (LTRs) at both the 5’ and 
3’ ends which can be divided into 3 elements, U5, U3 and R, as discussed 
further in sections 1.2.3 and 1.2.6. Following the 5’ LTR is the packaging signal 
(ψ) which labels the RNA for incorporation into virions during particle assembly 
by the packaging machinery. Ψ is between 80 and 150 nucleotides long and 
contains four stem-loop structures (SL1-4) (as reviewed by Sundquist and 
Krausslich, 2012). Additionally, approximately 150 nucleotides from the 5’ end 
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of the RNA genome is a primer binding site (PBS) which is important for the 
initiation of reverse transcription (as reviewed by Hu and Hughes, 2012). 
 
 
 
 
 
 
 
 
 
 
Figure 1.5. The HIV-1 genome. The structure of the 9.8kb, single-stranded 
RNA HIV-1 genome is shown including the position of gag, pol, env, the 
accessory and regulatory genes and the LTRs. The three enzymes derived from 
the pol gene are also denoted: protease, reverse transcriptase (RT) and 
integrase (INT). In addition, the individual subunits of the Gag polyprotein are 
shown: matrix (MA), capsid (CA), p2, NC (nucleocapsid), p1 and p6.  
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1.2.2 Cell entry 
1.2.2.1 Cellular receptors 
HIV-1 binds to one primary cellular receptor (CD4) and one of two co-receptors 
(CCR5 and CXCR4) to enable entry into host cells, as shown in figure 1.4 
(Doms and Peiper, 1997; Bour et al., 1995). CD4 is a member of the 
immunoglobulin superfamily that interacts, along with the T cell receptor, with 
MHC class II molecules on antigen presenting cells inducing T cell activation via 
a signaling cascade (as reviewed by Wilen et al. 2012). CCR5 and CXCR4 
have a role in immune cell trafficking and belong to a family of chemokine 
receptors with a seven-transmembrane domain coupled to a G-protein. CCR5 is 
expressed on CD+ T cells, whilst CXCR4 is found on a wider range of cells both 
within and outside the immune system (as reviewed by Didigu and Doms, 
2012). Viruses either use CCR5 (R5 tropism), CXCR4 (X4) or both co-receptors 
(R5X4) for entry. The majority of transmitted viruses use CCR5 for entry, 
whereas switch to X4-tropism is associated with progression of disease (as 
reviewed by Wilen et al., 2012).  
Prior to the binding of HIV-1 to CD4 and secondary co-receptors, Env-
dependent attachment to a number of cell-surface molecules can occur. DC-
SIGN, a type II membrane protein with C-type lectin domain, along with several 
other lectins, have been shown to bind Env and boost in vitro infection 
(Geijtenbeek et al., 2000). DC-SIGN is expressed on dendritic cells (DCs) and 
captures HIV-1, enabling its presentation to CD4+ T cells, thus enhancing the 
efficiency of infection (Hijazi et al., 2011).   
1.2.2.2 Viral envelope proteins 
The HIV-1 env gene encodes the Env proteins that mediate attachment and 
fusion of the virion with the host cell membrane. Env is a type I integral 
membrane viral glycoprotein and is expressed as a monomeric protein, gp160.  
Gp160 undergoes post-translational modifications including N-linked 
glycosylation and is subsequently cleaved by furin cellular proteases, resulting 
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in the production of two subunits gp120 and gp41 (as reviewed by Wilen et al., 
2012). Gp41 is a transmembrane glycoprotein that anchors the Env protein to 
the virus membrane, whilst gp120 is a surface glycoprotein responsible for 
receptor binding. Within the viral envelope, Env is trimeric with three gp120s 
each noncovalently bound to a gp41 subunit. Gp120 is composed of five 
conserved (C1-C5) and five variable (V1-V5) domains (as reviewed by Didigu 
and Doms, 2012).  
1.2.2.3 Cellular binding and membrane fusion   
The viral envelope is derived from the host cell membrane and studies have 
shown that as few as 7 to 15 Env spikes may be found on each virion. There is 
evidence that Env spikes are present in a single cluster on the surface of the 
mature virion and that the clustering is dependent on the cleavage of the Gag 
MA subunit from the CA subunit during maturation (Chojnacki et al., 2012). Env 
gp120 initially binds the N terminus of CD4, inducing a conformational change 
in gp120 that allows the binding of gp120 to either co-receptor. Interactions 
between the co-receptor binding site and co-receptors result in the exposure of 
the 15 amino acid fusion peptide within gp41, which is inserted into the plasma 
membrane and brings about membrane fusion (as reviewed by Wilen et al., 
2012).   
1.2.3 Reverse transcription 
1.2.3.1 HIV reverse transcriptase enzyme 
HIV-1 pol encodes a reverse transcriptase (RT) enzyme that catalyses the 
conversion of viral RNA to a double stranded cDNA intermediate, which is later 
integrated into host DNA forming the proviral template from which transcription 
of viral genes by host cellular machinery occurs (figure 1.4). RT has two distinct 
enzymatic activities: RNA polymerase and RNAseH (degrades RNA in an 
RNA/DNA hybrid). It is composed of two subunits, p66 and p51, that share a 
common N terminus. The p66 subunit contains two spatially distinct active sites 
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for the separate activities of RT, whilst the p51 subunit has a structural role 
(Sarafianos et al., 2009).   
1.2.3.2 The process of reverse transcription 
Reverse transcription is a complex, multi-stage process, as illustrated in figure 
1.6. A tRNALys binds to the primer binding site (PBS) 180 nucleotides from the 
5’ end of RNA, acting as a primer for reverse transcription. DNA synthesis 
proceeds from the tRNALys primer to the 5’ end of the RNA generating an 
RNA/DNA hybrid. The RNA within the RNA/DNA hybrid is degraded by the 
RNaseH activity of RT leaving a single-stranded DNA fragment, the minus-
strand strong stop DNA. Short regions of homology (‘R’ regions) exist which 
enable the minus-strand strong stop DNA to ‘jump’ to the 3’ end of the genome, 
the first DNA strand transfer. Minus-strand DNA synthesis and RNaseH activity 
proceed (as reviewed by Wu and Hughes, 2012). However, the polypurine tract 
(PPT) is resistant to degradation and remains to act as a primer for positive 
strand DNA synthesis. Following positive-strand synthesis, the RNaseH activity 
removes the tRNALys primer from the 3’ end of minus-strand DNA, exposing a 
single stranded DNA sequence complementary to sequences near the 3’ end of 
the plus-strand RNA. The complementary PBS sequences cause the two DNA 
strands to anneal, the second DNA strand transfer. DNA synthesis is then 
completed with both the positive and negative strand acting as templates (as 
reviewed by Wu and Hughes, 2012).    
HIV has an additional PPT located in the centre of the genome (cPPT). When 
positive strand DNA synthesis from the PPT proceeds past the cPPT, the strand 
produced from the cPPT is displaced for approximately 90-100 nucleotides (Hu 
et al., 2010). The resulting triple-stranded DNA flap has been reported to be 
important for nuclear entry, infectivity and protection from APOBEC3 host 
proteins, although its exact contribution remains controversial (Iglesias et al., 
2011).    
  
35 
 
 
The RT enzyme has two features that contribute to the high levels of viral 
variation within an infected individual and between different hosts. Firstly, RT 
has a high error rate due to the lack of proof-reading capability, with an error 
occurring every 1 in 2000-7000 base pairs during replication. Secondly, RT has 
low affinity for RNA and so can switch between the two RNA copies during 
reverse transcription which will results in a recombinant cDNA molecule if the 
two RNA molecules are distinct. Studies using different techniques report 
different frequencies for these recombination events, but the current estimate is 
between four and five times per genome produced (as reviewed by Onafuwa-
Nuga and Telesnitsky, 2009). These features of RT, along with the high rate of 
viral replication, result in the existence of ‘quasispecies’ within a patient with 
differing fitness and replication capacities. In the presence of selective pressure, 
such as that applied by drug therapy, the random distribution of genetic 
changes present within the quasispecies facilitates the evolution of drug 
resistance.   
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Figure 1.6. Reverse transcription in HIV-1. The conversion of the single-
stranded RNA genome to double stranded cDNA is shown. A tRNA primer 
binds to the PBS at the 5’ end of the RNA (light blue) and DNA synthesis 
proceeds, generating minus-strand DNA (purple). RNAseH activity degrades 
the RNA and the DNA jumps to homologous R regions at the 3’ end of the RNA, 
enabling minus-strand DNA synthesis to continue accompanied by RNAseH 
degradation. The PPT is resistant to degradation and acts as a primer for 
positive-strand DNA synthesis (red line). RNAseH activity results in 
complementary PBS at each end of the RNA and the second strand transfer 
occurs, with each DNA strand acting as a template for synthesis. The presence 
of the cPPT results in the formation of a triple-stranded DNA flap.  
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1.2.4 Virus uncoating and nuclear entry 
Following entry into the cell, the viral capsid moves through the cell by active 
transport and studies have provided evidence for the role of microtubules and 
the actin cytoskeleton it this process (as reviewed by Lehmann et al., 2011). 
HIV-1 is able to enter the nucleus of a non-proliferating cell enabling it to infect 
important cell types such as terminally differentiated macropahges. However, 
other retroviruses including murine leukemia virus (MLV) and spleen necrosis 
virus (SNV) require mitosis for productive infection and cannot integrate in non-
diving cells (Yamashita and Emerman, 2006).  
The exact mechanisms of the uncoating of the capsid core and the transport of 
the viral nucleic acid into the nucleus are yet to be fully elucidated. However, 
the HIV capsid is too large to enter the nucleus through the nuclear pore 
suggesting that uncoating of the viral cDNA must occur before nuclear entry 
(Hilditch and Towers, 2014). Despite numerous studies, it is currently unclear 
when uncoating occurs in relation to the timing of reverse transcription and 
where in the cell uncoating takes place (as reviewed by Fassati, 2012). 
Technical difficulties have contributed to this lack of understanding, in particular 
that some assays measure what occurs in the majority of virions, but these are 
not necessarily the virions that cause productive infections (as reviewed by 
Hilditch and Towers, 2014). Studies have provided evidence for the importance 
of host factors in directing HIV uncoating and nuclear entry, and it has been 
suggested that the use of host cofactors enables evasion of the innate immune 
response. When mutations in CA are present that prevent interactions with the 
host cofactors used for uncoating and nuclear entry, innate sensors are 
triggered and an antiviral state is induced (Rasaiyaah et al., 2013).  
A number of cofactors have been suggested to play a role in the targeting of the 
viral capsid to the nucleus and in nuclear entry: cyclophilin A (CypA), CPSF6, 
TNPO3, Nup358 and Nup153. CypA binds CA directly and when binding is 
  
38 
 
 
prevented, subsequent interactions with other cofactors and the integration sites 
are affected (Schaller et al., 2011). CPSF6 also binds CA directly and is has 
been suggested that this interaction directs HIV to a particular nuclear binding 
pathway involving TNPO3 and Nup358 and prevents premature reverse 
transcription. HIV CA interacts directly with nuclear pore protein Nup358 
through its cyclophilin-like domain and it has been hypothesised that this 
interaction tethers the capsid to the nuclear pore enabling the subsequent 
interactions required for nuclear entry (Schaller et al., 2011). Entry of the viral 
cDNA is thought to occur through the nuclear basket protein Nup153 and 
studies have provided evidence for the interaction of Nup153 with integrase and 
CA (as reviewed by Hilditch and Towers, 2014). 
1.2.5 Integration  
1.2.5.1 HIV integrase enzyme 
Once inside the nucleus the integration of viral DNA into the host genome is 
catalysed by the viral integrase (IN) enzyme, which enters the nucleus as part 
of the PIC, as shown in figure 1.4. Integrase has three distinct domains: the N 
terminal domain, the catalytic core domain and the C terminal domain. The N 
terminal domain contains an HHCC motif that plays a role in the dimerisation of 
integrase monomers and the binding of cellular factors. The catalytic domain 
contains the integrase active site, essential for enzyme function. The C terminal 
domain contains domains that non-specifically bind to DNA, so has been 
implicated in stability of the integrase/DNA complex (Delelis et al., 2008). It is 
thought that integrase functions as a tetramer, composed of two symmetrical 
dimers of integrase (as reviewed by Mbisa et al. 2011). 
1.2.5.2 Integration 
Initiation of integration occurs when integrase catalyses the cleavage of two 
nucleotides from both 3’ ends of the viral DNA, resulting in free 3’ hydroxyl 
groups. Once in the nucleus, the free 3’ hydroxyl groups attack phosphodiester 
bonds of the host DNA. This strand transfer reaction results in the ligation of the 
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viral DNA into the host genome. Host cellular repair enzymes fill the gaps 
remaining (as reviewed by Craigie and Bushman, 2012). HIV-1 has been shown 
to preferentially integrate at sites of active genes and integration can lead to 
latent infection if it occurs at a transcriptionally inactive site. There is evidence 
that the nuclear entry pathway impacts on integration site selection (Schaller et 
al., 2011). Host factor LEDGF has been shown to tether the integrase-DNA 
complex to the host chromatin, enabling correct targeting of integration. In 
addition, LEDGF stimulates the activity of the integrase enzyme and protects it 
from degradation (as reviewed by Christ and Debyser, 2013).  
In addition to integrated cDNA, other forms of viral DNA are present in the 
nucleus: linear cDNA, 1-LTR and 2-LTR circles. 1-LTR circles can be formed by 
homologous recombination of linear cDNA. However, it has been shown that 2-
LTR circles are the product of non-homologous end joining (NHEJ) repair 
mechanisms within the nucleus (as reviewed by Sloan and Wainberg, 2011). 2-
LTR circles are used as markers of nuclear entry as PCR can be designed to 
amplify across the unique LTR-LTR joint. It has also been shown that when 
integrase is blocked, for example when integrase inhibitors are present, there is 
an increase in the number of 1-LTR and 2-LTR circles (Buzon et al. 2010).    
1.2.6 Transcription and translation of viral genes 
Transcription of viral proteins occurs from the proviral template, cDNA 
integrated into the host genome. The viral LTR contains promoter regions 
including an initiator and TATA-box, which enable the correct positioning of host 
RNA polymerase II at the site of initiation of transcription (Berkhout and Jeang, 
1992). The cellular NF-ĸB and viral Tat proteins are involved in increasing the 
rate of initiation and elongation of viral transcription. Tat stimulates elongation of 
the viral RNA via its interaction with the Transactivation Response Element 
(TAR) in the cDNA. Tat is encoded by two exons: the first encodes 72 amino 
acids and is found upstream of env and the second exon varies between 14 and 
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29 amino acids long and is located at the 3’ end of env, as shown in figure 1.5. 
Tat complexes with host factor pTEFb and host proteins CDK9 and CycT1 are 
also recruited to the elongation complex. Recruitment of CDK9 kinase leads to 
its activation and the hyperphosphorylation of the RNA polymerase II enzyme, 
leading to enhanced elongation. In the absence of Tat viral RNA elongation is 
blocked by the negative elongation factor NELF (as reviewed by Karn and 
Stoltzfus, 2012). This is different from traditional transcription factors that bind to 
DNA and promote the recruitment of RNA polymerase. 
Studies have shown that large numbers of differentially spliced mRNA species 
are produced, with up to 40 distinct mRNA species identified (as reviewed by 
Stoltzfus, 2009). The viral RNA undergoes posttranscriptional processing 
including the addition of a 5’ cap and polyadenylation of the 3’ end, as with 
cellular mRNA to shield it from recognition by the host innate immune system. 
The early genes tat, rev and nef are expressed from a fully spliced mRNA 
species that is expressed early in the HIV life cycle and can be exported from 
the nucleus without any additional viral mechanisms as it does not contain 
introns. Other mRNA species that are partially spliced or un-spliced, containing 
introns, require the presence of Rev that interacts with the rev response 
element (RRE) for their nuclear export. Rev is encoded by two exons which 
overlap with those of tat and contains a nuclear export signal and an RNA 
binding region. Rev binds to and mulitmerises on the RRE, and forms an export 
complex with host proteins Crm1 and RanGTP that is exported from the nucleus 
through the nuclear pore. Crm1 has been shown to interact with nuclear pore 
proteins including Nup358 and Nup214 (as reviewed by Kuzembayeva et al., 
2014). Once exported, the partially spliced mRNAs express Env, Vif, Vpu, Vpr 
and Tat whilst the unspliced mRNA expresses full-length Gag-Pol and acts as 
genomic RNA for incorporation in new virions (as reviewed by Karn and 
Stoltzfus, 2012).   
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Translation of gag from unspliced mRNA results in two polyproteins of different 
lengths: Gag and the Gag-Pol polyprotein. The pol gene is at a -1 reading frame 
relative to gag so its translation requires a ribosomal frameshift event following 
the translation of gag to express the Gag-Pol polyprotein. This frameshift event 
occurs in approximately 5% of translations when the ribosome reaches an 
internal secondary hairpin structure coupled with a slippery sequence, 
UUUUUU, at the end of the gag gene (as reviewed by Karn and Stoltzfus, 
2012). The ratio of 1 Gag-Pol polyprotein molecule to 20 Gag polyprotein 
molecules results in the optimum levels of the polymerase proteins for viral 
fitness. Translation of the viral proteins occurs in different regions of the cell.  
Gag and Gag-Pol are translated in the cytosol by free ribosomes before 
migrating through the cytosol to the plasma membrane, the site of viral particle 
assembly. Env is translated from a spliced transcript as it travels through the 
rough endoplasmic reticulum to the plasma membrane, via the Golgi apparatus 
(as reviewed by Sundquist and Krausslich, 2012).  
1.2.7 Virion assembly and release 
1.2.7.1 Virion assembly 
Virion assembly takes place at the host cell plasma membrane from which 
budding of the virion occurs, as shown in figure 1.4. Particle assembly involves 
a number of stages: targeting of Gag to and interaction with the plasma 
membrane, Gag multimerisation, recruitment of genomic RNA, incorporation of 
Env protein and budding and release of immature particles from the plasma 
membrane (as reviewed by Ono, 2010). The Gag protein drives particle 
assembly, in particular it directs virion budding, controls virion size and ensures 
the inclusion of other vital components. Four Gag subunits are directly involved 
in different stages of viral assembly: matrix (MA), capsid (CA), nucleocapsid 
(NC) and p6.  
Once synthesized in the cytosol, a highly basic sequence between amino acids 
16 to 31 of Gag MA has been identified as the region responsible for targeting 
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Gag to the plasma membrane. These residues form a cluster on the surface of 
the MA globular domain that is conserved among retroviruses. A myristic acid is 
covalently attached to the basic residues in the MA amino terminus which 
anchors Gag to the plasma membrane lipid bilayer and has been shown to be 
essential for viral budding (Bukrinskaya, 2004). In particular, amino acids 29 
and 31 of MA are necessary for membrane targeting as substitution results in 
localisation of Gag to intracellular compartments (Ono and Freed, 2004). Gag 
targets PI(4,5)P2 [phosphatidylinositol-(4,5)-bisphosphate] within the plasma 
membrane and in its absence Gag localises to internal cellular membranes 
(Ganser-Pornillos et al., 2008; Ono et al., 2004).   
Studies using fluorescence imaging techniques (FRET) have shown that 
multimerisation of full-length Gag occurs at the plasma membrane (Derdowski 
et al., 2004). Viral RNA and Gag subunits CA and NC have been implicated in 
Gag multimerisation. Viral RNA has been shown to promote Gag 
multimerisation through its interactions with NC, so it is thought that NC does 
not mediate multimerisation directly (Martin-Serrano et al., 2011). Mutations in 
the C terminal domain of CA have been shown to affect assembly (as reviewed 
by Martin-Serrano et al., 2011; Kutluay and Bieniasz, 2010).  
Two copies of the viral RNA genome are incorporated into each virion from the 
full-length, unspliced viral RNA present in the cytoplasm. NC is involved in 
genomic RNA recruitment and RNA dimerisation is required for its incorporation 
into virions (as reviewed by Moore and Hu, 2009). Genomic RNA encodes a 
packaging signal, ψ, in the 5’ region of Gag which labels it for packaging into 
the virion. Ψ encodes 4 stem loop structures (SL1-4) which interact with two 
zinc finger motifs of Gag NC to bring about RNA encapsidation. However, most 
of the 5’ UTR is involved in RNA genome encapsidation (as reviewed by 
Sundquist and Krausslich, 2012).  
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The viral envelope proteins, gp120 and gp41, are also sequestered to the host 
cell membrane for incorporation in the viral membrane. The Env gp160 
precursor is synthesised in the rough endoplasmic reticulum and cleaved into 
two subunits by cellular furin proteases during its transport to the cell surface 
via the golgi apparatus. The process of Env recruitment is not yet fully 
understood, but it has been shown to require the MA subunit of Gag (as 
reviewed by Sundquist and Krausslich, 2012). A mutation at position 49 of MA 
decrease the incorporation of Env into the virion, but deletion of the gp41 C 
terminal domain reverses this effect, implying that the interaction occurs 
between MA and the C terminus of Env (Davis et al., 2006). Recent work has 
shown that cleavage of Gag, in particular the separation of MA, during 
maturation is essential for the formation of a single focus of Env, required for 
viral infectivity (Chojnacki et al., 2012).      
A number of viral accessory proteins are also packaged into the assembling 
virion as they are required in the early stages of the life cycle in the next 
infected cell. Vpr is incorporated via a direct interaction with the Gag p6 subunit, 
which has been shown to be sufficient for its inclusion (as reviewed by 
Sundquist and Krausslich, 2012).  
1.2.7.2  Virion budding and release 
The Gag lattice that forms during HIV-1 virion assembly is continuous, but 
consists of a gap thought to cover approximately 30% of the virion, as shown in 
figure 1.9a.  This gap is thought to correlate with the area of the membrane from 
which scission occurs, required for resolution of the membrane stalk connecting 
the cell and virion (as reviewed by Briggs and Krausslich, 2011). This scission 
process requires the p6 subunit of Gag which has late-budding domain (L-
domain) activity and mutations in p6 prevent release of budding virus from cells 
(Gottlinger et al., 1991). The p6 subunit contains two regions required for viral 
budding: a P(S/T)AP domain and the (L)YPXNL motif. The P(S/T)AP domain 
interacts with the cellular endosomal sorting (ESCRT) machinery within the cell 
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to bring about membrane scission.  During the assembly and budding stages of 
HIV-1 virion assembly, ESCRT-I is recruited to the plasma membrane at the site 
of virion assembly. The P(S/T)AP motif in p6 Gag, required for this recruitment 
event, binds ESCRT-I via a direct interaction with host protein TSG101 (Martin-
Serrano et al., 2001; Garrus et al., 2001). Recruitment of ESCRT-III follows the 
recruitment of ESCRT-I, although the intermediate proteins responsible have 
not been conclusively determined (as reviewed by Meng and Lever, 2013). The 
(L)YPXNL motif binds cellular ALIX (apoptosis-linked gene 2-interacting protein) 
to promote virion budding (Zhai et al., 2011). It has been shown that in a system 
where P(S/T)AP is missing and TSG101 mediated budding is blocked, over-
expression of ALIX can rescue budding defects (Fisher et al., 2007).   
1.2.8 Virion maturation 
Once assembled, during or just after budding, the virion undergoes a maturation 
process which is required for the virion to become infectious, as shown in figure 
1.4. This maturation event involves the cleavage of the Gag and Gag-Pol 
polyproteins into functional units by the viral protease enzyme, resulting in 
structural changes within the virion.   
1.2.8.1 HIV protease enzyme 
HIV-1 protease is a 99 amino acid aspartic protease that functions as a 
homodimer, as shown in figure 1.7 (Fisher et al., 2007). The protease active site 
is found along the dimer interface and each protease monomer contributes a 
single catalytic aspartic acid residue. The active site is formed by the triplet Asp-
Thr-Gly amino acids from positions 25-27 of each protease monomer. Protease 
has two flexible flaps, which are dynamic in solution enabling entry of inhibitors 
and substrate into the binding cleft situated above the active site (Collins et al., 
1995). 
The mechanism of protease autocleavage from the Gag-Pol polyprotein is not 
fully understood, but it has been shown that dimerisation of Gag-Pol is required 
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for protease activation. Following dimerisation, cis cleavage of the protease 
from within the Gag-Pol polyprotein occurs before protease cleaves the 
remainder of the Gag-Pol polyprotein in trans at specific cleavage sites, 
recognised by their secondary structure and not their amino acid sequence 
(Davis et al., 2012; Prabu-Jeyabalan et al., 2004). It has been shown, in vitro, 
that protease autocleavage can be controlled by the oxidation of cystiene 
residues 67 and 95 (Daniels et al., 2010).   
 
 
 
 
 
 
 
 
 
 
Figure 1.7. The HIV-1 protease enzyme. The structure of the HIV-1 protease 
homodimer is displayed, with one monomer shown in dark blue and the second 
in light blue. The active site of the enzyme contains three catalytic amino acids 
at positions 25-27, Asp-Thr-Gly. The dynamic flaps that enable the entry of 
substrate and inhibitors into the substrate binding cleft are labelled.   
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1.2.8.2 Protease cleavage of the Gag polyprotein  
Protease cleavage of Gag, during or just after the release of the virion from the 
plasma membrane, results in the release of the six subunits: matrix (p17, MA), 
capsid (p24, CA), nucleocapsid (p7, NC), p6 and the spacer peptides p1 and 
p2. Cleavage of Gag-Pol additionally results in the release of the protease, 
reverse transcriptase and integrase enzymes. Whilst the exact timing of 
cleavage remains unknown, it occurs late enough into the budding process to 
ensure that all cleavage products remain in the budding virion. There are five 
cleavage sites within Gag that lead to the separation of the six subunits, as 
shown in figure 1.8. Protease recognition of the cleavage sites is determined by 
the secondary structure and not the amino acid sequence of each site, hence 
there is significant variation in amino acid sequences between cleavage sites 
(Prabu-Jeyabalan et al., 2002). The secondary structures are fairly well 
conserved between cleavage sites, however there are differences in the 
protruding side chains which are thought to contribute to the different rates of 
cleavage at each site.   
Whilst amino acids are not conserved across cleavage sites, studies have 
demonstrated that the amino acids at the cleavage site in direct contact with 
protease regulate the rate of cleavage (four amino acids before the cleavage 
site and three after) (Pettit et al., 2002; Pettit et al., 2005). In addition, residues 
more distant from the cleavage site, in particular the fourth and fifth amino acids 
following the cleavage site p4’ and p5’, have been shown to affect rates of 
cleavage (Dam et al., 2009; Nijhuis et al., 2007b). The amino acid residues are 
mostly hydrophobic and it has been shown that a hydrophobic residue at the 
amino acid position before the cleavage site (p1) is required for cleavage to 
occur (Pettit et al., 1991).   
The order of cleavage at the sites within Gag is tightly controlled and, as with 
the rate of cleavage, is a result of the variation in protruding side chains and 
amino acid sequences present. The order in which the Gag sites undergo 
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cleavage is shown in figure 1.8, along with the amino acid positions at each 
cleavage site (as reviewed by Fun et al., 2012). The first cleavage event occurs 
at the C terminal of p2, releasing two intermediates: MA-CA-p2 and NC-p1-p6 
(Krausslich et al., 1989). This cleavage event permits the condensation of the 
genomic RNA to the centre of the virion. The second cleavage events occur 
between MA and CA, leading to release of MA from CA-p2, and between p1 
and p6, releasing p6 from NC-p1. These cleavage steps occur at a ten-fold 
lower rate than the first cleavage step (Pettit et al., 1994). The separation of the 
spacer peptides (p1 and p2) from NC and CA, respectively, are the final 
cleavage events and are thought to be the rate limiting steps, occurring at a rate 
several hundred fold reduced in comparison to that of the first cleavage step 
(Nijhuis et al., 2007b). The separation of p2 from CA has been shown to be 
essential for the formation of the mature core surrounding the viral RNA (as 
discussed in Briggs and Krausslich, 2011). The structural differences between 
the mature and immature virions can be seen diagrammatically and in electron 
micrographs in figure 1.9.   
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Figure 1.8. Ordered cleavage of the Gag polyprotein into its functional 
subunits by viral protease. The top panel of the figure shows the subunits of 
the Gag-Pol polyprotein and highlights the cleavage sites. The order of Gag 
cleavage and the consensus nucleotide and amino acid sequences at each Gag 
cleavage site are shown. The first cleavage step results in the release of p2 
from NC. The second cleavage steps are the release of MA from CA, and of p6 
from p1. The final, rate limiting, steps are the release of CA from p2 and NC 
from p1. Figure from Nijhuis et al., 2012.
 
 
  
49 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.9. The structure of Gag in the virion. (a) An electron micrograph and 
schematic representation of the structure of immature HIV-1 virions. The Env 
protein spikes (blue), viral envelope (green), Gag matrix (yellow), capsid 
(orange) and nucleocapsid subunits (red) are shown. In the immature virion all 
Gag subunits are attached to the outer viral envelope. (b) An electron 
micrograph and schematic representation of the structure of mature HIV-1 
virions. Gag cleavage releases the capsid and nucleocapsid subunits. 
Nucleocapsid complexes with RNA and capsid forms the conical capsid 
surrounding the RNA. Figure adapted from Sundquist and Krausslich, 2012. 
 
 
 
a 
b 
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1.2.8.3 Structure of the mature virion  
The structure of the HIV-1 mature virion is shown in figures 1.9 and 1.10. The 
host cell membrane derived envelope surrounds the virion, studded with viral 
Env proteins. The MA protein is found attached to the virus envelope, although 
this lattice is not continuous containing a gap correlating with the area where 
scission from the host cell occurred. Viral protease is found between the 
envelope and the core as it is necessary for the maturation process. The CA 
protein forms the capsid which surrounds the genome-nucleocapsid complex. It 
comprises multiple CA hexamers which form a tube and a number of CA 
pentamers which result in the formation of a conical shape, as shown in figure 
1.10 (Pornillos et al., 2011). The capsid contains two copies of the single 
stranded RNA genome complexed with NC and p6, protecting it from digestion 
by host nucleases. The viral enzymes reverse transcriptase and integrase are 
also packaged within the capsid alongside the viral genome.    
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Figure 1.10. The structure of the mature virion. (a) A schematic showing the 
structure of the mature HIV-1 virion. Env spikes comprise trimeric gp41 and 
gp120 proteins. Gag MA subunit is stuck to the viral envelope, CA has formed 
the conical capsid and NC is in complex with the viral RNA. Reverse 
transcriptase is packaged along with the RNA. (b) The structure of the mature 
capsid surrounding the viral RNA is shown, comprised of CA hexamers and 
pentamers, shown in (c). Figure taken from NIH website (a) and Pornillos et al. 
2011 (b,c).  
b 
a 
 
  
c 
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1.2.9 Cell-to-cell spread 
In addition to the above mechanism of infection involving release of the virion 
into the extracellular environment (cell-free spread), direct cell-to-cell 
transmission of HIV can occur in which the virus is never released into the 
extra-cellular environment. This occurs via the formation of the virological 
synapse between infected (donor) and uninfected cells (Chen et al., 2007).  
Polarisation of viral proteins and cellular organelles occurs at the site of contact 
between cells. Cell-to-cell spread has been shown to be mediated by the viral 
Env protein in the infected cell and the CD4 receptor of the uninfected cell  
(Jolly et al., 2004).    
The importance of cell-to-cell spread in vivo is still under investigation, although 
it has been suggested to play a role in the spread of virus in areas densely 
populated by CD4+ cells such as lymph nodes. In vitro, cell-to-cell spread is 
more efficient than cell free spread with both reverse transcription and 
integration occurring more rapidly, possibly as rate limiting steps in cell-free 
infection such as virion attachment are not required. Different studies have 
reported varying significance of cell-to-cell spread in vitro with some studies 
reporting cell-to-cell spread as the main mechanism (Chen et al., 2007) and 
others reporting an equal contribution of cell-free and cell-to-cell spread 
(Komarova et al., 2013).   
Cell-to-cell spread has been implicated in the persistence of low levels of viral 
replication in the presence of ART and as such there are questions over the 
effectiveness of ART in preventing this mode of transmission (Sigal et al., 
2011). Studies have shown that entry inhibitors and protease inhibitors are 
effective in preventing cell-to-cell spread (Martin et al., 2010; Sigal et al., 2011). 
However, a recent study has shown that whilst protease inhibitors are equally 
effective at blocking cell-to-cell spread, certain reverse transcriptase inhibitors 
are between 4 and 20 fold less effective (Titanji et al. 2013). In addition, cell-to-
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cell spread is thought to enable immune evasion from both antibodies and the 
complement system.   
1.2.10 Host factors involved in the HIV-1 life cycle 
A number of host factors interact with HIV-1 during the course of its life cycle to 
affect its infectivity, as shown in figure 1.4. HIV uses cellular factors and 
pathways for replication and conversely cells also produce proteins that 
suppress replication (restriction factors). During the early stages of the life 
cycle, cyclophilin A (CypA) is recruited into virions as they assemble following 
interaction with Gag (Franke et al., 1994). It binds to a loop on the CA subunit 
and this binding can be blocked by mutations at positions 89 and 90 of CA (as 
reviewed by Hilditch and Towers. 2014). It has been hypothesised that in 
binding CA, CypA inhibits the CA-CA interactions necessary for the stability of 
the viral core leading to progressive uncoating of the core as increasing 
amounts of CypA bind (Gamble et al., 1996). Recent data has shown that 
blocking the binding of CypA and CA influences the pathway of nuclear entry 
and alters integration site targeting (Schaller et al., 2011)  
Trim5α is a component of the innate immune system and its expression is 
induced by interferon (Asaoka et al., 2005). Trim5α contains a tripartite motif (an 
RBCC) domain which comprises a RING domain, a B Box 2 domain and a 
coiled coil. The exact mechanism by which Trim5α inhibits viral infection has yet 
to be determined. However, it has been suggested that Trim5α may interfere 
with uncoating of the viral core or the trafficking of the viral core to the nucleus 
(as reviewed by Towers, 2007). Trim5α binds HIV-1 CA directly capsids and is 
heavily ubiquitinylated in cells (Diaz-Griffero et al., 2006). It is rapidly degraded 
by the proteosome in a RING domain dependent manner, therefore it has been 
suggested that once bound to virions it targets them for proteosomal 
degradation, leading to a block in early infection. However, when the 
proteosome is inhibited the virus remains un-infectious and proteosome 
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independent mechanisms of degradation have also been described (Chatterji et 
al., 2006; as reviewed by Malim and Bieniasz, 2012).  Whilst Trim5α from other 
animals successfully restricts HIV-1 infection, HIV-1 is resistant to restriction by 
human Trim5α.  
Another important restriction factor that acts in the early stage of the HIV-1 life 
cycle is APOBEC3G, one of a family of cytidine deaminase enzymes of the 
APOBEC3 family. APOBEC3G causes steric inhibition of reverse transcription 
by causing the conversion of deoxycytidine to deoxyuridine in the negative DNA 
strand, resulting in G to A hypermutations and eventually leading to the 
production of uninfectious virions (Bishop et al., 2008). The viral protein Vif 
prevents APOBEC3G action in human cells by targeting it for proteosomal 
degradation (Sheehy et al., 2003). In the absence of Vif, APOBEC3G is 
packaged into the assembling virion through interactions with RNA and Gag NC 
(as reviewed by Malim and Bieniasz, 2012).    
SAMHD1 is a more recently described restriction factor shown to block the early 
stage of viral replication in dendritic and resting CD4+ T cells (Baldauf et al., 
2012). SAMHD1 functions by hydrolysing cellular dNTPs which inhibits reverse 
transcription and prevents cDNA synthesis (Goldstone et al., 2011; Lahouassa 
et al., 2012). SAMHD1 restriction can be overcome by the Vpx accessory 
protein, which is thought to sequester SAMHD1 and target it for proteaosomal 
degradation (Sharova et al., 2008). However, Vpx is not present in HIV-1 
although it is present in HIV-2 and SIV viruses.  
Tetherin restricts infectivity of HIV-1 at the budding stage of the virus life cycle. 
In the absence of the antagonist Vpu the virus assemble normally, but tetherin 
anchors the virions to the cell membrane and virions are internalised, leading to 
their accumulation in endosomes (Neil et al., 2008). Tetherin contains a coiled 
coil domain that enables dimerization, thought to result in a protein tether which 
links virions to the cell (as reviewed by Neil and Bieniasz, 2009). The HIV-1 
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accessory protein Vpu is the tetherin antagonists, whereas SIVs use Nef.or Env 
(Gupta et al., 2009a; Sauter et al., 2009). The viral proteins Vpu, Env and Nef 
reduce the surface expression of tetherin by a number of mechanisms including 
interference with its transport to the membrane, internalisation and degradation 
(as reviewed by Sauter, 2014).  
1.3 Treatment of HIV-1 infection 
Currently there is no vaccine or cure for HIV, the only treatment available is 
antiretroviral therapy (ART) which halts the progression of infection to AIDS.  
There are a variety of classes of inhibitors that act at different stages of the HIV 
life cycle to prevent virus replication: cellular entry, reverse transcription, 
integration, protease cleavage and virion maturation (as reviewed by Arts and 
Hazuda, 2012). Current guidelines recommend the use of multiple ART drugs, 
known as highly active antiretroviral therapy (HAART). HAART normally 
comprises three drugs; either two nucleoside reverse transcription inhibitors 
(NRTIs) and one protease inhibitor (PI) or two NRTIs and one non-nucleoside 
reverse transcriptase inhibitor (NNRTI) (World Health Organisation, 2013). 
Currently, first line therapy of two NRTIs and one NNRTI, PI or INI is 
recommended as the starting point of therapy (Williams et al., 2012). If 
treatment failure occurs, other drugs in the same classes of ART can be 
considered.   
HAART is used with the aim of suppressing viral replication to levels below the 
limit of detection in commercial viral load assays, approximately 50 RNA 
copies/ml. When viral suppression is achieved, the patients CD4+ T cell count 
rises again towards that of normal levels, resulting in improved immune function 
(as reviewed by Arts and Hazuda, 2012). As well as improving the prognosis of 
the individual patient, HAART reduces transmission rates between sero-
discordant couples and mothers and their babies (Cohen et al., 2011). Until 
recently WHO guidelines recommended commencement of HAART in patients 
with a CD4+ T count below 350 cells/ml but in the summer of 2013 this was 
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raised to 500 cells/ml given the benefits of earlier treatment (Kitahata et al., 
2009; World Health Organisation, 2013).  
1.3.1 Entry and fusion inhibitors 
Entry inhibitors are a relatively new class of drug which target the cell entry 
steps of the HIV life cycle. There are two classes of entry inhibitors that have 
compounds that are FDA approved: fusion inhibitors and CCR5 co-receptor 
antagonists.   
Fusion inhibitors act to prevent the fusion of the virion envelope with the host 
cell membrane. Since they act outside the host cell, they have minimal side 
effects in comparison to other ARTs. Enfuviritide (T20) is a fusion inhibitor 
which binds to viral gp41 and disrupts the interaction between the N and C 
terminal heptad repeats (NHR and CHR, respectively) of the gp41 ectodomain 
by mimicking the CHR. Hence it prevents the subsequent interaction between 
gp41 and cellular receptors required for virus entry. It has been shown to be 
effective again viruses of all tropisms, R5, X4 and R5X4 (Fletcher, 2003). It was 
approved by the FDA in 2003, however its short half-life of less than four hours 
has limited its use, as it must be administered twice daily at fairly high doses. 
Additionally, it is administered as a subcutaneous injection which is expensive 
and can result in side effects at the injection site. A second fusion inhibitor, 
sifuviritide, has been developed and is currently in Phase II clinical trials. It 
mimics the gp41 CHR more closely than T20 resulting in a higher affinity for the 
NHR peptide of gp41. It has improved potency (20-fold higher) and half-life in 
comparison to T20 and a different mechanism of action means cross resistance 
between the two fusion inhibitors does not appear to occur (He et al., 2008).   
Co-receptor antagonists have been developed, particularly to CCR5 as this is 
the co-receptor regularly involved in early infection. Maraviroc is the only FDA 
approved CCR5 receptor inhibitor (in 2007), and the only FDA approved drug 
that functions by targeting a host protein (CCR5) and not the virus (Latinovic et 
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al., 2009). Co-receptor antagonists are allosteric inhibitors of CCR5, binding 
hydrophobic pockets within the transmembrane helices of CCR5. This causes a 
conformational change in the second extracellular loop of CCR5 which the V3 
stem loop of gp120 HIV-1 cannot recognise (Dragic et al., 2000). In the clinical 
setting it has limited use as it only works against R5 viruses, not X4 or dual-
tropic, so each patient must be tested to ensure they are only infected with R5 
virus before maraviroc can be introduced to their treatment regimen. A second 
CCR5 co-receptor antagonist, vicriviroc, has been developed however its 
development was abandoned in Phase III clinical trials.   
1.3.2 Reverse transcriptase inhibitors 
1.3.2.1 Nucleoside/Nucleotide reverse transcriptase inhibitors (NRTIs) 
Nucleoside/nucleotide RT Inhibitors (NRTIs) were the first class of drug to be 
approved by the FDA, with Zidovudine (AZT) receiving approval in 1986.  NRTIs 
are alternative substrate inhibitors of RT that compete with the host dNTPs for 
incorporation into cDNA.  NRTIs lack the 3’ OH group on the ribose ring, 
preventing phosphodiester bond formation to the next nucleotide. This leads to 
a block in DNA elongation and results in chain termination (as reviewed by 
Tsibris and Hirsch, 2010).  A total of eight NRTIs have now been approved by 
the FDA for treatment of HIV: zidovudine (AZT/ZDV), didanosine (ddI, second to 
be approved), zalcitabine (ddC, now discontinued), stavudine (d4T), lamivudine 
(3TC, approved for both HIV-1 and Hepatitis B treatment), abacavir (ABC), 
emtricitabine (FTC, approved for HIV and in trials for Hepatitis B treatment) and 
tenofovir (TDF) (as reviewed by Arts and Hazuda, 2012).  Each of these 
competes with one of the nucleotides for incorporation into the elongating DNA 
strand.  Figure 1.11 demonstrates the structural similarity of the NRTI AZT and 
the thymidine nucleotide.   
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Figure 1.11. The structure of RT inhibitors; NRTIs. The structure of the NRTI 
Zidovudine (AZT) (a) and dNPT deoxy-thymidine (b) are shown, demonstrating 
the structural similarity of the NRTI to the dNTPs they competitively inhibit.  
Figure adapted from Arts and Hazuda, 2012.  
 
 
Zidovudine (drug)     Deoxy-Thymidine (nucleotide) 
a b 
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Nucleoside RTIs are administered in pro-drug form and require phosphorylation 
by intracellular kinases within the body before they function and can be 
incorporated into the elongating DNA strand.  Conversely, nucleotide RTIs do 
not require phosphorylation before they become biologically active (as reviewed 
by Cihlar and Ray, 2010).  NRTIs form the backbone of most HAART regimens, 
partly because the long half-life of the metabolised form enables once daily 
dosing.  In addition, clinical trials are ongoing to test the effectiveness of TDF 
based microbicide gels in the prevention of HIV infection.  The CAPRISA 004 
trial reported up to 54% reduction in the rate of new infections in individuals with 
good adherence, and the VOICE MTN 003 and MDP 302 trials with the same 
gel and different dosing are ongoing (Abdool et al., 2010).  NRTIs given orally 
as part of HAART have side effects that are caused by the inhibition of cellular 
DNA polymerase activity, including mitochondrial DNA polymerase which is 
particularly susceptible. 
1.3.2.2 Non-nucleoside reverse transcriptase inhibitors   
Non-nucleoside RT Inhibitors (NNRTIs) are allosteric, non-competitive inhibitors 
of RT.  NNRTIs bind to a hydrophobic pocket approximately 10Å from the active 
site of RT, inducing a conformational change that reduces the rate of nucleotide 
incorporation into DNA (Bacheler et al., 2001; Kohlstaedt et al., 1992).  The 
affinity of RT to the dNTPs is not affected by the binding of NNRTIs.  NNRTIs 
differ from NRTIs in that they do not require intracellular processing for drug 
activity.   
The first NNRTI, nevirapine (NVP), received FDA approval in 1996 followed by 
delavirdine (DLV) in 1997 and efavirenz (EFV) in 1998.  NVP and EFV are 
regularly used as the third agent in HAART regimens, with EFV the most 
frequently used NNRTI in the developed world.  However, the low genetic 
barrier to resistance means there is a requirement for two fully-active additional 
non-NNRTIs (as reviewed by Arts and Hazuda, 2012).  In addition NVP has 
been shown to be safe in pregnant women and superior to AZT in the 
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prevention of mother-to-child transmission as a single dose in the developing 
world, although resistance can occur in the mother (as reviewed by de Bethune, 
2010).  The fourth drug in the class, and the first of the second generation 
drugs, etravirine (ETV) was the first NNRTI shown to be efficacious in patients 
harbouring resistance to other first generation NNRTIs in the DUET trials 
(Katlama et al., 2010a).  Rilpivirine (RPV) was approved in 2011 for use in 
treatment-naive patients, following evidence of efficacy and safety from the 
ECHO and THRIVE trials.  ETV and RPV have molecular flexibility which 
enables binding to RT containing certain resistance mutations (as reviewed by 
Jayaweera and Dilanchian, 2012). 
1.3.3 Integrase inhibitors 
IN inhibitors are the most recent class of antiretroviral drugs to be developed 
that target viral enzymes. The first inhibitor, raltegravir (RAL), was approved by 
the FDA in 2007 and other integrase inhibitors are currently in late clinical trials 
including elvitegravir (EVG) and dolutegravir (DTG), which is approved for use 
in the US (Arts and Hazuda, 2012; Sato et al., 2006). However, studies have 
shown extensive cross-resistance between RAL and EVG (as reviewed by 
Shimura and Kodama, 2009). Second generation DTG has shown good efficacy 
in extensively PI-experienced patients including those failing on RAL regimens 
in the VIKING trial (as reviewed by Katlama et al., 2010b).   
IN inhibitors competitively inhibit the DNA strand transfer reaction of DNA by 
binding in the IN active site (Espeseth et al., 2000). This DNA strand transfer 
stage is targeted as IN inhibitors only bind to the complex formed between viral 
DNA and the integrase enzyme. Binding of two metal ion co-factors in the 
integrase active site is required for enzyme function in vitro. Hence, IN inhibitors 
are designed with two functional components – a metal binding core which 
enables the sequestering of magnesium ions from the active site and a 
hydrophobic group which interacts with both the viral DNA and the IN enzyme 
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(Grobler et al., 2002). Structural methods have shown that integase is a 
tetramer and that the binding of IN inhibitors displaces the reactive viral DNA 
from the active site, preventing integration (Hare et al., 2010).  
1.3.4 Protease inhibitors 
Protease inhibitors (PIs) are a potent class of inhibitors which are also used 
against other viruses including Hepatitis C.  Nine PIs in total have received FDA 
approval, of which 6 are currently in regular clinical use, as detailed in Table 
1.1.   
Table 1.1. Protease inhibitors approved for clinical use. 
Protease Inhibitor Abbreviation 
(fos) Amprenavir APV 
Atazanavir ATV 
Darunavir DRV 
Indinavir IDV 
Lopinavir LPV 
Nelfinavir NFV 
Ritonavir RTV 
Saquinavir SQV 
Tipranavir TPV 
 
PIs are competitive inhibitors of the protease enzyme, which enter and block the 
active site of protease, preventing cleavage of the natural substrates the Gag 
and Gag-Pol polyproteins (Wensing et al., 2010).  Without this cleavage step, 
immature virions are still produced but maturation does not occur, so the virions 
remain immature and thus un-infectious.  A recent study identified that using a 
PI as the third drug in HAART led to significantly fewer patients experiencing 
virological failure than HAART using NNRTI as the third agent (Gupta et al., 
2008).   
  
62 
 
 
PIs were rationally designed using the known crystal structure of HIV protease 
resulting in competitive peptidomimetic inhibitors which mimic Gag, the 
protease natural substrate.  All PIs, except Tipranavir (TPV), contain a 
hydroxyethylene core which cannot be cleaved by the viral protease, as shown 
in figure 1.12 (Craig et al., 1991; Kempf et al., 1995).  In its place, TPV contains 
a dihydropyrone ring as a central scaffold (Turner et al., 1998).  Saquinavir 
(SQV) was the first PI to receive FDA approval in 1995.  When used as 
monotherapy it proved relatively unsuccessful with 50% of patients harbouring 
viruses with reduced susceptibility after one year, but it was efficacious when 
used as part of combination therapy once bioavailability issues had been 
addressed (Jacobsen et al., 1996; Schapiro et al., 1996).  The next two PIs 
were approved in 1996 – ritonavir (RTV) and indinavir (IDV).  RTV was shown 
to be efficacious, but poorly tolerated with side effects including severe 
gastrointestinal symptoms and as such it is no longer used as a protease 
inhibitor on its own (Notermans et al., 1998).  IDV, as with SQV, proved to have 
limited efficacy when given as monotherapy but was efficacious when given as 
part of triple therapy (Gulick et al., 1997; Stein et al., 1996).  Nelfinavir (NFV) 
was FDA approved in 1997 and showed good efficacy as part of triple therapy 
in clinical trials (Saag et al., 2001).   
Although SQV, RTV, IDV and NFV proved efficacious, poor bioavailability and 
short half-lives meant frequent dosing was required.   ‘Boosting’ of PIs by 
administering with low doses of RTV was introduced to increase the therapeutic 
levels without having to increase the dose – the second generation of PI 
therapy (van Heeswijk et al., 2001).   RTV is an inhibitor of CYP3A4 – part of 
the cytochrome p450 pathway which degrades PIs in the liver.  Boosting with 
ritonavir reduces the rate that the body metabolises PIs thereby raising the 
therapeutic levels without having to increase the dose and toxicity (as reviewed 
by Wensing et al., 2010).   Boosting strategies cannot be used with IDV, as it 
increases nephrotoxicity, or NFV, as it did not increase its bioavailability (Boyd 
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et al., 2005).  As a result, the use of IDV and NFV is now limited, with NFV 
being used only during pregnancy as it has been shown to be relatively safe.  
Amprenavir (APV) received FDA approval in 1999, but suboptimal 
concentrations in the blood lead to weak activity and frequent development of 
resistance (Sadler et al., 2001).  Introduction of a pro-drug fosamprenavir and 
RTV boosting have resulted in increased efficacy when given as part of a 
HAART regimen (Rodriguez-French et al., 2004).  PIs lopinavir (LPV), 
atazanavir (ATV), TPV and darunavir (DRV) were FDA approved in 2000, 2003, 
2005 and 2006, respectively (Arts and Hazuda, 2012).  All are co-administered 
with RTV and are available in formulations that can be taken once daily, 
reducing pill burden for patients and hence increasing drug adherence.  LPV is 
available co-formulated with RTV (LPV/r) and marketed under the trade name 
Kaletra.  LPV was shown to be efficacious with 75% of patients achieving viral 
suppression after 48 weeks on LPV based HAART (Walmsley et al., 2002).  
LPV/r was the first PI shown to be efficacious in treatment-naïve patients, thus 
demonstrating efficacy of PIs as first line therapy in HAART (Riddler et al., 
2008).  Both LPV and ATV have been shown to be efficacious in PI-
experienced individuals, with viral suppression achieved in 50% of individuals in 
the CASTLE study (Molina et al., 2008).  TPV was approved for use in patients 
with resistance to multiple PIs (Hicks et al., 2006).  Although shown to be 
superior in salvage therapy in the RESIST trial, TPV is not widely used as it 
does not demonstrate superiority over other PIs in PI-naïve patients and has 
significant side effects.  The most recently developed PI, DRV, was specifically 
designed to inhibit viruses that are resistant to other PIs for use in treatment 
experienced individuals.  The POWER studies demonstrated superiority of DRV 
in comparison to other PIs in treatment-experienced patients (Katlama et al., 
2007).  In addition, the ARTEMIS trial showed the superiority of DRV in 
comparison to LPV as part of a HAART regimen in treatment-naïve patients 
(Mills et al., 2009). 
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1.12. The structures of protease inhibitors (PIs).  The chemical structures of 
all FDA approved PIs are shown. (a) PIs with a hydroxyethylene core and with 
(b) a dihydropyrone ring are shown. The scaffolds are highlighted with a dashed 
box. Figure taken from Wensing at al. 2010 
Saquinavir 
Ritonavir 
Indinavir 
Nelfinavir 
Amprenavir 
Lopinavir 
Atazanavir 
Darunavir 
Tipranavir 
a 
b 
  
65 
 
 
1.3.5 Maturation inhibitors 
Maturation inhibitors are the only class of drug, along with entry inhibitors, that 
do not target a viral enzyme, but instead they target the maturation of new 
virions during or after budding from the cell (as reviewed by Arts and Hazuda, 
2012; as reviewed by Tilton and Doms, 2010).  There are only two drugs in this 
class that has been evaluated in clinical trials.  Bevirimat inhibits the late step of 
Gag processing, preventing the conversion of CA-SP1 to mature CA protein by 
protease cleavage (Ghosn et al., 2011).  It has been demonstrated that this 
block in processing occurs because bevirimat stabilises the immature Gag 
lattice, thus preventing the subsequent maturation steps (Keller et al., 2011).  
This results in the production of immature and aberrant virions.   
The development of bevirimat is currently on hold because of its performance in 
trials to date.  A significant number of patients do not respond, which is thought 
to be caused by polymorphisms in SP1 residues 6 to 8, which have been found 
to prevent its function (Wainberg and Albert, 2010).  It has been shown that the 
sequence of the SP1 can be used to predict the function of bevirimat in vivo 
(Heider et al., 2010).  The development of a second maturation inhibitor, 
vivecon MP-9055, has also been discontinued after it reached phase II clinical 
trials.   
1.4 Resistance to antiretroviral therapy 
Even when HAART is given, HIV-1 is still able to develop resistance.  A recent 
study estimated that after 10 years of HAART treatment, 9.2% of patients will 
have developed resistance to all three classes of drug included in the treatment 
regimen, and that the risk of death within 5 years of the development of 
extensive triple-class resistance is 10% (Phillips et al., 2007).  As well as the 
risk to the individual patient, drug resistant viruses can be transmitted and can 
persist in the absence of the selective pressure of drugs complicating the 
treatment of patients with newly acquired drug resistant infections in the future 
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(Brenner et al., 2002; Pao et al., 2004).  Of particular concern are viruses that 
develop resistance to multiple drug classes or cross-resistance to multiple drugs 
within one class (Condra et al., 1995).  As a result, it is recommended that all 
newly diagnosed individuals in the UK are subjected to resistance testing before 
starting therapy.  Several factors enable the development of resistance to ART 
including the nature of RT (its high error rate and low RNA affinity, as discussed 
in 1.2.3.2), the high level of replication and sub-optimal drug levels in patients, 
caused by non-compliance or by sub-optimal treatment regimens.  
1.4.1 Resistance to entry inhibitors 
Resistance to fusion inhibitor, T20, is conferred via mutations at the T20 binding 
site within gp41 including G36D, I37T, V38A/M, N42T/D and N43K (Wei et al., 
2002).  These mutations reduce the affinity of T20 to gp41, however they also 
confer reduced fitness as a result of decreased fusion efficiency.  
Compensatory mutations in the CHR domain of gp41occur that can restore the 
viral fusion kinetics and thus viral fitness (Ray et al., 2009).   
The mechanisms of resistance to the CCR5 co-receptor antagonist maraviroc 
are not yet fully understood.  Lack of response can be conferred by a switch in 
viral tropism to the use of the CXCR4 co-receptor.  This has been observed in 
patients, although some studies indicate that this mechanism of resistance only 
occurs in patients with pre-existing CXCR4 tropic viruses (Westby et al., 2006).  
Secondly, the virus can evolve to use the maraviroc bound CCR5 receptor for 
cellular entry, noncompetitive resistance, which has been observed in patients 
failing therapy in the absence of a switch in co-receptor usage (Westby et al., 
2007).  Resistance has been shown to map to multiple regions of the gp120 and 
gp41 proteins (Westby et al., 2007).  There are two additional theoretical 
mechanisms of resistance although their role in vivo is not yet known: an 
increase in affinity of the virus for the CCR5 receptor and an increase in 
efficiency of the viral entry process (as reviewed by Arts and Hazuda, 2012).   
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1.4.2 Resistance to reverse transcriptase inhibitors 
Resistance to NRTIs is conferred by two main mechanisms: first, ATP 
dependent pyrophosphorolysis resulting in the removal of the 3’ end of the 
elongating DNA chain and reversal of chain termination and second, increased 
discrimination between native dNTPs and the NRTI by RT.  Resistance via ATP 
dependent pyrophosphorolysis is conferred by the development of thymidine 
analogue mutations (TAMs) in RT in response to AZT and d4T exposure.  
There are two distinct TAM mutation pathways that confer resistance: TAM1 
(M41L, L210W, T215Y and occasionally D67N) and TAM2 (D67N, K70R, 
T215F and 219E/Q).  The second mechanism of resistance, the prevention of 
incorporation of NRTIs into the elongating DNA chain, is conferred by mutations 
at two amino acid positions M184V/I and K65R (as reviewed by Arts and 
Hazuda, 2012).  K65R develops on exposure to TDF, ddC, ddI, d4T and ABC 
(Wainberg et al., 1999).  Conversely, M184V/I emerges following 3TC or FTC 
therapy (Schinazi et al., 1993).  Each of these resistance mutations confer a 
reduction in viral fitness, and secondary mutations accumulate in RT that 
partially compensate for this reduced fitness. 
Resistance to NNRTIs is conferred by mutations in the NNRTI binding pocket of 
RT including those at amino acid positions L100, K101, K103, E138, V179, 
Y181, Y188 and G190A (Tantillo et al., 1994).  Resistance mutations K103N 
and Y181C are most common, and notably single NNRTI resistance mutations 
do not convey significant reductions in fitness, as observed for NRTI resistance 
mutations (Dykes et al., 2001).  However, ETV is active against HIV viruses 
harbouring the K103N mutation and the DUET trials identified amino acid 
substitutions Y181I/V as conveying the highest levels of resistance to ETV.  
Following RPV exposure the E138K mutation is most frequently observed and it 
often appears alongside M184I (as reviewed by Jayaweera and Dilanchian, 
2012).        
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1.4.3 Resistance to integrase inhibitors 
Resistance to the IN inhibitor RAL is conferred by one of three independent 
pathways of mutations at positions Y143, N155 and Q148 (Fransen et al., 
2009).  These mutations are thought to be mutually exclusive in that they don’t 
occur on the same viral genome, although viruses with resistance via different 
pathways can be harboured within the quasispecies of a single patient.  These 
mutations are located in the catalytic core domain of IN which is located near 
the IN inhibitor binding site.  The N155H pathway is associated with secondary 
resistance mutations V151I, T97A, G163R and L74M.  Primary resistance 
mutations Q148 K/R/H are associated with secondary mutations G140S/A and 
E138K (as reviewed by Arts and Hazuda, 2012).  The mechanisms of 
resistance to DTG are yet to be fully elucidated.  However, studies suggest that 
mutations at position Q148 confer resistance to DTG, but changes at positions 
Y143 and N155 do not (as reviewed by Katlama et al., 2010b). 
1.4.4 Resistance to protease inhibitors 
Resistance to PIs develops via the accumulation of resistance mutations in 
protease and Gag which fall into two categories: major and minor resistance 
mutations (Molla et al., 1996).  Major mutations confer resistance to PIs by 
reducing the affinity of the protease to the PI, preventing the PI from blocking 
the protease active site and leading to protease activity in the presence of PI 
(Condra et al., 1995).  Major mutations also reduce the affinity of the protease 
to the natural substrate, Gag, thus reducing the fitness of the resistant virus 
(Zennou et al., 1998).  Minor mutations may partially compensate for the 
reduced fitness of major mutations in resistant protease (Croteau et al., 1997).  
These are found in protease and within Gag, both at cleavage sites and other 
distant sites, as discussed in 1.4.4.4 (Clavel and Mammano, 2010; Gatanaga et 
al., 2002). 
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1.4.4.1 Resistance mutations in protease 
To date, the Stanford Resistance Database describes PI resistance mutations 
at 33 of the 99 amino acids positions in protease (Liu and Shafer, 2006).  These 
are collated every year by the International Aids Society, as shown in figure 
1.13.  Mutations at twelve of these positions are described as major mutations, 
conferring high levels of phenotypic resistance or evidence of a reduced 
response to treatment in vivo for at least one PI.  These 12 positions are: 30, 
32, 46, 47, 48, 50, 54, 76, 82, 84, 88 and 90 (Johnson et al., 2011).  Of these 
30, 32, 48, 50, 82 and 84 are located in the substrate binding cleft of protease 
and 46, 47 and 54 near the cleft (Kagan et al., 2005; Wu et al., 2003).  These 
mutations confer resistance by enlarging the binding cleft, thus reducing the 
affinity of the PI (as reviewed by Nijhuis et al., 2007a).  Mutations at positions 
76, 88 and 90 affect PI susceptibility indirectly and are not located at or near the 
substrate binding cleft (Louis et al., 2011).  The position of each of the PI 
resistance mutations within protease is shown in figure 1.14. 
In addition, there are also a number of minor mutations found in protease which 
affect PI susceptibility primarily through compensatory mechanisms which are 
further discussed in 1.4.4.4.  These cause reduced PI susceptibility when found 
in combination with other PI resistance mutations.  Non-polymorphic mutations 
are those that are not found in treatment-naïve patients and only observed as a 
result of PI exposure.  Conversely, polymorphic mutations are found in a 
significant proportion of treatment-naïve viruses, especially in non-B subtypes.  
Of interest, figure 1.13 demonstrates that the PI resistance mutations that occur 
are different for each PI, indicating different pathways to the development of 
resistance for each drug.   
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Figure 1.13. The known PI resistance mutations within protease. Diagram showing the PI resistance mutations within protease that 
have been documented to date.  The mutations for each of the nine FDA approved PIs are shown, with major mutations shown in bold.  
Figure produced by the International AIDS Society (IAS), taken from Johnson et al., 2013.
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Figure 1.14. The position of known PI resistance mutations within the HIV 
protease protein structure. (a) The position of known major resistance mutations to 
the PI LPV are shown in blue, as defined by the IAS. (b) In addition to the position of 
major resistance mutations, the location of minor resistance mutations to the PI LPV 
are also shown, highlighted in red. Diagrams were produced using PyMol software 
from the 3ELI model of protease (RBSC PDB).
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For APV/r the following major resistance mutations have been described to 
date: V32I, M46I/L, I47V/A, I50V, I54A/T/A/L/M, L76V, V82A/T/S/F, I84V, L90M 
(Rhee et al., 2003).  In addition minor mutations L10F/I/R/V and G73S have 
been observed.  Four main pathways to resistance to APV/r were identified in 
previously PI-naïve patients, either I50V, I54L/M, I84V or V32I with I47V 
(Maguire et al., 2002).  These main pathways to resistance were also observed 
in PI-experienced patients (Ait-Khaled et al., 2003).  Conversely, the I50V 
mutation, accompanied by L10F, M46I/L or I47V, is the key resistance pathway 
observed following in vitro passage with APV/r (Partaledis et al., 1995; Tisdale 
et al., 1995).  It is thought that this difference in in vitro and in vivo observations 
occurs because I50V confers the greatest reduction in susceptibility, but it also 
has the most significant impact on viral fitness.  
To date the following major resistance mutations to ATV/r have been described:  
V32I, M46I/L, I47V, G48V/M, I50L, I54V/T/A/L/M, V82A/T/F/S, I84V, N88S and 
L90M.  In addition changes L10I/F/V/C, G16E, K20R/M/I/T/V, L24I, L33I/F/V, 
E34Q, F53L/Y, D60E, I62V, I64L/M/V, A71V/I/T/L, G73C/S/T/A, I85V and 
I93L/M have been described as minor resistance mutations (Rhee et al., 2003).  
I50L is the most commonly described major resistance mutation in vivo and is 
recognized as the signature resistance mutation to ATV (Colonno et al., 2004).  
Following in vitro passage with ATV the emergence of V32I, M46I, I50L, I84V 
and N88S was observed in resistant strains (Gong et al., 2000).  Phenotypic 
analysis of a large panel of PI-resistant patient viruses demonstrated an 
association between L10I/V/F, K20R/M/I, L24I, L33I/F/V, M46I/L, G48V, 
A71V/I/T/L, G73C/S/T/A, V82A/F/S/T, I84V and L90M with reduced 
susceptibility to ATV (Colonno et al., 2003).  
The following major resistance mutations to DRV/r have been described mainly 
identified during the POWER clinical trials: V32I, I47V/A, I50V, I54L/M, L76V, 
V82F, I84V (De et al., 2008).  In addition minor resistance mutations V11I, 
L33F, T74P and L89V have been described (Rhee et al., 2003).  Identification 
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of major mutation in previously PI-naïve patients has been difficult as many 
experiencing virological failure on DRV/r based therapy harbour no PI 
resistance mutations.  As a result, most DRV/r resistance mutations have been 
described in previously PI-experienced patients.  Attempts to create resistance 
viruses by in vitro passage with DRV have also proven to be challenging due to 
its high genetic barrier (Koh et al., 2010).   
For IDV/r the following major resistance mutations have been reported: V32I, 
M46I/L, I47V, I54A/T/A/L/M, L76V, V82A/T/S/F, I84V, N88S, L90M.  Minor 
resistance mutations L10I/R/V, K20M/R, L24I, M36I, A71V/T, G73S/A and V77I 
have also been described (Rhee et al., 2003).  Clinical trials identified that the 
M46I/L and V82A/F/T mutations account for most treatment failures with IDV, 
but that these mutations singly do not convey reduced susceptibility 
phenotypically (Condra et al., 1996).  Following therapy in vivo, changes at 
positions 46, 54, 71, 82, 89 and 90 have been observed (Zhang et al., 1997).  
Currently, the following major resistance mutations have been described for 
LPV/r: V32I, M46I/L, I47V/A, G48V/M, I50V, I54A/T/A/L/M, L76V, V82A/T/S/F, 
I84V, L90M (Rhee et al., 2003).  Mutations V32I, M46I and I47V/A have been 
observed following in vitro passage of virus with LPV, as was I50L at a lesser 
frequency (Carrillo et al., 1998).  In LPV/r treated patients M46I/L, I54V/T/A/M/S 
and V82A/F/S have been described (Maguire et al., 2002).  A recent UK study 
showed that of 291 patients failing LPV/r based therapy, PI resistance 
mutations were detected in only 11%.  The most frequent mutations were I54V, 
M46I, V82A and L76V (Barber et al., 2012).  In a French study, L10V, K20R, 
L33F, M36I, I47V, I54V, A71V and I85V were selected by LPV/r based therapy 
(Lambert-Niclot et al., 2012).    
At present the following major resistance mutations have been described for 
NFV: D30N, M46I/L, I47V, G48V/M, I54A/T/A/L/M, V82A/T/S/F, I84V, N88D/S, 
L90M (Rhee et al., 2003).  D30N has been described in patients following 
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treatment with NFV (Patrick 1998). Mutations at positions 48, 82, 84 and 90 
have been associated with reduced rates of virological response in patients 
(Walmsley et al., 2001).  In addition, the K20I mutation has been shown to 
reduced susceptibility to NFV when present in combination with other mutations 
(Perno et al., 2001).  L23I is a rare mutation positioned in the substrate binding 
cleft which has been shown to cause low-level resistance to NFV (Johnston et 
al., 2004).  The VIRAPHAR study reported the development of L10I, D30N, 
M36I, V77I, N88S/D and L90M in response to NFV/r based therapy (Pellegrin et 
al., 2002).   
The following major resistance mutations for SQV/r have been described to 
date: G48V/M, I54A/T/A/L/M, V82A/T, I84V, N88S and L90M (Rhee et al., 
2003).  Mutations G48V, V82A and L90M were observed following in vitro 
passage of virus with SQV (Jacobsen et al., 1996).  Mutations at position 73 – 
G73S/T/C/A – are important accessory mutations for SQV/r, particularly in 
combination with the L90M major resistance mutation.  L90M is the most 
commonly occurring major resistance mutation on failure with SQV and has 
been reported to occur with I84V, conferring a significant reduction in 
susceptibility (Rhee et al., 2006) 
For TPV/R, the following major resistance mutations have been described: 
V32I, M46I/L, I47V/A, I54V/A/M, V82T/L, I84V.  The major mutations V32I, 
V82A and I84V were most commonly observed following in vitro passage of 
virus with TPV/r (Doyon et al., 2005).  As TPV/r is approved for use in 
previously PI-exposed patients, V82T develops only in the presence of the 
major mutation V82A at baseline.  In patients who had wild-type virus at 
baseline, V82L was observed (Baxter et al., 2006).  The RESIST trial 
demonstrated mutations T74P, I47V, V82L/T, Q58E and N83D were the best 
predictors of viral failure to TPV/r.  The most commonly observed minor 
mutation is L33F, shown to be associated with reduced virological response in 
combination with other mutations (Vermeiren et al., 2007).      
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1.4.4.2 Mutations at Gag cleavage sites 
It is now well established that Gag cleavage site mutations contribute to PI 
resistance by partially compensating for the reduction in replicative capacity 
(RC) caused by major mutations in protease (Mammano et al., 1998).  
However, several recent studies have shown that Gag mutations can directly 
influence PI resistance, independent of compensating for reduced single-round 
infectivity and in the absence of mutations in protease (Dam et al., 2009; 
Jinnopat et al., 2009; Nijhuis et al., 2007b; Parry et al., 2009).  Mutations in Gag 
have mainly been reported to occur at the protease cleavage sites (cleavage 
site mutations, CSMs) and at sites distant from cleavage sites, which will be 
discussed later (Clavel and Mammano, 2010; Gatanaga et al., 2002).  All 
mutations in Gag reported to be associated with PI exposure or resistance to 
date are displayed in table 1.2.   
  
76 
 
 
Table 1.2.  Mutations in Gag previously associated with PI resistance or 
exposure   
Gag Mutations 
associated 
with PI 
exposure or 
resistance 
Position 
within 
Gag 
References 
E12K MA Gatanaga et al. 2002, Aoki et al. 2009 
G62R MA Koh et al. 2009 
L75R MA Gatanaga et al. 2002, Aoki et al. 2009 
R76K MA Parry et al. 2011 
Y79F MA Parry et al. 2011 
T81A MA Parry et al. 2011 
K112E MA Callebaut et al. 2007 
V128A/I/T/del 
 Callebaut et al. 2007, Dierynck et al. 2007, 
Larrouy et al. 2010, Knops et al. 2010 
165 CA Kameoka et al. , Jinnopat et al.  
M200I CA Callebaut et al. 2007 
H219Q CA Gatanaga et al. 2002, Aoki et al. 2009 
A360V CA Mammano 1998 
V362I CA Doyon et al. 2005, Margot et al. 2010 
L363M/F/C/N/Y p2 Koh et al. 2009 
S368C/N p2 Cote et al. 2001, Verheyen et al. 2010 
Q369H p2 Verheyen et al. 2010 
T371del p2 Verheyen et al. 2010 
S373P 
p2 Cote et al. 2001, Malet et al. 2007, Verheyen et 
al. 2010  
A374P/S p2 Malet et al. 2007 
T375N/S p2 Mammano et al. 1998, Malet et al. 2007 
I376V p2 Cote et al. 2001, Mammano et al. 1998 
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R380K NC Myint et al. 2004 
G381S NC Mammano et al. 1998 
I389T NC Myint et al. 2004 
V390D/A NC Gatanaga et al. 2002, Aoki et al. 2009 
I401T/V NC Myint et al. 2004, Callebaut et al. 2007 
R409K 
NC Gatanaga et al. 2002, Aoki et al. 2009, 
Callebaut et al. 2007,  
Koh et al. 2009 
E428G NC Dierynck et al. 2007 
Q430R NC Doyon et al 1996 
A431V 
NC Zhang et al. 1997, Mammano et al 1998, Kolli et 
al. 2009 and others as reviewed in Fun et al. 
2012 
K436E/R 
p1 Verheyen et al. 2006, Nijhuis et al. 2007, Kolli et 
al. 2009, van Maarseveen et al. 2012 
I437V/T 
p1 Zhang et al. 1997, Mammano et al 1998, Nijhuis 
et al. 2007, Dam et al 2009 and others as 
reviewed in Fun et al. 2012  
L449F/P 
p6 Doyon et al. 1996, Zhang et al. 1997, Maguire 
et al. 2002, Myint et al. 2004, Kolli et al. 2009 
and others as reviewed in Fun et al. 2012 
S451N/T/G/R p6 Dierynck et al. 2007, Kolli et al. 2009 
P452S/K 
p6 Yates et al. 2006, Verheyen et al. 2006, 
Dierynck et al. 2007,  
Mo et al. 2007, Kolli et al. 2009 
T456S p6 Breuer et al. 2011 
E468K p6 Gatanaga et al. 2002 
Q474L p6 Myint et al. 2007 
R479 p6 McKinnon et al. 2010 
A487S p6 Myint et al. 2007 
P497L p6 Myint et al. 2007 
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Most CSMs are found in the C terminus of Gag - the NC/p1/p6 region – and 
have been identified in vitro, following passage of virus with PIs (Carrillo et al., 
1998; Doyon et al., 1996) and in vivo in patients undergoing PI treatment, some 
of whom were failing therapy (Cote et al., 2001; Zhang et al., 1997).  The 
A431V mutation in the NC/p1 CS is the most frequently observed CSM 
following exposure to PIs and has been observed both in vitro, following 
passage with PIs, (Carrillo et al., 1998; Doyon et al., 1996) and in vivo in 
patients undergoing therapy with RTV, IDV, NFV and SQV (Cote et al., 2001; 
Nijhuis et al., 2007b).  A431V has been shown to convey reduced susceptibility 
to all PIs except DRV in phenotypic drug susceptibility assays (Dam et al., 
2009; Nijhuis et al., 2007b).   
Changes at positions 436 and 437 in the NC/p1 cleavage site have also been 
observed following exposure to PIs both in vitro and in vivo (Mammano et al., 
1998; Zhang et al., 1997; Cote et al., 2001).  A recent study demonstrated that 
these two mutations can directly affect susceptibility in the absence of mutations 
in protease (Nijhuis et al., 2007b).   In vitro passage with a PI produced a 
number of mutants exhibiting substitutions in the Gag p2 spacer peptide – 
K436E and I437T/V – and none in protease.  Synthesis of recombinant virus 
with wild-type protease showed that the presence of the mutant Gag alone 
significantly increased the EC50 of the recombinant virus to various PIs.  A 
second study examining A431V and I437V, showed that the reversion of the 
Gag CSM to wild type had a significant effect on PI resistance, but a far more 
modest effect on RC, indicating a direct effect on resistance of these mutations 
independent of replication capacity (RC) compensation (Dam et al., 2009; van 
Maarseveen et al., 2012).   
Mutations at the p1/p6 CS, in particular at positions 449, 452 and 453 have 
been observed following exposure to PIs both in vitro and in vivo.  In particular 
L449F/V/P is commonly associated with therapy and observed following 
exposure in vivo to a number of PIs: APV, ATV, IDV, NFV, RTV and SQV (Fun 
  
79 
 
 
et al., 2012; Larrouy et al., 2010; Maguire et al., 2002; Mammano et al., 1998; 
Zhang et al., 1997).  L449F has been selected following in vitro passage with 
both APV and LPV, as well as a number of experimental PIs (Carrillo et al., 
1998; Doyon et al., 1996).  Mutations at positions 452 and 453 of Gag have 
been observed in vivo following exposure to a number of PIs (Bally et al., 2000; 
Maguire et al., 2002).  In addition changes at these positions have also been 
observed in vitro following PI exposure, P452K, P453L and P453T, although 
these have been shown to only convey resistance when found with resistance 
mutations in protease (Yates et al., 2006).  
The only CSM in the N terminus of Gag reported to affect susceptibility is near 
the MA/CA CS at position 128.  It has been associated with PI exposure in vivo 
and in vitro, and associated with an increased risk of virological failure following 
administration of DRV-containing regimens (Callebaut et al., 2007; Larrouy et 
al., 2010).   
There is evidence regarding the effect of Gag CSMs present at baseline on the 
outcome of subsequent PI-based therapy.  Mutations at position 128 near the 
MA/CA CS have been negatively associated with viral response in the ANRS 
127 trial and V128I was observed in >10% patients experiencing virological 
rebound in the POWER 1, 2 and 3 clinical trials (Dierynck et al., 2007; Larrouy 
et al., 2010).  The ANRS 127 trial also showed that the presence of L449P was 
negatively associated with virological response (Larrouy et al., 2010).  Analyses 
of data from the POWER trials showed a number of other mutations were also 
associated with reduced response to DRV-based regimens: E428G, S451T and 
R452S (Dierynck et al., 2007).  Surprisingly, given its frequency and proven role 
in PI resistance in vitro, A431V was not associated with poor outcomes in 
several clinical trials and was actually associated with positive outcomes with 
DRV-based treatments (Larrouy et al., 2011; Malet et al., 2007).  I437V was 
associated with reduced virological responses to a number of PIs in the 
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NARVAL trial and with virological failure in DRV-based regimens (Meynard et 
al., 2002).  
Mutations in Gag cleavage sites are thought to affect PI resistance by 
enhancing the efficiency of Gag cleavage, as discussed in 1.4.4.4 (Nijhuis et al., 
2007b).  Several mechanisms by which Gag cleavage site mutations may cause 
resistance independent of compensating for reduced fitness have been 
suggested.  Gag mutations may improve the kinetics of cleavage, beyond the 
level of compensating for fitness, and even in the absence of PIs.  Alternatively, 
Gag CSMs may result in a substrate that competes more effectively with PIs for 
the protease active site (as reviewed by Clavel and Mammano, 2010).   
1.4.4.3 Non-Cleavage site mutations in Gag 
A number of mutations occurring at sites distant from the cleavage sites have 
been shown to be involved in protease inhibitor resistance, as shown in table 
1.2.  Since these are found in different regions of Gag, it is thought that the 
mechanisms by which they convey resistance are distinct.  Previous work in our 
lab has identified changes within MA which directly affect PI susceptibility.  In a 
single cycle in vitro assay, the N terminal portion of Gag from a treatment-
experienced patient exhibiting high-level resistance was shown to convey 
resistance when separated from its cognate protease (Parry et al., 2009).  
Specifically, three amino acids in MA were shown to be responsible for 
decreased susceptibility these being: R76K, Y79F and T81A (Parry et al., 
2011).  These mutations are found in a predicted alpha helix region of MA, and 
it is thought that the changes may cause the loss of a hydrogen bond resulting 
in increased flexibility of the region.  It has been suggested that this alteration in 
the conformation of the Gag protein may enhance the efficiency of cleavage 
(Parry et al., 2011).  Other changes in MA have been identified following in vitro 
exposure to APV, E12K and L75R, and an experimental PI, G62R and K112E 
(Aoki et al., 2009; Callebaut et al., 2007; Gatanaga et al., 2002).  It is possible 
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that these mutations affect Gag multimerisation during virion assembly, 
explaining their involvement in PI resistance.  
Several mutations in CA have been observed following exposure to PIs in vitro, 
at positions M200I and H219Q (Aoki et al., 2009; Callebaut et al., 2007; 
Gatanaga et al., 2002; Gatanaga et al., 2002; Callebaut et al., 2007; Aoki et al., 
2009), although mutations in CA have not been reported to be associated with 
therapy failure in vivo (Fun et al., 2012).  The H219Q/R mutation affects the 
binding of CypA to Gag, and it is thought that this mutation may reduce the 
requirement of CypA for replication thus increasing replication efficiency.  
Another study has shown that the presence of a lysine residue at position 165 
of Gag in subtype CRF01_AE viruses can directly reduce PI susceptibility 
(Kameoka et al., 2010).    
To date, the role of changes in other regions of Gag in PI resistance remains 
unclear.  Whilst mutations at positions 369-371 within the p2 spacer peptide 
accumulate during PI therapy in vivo, they are not associated with treatment 
failure nor observed following in vitro PI exposure (Myint et al., 2004).  In 
addition, mutations at these positions have not been shown to convey changes 
in susceptibility in vitro.  Similarly, the role of changes within NC remains 
unknown.  Several mutations have been associated with treatment failure, 
I389T and I401V, however the mechanism by which they affect treatment 
outcome is unknown (Myint et al., 2004).  A number of mutations have been 
observed following PI exposure in vitro, V390A/D, I401T and R409K; however 
they have not been shown to confer changes in susceptibility in vitro (Aoki et al., 
2009; Callebaut et al., 2007; Gatanaga et al., 2002). 
1.4.4.4 Effect of PI resistance mutations on viral fitness  
PIs were designed to have the maximum affinity for the protease active site, 
and as a result PIs occupy more space within the active site than the natural 
substrates (Prabu-Jeyabalan et al., 2003).  Most major PI resistance mutations 
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confer resistance to PIs by enlarging the protease active site, thus reducing the 
affinity of the PI to the protease enzyme.  It has been suggested that the 
enlarging of the active site will have more of an effect on the binding of PIs than 
the substrate to protease (Nijhuis et al., 2007a).  Despite this, major PI 
resistance mutations reduce the rate of Gag and Gag-Pol processing, resulting 
in a reduction of viral fitness (Zennou et al., 1998).  Major resistance mutations 
are usually observed first and the accumulation of secondary mutations follows 
with continuing PI-exposure.   
Different PI resistance mutations affect viral fitness to different extents and it 
can be difficult to measure the effect of single mutations on fitness as resistance 
mutations are often found in combination (methods used to measure fitness are 
described in 1.5.3).  When present in clinical isolates or molecular clones, the 
following major PI resistance mutations have been associated with a significant 
reduction in viral fitness: D30N, M46I/L, G48V, I50L, I54V, V82A/T, I84V, 
N88D/S and L90M (Luca, 2006).  A number of studies have examined the exact 
role of resistance mutations on viral fitness in vitro, both independently and 
when present in combination.  For example, major mutations V82T, I84V, M36I 
and I54V were observed following in vitro passage of virus with RTV and a 
significant reduction in fitness was observed.  However, continued passage led 
to the appearance of A71V and K20R, which increased the fitness of the virus 
towards that of wild-type (Nijhuis et al., 1999).  Mutations I84V and V82A 
independently confer a reduction in fitness to around 80-90% that of wild-type, 
but the mutation L10I has been shown to compensate for this reduction in 
fitness when present with either change (Devereux et al., 2001; Menzo et al., 
2003).  L10I, alongside L63P, has also been shown to compensate for the 
reduced fitness conferred by the major mutation L90M (Martinez-Picado et al., 
1999).   
A second mechanism of compensation for reduced fitness is via mutations in 
Gag; both at the cleavage sites and at other sites distant from the cleavage 
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sites.  Cleavage site mutations found in concert with protease mutations are 
thought to alter the tertiary structure of the Gag to make it fit more tightly within 
the active site of mutant protease, thus compensating for the reduced RC 
caused by mutant protease.  The protease resistance mutation V82A creates a 
gap between the protease active site and the PI, simultaneously reducing the 
affinity of Gag to protease and to the PI.  A413V in Gag has been shown to 
create a protrusion into the substrate binding pocket, compensating at least 
partially for the reduction in affinity to protease (Prabu-Jeyabalan et al., 2004).  
In addition, L449F is associated with increased fitness when present with major 
PI resistance mutations (Maguire et al., 2002). 
1.4.4.5 Association between mutations in protease and Gag 
The emergence of mutations in Gag in response to PI-exposure provides 
compelling evidence as to the co-evolution of Gag-protease in response to 
selective pressure.  As mentioned above, mutations in Gag can develop to 
compensate for reduced fitness conferred by mutations in protease.  In addition, 
a number of studies have reported strong associations between specific 
mutations in Gag and protease that develop together following therapy (as 
reviewed by Clavel and Mammano, 2010).  The exact mechanisms and fitness 
advantages conferred by this co-evolution are yet to be fully elucidated.  
Gag mutations A431V and I437V are associated with V82A in protease, 
although A431V is also associated with M46I and changes at position 54 of 
protease (Bally et al., 2000; Verheyen et al., 2006).  Mutations at Gag positions 
L449 and P453 have been linked to the I50V resistance mutation in protease, 
and shown to confer reduced susceptibility to APV and improve viral fitness in 
vitro (Maguire et al., 2002).  The Gag mutation L449F is associated with D30N 
and I84V, it has even been suggested that the emergence of I84V is protease in 
favoured by the pre-existence of L449F.   P453L has also been demonstrated to 
emerge with protease mutation I84V (Bally et al., 2000).  In addition P453L has 
been associated with D30N and N88D in protease and it has been 
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hypothesised that the presence of P453L restores the hydrogen bond that 
occurs between D30 of protease and position 452 of Gag that is disrupted by 
the D30N mutation (Shibata et al., 2011).    
1.4.4.6 Transmission and persistence of PI resistance 
After the development of resistance whilst a patient is on therapy, it is possible 
that these resistant viruses could be transmitted to other individuals.  Studies 
have shown that patients infected with drug resistant viruses still engage in 
high-risk sexual behavior, with up to 27% reporting engaging in unprotected 
sexual intercourse with a partner of either negative or unknown HIV status 
(Chin-Hong et al., 2005).  The acquisition of resistant viruses at new diagnoses 
is an important consideration in countries where ART is widely used.  Infection 
with a resistant virus can limit treatment options and it has been shown to 
negatively impact treatment response and decrease time to first virological 
failure (Little et al., 2002).  Transmission of resistant viruses has been well 
documented throughout geographical areas where ART is in use.  Rates of 
transmitted drug resistance (TDR) are normally monitored by looking at the 
prevalence of drug resistance in treatment-naïve, recently infected individuals.  
Reported rates of TDR vary depending on location, time and the methods of the 
individual study, but have been reported to be more than 10% in every continent 
by at least one study (http://hivdb.stanford.edu/surveillance/map/).  Rates of up 
to 24.9% have been reported in the USA (Smith et al., 2009), although other 
reports have found rates of 12.6% and 8.3% (Rhee 2012, CROI poster).  Within 
Europe, the SPREAD study reported TDR rates of 8.4% (Vercauteren et al., 
2009). 
Since resistant viruses have lower replicative capacities, it has previously been 
assumed that transmitted resistant viruses would revert to wild-type in the 
absence of the selective pressure of drug therapy in the newly infected 
individual.  The disappearance of PI DRMs over time has been demonstrated in 
several reports (Brenner et al., 2002).  Conversely, a number of studies have 
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reported the persistence of resistant viruses over time, despite the absence of 
drug pressure and the reduced replicative capacity.  A study followed 3 patients 
with PI resistance mutations which persisted throughout the observation period, 
median time of one year (Barbour et al., 2004).  For this reason, all newly 
diagnosed patients in the UK are now subjected to a genotypic resistance test 
before therapy begins.   
As well as the role for persistence of drug resistance in transmission, it is also 
an important consideration in the context of treatment interruptions.  If a patient 
develops resistance to PIs during therapy, then the persistence or reversion of 
the resistance mutations once PI treatment has been stopped has important 
implications for future treatment options.  If resistance mutations persist over 
time then PI therapy cannot be re-introduced successfully, however, if the 
mutations disappear and revert to wild-type it may be possible to use the same 
PI successfully.  A study of 25 patients observed a reduction in the number of 
drug resistance mutations in 50% of patients, over a median of 53 weeks follow 
up (Gianotti and Lazzarin, 2005).  However, in the remaining 50% no reduction 
in the number of DRMs was observed.  A second study reported that after 4 
years observation, PI DRMs did not revert to wild type in two patients.  The 
authors suggest that PI DRMs do not revert to wild type due to compensatory 
fixation - the reversion of one PI DRM to wild type results in a loss of replicative 
capacity, effectively blocking the route of evolution back to wild type (van 
Maarseveen et al., 2006).      
1.4.5 Resistance to maturation inhibitors  
Resistance to the maturation inhibitor, bevirimat, can be predicted by the amino 
acid sequence of the p2 spacer peptide SP1.  Gag positions 369 to 376 have 
the highest impact, with positions 370 and 372 shown to be particularly 
important (Heider et al., 2010).  In vitro studies have shown six amino acids that 
independently confer resistance to bevirimat: 3 at or near the C terminus of CA 
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(CA-H226Y, -231F and -231M) and the first three amino acids of SP1 (SP-A1V, 
-A3T and –A3V).  Of these, CA-H226Y, CA-L231F/M and SP1-A1V have no 
significant effect on the fitness of the virus (Adamson et al., 2006).  The 
prevalence of these mutations in patient viruses is high, with 30% of treatment-
naïve patient-derived viruses and 45% of PI-resistant patient-derived viruses 
containing at least one mutation conferring resistance to bevirimat therapy.  
These changes increase in frequency in patient whose viruses contain more 
than three PI associated resistance mutations (Verheyen et al., 2010).  Of 
particular interest, a study showed that PI resistance mutations may delay the 
development of resistance to bevirimat (Adamson et al., 2009). 
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1.5 Protease inhibitor resistance testing methods 
1.5.1 Genotypic resistance testing methods 
Genotypic assays are generally used in clinical practice and involve the 
prediction of the resistance of a virus based on the presence or absence of 
known resistance mutations.  PCR amplification of pol sequences from the 
patient viruses using RT-PCR is carried out, often using a cDNA synthesis step 
and nested PCRs.  This is followed by DNA sequencing and analysis of 
sequence data.  Commercial kits are available or some centres have developed 
in-house assays, such as the one used in the Antiviral Unit at PHE Colindale 
(as described in the materials and methods section).  Genotypic analysis 
involves a prediction of the susceptibility of a virus, based on the presence of 
known resistance mutations within the sequence.  This prediction can be 
complicated as the patterns of resistance mutations are complex.  Algorithms 
which predict the susceptibility of a virus based on DNA sequences are 
available, such as the Stanford HIVdb Genotypic Resistance Interpretation 
Algorithm (http://hivdb.stanford.edu/) (Rhee et al., 2003).   
1.5.2 Phenotypic resistance assays 
Conversely, phenotypic assays involve a direct measure of the susceptibility of 
a virus or enzyme in vitro, as opposed to a prediction.  These generally include 
replication based assays, such as the one which will be utilised in this project, 
or enzyme susceptibility assays.  These assays are used to determine the EC50 
of each virus, the concentration of drug that inhibits 50% of replication or 
enzyme activity, and this value is compared to that of a designated wild-type 
virus.   
There is currently only one commercially available phenotypic drug 
susceptibility assay – Phenosense, provided by Monogram – following the 
discontinuation of the Antivirogram assay which was provided by Virco.  Both 
assays are replication-based cell assays, not enzyme based, and use 
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recombinant viruses.  Use of recombinant viruses avoids the need to isolate live 
virus from patient samples which can be technically challenging and means the 
tropism of the patient virus does not affect the performance of the assay.   
The Phenosense assay utilises a resistance test vector with part of the pol gene 
(N-termial region) that contains known PI and RTI resistance mutations derived 
from patient virus, but with a luciferase reporter gene in the place of the HIV env 
gene.  The vectors are co-transfected into cells with a plasmid encoding a MLV-
env, resulting in the production of pseudovirions.  The infectivity in the presence 
of drug is tested using a single-round of replication assay, since the nature of 
viruses limits them to a single-round of replication.  Infectivity is measured by 
recording the amount of luciferase activity (Petropoulos et al., 2000).  A number 
of studies have examined the degree of concordance between the Monogram 
and Virco commercial assays, and in general the results are good.  One study 
showed that 92% of results were in agreement between the two assays, and 
most of the viruses for which different results were observed fell just under the 
respective clinical cut-offs (Qari et al., 2002).  
Thus, it follows that one of the complications associated with using phenotypic 
resistance assays is the determination of clinical cut-offs, the fold difference 
EC50 values at which a difference in clinical outcome would be observed.  To 
determine these values, large numbers of paired clinical outcome and 
phenotypic susceptibility data are required.  For example the clinical cut-offs 
defined for the Virco assay required >6500 data sets for their determination 
(Winters et al., 2009).   
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1.6 Viral fitness assays 
A number of different methods to measure viral fitness have been developed, 
(as reviewed by Quinones-Mateu and Arts, 2001).  In vivo assays are available 
that examine viral kinetics in a host environment such as in blood plasma.  
These have the advantage that an accurate estimate of viral fitness in the host 
environment is obtained, however this can produce inaccuracies for variants 
adapted to other compartments such as the CNS.   
In addition, a number of in vitro assays have been developed which can be 
divided into growth kinetic assays or growth competition assays.  Growth kinetic 
assays involve infection with single viruses carried out in parallel, with the 
amount of virus produced over time measured, for example by p24 ELISA.  The 
amount of virus production can then be compared between viruses, although 
small differences in fitness may not be detected by this method.  These assays 
can be carried out using replication competent viruses or with pseudovirions 
resulting in analysis of a single round of replication, as with the commercial 
Phenosense assay.  Pseudovirions containing reporter genes such as 
luciferase enable more accurate measurment of the amount of virus production 
than in assays with replication competent viruses where p24 ELISA is used.  
However, single-cycle assays only include the stages of the viral life-cycle up to 
the transcription of viral genes, meaning that the efficiency of viral assembly is 
not represented.   
Growth competition assays can only be used with replication competent viruses 
and involved direct competition between at least two viruses over multiple 
cycles of replication.  Over time, the fittest of the viruses will outgrow the 
other(s) which enables a distinction between viruses with subtle differences in 
fitness.  However, measurement of the proportion of each virus can be 
challenging with methods such as RT-PCR or use of different reporter genes 
being required (Quinones-Mateu and Arts, 2001).   
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1.7 Project overview 
The determinants of PI resistance and susceptibility have been investigated for 
many years.  However, most studies to date have utilised commercially 
available phenotypic susceptibility assays PhenoSense and Antivirogram which 
do not include co-evolved Gag from the virus of interest (Petropoulos et al., 
2000).  A number of recent studies have provided evidence that Gag can 
directly confer PI resistance in the absence of known resistance mutations 
(Dam et al., 2009; Nijhuis et al., 2007b; Parry et al., 2011).  In addition, recent 
studies have shown that the inclusion of co-evolved Gag alongside protease in 
phenotypic assays can affect the susceptibility of the virus (Gupta et al., 2010; 
Parry et al., 2009).   
To date, studies have examined the role of Gag from treatment-naïve subtype A 
and C viruses and PI-experienced subtype B viruses in phenotypic susceptibility 
assays.  However, no data exist to indicate whether inclusion of co-evolved Gag 
would affect the phenotypic PI susceptibility of PI-naïve subtype B viruses.  This 
report aimed to investigate the phenotypic PI susceptibility of full-length Gag-
protease from a variety of PI-naïve subtype B viruses.  Using a previously 
described single-cycle phenotypic PI susceptibility assay, this report 
demonstrates variation in PI susceptibility of both molecular clones and patient-
derived subtype B viruses.  This report describes the creation of a number of 
chimeric viruses containing fragments of Gag and protease to further 
investigate the regions of Gag and protease that contribute to variation in PI 
susceptibility of PI-naïve viruses.  An investigation of particular amino acid 
positions conferring variation in PI susceptibility was carried out.  In addition, 
this report describes the development of a protocol to investigate variation in the 
rates of maturation between pseudovirions using electron microscopy.   
The second half of this project aimed to investigate the determinants of 
treatment failure on PI monotherapy, which almost always occurs in the 
absence of major PI resistance mutations.  Plasma samples were available 
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from patients enrolled in the MONARK trial and randomised to the LPV/r 
monotherapy arm.  A detailed investigation was carried out of five patients who 
failed PI monotherapy for which plasma samples were available at baseline and 
the time of treatment failure, which occurred in the absence of major resistance 
mutations.  This report details the clonal analyses, phenotypic resistance and 
fitness testing and positive selection analyses carried out for each.  In addition, 
similar data for three control patients who succeeded on PI monotherapy are 
included to enable an assessment of the clinical significance of any findings.  
This study is the first to assess PI susceptibility using full-length Gag-protease 
in paired samples at baseline and time of treatment failure, enabling an 
assessment of the potential role of reduced susceptibility in treatment failure.  
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2 Materials and methods 
2.1 General microbiological techniques 
2.1.1 Plasmid DNA preparation 
2.1.1.1 Competent bacteria 
The following strains of competent E. Coli cells were utilised: HB101 (Promega), 
JM109 (Promega) and XL10 Gold (Stratagene).  HB101 cells were used for 
general cloning techniques and to produce plasmid DNA stocks, JM109s were 
utilised for cloning into pGEM as they enable colour screening of colonies and 
XL10 Gold cells were used for site-directed mutagenesis. 
2.1.1.2 Transformation of bacteria 
Typically, 2 µl of plasmid DNA was incubated with 45 µl of cells on ice for 30 
minutes.  XL10 Gold cells required an additional pre-incubation step with 2 µl β-
methacapthanol for 2 minutes on ice before addition of DNA.  Cells were heat 
shocked at 42°C for 45 seconds, followed by incubation for 2 minutes on ice.  
Cells were incubated, shaking, at 37°C for 1 hour with 450 µl Super Optimal 
Broth (SOC).  Varying volumes of cells were plated out onto 10cm agar plates 
with 100 μg/ml  ampicillin and incubated overnight at 37°C.  Colour screening 
plates for JM109s were prepared with the addition of Bluo-Gal and IPTG 
(Invitrogen).   
Following selection as necessary, colonies were seeded into 5 ml of LB with 
100 μg/ml ampicillin and incubated, shaking at 37°C overnight.  Cells were 
pelleted by centrifugation at 300 g for 3 minutes and the culture supernatant 
discarded.  Cell pellets were either frozen, or processed immediately as detailed 
below.  Where required, glycerol stocks of transformed bacteria were created by 
mixing 1 ml of bacterial culture with 200 µl glycerol solution (Sigma) in 
cryotubes and stored at -80°C. 
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2.1.1.3 Plasmid DNA preparation  
Double stranded plasmid DNA was purified from bacteria using the Qiagen 
Miniprep Kit (Qiagen), as per manufacturer’s protocol.  Bacterial cells were 
lysed and clarified, then spun through a column containing silica membranes to 
which the plasmid DNA bound.  The membranes were washed and the DNA 
subsequently eluted into 50 µl of elution buffer (10 mM Tris-Cl, pH 8.5).  DNA 
concentration was measured using 2 µl of eluate on a Nanodrop 3100 
Spectrophotometer.   
2.1.2 Polymerase Chain Reaction (PCR) 
PCR was performed using the Expand High Fidelity PCR system (Roche) when 
high fidelity DNA synthesis was required, or Taq polymerase (Roche).  
2.1.2.1 Expand High Fidelity 
Expand High Fidelity reactions contained 0.5 µM final concentration each of the 
sense and antisense primers.  Typical cycling conditions were:   
1 (x1) 94°C 2 minutes 
2 (x35) 94°C 30 seconds 
53°C 30 seconds 
72°C 2 minutes  
3 (x1) 72°C 7 minutes 
The annealing temperature was reduced to 50°C when primers containing 
mismatched bases were used, such as GagNot+ and ProXhoR2.  DNA primers 
used for PCR are listed in table 2.1.  
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2.1.2.2 Taq polymerase 
Primers were used at a final concentration of 1 µM each and are detailed in 
table 2.1.  Typical reaction conditions were as follows:  
1 (x1) 94°C 2 minutes 
2 (x20) 94°C 30 seconds 
  53°C  30 seconds 
  72°C 45 seconds   
3 (x1) 72°C 2 minutes 
2.1.2.3 Addition of polyA tails 
Where cloning into the intermediate vector pGEM was performed (as detailed in 
2.1.7.2), the addition of 3’ A-overhangs to the PCR product from the Expand 
High Fidelity PCR system was required.  PCR product from the Expand High 
Fidelity reaction was purified using the GFX PCR DNA and Gel Band 
purification kit (GE healthcare) as detailed in 2.1.6.1 and incubated with Taq 
polymerase and 0.1 µM dNTPs, to add 3’ A overhangs.  Cycling conditions 
were: 3 cycles of 53°C for 30 seconds and 72°C for 4 minutes, followed by 72° 
for 7 minutes. 
2.1.3 Sequencing 
DNA sequencing was carried out in-house by the Department of Bio-Analysis 
and Horizon Technologies (DBHT).   
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2.1.4 Primers 
Throughout the project, various primers were utilised for PCRs and sequencing, 
listed in table 2.1.  The areas of primers designed with mismatches to introduce 
restriction enzyme sites are underlined.  Those used for site-directed 
mutagenesis are detailed later.  
Table 2.1. Primers used for cDNA synthesis, nested PCR and sequence 
analysis  
Primer Sequence 
GagNot+ GCGGCGGCCGCAAGGAGAGAGATGGGTGCG 
Gag1F CATTATCAGAAGGAGCCACC 
Gag1.5R TCTATCCCATTCTGCAGC 
Gag2F ATGATGACAGCATGTCAGGG 
ProXhoR2 CTGGTACAGTCTCGAGRGGACTRATKGG   
KVL0651  TCCTAATTGAACYTCCCARAARTCYTGAGTTC 
ProOutR TTGGGCCATCCATTCCTGG 
BKTO3 CGCAGGACTCGGCTTGC 
1Van Laethem et al., 2006. 
 
2.1.5 Restriction enzyme digestion 
Restriction enzyme digestion was carried out using the appropriate 
endonucleases (NEB and Roche).  Typical reaction conditions were: 1 µg of 
DNA, 5 U of NotI and 5 U of XhoI in a 20 µl reaction.  Reaction was carried out 
at 37°C (or the temperature recommended by the manufacturer) for 2 hours.  
Heat inactivation of restriction enzymes was carried out at 65°C, depending on 
the onward use of DNA.  
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2.1.6 DNA purification 
2.1.6.1 PCR/Gel band purification 
DNA fragments were purified either directly from the PCR reaction, or from gel 
bands excised following agarose electrophoresis to exclude primer dimers.  
DNA was purified using the GFX PCR DNA and Gel Band Purification Kit (GE 
healthcare) as per manufacturer’s protocol and eluted into 50 µl of elution 
buffer.   
2.1.6.2 Ethanol precipitation 
To further concentrate fragment DNA following purification, DNA was ethanol 
precipitated.  2-2.5 X volume 100% ethanol and 6 µl sodium acetate were 
added to eluted DNA, and incubated at -20°C overnight.  The mix was 
centrifuged at 15000 g for 15 minutes to pellet the DNA, and the pellets were 
washed with 100 µl of 70% ethanol, then air dried.  DNA pellets were re-
suspended in water, typically 3-6 µl depending on the onwards ligation reaction.   
2.1.7 Molecular cloning 
Cloning of full-length Gag-protease from both molecular clones and clinical 
samples into the test vector p8.9NSX+ (described in more detail in 2.2.3) was 
carried out.  For molecular clones, where only one clone was required, direct 
cloning into the p8.9NSX+ vector was sufficiently efficient.  However, for cloning 
from clinical samples where the presence of quasispecies meant that many 
individual clones had to be investigated, a cloning method utilising an 
intermediate vector was required.   
2.1.7.1 Direct cloning into test vector p8.9NSX+ 
Cloning of either full-length gag-protease or smaller fragments within this length 
into p8.9NSX+ was performed.  The positions of the unique restriction sites 
present in p8.9NSX+ used for cloning in this project are shown in figure 2.1.  
Full-length gag-protease was cloned from the molecular clones into p8.9NSX+ 
using NotI and XhoI restriction sites located 13 nucleotides before the beginning 
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of the gag ORF and after the end of protease ORF, respectively.  Other 
restriction sites utilised for cloning as part of this project were SpeI, located in 
the middle of gag within CA, ApaI, located at the C terminus of gag, and SmaI 
found at the end of pol.    
 
 
 
Figure 2.1. Unique restriction sites within p8.9NSX+ gag-pol  
‘Insert’ DNA was derived either by PCR amplification to introduce restriction 
sites or by restriction digest from an existing p8.9NSX+ based plasmid.  PCR 
amplification was carried out as in section 2.1.2.1, using the GagNot+ and 
ProXhoR2 primers to introduce NotI and XhoI restriction sites, respectively, into 
the full-length gag-protease fragment.   
Insert was ligated into ‘empty’ p8.9NSX+ vector, prepared by restriction digest 
with appropriate enzymes and vector dephosphoryation, using the Rapid 
Dephos and Ligation kit (Roche).  Typically ligation reaction was carried out with 
insert DNA resuspended in 6 µl water following ethanol precipitation, 2 µl 
empty, dephosphorylated vector and 1 µl DNA ligase.  Reaction proceeded for 1 
hour at room temperature before transformation into HB101 cells as detailed in 
section 2.1.1.2. 
2.1.7.2 Cloning using pGEM 
Cloning of gag-protease from clinical samples was carried out using an 
intermediate vector – pGEM-T Easy (Promega) – to enable clonal sequencing.  
Following RNA extraction, cDNA synthesis and nested PCR, the addition of 3’ 
A-overhangs was carried out as detailed in section 2.1.2.3.  PCR products were 
then TA cloned into the pGEM-T vector.  Ligation proceeded at 4°C overnight in 
  gag protease 
NotI SpeI ApaI XhoI SmaI 
EcoRI 
pol 
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10 µl total volume with 1 µl DNA ligase enzyme.  DNA was transformed into 
XL10 Gold Competent cells as described above. 
2.1.8 Site-directed mutagenesis 
Site-directed mutagenesis was utilised to introduce restriction sites and amino 
acid substitutions.  Site-directed mutagenesis was carried out using the Quik-
Change Lightning Site-Directed Mutagenesis Kit (Stratagene) as per 
manufacturer’s protocol or the Quik-Change Lightning Multi Site-Directed 
Mutagenesis Kit (Stratagene), where multiple changes were introduced 
simultaneously.  The primers designed for mutagenesis are listed in table 2.2.  
Table 2.2. Primers designed for site-directed mutagenesis. 
Primers Sequence 
MutProSpe GCTATAGGTACAGTACTAGTAGGACCTACACC 
MutProSpeR GGTGTAGGTCCTACTAGTACTGTACCTATAGC 
Y_GagApaF GCCAAAAATTGCAGGGCCCCTAGGAAAAAGGGC 
Y_GagApaR CGGTTTTTAACGTCCCGGGGATCCTTTTTCCCG 
JRFL_R30K_F GGCCAGGAGGAAAGAAAAAATATAAATTAAAACATA
TAGTATGGGC 
JRFL_R30K_R CCGGTCCTCCTTTCTTTTTTATATTTAATTTTGTATAT
CATACCCG 
YU2_R30K_F GGCCAGGGGGAAAGAAACAATATAAATTAAAACATA
TAGTATGGGC 
YU2_R30K_R CCGGTCCCCCTTTCTTTGTTATATTTAATTTTGTATA
TCATACCCG 
YU2_JRFL_E102D_F CCAAGGAAGCTTTAGACAAGATAGAGGAAGAGC 
YU2_JRFL_E102D_R GGTTCCTTCGAAATCTGTTCTATCTCCTTCTCG 
p2T71A CTGTGGACATAAAGCTGTAGGTACAGTGTTAATAGG
ACC 
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p2T71A_V13I GGCAACGACCCCTTGTCACAATAAAAGTAGGGGGG
C 
p2T71A_V13I_P63L GACAGTATGAACAGATACTCATAGAAATCTGTGGAC 
p4T71A CTGTGGACATAAAGCTATAGGTACAGTATTAGTAGG
ACCTACACC 
p4T71A_V13I CCCCTCGTCACAATAAGGATAGGGGGACAGC 
p4T71A_V13I_P63L GACAGTATGATCAGGTACTCATAGAAATCTGTGGAC 
 
Reactions included 25 ng of DNA template and 125 ng of each primer – sense 
and antisense.  Typical cycling conditions were as follows: 
1 (x1) 95ºC 2 minutes 
2 (x18) 95°C 20 seconds 
60°C 10 seconds 
68°C 6 minutes 15 seconds (30 seconds per kb of   
template DNA) 
3 (x1) 68°C 5 minutes 
2.1.9 RNA extraction 
Viral RNA was manually extracted from plasma samples using one of two 
methods, depending on the viral load of the samples.  For clinical samples with 
a viral load >1000 copies/ml, viral RNA was extracted from 200 µl of plasma 
using the QIAmp UltraSens Virus Kit (Qiagen), following the manufacturer’s 
protocol.   For clinical samples with a viral load <1000 copies/ml, 1 ml of plasma 
was ultracentifuged at 55,000 g for 1 hour at 4°C.  The resulting pellet was 
resuspended in DMEM and AVL buffer added (Qiagen) and washing with 
ethanol carried out.  Following addition to columns from the QIAmp UltraSens 
Virus Kit (Qiagen) kit, samples were processed as per manufacturers 
instructions.    
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2.1.10 cDNA synthesis  
10 µl RNA was denatured for 10 minutes at 80°C prior to the cDNA synthesis 
reaction.  cDNA synthesis was carried out using the antisense primers ProOutR 
or KVL065 (Van Laethem et al., 2006), RNAseOut (Invitrogen) and 
SuperScriptIII enzyme (Invitrogen) in a 20 µl reaction at 53° for 60 minutes, 
followed by an RT inactivation step at 70°C for 15 minutes.  Resultant cDNA 
was either used immediately for nested PCR as detailed above, or stored at      
-80°C.   
2.1.11 Agarose gel electrophoresis 
Varying volumes of DNA, between 5 µl and 18 µl, depending on the DNA 
concentration were visualised on a 1% agarose gel (Invitrogen) containing 
1:16000 RedSafe DNA Stain (Chembio).  Samples were loaded with 10X Blue 
Juice loading buffer and 1 kb DNA ladder to confirm band size (Invitrogen).  
Gels were run for 30-45 minutes at 110 to 150 V, depending on the size of the 
gel tank used.  The gel was either photographed using a Gel Dock XR+ Imager 
(BioRad), or bands were visualised using a UV transilluminator (UVP) and the 
insert DNA band excised using a scalpel. 
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2.2 HIV-1 viruses 
2.2.1 Molecular clones 
The following six subtype B molecular clones were obtained from the NIH AIDS 
Research and Reagent Program: pYU2, pSF2, pJRFL, p89.6, pHXB2 and 
pNL4-3. 
2.2.2 Clinical samples 
2.2.2.1 Treatment-naïve, subtype B clinical samples 
Plasma samples from HIV-1 infected patients were obtained from the HIV drug 
resistance genotypic testing service at PHE, Colindale.  Anonymised samples 
were selected from newly diagnosed patients based on high viral load (above 
10,000), subtype (B) and absence of major drug resistance mutations in 
protease and RT (to reduce the possibility of the presence of transmitted drug 
resistance mutations).  The viral loads for each patient are shown in table 2.3. 
Table 2.3. Viral loads for treatment-naïve patients infected with subtype B 
viruses.  
Patient Number 
Sample Viral Load 
 (RNA copies/ml) 
1 2,599,453 
2 17,000 
3 16,066 
4 103,999 
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2.2.2.2 MONARK trial samples 
Plasma samples from HIV-1 infected patients enrolled in the MONotherapy 
AntiRetroviral Kaletra (MONARK) clinical trial were obtained.  MONARK was 
the first PI monotherapy trial to compare LPV/r monotherapy with LPV/r based 
HAART in previously treatment-naïve patients.  For this study, five patients who 
experienced virological failure in the PI monotherapy arm were investigated. 
Therapy failure was defined as viral load >400 copies/ml at week 24 or viral 
load >50 copies/ml by week 48 of the trial.  Patients were only included if 
genotypic resistance testing carried out as part of clinical care during the trial 
did not identify any major PI resistance mutations.  For each patient, plasma 
samples from baseline before treatment initiation and from the time of treatment 
failure were obtained.  In addition, 10 patients were selected from the PI 
monotherapy arm who succeeded on PI monotherapy, achieving a sustained 
virological response, as control patients.  For these patients only baseline 
plasma samples were included in this study.  The details for each of the patient 
samples are shown, including viral load and virus subtype, in table 2.4. 
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Table 2.4. Sample details for MONARK clinical trial patients 
Treatment 
Outcome 
Patient 
number 
Time point Subtype  Viral Load 
(copies/ml) 
Failure 
508 (SP) Screening B 37800 
508 (SP) Failure B 25300 
1403 (KON) Screening CRF02_AG 44600 
1403 (KON) Failure CRF02_AG 24000 
1404 (DIO) Screening CRF02_AG 166000 
1404 (DIO) Failure CRF02_AG 1080 
3204 (HG) Screening B 23800 
3204 (HG) Failure B 603 
4201 (SO) Screening G 79500 
4201 (SO) Failure G 342 
Success 
(Controls) 
110 (FRD) Screening CRF02_AG 25600 
4003 (MD) Screening CRF02_AG 29000 
2112 (WA) Screening B 78800 
4202 (LR) Screening G 36500 
909 (TH) Screening B 16200 
509 (MBF) Screening B 40800 
515 (MF) Screening CRF02_AG 67500 
1702 (BOY) Screening CRF02_AG 50500 
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2.2.3 Viral vectors 
p8.9NSX+ is a ~12.2 kb HIV-based retroviral vector that contains Gag-Pol from 
HIV-1 (Parry et al., 2009).  Nucleotide 1592 to 2325 of p8.9NSX+ (correlating to 
the beginning of gag to the middle of the CA subunit) is derived from the 
molecular clone HXB2 and the rest of the HIV-1 gag-pol derived fragment is 
from the NL4-3 molecular clone.  p8.9NSX+ contains the following unique 
restriction sites: NotI site upstream of the gag open reading frame (position 
1592), SpeI and ApaI sites in gag (positions 2325 and 2825 respectively), XhoI 
site at the end of protease open reading frame (3380) and a SmaI site in 
integrase (5221) which allows for the cloning of gag-pol sequences, as shown in 
figure 2.1 (Parry et al., 2009).  It contains an ampicillin resistance gene and an 
SV40 origin of replication which increases the copy number of plasmids once 
transfected into cells expressing the SV40 large T antigen (such as 293T cells).  
The expression of the HIV-1 derived genes within cells is driven by a CMV 
promoter.  The vector was originally derived from pCMVΔR9 which encoded the 
full-length HIV-1 genome with the reading frames of Vpu and Env blocked 
(Naldini et al., 1996).   
As part of this project, to avoid the additional screening of clones after the 
cloning of clinical samples, the p8.9Δpro vector was generated by deleting a 
fragment, including part of gag and most of protease, from p8.9NSX+.  This was 
achieved by introducing a SpeI site in protease at position 3297 by site directed 
mutagenesis using the Quik-change Site-Directed Mutagenesis Kit (Stratagene) 
with the sense primer MutProSpe and antisense primer MutProSpeR, table 2.2.  
SpeI restriction digest was then carried out to remove the fragment between the 
new and existing SpeI sites, followed by gel extraction and purification of the 
vector backbone.  The vector backbone was then self-ligated using T4 ligase 
(Roche), which was confirmed by sequencing, to produce p8.9Δpro.  See figure 
4.1 and section 4.2.1 for further details.  
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The HIV-1 based retroviral packaging vector pCSFLW expresses the firefly 
luciferase reported gene under the spleen focus-forming virus (SFFV) promoter 
and has the HIV-1 packaging signal, both flanked by HIV-1 long terminal 
repeats (Wright et al., 2008).  pCSGW has the same promoters and packaging 
signal as pCSFLW, but instead expresses the green fluorescence protein (GFP) 
(Demaison et al., 2002).  pMDG expresses the vesicular stomatitis virus 
envelope glycoprotein (VSV-G).  pGEM-T vector for the TA cloning of PCR 
products was purchased from Promega.   
As part of this project, a large number of p8.9NSX+ based vectors were created 
by cloning techniques in which gag and protease were derived from various 
sources, including molecular clones, patient-derived viruses and the assay 
reference strain, in different combinations.  In addition, a number of vectors 
containing mutations at specific amino acids of interest were generated.  The 
molecular clone-based vectors are listed in table 2.5, those derived from 
patients infected with subtype B viruses in table 2.6.   
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Table 2.5. p8.9NSX+ based vectors derived from subtype B molecular 
clones, generated during this study 
Vector Name Description 
p8.9NSX+ Resistance test vector, used as the assay reference 
strain control throughout this project 
p8HXB2gagpro p8.9NSX+ with Gag-protease derived from HXB2  
p8NL4-3gagpro p8.9NSX+ with Gag-protease derived from NL4-3  
p8YU2gagpro p8.9NSX+ with Gag-protease derived from YU2  
p8JRFLgagpro p8.9NSX+ with Gag-protease derived from JRFL  
p8SF2gagpro p8.9NSX+ with Gag-protease derived from SF2  
p89.6gagpro p8.9NSX+ with Gag-protease derived from 89.6  
p8YU2gag Chimeric virus with Gag derived from YU2, and 
protease and pol from p8.9NSX+ 
p8JRFLgag Chimeric virus with Gag derived from JRFL, and 
protease and pol from p8.9NSX+ 
p8SF2gag Chimeric virus with Gag derived from SF2, and 
protease and pol from p8.9NSX+ 
p8.89.6gag Chimeric virus with Gag derived from 89.6, and 
protease and pol from p8.9NSX+ 
p8YU2pro Chimeric virus with protease derived from YU2, and 
Gag and pol from p8.9NSX+ 
p8JRFLpro Chimeric virus with protease derived from YU2, and 
Gag and pol from p8.9NSX+ 
p8SF2pro Chimeric virus with protease derived from YU2, and 
Gag and pol from p8.9NSX+ 
p8.89.6pro Chimeric virus with protease derived from YU2, and 
Gag and pol from p8.9NSX+ 
p8YU2gagN Chimeric virus with the N terminus of Gag (MA and 
half of CA) derived from YU2, and the remainder of 
Gag-pol from p8.9NSX+ 
p8YU2gagC Chimeric virus with the C terminus of Gag (half of CA 
to x) derived from YU2, and the remainder of Gag-
pol from p8.9NSX+ 
p8JRFLgagN Chimeric virus with the N terminus of Gag (MA and 
half of CA) derived from JRFL, and the remainder of 
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Gag-pol from p8.9NSX+ 
p8JRFLgagC Chimeric virus with the C terminus of Gag (half of CA 
to x) derived from JRFL, and the remainder of Gag-
pol from p8.9NSX+ 
p8YU2_R30K p8YU2, with position 30R of Gag reverted to 
consensus B sequence K 
p8YU2_E102D p8YU2, with position 102E of Gag reverted to 
consensus B sequence D 
p8YU2_2M p8YU2, with both R30K and E102D reversions to 
consensus B sequence 
p8JRFL_R30K p8JRFL, with position 30R of Gag reverted to 
consensus B sequence K 
p8JRFL_E102D p8JRFL, with position 102E of Gag reverted to 
consensus B sequence D 
p8JRFL_2M p8JRFL, with both R30K and E102D reversions to 
consensus B seqeunce 
p8YU2gN_R30K p8YU2gagN, with position 30R of Gag reverted to 
consensus B sequence K 
p8YU2gN_E102D p8YU2gagN, with position 102E of Gag reverted to 
consensus B sequence D 
p8YU2gN_2M p8YU2gagN, with both R30K and E102D reversions 
to consensus B sequence 
p8JRFLgN_R30K p8JRFLgagN, with position 30R of Gag reverted to 
consensus B sequence K 
p8JRFLgN_E102D p8JRFLgagN, with position 102E of Gag reverted to 
consensus B sequence D 
p8JRFLgN_2M p8JRFLgagN, with both R30K and E102D reversions 
to consensus B sequence 
 
Table 2.6. Subtype B, treatment-naïve, patient-derived, p8.9NSX+ based 
vectors generated during this study. 
Vector Name Description 
p8Pt1gagpro p8.9NSX+ with Gag-protease derived from the 
majority variant from patient 1 
p8Pt2.1gagpro p8.9NSX+ with Gag-protease derived from the first of 
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the majority variants from patient 2 
p8Pt2.2gagpro p8.9NSX+ with Gag-protease derived from the 
second of the majority variants from patient 2 
p8Pt3.1gagpro p8.9NSX+ with Gag-protease derived from the first of 
the majority variants from patient 3 
p8Pt3.2gagpro p8.9NSX+ with Gag-protease derived from the 
second of the majority variants from patient 3 
p8Pt4gagpro p8.9NSX+ with Gag-protease derived from the 
majority variant from patient 1 
p8Pt2.1gag Chimeric virus with Gag derived from p8Pt2.1gagpro, 
and protease and pol from p8.9NSX+ 
p8Pt4gag Chimeric virus with Gag derived from p8Pt4gagpro, 
and protease and pol from p8.9NSX+ 
p8Pt2.1pro Chimeric virus with protease derived from 
p8Pt2.1gagpro, and Gag and pol from p8.9NSX+ 
p8Pt4pro Chimeric virus with protease derived from 
p8Pt4gagpro, and Gag and pol from p8.9NSX+ 
p8Pt2.1_1M p8Pt2.1gagpro with T71A in protease, reversion of 
polymorphism to consensus B sequence   
p8Pt2.1_2M p8Pt2.1gagpro with T71A and V13I in protease, 
reversion of polymorphisms to consensus B 
sequence   
p8Pt2.1_3M p8Pt2.1gagpro with T71A, V13I and P63L in 
protease, reversion of polymorphisms to consensus 
B sequence   
p8Pt4_1M p8Pt4gagpro with T71A in protease, reversion of 
polymorphism to consensus B sequence   
p8Pt4_2M p8Pt4gagpro with T71A and V13I in protease, 
reversion of polymorphisms to consensus B 
sequence   
p8Pt4_3M p8Pt4gagpro with T71A, V13I and P63L in protease, 
reversion of polymorphisms to consensus B 
sequence   
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2.3 Tissue culture methods 
2.3.1 General cell culture 
293T cells were maintained at 37°C and 5% CO2 in DMEM (Invitrogen), 
supplemented with 10% Foetal Calf Serum, 1% Penicillin Streptomycin and 1% 
Sodium Pyruvate (Invitrogen).  Cells were maintained in 10 cm tissue culture 
dishes and passaged every two or three days.  Cells were split between 1:4 and 
1:8 depending on cell density.  Media was removed, cells were washed with 10 
ml PBS and 1.5 ml trypsin (Invitrogen) was used to dislodge cells.     
2.3.2 Transfection 
Transfection of 293T cells for PI susceptibility assay was typically carried out in 
6 cm tissue culture dishes with 3 x 106 cells.  293T cells were plated and co-
transfected after 5 hours with 1.1 µg total DNA, 300 ng p8.9NSX+ (or 
derivatives), 300 ng pCSFLW and 500 ng pMDG, using 6 µl Fugene 6 
transfection reagent (Roche) and 70 µl Optimem (Invitrogen).  Transfection 
conditions used for other plate sizes for both the PI susceptibility and single-
round infectivity assays are detailed in table 2.7. 
Table 2.7. Transfection conditions 
Plate Size Number of 
Cells 
Volume of 
Fugene (µl) 
Amount of 
DNA (µg) 
Harvest 
Volume (ml) 
24 well plate 2.5 x 105 1.2 0.22 N/A 
6 well plate 1.25 x 106 6 1.1 8 
6 cm plate 3 x 106 6 1.1 22 
10cm plate 1.25 x107 18 3.5 N/A 
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Pseudovirion production for electron microscopy required a higher transfection 
efficiency and virion yield.  Cells were plated in 6 well plates and cover slips 
were included for immunofluorescence.  Transfection conditions were optimised 
as part of this study, as discussed in section 3.2.8.1.      
2.3.3 Protease inhibitor susceptibility assay 
PI susceptibility was determined using a previously described phenotypic drug 
susceptibility assay (Gupta et al., 2010; Parry et al., 2009).  Briefly, 18 hours 
after transfection 293T cells were harvested into 22 ml of media for a 6 cm 
tissue culture dish, see table 2.8.  Pseudovirion production was carried out in 96 
well plates containing three-fold serial dilutions of PI, as shown in figure 2.2.  
The top concentration of drug used for each PI can be seen in table 2.8.  The 
first row of the plate (1) was a no-cell control used to calculate the background 
levels of luciferase and row 12 a no-drug control, used to control for variation in 
transfection efficiency and replicative capacity between viruses.     
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Figure 2.2. Layout of 96-well plate for PI susceptibility assays.  
 
Table 2.8. Top drug concentrations used in phenotypic drug susceptibility 
assay 
PI Top concentration (nM) 
APV 1000 
ATV 100 
DRV 200 
LPV 500 
SQV 200 
TPV 1000 
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150 µl of cells were added to each well, containing 150 µl of media with the 
required concentration of PI.  After 24 hours, media containing pseudovirions 
were harvested and used to infect fresh 293T cells in 96 well plates (layout as 
shown in figure 2.2).  Infectivity was then measured 48 hours after virus 
transfer, using SteadyGlo luciferase substrate (Promega) and a Glomax 
luminometer to determine luciferase activity levels.  From these data, EC50 
values were determined by linear regression and data were expressed as a fold 
difference of the EC50 of the reference strain (p8.9NSX+).  The experiment was 
repeated in duplicate within a single assay repeat (for example rows A and B) 
and mean values used for the calculation of fold-difference in EC50.  Assays 
were performed either in duplicate or in triplicate for each virus construct.   
2.3.3.1 Antiretroviral drugs 
The six PIs used in this study amprenavir (APV), atazanavir (ATV), darunavir 
(DRV), lopinavir (LPV), saquinavir (SQV) and tipranavir (TPV) were obtained 
from the NIH AIDS Research and Reference Reagent Program.  
2.3.4 Single-round infectivity assay 
2.3.4.1 Titrations 
Single-round infectivity was determined as previously described by titration of 
serial pseudovirion dilutions incubated with 293T cells in the absence of drug 
(Gupta et al., 2010; Parry et al., 2009).  Pseudovirus was harvested 48 hours 
post-transfection and passed through a 0.45 µm filter to remove cellular debris.  
100 µl virus was used immediately for titration, and the remaining volume stored 
-80°C until required.  Titration was carried out in 96 well, white plates with each 
virus in a single row as shown in figure 2.3.  Virus was plated using two-fold 
dilutions across the plate, resulting in a range from 50 µl volume of virus in the 
first column to 0.025 μl of virus in the twelfth.  A blank row was included in each 
run to measure background luminescence.  48 hours post-titration, infectivity 
was measured using SteadyGlo luciferase substrate (Promega) and a Glomax 
luminometer.  
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Figure 2.3.  Layout of 96-well plate for single-round infectivity assay. 
 
2.3.4.2 p24 ELISA 
For the molecular clone-derived vectors, the titration readouts were adjusted 
based on the amount of p24 present in the harvested pseudovirus sample as 
previously described (Parry et al., 2009).  However, for the MONARK vectors 
adjusting for p24 was not carried out to capture the effect on PI susceptibility of 
all life cycle stages.  In addition, this has been previously shown not to 
significantly affect the susceptibility data (Gupta et al., 2010).   
The amount of p24 was measured for each pseudovirus using the Genscreen 
HIV-1 Ag Assay (BIORAD), an enzyme immunoassay for the detection of HIV-1 
p24 antigen.  The assay was carried out as per manufacturers protocol with OD 
measured at 450 nM.  For each test virus, the assay was carried out for two 
dilutions – 1:900 and 1:2700 – and negative controls of tissue culture media 
were included.  A p24 standard curve was created using two-fold dilutions 
  
114 
 
 
between 100 pg/ml and 6.25 pg/ml to enable a calculation of the amount of p24 
in each virus preparation.  This value was expressed as a fold-difference of that 
of the p8.9NSX+ reference strain included on the same p24 ELISA plate and 
this value used to adjust the single-round infectivity value obtained from 
titration.   
2.4 Imaging methods 
2.4.1 Immunofluorescence (IF) 
To visualise the presence of Gag following transfection, IF imaging techniques 
were utilised.  Cells were fixed on coverslips in 3 % paraformaldehyde for 15 
minutes at room temperature.  Coverslips were quenched and permeabilised in 
PBS with 50 nM NH4Cl and 0.2% saponin for 10 minutes before rinsing in IF 
buffer PGAS (PBS with 0.2% fish skin Gelatin, 0.02% sodium azide and 0.02% 
saponin).  Coverslips were stained with a monoclonal antibody targeting Gag 
CA (p24) #4121 obtained from the AIDS Research and Reference Reagent 
Program (Simm et al., 1995).  Coverslips were incubated with primary antibody 
at a concentration of 1:250 in PGAS for 30-40 minutes.  Coverslips were 
washed three times in PGAS before incubation with secondary antibody Alexa 
488 coupled anti-mouse (Molecular probes) for 30 minutes, diluted 1:300 in 
PGAS with 1 µg/ml bisbenzimide.  Post-staining, coverslips were washed with 
PGAS, PBS and water before mounting on coverslips with Mowiol 4-88 
(Calbiochem).  Imaging was carried out using Leica SP8 Laser scanning 
confocal microscope.   
Visualisation of GFP in live cells to monitor transfection efficiency was carried 
out using a Zeiss Axiovert 200 microscope.    
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2.4.2 Electron microscopy (EM) 
Electron microscopy was carried out with the help of Electron Microscopist, Dr 
Matthew Hannah, based at PHE.   
Following transfection in 6 well plates as described above and addition of PI 18-
hours post-transfection where applicable, cell media containing pseudovirions 
was harvested 48 hours post-transfection.  Media was centrifuged at 300 g for 
10 minutes to remove cellular debris before ultracentrifugation at 100,000 g for 
1 hour at 4°C to concentrate the pseudovirions into a pellet.  The pseudovirus 
pellet was fixed with 2% paraformaldehyde and 1.5% glutaraldehyde in 100 mM 
sodium cacodylate pH 7.2 for 20 minutes.  After washing, the fixed pellet was 
postfixed with 1% osmium tetroxide, further contrasted with 1% w/v tannic acid 
and the pellet (in situ in the tube following centrifugation) embedded in epoxy 
resin after dehydration through a graded series of ethanol solutions.  The epon 
blocks for each pellet were carefully removed from the tube and re-embedded in 
the same orientation to avoid the introduction of bias during sectioning.  Serial 
ultrathin sections, between 60 and 70 nm, were cut from each pellet using a 
Leica UC7 and Diaotome diamond Knife, mounted on pioloform coated slot 
grids and stained using Reynolds lead citrate.  Pseudovirions were visualised 
using a JEOL JEM 1400 TEM and images acquired with an AMT 11 megapixel 
digital camera at 10,000-20,000 x magnification.   
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2.5 Bioinformatic analyses 
2.5.1 Sequence analysis 
Sequencing data were aligned and analysed using DNAdynamo software 
(BlueTractor Software).  Sequences were trimmed and manually checked for 
any discrepancies between overlapping primers.  Alignment of multiple 
sequences for further analyses, for example clonal sequences within a patient, 
was carried out using MEGA 4.1 or MEGA 5.0 software (Tamura et al., 2011).  
Virus subtype was determined using the REGA HIV-1 Subtyping tool provided 
by Stanford University (http://dbpartners.stanford.edu/RegaSubtyping/) (de 
Oliveira et al., 2005).  Analyses for PI resistance mutations within protease was 
carried out using the Stanford HIV Drug Resistance Database 
(http://hivdb.stanford.edu/) which reports major and minor resistance mutations 
and other polymorphisms (Liu and Shafer, 2006).  Reference to the IAS-USA 
list of drug resistance mutations was also made (Johnson et al., 2013).  Gag 
changes were identified manually by reference to table 1.2 containing all 
previously described mutations in Gag associated with PI exposure or 
resistance.   
2.5.2 Genetic distance calculation 
Mean pairwise genetic distance (MPWGD) calculation was carried out in MEGA 
using standard parameters, based on amino acid alignment performed using 
the ClustalW algorithm.  Data were expressed as mean amino acid substitutions 
per site.  
2.5.3 Positive selection analysis  
Selective pressure testing was performed to test for evidence of positive 
selection using a number of methods available on the datamonkey webpage 
(www.datamonkey.org).  Analyses were performed for all clonal sequences 
from each patient, from both baseline and failure time points, in alignments.  To 
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test for alignment wide evidence of selection the PARRIS method was used (A 
PARtitioning approach for Robust Inference of Selection) (Scheffler et al., 
2006).  For identification of particular sites under diversifying/purifying selection 
the FUBAR (Fast Unbiased Bayesien AppRoximation) method was used (as 
discussed by Kosakovsky Pond and Frost, 2005).    
2.5.4 Molecular Modeling 
Molecular modeling of the position of amino acid changes within the crystal 
structures of proteins was carried out using RasMol software.  Models were 
obtained from the Research Collaboratory for Structural Bioinformatics (RCSB) 
protein database (www.rcsb.org) (Berman et al., 2000).  For protease, two 
molecular models were utilised: 7HVP (protease homodimer) and 3ELI 
(protease structure when bound to the PI ATV) (King et al., 2012; Swain et al., 
1990).   
2.5.5 Phylogenetics 
Nucleotide sequences were aligned in MEGA 5.0 using the ClustalW algorithm, 
as above, and imported into the PHYLIP program for phylogeny construction 
using the Maximum Likelihood method under the GTR model of nucleotide 
substitution.  Additional maximum likelihood trees were constructed using 
PhyML 3.0 software (Guindon et al., 2010) with the confidence of the tree tested 
using 500 bootstrap replications.  Phylogenetic trees were viewed using FigTree 
v1.3.1 and MEGA 5.0 software.  
2.5.6 Ancestral site reconstruction 
Ancestral state reconstruction was performed using a maximum parsimony 
approach, with the software McClade version 4.07 by Stephane Hue, UCL 
(Maddison and Maddison, 2001). Amino acid substitutions were mapped along 
maximum likelihood phylogenies reconstructed for each patient with the 
software FastTree v2.1.7 (Prince et al., 2010). 
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2.5.7 Statistical analyses 
Statistical analyses were performed using Minitab16 software and formulae in 
Microsoft Excel.  In most cases, unpaired t-tests were used to compare the 
means of two populations, with P < 0.05 considered statistically significant. 
Mann Whitney U rank sum testing for the MONARK chapter was performed by 
John Gregson (London School of Hygiene and Tropical Medicine). 
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3 Investigation of the role of co-evolved Gag and 
protease in PI susceptibility of HIV-1 subtype B 
molecular clones 
3.1 Introduction 
At present, commercial phenotypic PI susceptibility assays include only 
protease and a short length of the C terminus of Gag from the patient (the 
portion of Gag included is p6 which overlaps with the protease in the Gag-Pol 
transframe region), with the rest of the genome coming from the test vector 
(Hertogs et al., 1998; Petropoulos et al., 2000).  To date, studies investigating 
variation in phenotypic susceptibility of patient-derived viruses to PIs have used 
one of these assays – Antivirogram or Phenosense (Parkin et al., 2004; Vergne 
et al., 2006).  However, recent in vitro studies using phenotypic drug 
susceptibility assays have demonstrated that inclusion of Gag from patients 
alongside co-evolved protease can affect susceptibility to PIs in comparison to 
protease with a wild-type Gag.  This has been shown in patients infected with 
subtype CRF01_AE viruses (Jinnopat et al., 2009), in subtype A and C 
molecular clones and viruses derived from treatment-naïve patients, and in an 
extensively PI treated patient infected with subtype B virus (Gupta et al., 2010; 
Parry et al., 2009). 
It is now well established that changes in Gag can compensate for the reduced 
fitness caused by major PI resistance mutations found in protease (Zhang et al., 
1997).  However, more recent data have indicated that Gag can affect protease 
inhibitor resistance, independent of this compensatory effect (Dam et al., 2009; 
Jinnopat et al., 2009; Nijhuis et al., 2007b; Parry et al., 2009). Changes in Gag 
cleavage sites, in particular within the C terminus of Gag, have been shown to 
affect PI susceptibility both at levels beyond compensation (Maguire et al., 
2002; Zhang et al., 1997) and directly in the absence of co-evolved protease 
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(Nijhuis et al., 2007b).  Data from our lab and others have shown the role of 
changes in the N terminus of Gag on PI susceptibility, at sites distant from the 
cleavage sites – positions 76, 79 and 81 within MA and 165 within CA (Jinnopat 
et al., 2009; Kameoka et al., 2010; Parry et al., 2009; Parry et al., 2011).       
Given the mounting evidence for the role of Gag in protease inhibitor 
susceptibility, an assessment of the contribution and variability of full-length 
Gag to PI susceptibility in in vitro phenotypic PI susceptibility assays was 
required.  This study was undertaken to further our understanding of the role of 
Gag in PI susceptibility by examining the variation in PI susceptibility of 
treatment-naïve subtype B HIV-1.  Subtype B viruses were selected for several 
reasons.  Firstly, subtype B HIV-1 has a high prevalence in the UK, Western 
Europe and the USA, where routine pre-treatment susceptibility testing is 
performed.  Secondly, a small study looking at subtypes A and C had already 
been carried out so investigation of the other prevalent subtype was prudent 
(Gupta et al., 2010).  Given the highly polymorphic nature of Gag, and that 
some of the changes reported to be associated with resistance are present in 
PI-naïve viruses, we wanted to investigate whether natural variation in Gag 
present in PI-naïve viruses may cause variation in susceptibility to PIs.   
Chapter aims: 
1) Determine PI susceptibility of full-length Gag-protease from six subtype B 
molecular clones utilising a single replication-cycle phenotypic PI 
susceptibility assay 
2) Investigate any variation in PI susceptibility to determine the contribution 
of Gag and protease separately 
3) Identify regions or particular amino acid changes contributing to the 
variation in susceptibility 
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4) Investigate the single-round infectivity of all vectors generated for the 
investigation of PI susceptibility  
5) Investigate the mechanisms by which the change in susceptibility may 
occur  
 
3.2 Results 
3.2.1 Variation in PI susceptibility of full-length Gag-protease observed 
between six different subtype B molecular clones   
Six subtype B molecular clones namely, pHXB2, pNL4-3, pYU2, pJRFL, p89.6 
and pSF2 were obtained from the NIH AIDS Research and Reference Reagent 
Program.  The protease sequences of the molecular clones indicated that none 
had any major or minor PI resistance mutations, as determined by the Stanford 
HIVdb Genotypic Resistance Interpretation Algorithm and comparison to the 
IAS list of Resistance Mutations (Johnson et al., 2013; Liu and Shafer, 2006).  
Full-length gag-protease from the six molecular clones was cloned into 
p8.9NSX+, the Gag-Pol expression vector, using the NotI restriction site located 
before the gag open reading frame and the XhoI restriction site located after the 
protease/RT cleavage site within p8.9NSX+, as shown in figure 2.1.  NotI and 
XhoI restriction sites were introduced into the molecular clone gag-protease 
fragments using standard PCR techniques with primers GagNot+ and 
ProXhoR2.  This led to the creation of six vectors, designated HXB2gagpro, 
NL4-3gagpro, YU2gagpro, SF2gagpro, 89.6gagpro and JRFLgagpro, as 
detailed in table 2.5.  The susceptibility of pseudovirions derived from these six 
constructs was then determined using the single replication-cycle PI 
susceptibility assay, as described in chapter 2, for six PIs: APV, ATV, DRV, 
LPV, SQV and TPV.    
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Differences in susceptibility to each of the six PIs were observed for the 
molecular clone-derived vectors in comparison to that of the assay reference 
strain, p8.9NSX+, as shown in figure 3.1.  Each of the molecular clone-derived 
vectors displayed reduced PI susceptibility in comparison to that of the 
reference strain, and the reduction was statistically significant to at least one PI 
for each molecular clone-derived vector (P < 0.05).  The reductions in 
susceptibility were most significant for PIs APV, ATV and LPV, with up to 9-fold 
reductions in EC50 in comparison to assay reference strain.   
In particular, full-length Gag-protease of three molecular clones (89.6, YU2 and 
SF2) showed statistically significant reductions in PI susceptibility in comparison 
to the assay reference strain to all six of the PIs tested and a fourth molecular 
clone (JRFL) showed statistically significant reductions to five of the PIs.  Using 
the previously determined significance cut-off value in phenotypic assays of ≥ 
four-fold (Gong et al., 2000), these four molecular clones displayed significantly 
decreased susceptibilities to three of the PIs (APV, ATV and LPV) to varying 
degrees in the order: YU2>JRFL>89.6>SF2 (P < 0.01; two sample t test).  The 
largest reductions in PI susceptibility were observed for YU2gagpro (for APV, 
ATV and LPV), JRFLgagpro (for ATV) and 89.6gagpro (for APV) of up to 9-fold, 
9-fold and 8.5-fold, respectively.  For molecular clones HXB2 and NL4-3, the 
EC50 values ranged from 1- to 5-fold reductions in comparison to that of assay 
reference strain for each of the PIs.  The reduction in PI susceptibility was only 
statistically significant for two PIs for NL4-3 (APV and SQV) and three PIs for 
HXB2 (APV, ATV and TPV).    
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Figure 3.1.  Variation in PI susceptibility of full-length Gag-protease derived from six subtype B molecular clones. VSV-g 
pseudotyped viruses encoding luciferase and containing full-length Gag-protease from six subtype B molecular clones were produced by 
co-transfection of 293T cells. PI susceptibility of pseudovirions was determined using a single replication-cycle drug susceptibility assay, 
with infectivity determined by measuring luciferase activity with SteadyGlo. Data displayed are fold difference in EC50 values in 
comparison with that of the reference strain control, p8.9NSX+, for each of six PIs: APV, ATV, DRV, LPV, SQV and TPV. Viruses for 
which the raw EC50 values were statistically different from that of assay reference strain as measured by an unpaired t-test (P < 0.05) are 
denoted with an asterisk(*). Error bars show the standard error of the mean of three independent experiments performed in duplicate. 
The dashed line shows the previously reported cut off for a significant reduction in susceptibility of greater than four-fold in comparison 
with the assay reference strain, derived using a different assay system (Gong et al., 2004). 
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3.2.2 Confirmation of the reproducibility of variation in PI susceptibility 
conferred by full-length Gag-protease from subtype B molecular 
clones 
The reproducibility of the observed reductions in PI susceptibility was further 
investigated to exclude the possibility that the differences were caused by 
variation between individual DNA preparations.  Thus, the PI susceptibility of 
two additional DNA preparations of YU2gagpro and 89.6gagpro was tested in 
parallel with the original DNA stock used for the production of the previous data 
set.  YU2 and JRFL were selected as they displayed the greatest difference in 
PI susceptibility in comparison to the assay reference strain.  The susceptibility 
to the two most variable PIs ATV and APV was determined using the 
phenotypic drug assay, as previously described.   
These data showed no statistically significant differences in PI susceptibility 
between any of the DNA preparations for each molecular clone to either PI, as 
shown in figure 3.2 (P < 0.05).  The pseudovirions derived from molecular clone 
89.6 displayed some variation in susceptibility to APV (between 5- and 8-fold 
difference EC50) and ATV (between 6- and 11-fold difference in EC50), but this 
fell within the limits of inter-assay variability of approximately two-fold and fold-
difference and EC50 values were not significantly different statistically (P <0.05; 
pairwise two-sample t-test).  The DNA preparations of vectors derived from YU2 
displayed little variation in susceptibility to APV (all DNA preparations showed 
around 9-fold difference in EC50) and some variation in susceptibility to ATV 
(between 6- and 12-fold difference in EC50).  The differences in susceptibility 
between DNA preparations were not statistically significant for either PI (P 
<0.05; pairwise two-sample t-test).   
These data demonstrate that the variation in susceptibility of full-length Gag-
protease observed between the six subtype B molecular clones was not an 
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artefact of individual DNA preparations, confirming the validity of the previous 
observations.   
 
Figure 3.2.  Reproducibility of PI susceptibility data shown by testing PI 
susceptibility of multiple DNA preparations.  VSV-g pseudotyped viruses encoding 
luciferase were produced from multiple DNA preparations of p8MCgagpro. Their PI 
susceptibility was measured using a single replication-cycle phenotypic assay and 
expressed as a fold difference in EC50 values in comparison to that of the assay 
reference strain, p8.9NSX+, for the PIs APV and ATV.  None of the differences in 
susceptibility to each PI of different preparations of the same vector were statistically 
significant, as measured by unpaired t-test (P < 0.05). Error bars represent the 
standard error of the mean of three independent experiments. The dashed line shows 
the previously reported cut off for a significant reduction in susceptibility of greater than 
four-fold in comparison with the assay reference strain (Gong et al., 2004). 
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3.2.3 Contribution of Gag to reduction in PI susceptibility observed for 
full-length Gag-protease of subtype B molecular clones 
Having confirmed the validity of our observations, we investigated the role of 
Gag and protease separately in the reduced PI susceptibility observed for 
pseudovirions containing full-length Gag-protease derived from molecular 
clones.  In this analysis, we included full-length Gag-protease vectors for which 
at least four-fold reduction in susceptibility was observed to at least three PIs.  
These criteria resulted in the inclusion of pseudovirions derived from YU2, 
JRFL, SF2 and 89.6 in the analysis, the molecular clones for which Gag-
protease conferred the greatest reduction in susceptibility in comparison to the 
assay reference strain.   
To determine the PI susceptibility of the gag and protease genes separately, 
chimeric vectors containing gag derived from the molecular clone and protease 
from p8.9NSX+, and vice versa, were generated using standard cloning 
techniques for each of the molecular clones of interest, as shown in figure 3.3 
and detailed in table 2.5.  The ‘Gag only’ vector contained the fragment 
between the NotI restriction site (located upstream of Gag) and the ApaI site 
flanking amino acids 406 and 407 of Gag (located within the NC subunit of Gag) 
from the molecular clone, and the remainder of Pol derived from the reference 
strain.  The ‘protease only’ vector contained the fragment between the ApaI site 
and the XhoI site (located downstream of protease) of the molecular clones.  
Use of the ApaI site for the generation of these chimeric vectors results in the 
protease only vector containing the C terminus of NC, p1 and p6 from Gag in 
addition to protease from the molecular clone, with the remainder derived from 
the assay reference strain, as shown in figure 3.3a.  Conversely, the Gag only 
chimeric virus did not contain full-length Gag derived from the molecular clone 
with the C terminal portion of NC, p1 and p6 derived from the reference strain.  
Since the ApaI restriction site was not present in molecular clone YU2 it was 
introduced by site-directed mutagenesis before cloning into p8.9NSX+.  The PI 
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susceptibility of the chimeric pseudovirions to the three PIs APV, ATV and LPV 
was determined using the single replication-cycle PI susceptibility assay, as 
previously described.  
For molecular clones JRFL and YU2, the Gag only chimeric pseudovirions 
displayed significant reductions in PI susceptibility in comparison to assay 
reference strain, whereas the protease only chimeric pseudovirions had PI 
susceptibilities similar to that exhibited by the assay reference stain (Figure 3.3b 
and 3c).  The difference in the fold-difference EC50 values for the Gag only and 
protease only chimeric viruses were statistically significant to APV and ATV for 
JRFL, and to all three PIs for YU2 (P < 0.05).  These data indicate that for 
molecular clones JRFL and YU2, Gag solely conferred the reduced PI 
susceptibility observed for the full-length Gag-protease fragment and provide 
evidence that the effect of Gag on PI susceptibility can be conferred in the 
absence of co-evolved protease. 
In contrast, both the Gag only and the protease only chimeric pseudovirions 
derived from molecular clones 89.6 and SF2 showed reduced susceptibilities of 
up to 4-fold in EC50 in comparison to assay reference stain (Figure 3.3d and 
3e).  For both SF2 and 89.6, the Gag only chimeric virus displayed a statistically 
significant reduction in PI susceptibility in comparison to the protease only 
chimeric virus to the PI LPV (P < 0.05).  Overall, both Gag and protease of 
molecular clones 89.6 and SF2 independently contribute to the reduced 
susceptibility observed for full-length Gag-protease.  However, Gag 
independently conveys greater reductions in susceptibility than protease, in 
particular for molecular clone 89.6.   
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Figure 3.3. Reduced PI susceptibility of molecular clone Gag-protease is independently conferred by both the gag and protease genes.  
Chimeric vectors containing only Gag or only protease from the molecular clone of interest were generated using cloning techniques, as shown in (a). 
Segments of the chimeric viruses derived from the assay reference strain, p8.9NSX+, are depicted in white, and that from molecular clones shaded 
grey. The PI susceptibility of Gag only and protease only chimeric pseudoviruses was determined for molecular clones (b) JRFL, (c) YU2, (d) SF2 
and (e) 89.6 using a single replication-cycle assay measuring luciferase activity with SteadGlo. Data are expressed as a fold difference in EC50 in 
comparison to that of the assay reference strain, p8.9NSX+. The PIs for which MCgag and MCpro displayed significantly different susceptibilities 
using an unpaired t-test (P < 0.05) are denoted with an asterisk(*). Error bars represent standard error of the mean of three independent experiments.    
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3.2.4 Role of the N terminus of Gag in reduced PI susceptibility exhibited 
by JRFL and YU2 Gag-protease 
To further investigate the reduced PI susceptibility conferred by JRFL and YU2 
Gag, we sought to identify a specific region of Gag conferring the reduced 
susceptibility observed.  Only JRFL and YU2 were included in this analysis as 
these were the molecular clones in which Gag was shown to solely confer the 
reduced susceptibility observed for full-length Gag-protease.  Chimeric gag 
vectors were constructed using a unique SpeI restriction site, flanking amino 
acids 240 and 241 of Gag within the CA subunit.  This led to the generation of 
two chimeric vectors for each molecular clone: gagN, containing the N terminus 
of Gag derived from the molecular clone and the C terminus of Gag and 
protease from p8.9NSX+, and gagC, containing the C terminus of Gag derived 
from the molecular clone and the N terminus of Gag and protease from 
p8.9NSX+, as shown in figure 3.4a and table 2.5.  In the resulting chimeric 
pseudovirions, the N terminal region included MA and partial CA, with the C 
terminal region encompassing the remainder of CA, p1, p2 and part of NC.  The 
remainder of NC, p6 and protease were derived from the reference strain 
p8.9NSX+.  The susceptibility of these vectors was then determined using the 
single replication-cycle drug susceptibility assay for PIs APV, ATV and LPV. 
Reduced susceptibility to the three PIs APV, ATV and LPV was observed for 
the gagN-derived pseudovirions of up to 7- and 16-fold difference for JRFL and 
YU2, respectively, as shown in figure 3.4b and c.  The gagC-derived 
pseudovirions of both JRFL and YU2 showed susceptibilities at levels similar to 
that of assay reference strain to all PIs with no significant fold-difference in 
EC50.  For each PI the difference in susceptibility between the gagN and gagC 
pseudovirions for each molecular clone was statistically significant (P < 0.05).  
These data demonstrate that for both YU2 and JRFL, the N terminal portion of 
Gag encompassing MA and the beginning of CA, is largely responsible for the 
reduced susceptibility observed for full-length Gag.  There is no evidence that 
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the C terminal portion of Gag can confer reduced susceptibility independent of 
the N terminus.   
 
 
 
 
 
 
 
 
 
 
Figure 3.4. PI susceptibility of chimeric viruses derived from the N terminus and 
C terminus of molecular clone Gag demonstrates reduced susceptibility is 
conferred by the N terminus of Gag. (a) Schematic diagram of chimeric vectors 
created by standard cloning techniques containing  either the N terminus (MCgagN) or 
the C terminus (MCgagC) from each molecular clone. Segments of the chimeric 
viruses derived from the reference strain, p8.9NSX+, are depicted in white, and those 
from the molecular clones shaded grey. The susceptibilities to three PIs (APV, ATV 
and LPV) of the pseudovirions generated from these chimeric vectors for two molecular 
clones are displayed (b) JRFL and (c) YU2. PI susceptibility was determined in a 
single-round assay by measuring luciferase activity. The PIs for which MCgagN and 
MCproC displayed significantly different susceptibilities using an unpaired t-test (P < 
0.05) are denoted with an asterisk(*). Error bars represent the standard error of the 
means of three independent experiments. The dashed line shows the previously 
reported cut off for a significant reduction in susceptibility of greater than four-fold in 
comparison with the assay reference strain (Gong et al., 2004).     
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3.2.5 Genetic determinants in Gag responsible for the reduced 
susceptibility to PIs in the molecular clones YU2 and JRFL   
Alignment and comparison of the molecular clone nucleotide sequences was 
performed to identify amino acid changes within Gag which could account for 
the reduced PI susceptibility observed. Sequence analysis of the Gag cleavage 
sites found no previously reported mutations that could account for this variation 
in susceptibility and only the p2/NC cleavage site, within the C terminus of Gag, 
showed sequence variation, as demonstrated in figure 3.5. The p2/NC is the 
most variable cleavage site, and the changes did not correlate with the 
molecular clones for which the reduced susceptibility of Gag was observed.   
 
 
 
 
 
 
 
 
 
Figure 3.5. The amino acid sequences of Gag cleavage sites for the six subtype 
B molecular clones included in this study demonstrate no correlation between 
genotype and phenotypic susceptibility. Consensus group M virus amino acid 
sequence at each Gag cleavage site is shown, and no variation was present at these 
sites in the molecular clones except at the p2/NC site. The amino acid sequence for 
each molecular clone is displayed for the p2/NC sequence. 
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In addition, nine amino acid changes in Gag that have been previously 
described as being associated with resistance or exposure to PIs were present 
in at least one of the molecular clones, as detailed in table 3.1.  However, none 
of these correlated with the changes in phenotypic PI susceptibility observed as 
none were present in both molecular clones in which Gag solely conferred the 
reduced susceptibility, YU2 and JRFL, or in all four molecular clones in which 
significant reductions in susceptibility for full-length Gag-protease were 
observed, YU2, JRFL, 89.6 and SF2. 
  
Table 3.1. Mutations in Gag of the molecular clones that have previously 
been associated with PI exposure or resistance do not correlate with 
phenotypic susceptibility.  
Previously described Gag mutation Present in (molecular clone)  
R76K 89.6 
H219Q 89.6 
S373P NL4-3, JRFL, SF2, p8.9NSX+ 
T375N SF2 
R380K NL4-3, p8.9NSX+ 
I389T NL4-3, YU2, SF2, 89.6 
I401T HXB2 
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Analysis of the amino acid sequence of the N terminus of Gag identified only 
one residue, at position 30, where an amino acid change occurs exclusively in 
YU2 and JRFL, the two molecular clones for which Gag solely contributed to 
reduced PI susceptibility observed for full-length Gag-protease, as 
demonstrated in figure 3.6. Another amino acid change at position 102 was 
present in both YU2 and JRFL and was also present in SF2, in which both Gag 
and protease contributed in part to the reduced PI susceptibility of full-length 
Gag-protease. Both of these positions are in the MA subunit within the N 
terminal segment of Gag shown to confer reduced susceptibility in these 
molecular clones. In addition, there were a number of unique changes from 
consensus B sequence in either YU2 or JRFL and within the N terminus of Gag 
these changes were T53S, Q69K, R76T, V94I, N109T, K112M and V159I for 
pJRFL and G10A, K28Q, N47D and R91K for pYU2.  
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HXB2  MGARASVLSG GELDRWEKIR LRPGGKKKYK LKHIVWASRE LERFAVNPGL 50 
NL4-3 .......... ....K..... .......Q.. .......... .......... 
JRFL  .......... .......... .........R .......... .......... 
YU2   .........A ....K..... .......Q.R .......... ......D... 
SF2   .......... ....K..... .......... .......... .......... 
89.6  .......... .......... .......... .......... ........S. 
 
HXB2  LETSEGCRQI LGQLQPSLQT GSEELRSLYN TVATLYCVHQ RIEIKDTKEA 100 
NL4-3 .......... .......... .......... .I.V...... ..DV...... 
JRFL  ..S....... ........K. .....T.... .......... .......... 
YU2   .......... .......... .......... .......... K..V...... 
SF2   .......... .......... .......... .......... ..DV...... 
89.6  .......... .....S.... .....K.... .......... ...V...... 
 
HXB2  LDKIEEEQNK SKKKAQQAAA --DTGHSNQV SQNYPIVQNI QGQMVHQAIS 150  
NL4-3 .......... .......... --...NNS.. .........L .......... 
JRFL  .E......T. .M........ --...N.S.. .........L .......... 
YU2   .E........ .......... --...N.S.. .........L .......... 
SF2   .E........ .......... AAG..N.S.. .........L .......... 
89.6  .......... .......... --...N.S.. .......... .......... 
 
HXB2  PRTLNAWVKV VEEKAFSPEV IPMFSALSEG ATPQDLNTML NTVGGHQAAM 200  
NL4-3 .......... .......... .......... .......... .......... 
JRFL  .......... I......... .......... .......... .......... 
YU2   .......... .......... .......... .......... .......... 
SF2   .......... .......... .......... .......... .......... 
89.6  .......... .......... .......... .......... .......... 
 
HXB2  QMLKETINEE AAEWDRVHPV HAGPIAPGQM REPRGSDIAG TTS 242         
NL4-3 .......... ......L... .......... .......... ... 
JRFL  .......... ......L... .......... .......... ... 
YU2   .......... ......L... .......... .......... ... 
SF2   .......... .......... .......... .......... ... 
89.6  .......... ......L... Q...V..... .......... ... 
 
Figure 3.6. Amino acid sequences of the N terminus of Gag of six subtype B 
molecular clones. Schematic showing the amino acid sequence of the six subtype B 
molecular clones used for this study, up to the SpeI cleavage site which is the length 
contained within the N terminus chimeric virus. p8.9NSX+ is not shown separately as it 
is derived from HXB2 so is identical up to the SpeI cleavage site, The SpeI site is 
denoted by a blue dashed line and the MA/CA cleavage site by a green dashed line. 
The amino acid substitutions found in both JRFL and YU2, the molecular clones for 
which Gag solely confers the reduced susceptibility observed for full-length Gag-
protease, are highlighted with a red arrow. The unique changes present in either YU2 
or JRFL are highlighted with a blue arrow.  
D102E MA/CA cleavage site 
SpeI cleavage site 
Gag & MA Start K30R 
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3.2.6 Role of amino acid changes in N terminal region of Gag on PI 
susceptibility  
To investigate the role of the identified changes within the N terminus of Gag in 
the observed reduction in PI susceptibility, the two changes present in both 
JRFL and YU2 – K30R and D102E – were reverted to consensus B sequence 
using site-directed mutagenesis.  Reversions were carried out in the vectors 
containing full-length Gag-protease derived from the two molecular clones 
leading to the creation of three vectors for each: pMC_R30K, pMC_E102D and 
pMC_2M, the latter which contained both the R30K and E102D reversions 
(figure 3.7a).  In addition, the amino acid changes were introduced into the 
pMCgagN vectors to examine the effect on PI susceptibility in the absence of 
co-evolved C terminus of Gag and protease.  These vectors were designated 
MCgagN_R30K, MCgagN_E102D and MCgagN_2M (figure 3.8a).  The 
susceptibility of pseudovirions derived from these vectors was determined for 
three PIs, APV, ATV and LPV, using the phenotypic drug susceptibility assay as 
previously described.   
In general, the reversion of at least one of the positions in both MCgagpro and 
MCgagN vectors increased the susceptibility of the virus to all three PIs towards 
that of the reference strain, as shown in figures 3.7 and 3.8.  The differences in 
susceptibility between MCgagpro and the mutant pseudovirions were 
statistically significant for JRFL and YU2 in susceptibility to ATV, figure 3.7 (P < 
0.05).  Similarly, the differences in PI susceptibility between MCgagN and the 
mutant pseudovirions were significant for ATV, figure 3.8 (P < 0.05).  For 
molecular clone JRFL, the reversion of K30R appeared to cause a greater 
increase in the PI susceptibility of the pseudovirions than the D102E reversion, 
although this observation was not statistically supported.  Conversely, for YU2 
the D102E appeared to cause the greatest increase in susceptibility of the two 
mutations, although again this was not statistically supported.  For each 
molecular clone, the independent effects of the single mutants on PI 
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susceptibility were comparable to that of the double mutant suggesting an 
additive rather than synergistic effect of the two amino acid changes.  Overall, 
these data indicate that the R30K and E102D changes contributed to the 
reduced susceptibility observed for full-length Gag-protease of JRFL and YU2.  
However, these reversions do not increase the PI susceptibility to levels similar 
to that of the assay reference strain Gag-protease, indicating the involvement of 
other as yet unidentified residues.  
A p8.9NSX+ vector in which the R30K and E102D changes were introduced 
was generated, denoted p8.9SDMgag.  However when transfected this vector 
did not produce any infectious pseudovirions in our system.  Hence, it was not 
possible to determine the effect of the R30K and E102D amino acid changes on 
the PI susceptibility of the assay reference strain.   
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Figure 3.7. Role of amino acids 30 and 102 of Gag in variation in PI susceptibility 
of full-length Gag-protease. (a) Schematic diagram of MCgagpro dervied vectors 
containing reversions to consensus B sequence of mutations at positions 30 and 102 of 
Gag, generated using standard site-directed mutagenesis techniques. The position of 
the mutations introduced is marked with an asterisk (*) on the schematic. The 
susceptibilities of pseudovirions generated with the vectors to three PIs (APV, ATV and 
LPV) are displayed for (b) JRFL and (c) YU2. PI susceptibility of pseudovirions was 
determined in a single-cycle assay by measuring luciferase activity. Pseudovirions for 
which the fold-difference in EC50 value was statistically different from that of MCgagpro 
using an unpaired t-test (P < 0.05) are denoted with an asterisk(*). Error bars represent 
the standard error of the mean of three independent experiments. The dashed line 
shows the previously reported cut off for a significant reduction in susceptibility of 
greater than four-fold in comparison with the assay reference strain (Gong et al., 2004).   
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Figure 3.8. Role of amino acids 30 and 102 of Gag in variation in PI susceptibility 
of MCgagN derived pseudovirions. (a) Schematic diagram of MCgagN dervied 
vectors containing reversions to consensus B sequence of mutations at positions 30 
and 102 of Gag, generated using standard site-directed mutagenesis techniques. The 
position of the mutations introduced is marked with an asterisk (*) on the schematic.  
The susceptibilities of pseudovirions generated with the vectors to three PIs (APV, ATV 
and LPV) are displayed for (b) JRFL and (c) YU2. PI susceptibility of pseudovirions 
was determined in a single-cycle assay by measuring luciferase activity. None of the 
differences in PI susceptibility from MCgagN were statistically significant using an 
unpaired t-test (P < 0.05). Error bars represent the standard error of the mean of three 
independent experiments. The dashed line shows the previously reported cut off for a 
significant reduction in susceptibility of greater than four-fold in comparison with the 
assay reference strain (Gong et al., 2004).   
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3.2.7 Single-round infectivity of the molecular clone-based vectors 
Having explored the PI susceptibilities of vectors containing full-length Gag-
protease from molecular clones, Gag and protease separately, the N terminus 
and C terminus of Gag separately and those with reversions at amino acids 30 
and 102 of Gag within full-length Gag-protease, the single-round infectivity of 
each of the vectors was investigated.  Pseudovirions were harvested 48 hours 
post-transfection from the supernatant of transfected cells and passed through 
a 0.45 μM filter to remove contaminants.  Pseudovirions were then titrated in the 
absence of drug to measure infectivity and the results were normalised by the 
amount of p24 in the pseudovirion preparations, quantified by ELISA.   
The single-cycle infectivity data for each of the vectors generated during this 
study are displayed in figure 3.9.  The values for the JRFL-based vectors were 
all comparable to that of the assay reference strain (set as 100%), ranging from 
76-112% as shown in figure 3.9a.  The values for the YU2 based vectors were 
also similar to that of assay reference strain ranging between 87-100%, except 
for that of YU2gag which had a value 189% that of the reference strain (figure 
3.9b).  However, the single-round infectivity of YU2gag was not significantly 
different statistically from YU2gagpro, YU2gagN or YU2gagC (P > 0.05).  The 
single-round infectivities of the SF2-based vectors were higher than that of the 
assay reference strain, ranging from 237% for SF2gagpro to 158% for SF2pro 
as shown in figure 3.9c.  However the differences in value between SF2gagpro 
and SF2gag or SF2pro were not statistically significant, nor was the difference 
between SF2gag and SF2pro (P > 0.05).  The single-round infectivities of the 
89.6-based vectors were broadly similar to that of reference strain, ranging from 
110-136% as shown in figure 3.9d.  The differences between 89.6gagpro and 
89.6gag or 89.6pro were not statistically significant, nor was the difference 
between 89.6gag and 89.6pro (P > 0.05).   
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For each molecular clone, the separation of co-evolved Gag and protease did 
not appear to affect the single-round infectivity of the p8.9NSX+ based vectors. 
In addition, there was no evidence that the reversion of changes at amino acid 
positions 30 and 102 of Gag, which were shown to affect PI susceptibility, 
affected the single-round infectivity significantly.   
 
Figure 3.9. Limited variation between the single-round infectivity of molecular 
clone derived, p8.9NSX+ based vectors. The infectivity of pseudovirions produced 
from co-transfection of 293T cells was determined by titration of a single-cycle of 
infection, adjusted following p24 quantification. Luciferase activity was measured using 
SteadyGlo and expressed as a fold difference in comparison with that of the assay 
reference strain, p8.9NSX+. The single-round infectivity of all p8.9NSX+ based vectors 
derived from molecular clones (a) JRFL, (b) YU2, (c) SF2 and (d) 89.6 explored in this 
study are displayed. None of the differences in susceptibility between related vectors of 
the same molecular clone were statistically different using unpaired t-test (P < 0.05). 
Error bars are standard error of the means of two independent experiments. 
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3.2.8 Analysis of the mechanisms underlying the reduced susceptibility 
to PIs conferred by Gag-protease of molecular clones 
HIV-1 Gag protein has been shown to control the proper assembly and 
morphology of HIV-1 nucleocapsid resulting in production of either immature 
(non-infectious) or mature (infectious) virus particles (as reviewed by Ono, 
2010).  To investigate whether an effect on virion morphology was contributing 
to the effect on PI susceptibility conferred by the Gag protein of molecular 
clones YU2 and JRFL, we used electron microscopy (EM) to visualise the 
morphology of nascent virions of reference strain- and molecular clone-derived 
virions, produced in the presence and absence of PI inhibitors.  
3.2.8.1 Optimisation of transfection protocol for EM 
Firstly, we undertook optimisation of our transfection protocol to ensure the best 
possible yield of pseudovirions for EM.  In total six different transfection 
conditions were compared, each a variation on the transfection method used 
successfully for the generation of pseudovirions for the PI susceptibility and 
single-round infectivity phenotypic assays.  The effect of three variables on 
transfection efficiency was tested, these being: volume of transfection reagent 
(Fugene-6), total amount of DNA and the ratios of the three assay plasmids 
(p8.9NSX+, pCSGW and pMDG).  In addition, a second transfection reagent 
was tested, PEI.  To enable visualisation of transfected and infected cells, 
pCSGW (which expressed GFP, green fluorescence protein) was utilised in the 
place of pCSFLW.  The six transfection conditions tested are detailed in table 
3.3.  At high confluence, 293T cells do not adhere adequately to cover-slips as 
required for IF so we also tested a two-fold reduction in the number of cells 
seeded for transfection.  Despite these optimisation steps the transfected cells 
still produced microvesicles and long membrane protrusions, as shown in figure 
3.10.  These structures were often difficult to distinguish from the real viral 
particles.  It was hypothesised that this could be partly due to the toxicity of 
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VSV-G envelope (Burns et al., 1993).  Hence, we also carried out transfection 
with reduced amounts of VSV-G envelope vector, pMDG.   
 
Table 2.3. Transfection optimisation conditions tested. 
Condition 
# 
Volume 
Fugene 
(μl) 
Total 
DNA (μg) 
Plasmid amount (ratio) 
p8.9NSX+ pMDG pCSFLW 
1 6 1.1 300 ng 300 ng 500 ng 
2 18 3 1 μg 1 μg 1 μg 
3 6 1.1 480 ng (2) 120 ng (1) 360 ng (3) 
4 6 1.1 600 ng (2) 150 ng (1) 300 ng (2) 
5 18 3 1.44 μg (2) 360 ng (1) 1.08 μg (3) 
6 none – 
PEI used 
1.1 300 ng 300 ng 500 ng 
 
Figure 3.10 (next page). Electron micrographs of 293T cells transfected 
using Fugene-6 reagent. 293T cells were plated on cover slips and co-
transfected with p8.9NSX+, pMDG expressing VSV-g and pCSFLW, expressing 
luciferase reported gene. After 48 hours, cells were fixed, strained, sectioned 
and mounted viewing by electron microscopy. (a) An electron micrograph of 
transfected cells is shown, and pseudovirions budding from the surface cannot 
be seen. (b) The presence of microvesicles and membrane protrusions as a 
result of transfection is shown.  Bar in (a) is 2 μm and (b) is 500 nm 
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Transfection efficiency was measured by a qualitative comparison of the 
number of cells expressing GFP and the levels of GFP expression using 
fluorescence microscopy. GFP expression was visualised 48-hours post-
transfection using fluorescence microscopy and pseudovirions were harvested 
at this stage by filtration using a 0.45 μM filter to remove cellular debris. The 
pseudovirions were titrated and the levels of GFP expression for the top 
pseudovirus concentration (50 μl in 125 μl DMEM) and a two-fold dilution were 
visualised using fluorescence microscopy.    
Representative microscopy pictures of transfected 293T cells taken 48-hours 
post-transfection for each set of transfection conditions are shown in figure 
3.11. The effect of a higher volume of Fugene-6 and amount of total DNA are 
shown in transfection conditions 2 and 5, that displayed higher levels of GFP 
expression than the other transfection conditions. Transfection condition 6 
utilised an alternative transfection reagent, PEI, which resulted in much lower 
GFP expression and thus transfection efficiency than those performed with 
Fugene-6. Plasmid ratios also affected GFP expression as comparison of 
conditions 1 (standard ratio: 300 ng p8.9NSX+, 500 ng pCSGW, 300 ng 
pMDG), 3 (3:2:1) and 4 (2:2:1) showed that the 2:2:1 plasmid ratio resulted in 
lower levels of GFP expression. Comparison of transfection conditions 2 (2:2:1) 
and 5 (3:2:1) demonstrated that the 3:2:1 plasmid ratio resulted in the highest 
levels of GFP expression. However, this may simply have occurred because 
less pCSGW was transfected and did not necessarily represent lower 
transfection efficiency and pseudovirion production. Finally, reduction of cell 
number as in transfection condition 7 resulted in markedly lower numbers of 
transfected cells and levels of GFP expression. Whilst visualizing GFP is a 
useful surrogate for transfection efficiency, it can overestimate the proportion of 
cells infected as pseudovirions can infect untransfected cells making them 
express GFP and hence appear transfected.        
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Figure 3.11. Transfection efficiency of different conditions, measured by 
GFP expression. 293T cells were co-transfected with p8.9NSX+, pCSGW and 
pMDG and GFP expression visualised 48-post transfection using fluorescence 
microscopy. Different volumes of the transfection reagent Fugene were tested 
(6 ul for 1, 3, 4 and 7 with 1.1 ug total DNA; 18 ul for 2 and 5 with 3 ug of total 
DNA), with PEI used for 7. In addition, different ratios of the three plasmids 
were tested as described fully in table 2.3. Pictures taken at x100 magnification.     
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Representative microscopy pictures taken following titration of pseudovirions 
are shown in figure 3.12, enabling an approximate quantification of the amount 
of pseudovirus production for each transfection condition. Levels of GFP 
expression and the number of cells expressing GFP at both the top pseudovirus 
concentration and the two-fold dilution are shown. At the top pseudovirus 
concentration, transfection conditions 1-5 appeared to result in similar levels of 
GFP expression, however conditions 6 and 7 resulted in far lower levels of GFP 
expression. At the two-fold dilution, GFP expression was lowest for conditions 1 
and 3 and highest for 2 and 5.  Overall transfection efficiency and virion 
production, as measured by GFP expression after titration, was optimal with 18 
μl Fugene-6 and 3 μg total DNA. As a plasmid ratio of 3 p8.9NSX+: 2 pCSFLW : 
1 pMDG resulted in the least amount of pMDG being used without 
compromising levels of pseudovirus production, these conditions were used for 
EM experiments.  
 
 
 
 
 
Figure 3.12 (next page). Pseudovirus yield of different transfection 
conditions. Pseudovirions produced from different transfection conditions were 
harvested 48 hours post-transfection and infectivity determined by titration for 
each transfection condition, as detailed fully in table 2.3. GFP expression at the 
top concentration and 1:2 dilution are shown. Pictures were taken at x100 
magnification. These data show that 18 ul of fugene with 3 ug was optimal 
(conditions 2 and 5), with a plasmid ratio of 3 pCSGW: 2 p8.9NSX+: 1 pMDG 
selected to minimise the amount of toxic pMDG used.   
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3.2.8.2 Development of EM methods for visualisation of HIV-1 virions  
EM methods for visualisation of HIV-1 pseudovirions were not established at 
PHE. We therefore developed these techniques in collaboration with the 
electron microscopist at PHE, Dr Matthew Hannah.   
Previous reports have visualised HIV-1 virus and pseudovirus assembly and 
maturation by capturing the virions as they bud from the cells (Muller et al., 
2009). Using sample preparation and EM techniques detailed in chapter 2, we 
visualised 293T cells 24- and 48-hours post-transfection. At both time points no 
pseudovirions were observed, although membrane protrusions and 
microvesicles were present, as shown in figure 3.12. IF confirmed the presence 
of Gag in approximately 30% of the cells, indicating that transfection efficiency 
was sufficient for virion production (figure 3.13). To accurately determine the 
proportion of mature pseudovirions, large numbers of pseudovirions would need 
to be counted and this preliminary experiment showed that this could not be 
achieved by sectioning of transfected cells.   
However, pseudovirions should be present in large numbers in the supernatant 
of transfected cells following budding so we developed methods to perform EM 
on the cell media. Supernatants were collected 48-hours post-transfection, 
subjected to low-speed centrifugation to remove cellular debris and high-speed 
centrifugation to concentrate the pseudovirions into a pellet. Pellets were fixed 
and embedded in epoxy resin. Serial ultrathin section of the pellets were cut 
and mounted on slot grids before staining and visualisation on the electron 
microscope. The first experiment included only p8.9NSX+ derived 
pseudovirions produced in the presence and absence of the PI ATV and a mock 
transfection control.  Electron micrographs in figure 3.14 showed the presence 
of many pseudovirions, both mature and immature. However, microvesicles of 
similar size to the pseudovirions were present in both the pseudovirion 
preparations and the mock transfected control, as shown in figure 3.14.  
Attempts to purify the pseudovirions away from the microvesicles using a 
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sucrose gradient were unsuccessful and further investigation revealed that the 
microvesicles co-purify with pseudovirions during ultracentrifugation (Greg 
Towers, personal communication). Thus, EM had to be carried out without 
purification of pseudovirions, but a stringent strategy was devised to prevent 
inclusion of the microvesicles in the final counts. The counting of immature 
virions was straightforward as they can be distinguished from mature virions 
and microvesicles by the uncleaved Gag polyrotein that is seen as a 
characteristic thick collar within the virion. However, mature virions can be 
similar morphologically to microvesicles, depending on the orientation at which 
the virion is sectioned. To avoid the accidental inclusion of microvesicles in the 
counts of mature pseudovirions, only virions with a conical capsid were 
included. This meant that mature pseudovirions sectioned in orientations that 
resulted in a circular or elliptical capsid were excluded, as shown in figure 3.15.  
Hence our mature pseudovirion counts were an underestimation, although still 
comparable between the molecular clones, as discussed in section 3.3 and 
shown in figure 3.20.  
Using these counting criteria, approximately 60 virions were counted in the 
p8.9NSX+ preparation with and without ATV (figure 3.14) and a significant 
difference in the proportion of mature virions was observed between the 
pseudovirions produced in the absence of PI (25.4% immature and 74.6% 
mature) and those produced with ATV (51.6% immature and 48.4% mature).   
As a difference in the proportion of mature pseudovirions was detected between 
the pseudovirions produced in the presence and absence of PI, this method 
could be applied to the molecular clone based pseudovirions to enable a 
comparison of the effect of the Gag-protease derived from molecular clones on 
assembly and maturation of HIV-1 virions.   
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Figure 3.13. Immunofluorescence demonstrates successful transfection of 293T 
cells and Gag expression. 293T cells were plated on coverslips and co-transfected 
with p8.9NSX+, pMDG and pCSFLW. Cells were fixed 48-hours post transfection and 
IF staining for Gag protein was carried out, using a monoclonal antibody targeting Gag 
CA (p24) #4121 (section 2.4.1).  Representative pictures of cells using light (a and c) 
and fluorescence (b and d) microscopy show expression of Gag in a significant 
proportion of cells. 
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Figure 3.14: Electron micrographs of pseudovirions. 293T cells were co-
transfected and pseudovirions harvested from supernatants and prepared for electron 
microscopy. Electron micrographs of supernatants from (a) mock transfection, (b) 
p8.9NSX+ pseudovirions produced without PI and (c) p8.9NSX+ with drug are shown. 
All at the same magnification x12,000, the bar represents 500 μm. 
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Figure 3.15 
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Figure 3.15. Counting strategy utilised for electron microscopy 
experiments. Following preliminary experiments demonstrating the presence of 
microvesicles of similar morphology to virions, a counting strategy was devised 
to avoid their accidental inclusion in the counts of the proportion of immature 
and mature pseuovirions. (a) A typical EM of pseudovirions at x15,000 
magnification is shown and (b) the counting strategy employed demonstrated 
(mature pseudovirions counted highlighted in blue and immature in orange). 
Immature (c) and mature pseudovirions (d) are shown at higher magnification 
25,000 x. Only mature pseudovirions with a clear conical-shaped capsid were 
included in the count.    
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3.2.8.3 Comparison of the proportion of mature pseudovirions in the 
presence of ATV for vectors p8.9NSX+, p8YU2gagpro, 
p8JRFLgagpro  
Having shown reduced susceptibility of p8YU2gagpro and p8JRFLgagpro in 
comparison to p8.9NSX+, the mechanisms by which the reduced susceptibility 
was conveyed were investigated.  Since PIs block Gag cleavage and virus 
maturation, we sought to use the EM techniques discussed above to investigate 
whether the presence of the EC90 of ATV for p8.9YU2gagpro (25 nM) resulted 
in different proportions of mature pseudovirions derived from vectors p8.9NSX+, 
p8YU2gagpro and p9JRFLgagpro.  Transfections were performed in duplicate 
for each vector and 18 hours post-transfection, ATV was added to the media at 
25 nM, the EC90 as determined by the PI susceptibility assays.  48 hours post-
transfection, pseudovirions were processed for EM as previously described.  
Pseudovirions were counted on sections taken from two different parts of each 
pseudovirus pellet to reduce the possibility of an effect of the position within a 
pellet on the proportions of mature pseudovirions present.  In addition, the 
experiment was performed in duplicate and the virus pellet created by 
centrifugation embedded in a different orientation and thus sectioned differently 
for each of the duplicate transfections, to further reduce the possibility of bias.  
400 virions in total were counted for each virus with and without drug, 200 from 
different sections of the pellet.   
Figure 3.16 shows the proportion of mature virions in each sample and 
representative electron micrographs for the assay reference strain and each 
molecular clone are shown in figures 3.17, 3.18 and 3.19. In the absence of 
ATV the proportion of mature pseudovirions was similar for each of the three 
molecular clones based vectors p8.9NSX+, p8YU2gagpro and p9JRFLgagpro, 
of between 83.9 and 87.7%. For p8.9NSX+ and p8JRFLgagpro, addition of ATV 
significantly reduced the proportion of mature pseudovirions to 47% and 52%, 
respectively (P < 0.05).  However, addition of ATV did not significantly affect the 
proportion of mature pseudovirions for p8YU2gagpro, 80%.   
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These data demonstrate that at an ATV concentration of 25 nM, the maturation 
of pseudovirions derived from p8.9NSX+ and p8YU2gagpro is significantly 
inhibited, but this has no effect on the maturation of p8JRFLgagpro-derived 
pseudovirions.   
 
Figure 3.16. Presence of ATV affects the proportion of mature pseudovirions 
present for YU2, but not JRFL. Pseudovirions were produced in the presence and 
absence of ATV by co-transfection of 293T cells. Pseudovirions were harvested from 
the cell media, then fixed, stained and embedded for EM. Data are results of two 
independent experiments, with each performed in duplicate, to count 200 virions as 
either mature or immature (in total these data represent the proportion of 800 virions 
that were mature, counted from four separate EM sections, derived from two 
transfections). The proportion of mature pseudovirions in the absence (blue bars) and 
presence (red bars) of ATV is shown. Error bars are derived from the standard error of 
the mean of the two independent repeats. Molecular clones for which the proportion of 
mature virions was statistically different in the presence of absence of drug, as 
measured by an unpaired t-test (p < 0.05), are marked by an asterisk(*).  
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Figure 3.17. Electron micrographs of p8.9NSX+ pseudovirions assembled in the 
presence and absence of the PI ATV. Pseudovirions were produced in 293T cells in 
the presence and absence of the PI ATV. Pseudovirions were harvested from the 
media and fixed, stained and sectioned for electron microscopy. Both electron 
micrographs are at 15,000x magnificication and bars represent 100 nm.  
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Figure 3.18. Electron micrographs of p8YU2gagpro pseudovirions assembled in 
the presence and absence of the PI ATV. Pseudovirions were produced by co-
transfection of 293T cells in the presence and absence of the PI ATV. Pseudovirions 
were harvested from the media and fixed, stained and sectioned for electron 
microscopy. Both electron micrographs are at 15,000x magnificication and bars 
represent 100 nm.  
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Figure 3.19. Electron micrographs of p8JRFLgagpro pseudovirions in the 
assembled in the presence and absence of the PI ATV. Pseudovirions were 
produced by co-transfection of 293T cells in the presence and absence of the PI ATV. 
Pseudovirions were harvested from the media and prepared for electron microscopy. 
Both electron micrographs are at 15,000x magnificication and bars represent 100 nm.  
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3.3 Discussion 
Here we demonstrate variation in PI susceptibility in PI-naïve subtype B viruses 
when full-length co-evolved Gag-protease is included in a phenotypic PI 
susceptibility assay. We show reduced PI susceptibility of four widely used 
molecular clones YU2, SF2, JFRL and 89.6, to a number of PIs of up to 9-fold in 
comparison to assay reference strain. To our knowledge this is the first 
demonstration of variation in PI susceptibility of full-length Gag-protease from 
wild-type subtype B HIV-1 viruses. However, this is in keeping with another 
study that has demonstrated variation in PI susceptibility of full-length Gag-
protease from PI-naïve subtype A and C viruses (Gupta et al., 2010).   
Generation of chimeric pseudovirions provided evidence that for YU2, SF2, 
JFRL and 89.6, Gag independently contributes to the reduced PI susceptibility 
observed for full-length Gag-protease, at least in part. For two molecular clones, 
JRFL and YU2, the reduced susceptibility can be attributed solely to the gag 
gene (the region of Gag up to the ApaI cleavage site, encompassing MA, CA, 
p2 and part of NC). This is in agreement with other studies which have shown 
the role of Gag in PI susceptibility for subtype A and C molecular clones (Gupta 
et al., 2010), subtype A and CRF01_AE viruses from treatment- naïve HIV-1 
infected patients (Gupta et al., 2010; Jinnopat et al., 2009), subtype B from 
treatment-experienced HIV-1 infected patients (Dam et al., 2009; Parry et al., 
2009) and from PI resistant viruses created by in vitro passage in the presence 
of PI (Nijhuis et al., 2007b). Current commercial resistance testing methods, 
both phenotypic and genotypic, include only the protease in their analysis 
alongside the 3’ end of Gag that overlaps with the protease ORF. Therefore, 
these methods would not have captured this observed reduction in PI 
susceptibility.    
Two of the six molecular clones selected for this study, HXB2 and NL4-3, did 
not display significant reductions in susceptibility to a number of PIs in 
comparison to the assay reference strain. The assay reference strain, 
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p8.9NSX+, is derived from HXB2 upstream of the SpeI site in Gag and from 
NL4-3 downstream of the SpeI site onwards. Hence, the little variation in 
susceptibility observed for these molecular clones was expected. However, both 
HXB2 and NL4-3 displayed reduced susceptibility in comparison to the 
reference strain to APV. This further emphasises the importance of considering 
full-length Gag alongside its cognate protease when investigating PI 
susceptibility as in the absence of the co-evolved Gag the susceptibility of both 
HXB2 and NL4-3 was reduced to APV. This indicates an effect of separating co-
evolved Gag and protease even in closely related viruses.  
The reason for the different roles of Gag and protease in PI susceptibility 
between each of the molecular clones remains unclear. JRFL was subjected to 
limited cell culture during its generation whereas YU2 was not subjected to any 
tissue culture propagation; however, the remaining molecular clones were all 
subjected to more extensive cell culture during their derivation (Koyanagi et al., 
1987; Li et al., 1991). It is therefore possible that tissue culture adaptation 
resulted in changes in Gag in the other molecular clones which are not present 
in JRFL and YU2, explaining the difference in susceptibility between these two 
molecular clones and the other four. However, molecular clones YU2 and JRFL, 
in which reduced susceptibility are both conferred solely by Gag, were both 
derived directly from brain tissue which is not the case for the other molecular 
clones. Thus, an alternative explanation could be that adaptation to replication 
in the central nervous system resulted in changes in Gag that affect PI 
susceptibility.  
The exclusion of the NC/p1/p6 cleavage sites from the Gag only chimeric virus 
further emphasises the role of other regions within Gag in PI susceptibility, as 
mutations in the NC/p1/p6 that affect PI susceptibility have already been 
described (Dam et al., 2009; Nijhuis et al., 2007b). The creation of further Gag 
chimeric viruses demonstrated that the N terminal end of Gag (the MCgagN 
vector, encompassing MA and the N terminus of CA), and not the C terminus, 
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conferred the reduced susceptibility observed for full-length Gag-protease in 
molecular clones JRFL and YU2. To date, two other studies have implicated the 
N terminus of Gag in contributing to reduced susceptibility in an extensively 
treated patient infected with HIV-1 subtype B and a treatment-naïve patient 
infected with subtype CRF01_AE HIV-1 (Jinnopat et al., 2009; Parry et al., 
2009).   
Amino acid alignment identified only two amino acids changes that were 
present in both JRFL and YU2, the molecular clones in which Gag solely 
conferred the reduced PI susceptibility observed for full-length Gag-protease.  
Use of site-directed mutagenesis provided evidence for the involvement of 
amino acid positions 30 and 102 in PI susceptibility, both in the context of co-
evolved Gag-protease and with a reference strain Gag C-terminal and protease.  
Amino acid changes at positions 30 and 102 of Gag have not been previously 
reported to affect susceptibility to PIs. However, these positions do not solely 
confer the observed reduction in susceptibility indicating that additional unique 
changes identified in the N terminus of Gag of YU2 or JRFL must also 
independently or in combination contribute to the observed reduction in PI 
susceptibility.   
The exact mechanism by which changes at position 30 and 102 of Gag may 
affect PI susceptibility remains unknown. However, positions surrounding amino 
acid 30 have been implicated in correct targeting of Gag to the plasma 
membrane, so it is possible that an increase in efficiency of Gag targeting may 
lead to an increase in the number of virions produced by JRFL and YU2 in 
comparison to other molecular clones (Ono and Freed, 2004). Of interest, 
position 30 of MA has been described as a key position for the switch in species 
specificity during evolution of SIV to HIV. In SIV viruses from chimpanzees and 
gorillas, position 30 is M, but in HIV viruses R or K is encoded and this is fairly 
well conserved (Wain et al., 2007). Amino acid changes R30K and E102D are 
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not uncommon in PI-naïve viruses, with Lysine (K) at position 30 in 27.9% of 
group M viruses and Glutamic acid (E) at 102 in 17% (http://www.hiv.lanl.gov/). 
This study also included the development and use of EM methods to investigate 
the mechanisms by which the change in PI susceptibility between 
p8YU2gagpro, p8JRFLgagpro and p8.9NSX+ was conferred. Preliminary 
experiments indicate that the maturation of JRFLgagpro-derived pseudovirions 
was unaffected by relatively high ATV concentrations (EC90). Conversely, 
p8.9NSX+ and YU2gagpro-derived pseudovirions displayed reduced levels of 
maturation and hence an increase in the proportion of immature pseduovirions 
generated in the presence of ATV. Although the infectivity of p8.9NSX+ and 
p8YU2gagpro are reduced by approximately 90% at this particular 
concentration of ATV, 50% of pseudovirions counted were mature and 
infectious, at least morphologically. Our data are perhaps not surprising, given 
that another study has shown that the morphology and cleavage of Gag do not 
account for differences in the infectivity of viruses produced in the presence of 
clinically suboptimal LPV concentrations (Muller et al., 2009). 
For JRFL Gag-protease, these data provide evidence that changes present in 
the N terminus of Gag enable efficient cleavage of Gag and pseudovirion 
maturation in the presence of ATV. However, the mechanism by which these 
changes enable efficient Gag cleavage and maturation remains to be 
elucidated. Conversely, for YU2 Gag-protease no difference in maturation 
efficiency in comparison to that of p8.9NSX+ reference strain was observed. 
Previous studies have shown that PIs act at multiple life cycle stages including 
cell entry, uncoating and nuclear entry so it is possible that changes in the N 
terminus of Gag mitigate the effect of PI at one or more of these stages (Muller 
et al., 2009; Rabi et al., 2013). This study provides further evidence that the 
presence of PI affects other stages of the life cycle, in addition to the well-
established effect on Gag cleavage and virion maturation.   
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The EM method employed here had a number of limitations, including the 
counting strategy utilised to avoid the counting of microvesicles as 
pseudovirions. The counting strategy will have excluded mature virions that 
were sectioned in orientations other than that which resulted in bullet shaped 
capsids, as illustrated in figure 3.20. It is also possible that defective and 
aberrant pseudovirions would not have been included in the count. This could 
have resulted in an underestimation of the effect of PI on maturation, as any 
block that did not result in an immature virion would not be captured.  However, 
it was necessary to exclude these from the counting to avoid inclusion of 
microvesicles in the pseudovirion counts. In the future, CD45 depletion could be 
used to purify the pseudovirions and this counting strategy would not be 
required (Ott, 2009). Additional controls would be required if this work was to be 
continued, in particular a count of the proportion of pseudovirions produced in 
the absence of protease and with an extensively PI resistant protease. In the 
future, virus maturation could be measured more effectively using other 
methods such as western blotting, as discussed in section 7.3.1.   
In conclusion, this study provides evidence of variation in PI susceptibility of 
subtype B molecular clones when full-length co-evolved Gag-protease is 
included in phenotypic assays.   We show that Gag can directly affect PI 
susceptibility via mechanisms independent of co-evolved protease and that the 
N terminus of Gag, including amino acid positions in MA, are involved.  Our 
data provide evidence that efficient Gag cleavage in the presence of PI 
contributes in part to the variation in PI susceptibility, but that other stage(s) of 
the virus life cycle may also be involved in the observed variation in PI 
susceptibility.   
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Figure 3.20. Limitations of the counting strategy utilised for electron microscopy experiments.  Following preliminary experiments, 
a counting strategy was devised to avoid accidental inclusion of microvesicles.  The schematics and electron micrographs highlight that 
only pseudovirions sectioned in the orientation ‘a’ would be captured by this counting strategy, and those sectioned in orientations ‘b’ or 
‘c’ would be missed.     
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4 Investigation of the role of co-evolved Gag and 
protease in susceptibility to PIs of different HIV-1 
subtype B viruses derived from treatment-naïve 
patients  
4.1 Introduction 
In chapter 3, results were presented that showed significant variation in PI 
susceptibility of full-length Gag-protease from subtype B molecular clones.  This 
chapter describes an extension of this work examining viruses derived directly 
from patients.  The generation of molecular clones can include extensive in vitro 
passage, and it has been shown that tissue culture adaptation of HIV-1 viruses 
can occur in short periods of time (Collman et al., 1992; Hahn et al., 1984; van 
Opijnen et al., 2007).  This could affect Gag in particular, as it contains a large 
number of CTL epitopes and these have been shown to vary in vivo in the 
absence of the relevant HLA type, a condition that is replicated in tissue culture 
conditions where no immune system is present (Smith, 2004).  For these 
reasons an assessment of the variation in PI susceptibility of full-length Gag-
protease directly derived from patients was required to confirm direct clinical 
relevance of our previous findings.  
To our knowledge, only two studies to date have examined the PI susceptibility 
of full-length Gag-protease from subtype B HIV-1 and in both studies the 
viruses were from extensively treated patients (Dam et al., 2009; Parry et al., 
2009).  The findings reported by Parry et al. (2009) were in keeping with those 
here for molecular clones, with Gag shown to confer up to 10-fold reduction in 
susceptibility to APV and ATV.  As with our data, this reduction in susceptibility 
mapped to the N terminus of Gag.  A second study has examined the PI 
susceptibility of full-length Gag-protease from PI-naïve viruses, although these 
were subtype A and C (Gupta et al., 2010).  This study included both molecular 
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clones of subtype A and C, and subtype A viruses derived directly from infected 
patients.  No difference in the role of Gag in PI susceptibility between molecular 
clones and viruses derived directly from patients was reported.  For each 
subtype A virus, inclusion of full-length Gag significantly affected the 
susceptibility of protease with up to 24-fold difference in susceptibility observed.  
In addition, for each virus Gag independently conferred reduced susceptibility of 
up to 8-fold to LPV in comparison to assay reference strain in the absence of its 
cognate protease.  Given that subtype B is the most prevalent subtype in the 
UK, accounting for ~40% of infections and that genotypic resistance testing is 
routinely carried out at diagnosis in UK before initiation of treatment, an 
assessment of the variability in PI susceptibility conferred by full-length Gag-
protease derived from treatment-naïve patients was of considerable interest 
(Dolling et al. 2013).  
Chapter aims: 
1) Adaption of the current single replication-cycle assay vector, p8.9NSX+, 
to enable efficient cloning of patient-derived full-length Gag-protease  
2) Investigate intra-patient variability in Gag-protease to ensure adequate 
representation of the patient quasispecies in the single replication-cycle 
assay 
3) Assess the variability in PI susceptibility of full-length Gag-protease in 
subtype B viruses derived directly from treatment-naïve, HIV infected 
patients 
4) Identify and investigate the regions and/or specific amino acid positions 
conferring variation in PI susceptibility between viruses 
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4.2 Results 
4.2.1 Modification of p8.9NSX+ vector for use with viruses from clinical 
samples  
In order to investigate the variation in PI susceptibility of full-length Gag-
protease derived directly from viruses from HIV infected individuals, 
modifications to the existing test vector p8.9NSX+ were required.  The method 
used to clone into p8.9NSX+ from extracted viral RNA utilises a pGEM 
intermediate vector and requires screening of clones by DNA sequencing at two 
stages – once after the cloning into pGEM and again after cloning into 
p8.9NSX+.  Colony PCR to check for the presence of a gag-protease fragment 
after sub-cloning into p8.9NSX+ is not sufficient as re-ligated p8.9NSX+ vector 
also gives a positive PCR result.  In order to shorten the cloning protocol, the 
requirement for a second sequencing step was removed by the generation of a 
vector that did not yield a positive colony PCR when religated, using primers 
GagNot+ and Gag1.5R.  A vector designated p8.9Δpro was created in which a 
fragment of gag-protease had been removed which included the Gag1.5R 
primer binding site, as shown in figure 4.1.  
The creation of the p8.9Δpro vector was achieved by the introduction of an 
additional SpeI site flanking amino acids 75 and 76 of protease by site-directed 
mutagenesis with primers MutProSpe and MutProSpeR (see table 2.2).  SpeI 
restriction digest was carried out to remove the fragment between the new 
(protease amino acids 75-76) and existing (Gag amino acids 240-241) SpeI 
sites, and the vector backbone was then re-ligated, as detailed in chapter 2.  
This resulted in the removal of the fragment between amino acids 241 of Gag 
and 75 of protease, meaning both the C terminal portion of gag and the majority 
of the protease gene were deleted (~1kb fragment).  Plasmid maps of 
p8.9NSX+ and p8.9Δpro are shown in figure 4.1 and the restriction sites of 
interest present in p8.9NSX+ are detailed in table 4.1. 
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Figure 4.1. Modifications to p8.9NSX+ vector and creation of p8.9NSXΔpro 
In order to increase the efficiency of our cloning protocol, a p8.9-based vector that did 
not produce a positive result in our colony PCR reaction when religated without the 
insert of interest was designed. (a) Existing restriction sites used for cloning in this 
study are shown, with the NotI and XhoI used for cloning in of full-length Gag-protease 
being of particular interest.  The SpeI site introduced during this study at position 3295 
of the vector is shown. The vector created following removal of the fragment 
encompassing part of Gag-protease by SpeI digest and re-ligation, named 
p8.9NSXΔpro, is shown (b).    
 
Restriction Site Nucleotide position in 
vector 
Amino acid position 
NotI (engineered) 1592 13 nt before Gag ORF 
SpeI (naturally present) 2325 240/241 of Gag 
ApaI (naturally present) 2828 406/407 of Gag 
SpeI (engineered) 3295 75-76 of protease 
XhoI (engineered) 3380 12 nt after end of 
protease ORF 
Table 4.1.  Unique restriction sites present in p8.9NSX+ utilised for cloning. 
Restriction sites used for cloning of Gag and protease fragments derived from patients, 
for example NotI and XhoI were used for full-length Gag-protease fragments. The 
second SpeI site was added to enable the creation of the p8.9Δpro. 
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4.2.2 Clonal analysis of Gag-protease from four treatment-naïve patients, 
infected with subtype B HIV-1 
Before an assessment of the variability of PI susceptibility of full-length Gag-
protease subtype B viruses derived from treatment-naïve patients could be 
carried out, it was necessary to determine a method by which the quasispecies 
within a patient could be represented in the phenotypic assay.  Whilst it would 
have been possible to test the phenotypic susceptibility of a large number of 
variants in a pool, this method was discounted as it would complicate further 
investigation of specific regions or changes contributing to any observed 
changes in susceptibility.  Thus, it was decided that just a small selection of 
Gag-protease variants should be used to represent the viruses derived from 
each patient in the phenotypic susceptibility assay.   
Viral RNA was manually extracted from patient plasma samples and cDNA 
synthesis using reverse primer ProOutR was carried out.  Nested PCR to 
amplify full-length gag-protease was performed and PCR product cloned into 
pGEM, as described in chapter 2.  Clonal analysis was carried out; colonies 
positive by colony PCR were cultured, the plasmid DNA purified and the gag-
protease fragment sequenced.   Sequences obtained that did not cover the full-
length gag -protease fragment were discarded, but those containing frameshift 
PCR errors were included in the analysis after manual correction of the PCR 
error.  Alignment of these clonal sequences enabled the construction of a 
consensus sequence for full-length gag-protease for each patient.  Gag amino 
acid sequences were compared to a table of all mutations in Gag previously 
reported to be associated with PI resistance or exposure (table 1.2) and 
protease sequences were submitted to the Stanford Resistance Database to 
determine whether any previously reported PI resistance mutations were 
present.   
An assessment of the variability of Gag-protease within the quasispecies of a 
patient was carried out for patient 1.  We aimed to sequence 33 viral variants as 
this is the number that will result in the capture of any variants present at a 
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frequency greater than 10% with 95% confidence, according to Poisson 
distribution (Palmer et al., 2005).  However, the efficiency of the cloning 
process, in particular fragment ligation and transformation into E. coli, limited 
the total number of variants to 27 that could be sequenced for patient 1.  
Alignment of these clonal sequences enabled the construction of a consensus 
sequence for full-length Gag-protease, as shown in figure 4.2 for Gag and figure 
4.3 for protease.  Of note, the consensus sequence from patient 1 contained a 
number of changes in Gag previously associated with PI resistance or 
exposure: E12K, Y79F, K113Q, V128A, V362I, T375 deletion and T375N (table 
1.2).  In addition within protease the L10I minor resistance mutation and 
polymorphisms G17E, L19I, E35D, M36I, L63T, E65D and I72T were present.  
Of the 27 clones for patient 1, 18 were identical and 9 contained one amino acid 
change from the patient consensus.      
Given the relatively homogeneous nature of the sequences from the first patient 
analysed, with 18 of 27 variants being identical, it was decided that 
approximately ten clonal sequences from each patient would be sufficient to 
enable the selection of representative viral variant(s) for phenotyping.  The 
number of clonal sequences obtained for the remaining patients was as follows: 
patient 2 (n=8), patient 3 (n=10) and patient 4 (n=9).  Alignment of the clonal 
sequences resulted in consensus sequences shown in figures 4.2 for Gag and 
4.3 for protease.    
Viral clonal sequences derived from patient 2 could be divided into two groups 
of variants with similar amino acid sequences (variants 1, 4 and 5 in one group, 
with variants 2 and 3 forming a second group).  Variants 6, 7 and 8 represented 
apparent recombinants between the first two groups..  Within Gag, there were 
five variable amino acids at positions 58, 127, 220, 341 and 480.  Within 
protease, two variable amino acid positions were present: variant 8 displays a 
G57R change and position 72 is mixed I/V, with variants dividing into the groups 
described above for Gag.  Of interest, the following changes in Gag previously 
associated with PI resistance or exposure were present: R76K, Y79F, H219Q 
(mixed H/Q within patient), V362I, S373P, I376V, K436R, L449P and T456S 
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(Table 1.2). In addition, protease polymorphisms I13V, I15V, P39E, D60E, 
L63P, A71T, I72V, V77I and I93L in comparison to consensus subtype B were 
present in viruses derived from patient 2. 
The estimation of the average intrapatient viral evolutionary divergence, by 
computing the genetic distance between clonal amino acid sequence pairs, 
demonstrated that the Gag sequences from patient 3 were more variable than 
those from patients 1 and 2 with a value of 0.015 amino acid substitutions per 
site compared to 0.001 and 0.005, respectively.  Eighteen variable amino acid 
positions were present within Gag and two within protease. Of interest, the 
following changes in Gag previously associated with PI resistance or exposure 
were present: R76K, S373P (mix of S/P), I376V, R380K and L449P – and a 
deletion of amino acid 375 within the p2/NC cleavage site (Table 1.2).  In 
addition within protease the L33I minor PI resistance mutation and the following 
protease polymorphisms were present: T12S, N37C, I62V, L63P, H69Q and 
I93L.  
The intrapatient viral divergence in patient 4 was comparable to that of patient 
3, with a mean genetic distance of 0.016 amino acid substitutions per site.  
Analysis revealed 23 variable amino acid positions in Gag, two 5 amino acid 
indels present in Gag in some variants and 5 variable positions within protease.  
Of note, a duplication of the PTAP domain of Gag was present in variants 2, 8 
and 9. The following changes in Gag previously associated with PI resistance or 
exposure were observed in patient 4: E12K (mix of E/K), R76K, Y79F, Y132F 
(Y/F mix), H219Q, R380K (R/K mix) and S451N.  Within protease, there were 5 
variable amino acids at positions 14, 18, 37, 77 and 87 and in total 8 
polymorphisms relative to subtype B consensus were present in protease: I13V, 
K14R, E35D, N37T, R41K, I62V, L63P and A71T.  
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#HXB2 MGARASVLSG GELDRWEKIR LRPGGKKKYK LKHIVWASRE LERFAVNPGL LETSEGCRQI LGQLQPSLQT GSEELRSLYN 
#1    ......I... .K..T..... .....N...R M..L...... .....L.SD. ...A...Q.. ID....A.R. .T......F. 
#2.1  .......... .Q........ .......Q.R .......... .......... .......K.. ......A... .....K..F. 
#2.2  .......... .Q........ .......Q.R .......... .......... .......... ......A... .....K..F. 
#3.9  .......... .......R.. .......T.. .......... .......... .......K.. .EH...T.R. .....K..N. 
#3.12 .......... .......... .......T.. .......... .......... .......K.. .EH...T.R. .....K.... 
#4.1  .......... ....K..... .........H .......... ..K..I.... .......... .......... .....K..F. 
 
#HXB2 TVATLYCVHQ RIEIKDTKEA LDKIEEEQNK SKKKAQQ-AA ADTGHSNQVS QNYPIVQNIQ GQMVHQAISP RTLNAWVKVV 
#1    .......... .......... ...L..I.KG K.Q.TP.-.. .A..S.S.A. ........L. .......L.. .........I 
#2.1  L..V...... .......... ........T. .......E.. ..V.N..K.. ........M. ......PL.. .......... 
#2.2  L..V...... .......... ........T. .......E.. ..V.N.SK.. ........M. ......PL.. .......... 
#3.9  LI.V...... ..DV...... ..R....... .......-.. .N..N.S... ........L. ..A....L.. .......... 
#3.12 L..V...... ..DV...... ..R....... .......-.. .N..N.S... ........L. ..A....L.. .......... 
#4.1  .I.V...... ...V...... .E......D. .......-.. .A..S.G... ........M. .......... .......... 
 
#HXB2 EEKAFSPEVI PMFSALSEGA TPQDLNTMLN TVGGHQAAMQ MLKETINEEA AEWDRVHPVH AGPIAPGQMR EPRGSDIAGT 
#1    .......... .......... .......... .......... .......... .....L.... .......... .......... 
#2.1  .......... ...T...... .......... .......... .......... .....L...Q .......... .......... 
#2.2  .......... ...T...... .......... .......... .......... .....L.... .......... .......... 
#3.9  .......... .......... .......... .......... .......D.. .D...L.... ...V...... .......... 
#3.12 .......... .......... .......... .......... .......D.. .D...L.... ...V...... .......... 
#4.1  .......... ...T...... .......... .......... .......... .....L..PQ ........I. .......... 
 
#HXB2 TSTLQEQIGW MTNNPPIPVG EIYKRWIILG LNKIVRMYSP TSILDIRQGP KEPFRDYVDR FYKTLRAEQA SQEVKNWMTE 
#1    ........A. .......... .......... .......... V......... .......... .......... T......... 
#2.1  .......... .......... .......... .......... .......... .......... .......... .......... 
#2.2  .......... .......... .......... .......... .......... .......... .......... .......... 
#3.9  ........A. ..S....... ........M. .......... .......... .......... .......... .......... 
#3.12 ........A. ..S....... ........M. .......... .......... .......... .......... .......... 
#4.1  .......VT. ..ST...... .......... .......... A......... .......... .......... .......... 
 
#HXB2 TLLVQNANPD CKTILKALGP AATLEEMMTA CQGVGGPGHK ARVLAEAMSQ VTNSATIMMQ RGNFRNQRKI VKCFNCGKEG 
#1    .......... .......... .......... .......... .KI....... .QSTN-.... ....KG.KR- I......... 
#2.1  ......S... .R........ T......... .......... ..I....... I..PT.V... ....K....P .......... 
#2.2  ......S... .R........ .......... .......... ..I....... I..PT.V... ....K....P .......... 
#3.9  ......S... .......... .......... .......... .......... ..SPN-V... K..Y.Y...T .......... 
#3.12 ......S... .......... .......... .......... .......... ..SPN-V... K..Y.Y...T .......... 
#4.1  .......... ..N....... .......... .......S.. .......... L.-PNA.... K...KG...A .......... 
 
#HXB2 HTARNCRAPR KKGCWKCGKE GHQMKDCTER QANFLGKIWP SYKGRPGNFL QSRPEPTAPP EESFRSGVET TTPPQKQEPI 
#1    .L........ .......... .......... .......... .H........ .......... M....F.E.. ...S...... 
#2.1  .I.K...... R......... .......I.. ......R... .H........ ......S... .....F.E.. A.......QV 
#2.2  .I.K...... R......... .......I.. ......R... .H........ ......S... .....F.E.. A.......Q. 
#3.9  .I.K...... .......... .....E.... .......... .H........ .......... .....F.E.. ...S.....K 
#3.12 .I.K...... .......... .....E.... .......... .H........ .N........ .....F.E.. ...S.....K 
#4.1  .I........ ........R. .......... .......... AH........ .N........ A....F.E.A A.......TV 
 
#HXB2 DKELYPLTSL RSLFGNDPSSQ 
#1    E..MP.MA.. K.......... 
#2.1  .......... K.......L.. 
#2.2  .......... K.......L.. 
#3.9  EQ.....A.. ........L.. 
#3.12 E......A.. ........L.. 
#4.1  .......... ........... 
 
MA/CA cleavage site 
CA/p2  p2/NC  
NC/p1  p1/p6  
Figure 4.2. Amino acid alignment of full-length 
Gag from patients 1-4.  An alignment of all viral 
variants subjected to phenotyping was produced 
using MEGA 4.0 and the ClustalW algorithm. Gag 
cleavage sites marked in green 
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#HXB2 PQVTLWQRPL VTIKIGGQLK EALLDTGADD TVLEEMSLPG RWKPKMIGGI GGFIKVRQYD  
#1    ..I......I ......E.I. .......... ....DIN... .......... ..........  
#2.1  ..I....... ..V.V..... .......... ......N.E. .......... .........E  
#2.2  ..I....... ..V.V..... .......... ......N.E. .......... .........E  
#3.9  ..I....... .S........ .......... ..I...C... .......... ..........  
#3.12 ..I....... .......... .......... ..I...Y... .......... ..........  
#4.1  ..I....... ..VR...... .......... ....D.T... K......... ..........  
 
#HXB2 QILIEICGHK AIGTVLVGPT PVNIIGRNLL TQIGCTLNF 
#1    ..T.D..... .T........ .......... ......... 
#2.1  ..P....... TV....I... .......... ..L...... 
#2.2  ..P....... T.....I... .......... ..L...... 
#3.9  .VP.....Q. .......... .......... ..L...... 
#3.12 .VP.....Q. .......... .......... ..L...... 
#4.1  .VP....... T......... .......... ......... 
 
Figure 4.3. Protease amino acid alignment for viruses derived from 
patients 1-4. Protease amino acid sequences of all viral variants subjected to 
phenotyping were aligned in MEGA 4.0 software using the ClustalW algorithm. 
Amino acid changes correlating with reduced susceptibility are highlighted in 
red.  
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4.2.3 Variation in PI susceptibility of full-length Gag-protease from 
treatment-naïve HIV-1 infected patients 
Following the sequencing of patient variants, we selected the variant(s) that 
would adequately represent the patient’s viruses for use in the phenotypic PI 
susceptibility assay.  When a variant identical to the consensus amino acid was 
present, this was selected for phenotyping.  For patient 1, a single variant that 
was identical to the consensus was selected, however for patients 2, 3 and 4 a 
variant identical to the consensus was not among the clones sequenced.  
Therefore for patients 2, 3 and 4, the variant(s) with the least number of non-
conserved amino acid changes from the consensus sequence determined after 
population-based sequencing was selected.  This resulted in the selection of 
two variants for each of patient 2 and 3, as two variants were equally similar to 
the consensus, and only a single variant for patient 4.  Once selected, variants 
were cloned from pGEM into p8.9NSX+ using the NotI and XhoI restriction sites 
as described in chapter 2.  The PI susceptibility of pseudovirions containing full-
length Gag-protease derived from the four patients viruses was determined, 
using the single replication-cycle PI susceptibility assay as described 
previously.  Susceptibility to the six PIs in widespread clinical use was 
determined, these being: APV, ATV, DRV, LPV, SQV and TPV.     
Variation in PI susceptibility of full-length Gag-protease derived from treatment-
naïve patient viruses was observed, both between patients and between 
different PIs as shown in figure 4.4.  Pseudovirions containing Gag-protease 
derived from all four patients exhibited reduced PI susceptibility in comparison 
to the assay reference strain, p8.9NSX+, to at least one PI.  In the majority of 
cases this reduction in susceptibility was statistically significant (P < 0.05; two 
sample t test).  Pseudovirions derived from patients 2 and 4 exhibited significant 
reductions in susceptibility to a number of PIs.  This reduction in susceptibility 
was greatest for PIs APV, ATV, LPV and TPV (P < 0.01; two sample t test), but 
was particularly pronounced for ATV where a reduction of up to 17- and 16-fold 
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in susceptibility was observed for patients 2 and 4, respectively.  For APV, LPV 
and TPV reduced PI susceptibilities of up to 6-, 8- and 6-fold difference in EC50, 
respectively, were observed for patients 2 and 4.  Conversely, full-length Gag-
protease from patients 1 and 3 conferred PI susceptibilities that were much 
closer to that of the reference strain, although in some cases statistically 
different, for DRV, LPV, SQV and TPV.  For the PIs APV and ATV small 
reductions in susceptibility of between 2- and 4-fold difference in EC50 were 
observed.  Of, interest for patients where two variants were tested, both showed 
broadly similar PI susceptibility levels.   
As the PI susceptibility of viruses derived from patients 1 and 3 was so close to 
that of the reference strain, they were not investigated further.  However, 
viruses derived from patients 2 and 4 were further analysed, as these showed 
the greatest reduction in susceptibility in comparison to the assay reference 
strain to a number of PIs.  
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Figure 4.4. Variation in PI susceptibility of full-length Gag-protease from HIV-1 infected, treatment-naïve patients. Full-length 
Gag-protease was amplified from plasma samples and cloned into p8.9NSX+. VSV-g pseudotyped viruses encoding luciferase were 
produced by co-transfection in 293T cells. PI susceptibility of pseudovirions derived from each patient was determined using a single 
replication-cycle drug susceptibility assay as measured by luciferase activity. Data displayed are fold difference in EC50 values in 
comparison to that of the assay reference strain, p8.9NSX+, for each of six PIs: APV, ATV, DRV, LPV, SQV and TPV. Viruses for which 
the raw EC50 values were statistically different from assay reference strain using unpaired t-tests (P < 0.05) are denoted with an 
asterisk(*). Error bars represent the standard error of the mean of three independent experiments performed in duplicate. The dashed 
line shows the previously reported cut off for a significant reduction in susceptibility of greater than four-fold in comparison with the assay 
reference strain (Gong et al., 2004). 
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4.2.4 Contribution of protease to reduction in PI susceptibility observed 
for full-length Gag-protease in subtype B clinical viruses 
To elucidate the role of Gag and protease individually in the reduced PI 
susceptibility observed for full-length Gag-protease from patients 2 and 4, the PI 
susceptibility of chimeric viruses containing Gag only or protease only from the 
patient was determined.  For each patient two chimeric viruses were created: 
p8PtGag containing Gag derived from the patient virus and protease from 
p8.9NSX+ and p8PtPro, which contained Gag from p8.9NSX+ and protease 
from the patient, as depicted in figure 4.5a.  Restriction sites NotI, ApaI and 
XhoI were used.  The location of the ApaI site resulted in the inclusion of MA, 
CA, p2 and the N terminus of NC from the patient virus in the p8PtGag chimeric 
virus.  The p8PtPro contained the C terminus of NC, p1 and p6 of Gag in 
addition to protease from the patient virus, as displayed in figure 4.5a.  For 
patient 2, variant 1 was selected for further analysis as it showed the highest 
fold-difference in EC50 of the two variants.  The PI susceptibility of these 
chimeric vectors to the four PIs APV, ATV, LPV and TPV, was determined using 
the single replication-cycle drug susceptibility assay. 
The results in figure 4.5b and c show that the protease only chimeric viruses 
from patients 2 and 4 displayed reduced susceptibility in comparison to assay 
reference strain of up to 9- and 13-fold-difference in EC50 for patients 2 and 4, 
respectively (figure 4.5).  Conversely, the Gag only chimeric viruses displayed 
PI susceptibility levels similar to that of the assay reference strain for all four PIs 
for which the susceptibilities were tested.  For each patient the difference in 
susceptibility between the Gag and protease only chimeric viruses was 
statistically significant for both APV and ATV (P < 0.05).     
There was no evidence that Gag from these patient-derived viruses confers 
reduced susceptibility to PIs when separated from its cognate protease, 
suggesting that in patients 2 and 4 the reduced susceptibility conferred by 
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protease alone largely accounts for the reduced susceptibility observed for full-
length Gag-protease.  This was contrary to the effect observed with the 
molecular clones in chapter 3, where the gag gene was shown to significantly 
contribute to the reduced PI susceptibility of full-length Gag-protease.   
 
Figure 4.5. Variation in PI susceptibility of full-length Gag-protease conferred 
independently by Gag in a single replication-cycle assay. Chimeric vectors 
containing only Gag or only protease from the patient were generated using standard 
cloning techniques and a schematic is shown in (a). Schematic diagram of chimeric 
viruses containing either Gag or protease from viruses derived from each patient. 
Segments of the chimeric viruses derived from the assay reference strain, p8.9NSX+, 
are depicted in white, and that from patient-derived viruses shaded grey. Pseudovirions 
encoding luciferase were generated by co-transfection in 293Ts of the chimeric vectors 
for two patients (b) patient 2 and (c) patient 4 for viruses for which the fold difference in 
EC50 values for Gag only and protease only chimeric viruses were statistically different 
using an unpaired t-test (P < 0.05) are denoted with an asterisk(*). Error bars are 
standard error of the mean, derived from three independent experiments performed in 
duplicate. The dashed line shows the previously reported cut off for a significant 
reduction in susceptibility of greater than four-fold in comparison with the assay 
reference strain (Gong et al., 2004). 
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4.2.5 Effect of minor resistance mutations and polymorphisms in 
protease on PI susceptibility of treatment-naïve, patient-derived 
viruses 
Having shown that the patient-derived protease largely conferred the reduced 
PI susceptibility observed for full-length Gag-protease, the determinants of the 
reduced susceptibility were investigated.  Analysis of protease sequences of the 
viral variants from patients 2 and 4 using the Stanford HIVdb Genotypic 
Resistance Interpretation Algorithm (http://hivdb.stanford.edu/) and the IAS list 
of drug resistance mutations showed no major PI resistance mutations.  
However, it indicated the presence of two minor resistance mutations, A71T and 
L63P, and a polymorphism I13V in both patients as shown in Figure 4.6 
(Johnson et al., 2013).  The Stanford Resistance Algorithm did not predict an 
effect of these minor mutations on phenotypic susceptibility, hence the inclusion 
of these patients in this study.  In addition, there were a number of other amino 
acid changes from consensus subtype B protease in each of the patients.  In 
contrast, patients 1 and 3 did not share all three of protease amino acid 
changes, A71T, I13V and L63P, with only the L63P mutation present in patient 
3.  However, patients 1 and 3 shared minor resistance mutations L10I and L33I 
and each had a number of other additional changes compared to consensus B 
protease sequence as detailed previously.   
As the reduced PI susceptibility mapped to protease, we next investigated the 
contribution of the amino acid changes I13V, L63P and A71T to the reduction in 
PI susceptibility.  The amino acids were sequentially reverted to the consensus 
subtype B amino acid using site-directed mutagenesis, leading to the creation of 
the following three vectors for each patient: 1M (T71A), 2M (T71A and V13I) 
and 3M (T71A, V13I and P63L), as shown in Figure 4.7a.  A71T was chosen to 
be studied alone as it was a minor resistance mutation reported to affect 
susceptibility to ATV, IDV, LPV, NFV, SQV (Johnson et al., 2011).  The 
polymorphism I13V was reverted next as it was present less frequently in PI 
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naïve viruses than L63P, which is a common polymorphism considered a minor 
resistance mutation to LPV only.  The susceptibility of the three vectors for each 
patient was then tested using the single replication-cycle drug susceptibility 
assay.    
Overall, reversion of protease positions 13, 63 and 71 to consensus subtype B 
increased the susceptibility of the virus towards that of the reference strain 
(Figure 4.7b and c).  This effect was statistically supported for patient 2 derived 
pseudovirions to ATV.  However, for some PIs reversion of A71T conferred a 
further reduction in PI susceptibility (for Pt 2 to APV and for Pt 4 to ATV and 
LPV).  In addition, for the PI APV reversion of protease positions to wild-type 
does not appear to increase the susceptibility of the viruses towards that of the 
reference strain, in fact reversion results in a virus significantly less susceptible 
for patient 2 derived viruses.  These data provided evidence that the minor 
resistance mutations and polymorphism present in the protease of viruses 
derived from patients 2 and 4 contribute in part to the reduced susceptibility 
observed in the absence of major PI resistance mutations. 
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   1              50 
Pt1    PQITLWQRPI VTIKIGEQIK EALLDTGADD TVLEDINLPG RWKPKMIGGI   
Pt2.1  .........L ..V.V.G.L. .......... ....EM..E. ..........   
Pt2.2  .........L ..V.V.G.L. .......... ....EM..E. ..........   
Pt3.1  .........L .S....G.L. .......... ..I.EMC... ..........   
Pt3.2  .........L ......G.L. .......... ..I.EMY... ..........   
Pt4.1  .........L ..VR..G.L. .......... .....MT... K.........   
 
   51             99 
Pt1    GGFIKVRQYD QITIDICGHK ATGTVLVGPT PVNIIGRNLL TQIGCTLNF  
Pt2.1  .........E ..P.E..... TV....I... .......... ..L......  
Pt2.2  .........E ..P.E..... TI....I... .......... ..L......  
Pt3.1  .......... .VP.E...Q. .I........ .......... ..L......  
Pt3.2  .......... .VP.E...Q. .I........ .......... ..L......  
Pt4.1  .......... .VP.E..... TI........ .......... .........  
 
 
minor resistance mutation 
polymorphism 
mutation that appears to correlate with phenotypic 
changes 
 
 
 
Figure 4.6. Protease variation of all patient 
derived viruses subjected to phenotypic PI 
susceptibility testing. An alignment of all protease 
amino acid sequences subjected to phenotypic 
testing was produced using the ClutalW algorithm – 
six viruses in total derived from four patients. Minor 
resistance mutations or protease polymorphisms 
identified by the Stanford Resistance Algorithm are 
highlighted in blue and pink, respectively. Amino 
acids 13V, 63P and 71T that correlated with 
reduced phenotypic susceptibility are highlighted in 
green.   
 
 
 
 
  
182 
 
 
 
Figure 4.7. Protease changes I13V, L63P and A71T affect PI susceptibility. 
Protease changes 13V, 63P and 71T were reverted to consensus amino acid using 
standard site-directed mutagenesis techniques. For each patient, three vectors were 
created containing one reversion, two reversions and all three changes reverted (a). 
For each vector, pseudovirions were produced by co-transfection in 293T cells and 
their PI susceptibility tested using a single replication-cycle assay. The susceptibilities 
to four PIs (APV, ATV, LPV and TPV) of the three reversion vectors are shown for (b) 
patient 2 and (c) patient 4. Data are expressed as a fold difference in comparison to 
that of the assay reference strain. Viruses for which the fold difference EC50 values 
were statistically different from that of Ptgagpro using an unpaired t-test (P < 0.05) are 
denoted with an asterisk(*). Error bars represent the standard error of the mean of 
three independent experiments performed in duplicate. The dashed line shows the 
previously reported cut off for a significant reduction in susceptibility of greater than 
four-fold in comparison with the assay reference strain (Gong et al., 2004). 
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4.2.6 Effect of amino acid changes in protease on PI susceptibility of 
assay reference strain 
Having demonstrated the contribution of amino acid changes I13V, L63P and 
A71T to the reduced susceptibility observed for full-length Gag-protease derived 
from patients 2 and 4, an investigation of the effect of these changes on the 
susceptibility of the reference strain was required. I13V, L63P and A71T were 
introduced into the p8.9NSX+ reference strain using site-directed mutagenesis 
techniques, giving a vector denoted p8.9proSDM. The susceptibility of this 
vector to four PIs, APV, ATV, LPV and TPV, was determined using a single 
replication-cycle PI susceptibility assay.   
Figure 4.8 demonstrates that the p8.9proSDM vector displayed small reductions 
in PI susceptibility to the PIs ATV, LPV and TPV in comparison to assay 
reference strain, p8.9NSX+. p8.9proSDM displayed a 3-fold reduction in EC50 in 
comparison to assay reference strain to the PI ATV, and 2-fold to PIs LPV and 
TPV.  However, to PI APV no difference in susceptibility in comparison to 
reference strain was observed.   
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Figure 4.8. Amino acid changes I13V, L63P and A71T reduce PI 
susceptibility of reference strain, p8.9NSX+. Amino acid changes I13V, L63P 
and A71T were introduced into the assay reference strain p8.9NSX+ using site 
directed mutagenesis techniques. Pseudovirions were produced by co-
transfection in 293Ts and PI susceptibility tested in a single replication-cycle 
assay to APV, ATV, LPV and TPV. Error bars represent the standard error of 
the mean of two independent experiments, each performed in duplicate.  
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4.2.7 Computer modelling of positions of amino acid changes within the 
protease homodimer 
Having demonstrated an effect of changes at amino acid positions 13, 63 and 
71 on PI susceptibility of patient-derived virus, the position of these changes 
within the structure of the protease homodimer was determined. Molecular 
modelling was carried out using RasMol software and protease structures 7HVP 
(the protease homodimer) and 3EL1 (protease homodimer structure in complex 
with ATV), obtained from the RCSB protein database (www.rcsb.org) (Berman 
et al., 2000; King et al., 2012; Swain et al., 1990). 
Figure 4.9a shows the position of amino acids 13, 63 and 71 within the protease 
enzyme structure. The three sites are located relatively close to one another on 
the outside of protease and are not found near the enzyme active site. The 
position of the amino acids in protease is not significantly altered when ATV is 
bound to the protease active site, as shown in figure 4.9b. The positions of the 
other unique polymorphisms present within patients 2 and 4 are shown in figure 
4.9c and 4.9d, respectively. The molecular modelling shows that none of these 
changes are present in the active site region of protease, instead they are found 
on the outside of the protease dimer. Only position 77 is found near the active 
site. 
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Figure 4.9. Computer modelling of the location of amino acids positions in 
protease shown to affect PI susceptibility. Molecular modelling was 
performed using RasMol software to determine the location of amino acid 
positions of interest within the 3D protein structure. The position of amino acids 
13 (red), 63 (blue) and 71 (green) are shown within the protease homodimer, 
7HVP, (a) and the structure of protease bound to the PI ATV, 3ELI, (b) from the 
RSCB PDB. Modelling demonstrates that these changes do not appear within 
the active site of the enzyme. In addition, positions 13, 63 and 71 are shown 
with the other amino acids in which changes were observed (yellow) for patient 
2 (c) and patient 4 (d).  
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4.3 Discussion 
Here, significant variation in PI susceptibility of full-length Gag-protease derived 
from four treatment-naïve patients infected with subtype B HIV-1 was observed.  
Whilst viruses derived from patients 1 and 3 displayed PI susceptibilities most 
similar to that of the reference strain, viruses from patients 2 and 4 displayed 
significant reductions in susceptibility to a number of PIs.  This finding is in 
keeping with the data for molecular clones in chapter 3 where up to 9-fold 
reductions in PI susceptibility were observed, and that of previous studies 
investigating PI susceptibility of patient-derived viruses of subtypes A, C and 
CRF01_AE which have also reported significant levels of variation when full-
length Gag-protease is incorporated (Gupta et al., 2010; Jinnopat et al., 2009).  
These data show that the reduction in susceptibility was particularly pronounced 
for ATV, with patient 2 showing a 17-fold reduction in EC50 in comparison to that 
of the reference strain.  This finding is of particular importance because a recent 
change in PI usage in London guidelines means ATV is now the recommended 
first line PI (London HIV Consortium, 2012).  The BHIVA guidelines also 
recommend ATV/r as an option for the third agent in first-line HAART (Williams 
et al., 2012).  In addition, the use of ATV is increasing in the developing world 
where pre-treatment resistance testing is not widespread so this finding of 
potential variation in susceptibility in treatment-naïve patients merits further 
investigation.   
Use of chimeric viruses demonstrated that protease solely conferred the 
reduced susceptibility observed for full-length Gag-protease in both patients 2 
and 4.  This is in contrast to the findings for molecular clones presented in 
chapter 3.  Here, there is no evidence that Gag can independently confer 
variation in susceptibility in these patient-derived viruses, despite the presence 
of changes in Gag that have previously been reported to be involved in PI 
resistance or associated with PI exposure.  In previous studies, Gag mutations 
were described and studied in combination and these particular combinations of 
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changes were not present in the patients in this study, which may explain why 
they did not confer reduced PI susceptibility (Aoki et al., 2009; Callebaut et al., 
2007; Gatanaga et al., 2002; Mammano et al., 1998).  For example, a previous 
study reported the role of three mutations at positions 76, 79 and 81 in PI 
susceptibility, but also demonstrated that they had little or no effect on 
susceptibility when present singly (Parry et al., 2011).  A number of these 
previously reported Gag mutations have been described in non-B subtypes and 
their role in subtype B viruses on PI susceptibility is unknown (Jinnopat et al., 
2009; Kameoka et al., 2010).   
Whilst not observed in this study, an independent effect of Gag derived from PI-
naïve patients infected with non-B subtype viruses was shown to result in the 
reduction of susceptibility to LPV, with a greater effect for Gag alone than for 
full-length Gag-protease in some cases (Gupta et al., 2010).  Although our 
study did not provide evidence of an independent role of Gag in susceptibility, 
for some PIs protease alone did not confer the same reduction in susceptibility 
observed for full-length Gag-protease, for example for patient 2 to ATV, LPV 
and TPV.  Under certain conditions a ‘wild-type’, p8.9NSX+ derived Gag does 
not appear to be sufficient to enable patient-derived protease to confer the 
same level of reduced susceptibility observed when present with co-evolved 
Gag.  This suggests that the matching of co-evolved Gag and protease is 
important.  Just as it has been shown that cleavage-site mutations in Gag can 
occur to compensate for reductions in fitness caused by major PI resistance 
mutations, it is possible that co-evolution at other sites may occur between Gag 
and protease that has not yet been described.  A similar effect was seen in an 
earlier study in which the fold-difference EC50 conferred by full-length Gag-
protease was greater than the total of the fold-difference EC50 values of Gag 
and protease independently (Parry et al., 2009).  This finding is potentially 
significant as commercially available assays which have been used for much of 
the phenotypic drug susceptibility research and clinical service to date do not 
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include co-evolved Gag, potentially resulting in an inaccurate determination of 
PI susceptibility.    
Analysis using the Stanford HIVdb Genotypic Resistance Interpretation 
Algorithm and the IAS list of drug resistance mutations identified three protease 
changes that were common in both patients 2 and 4: A71T, I13V and L63P 
(Johnson et al., 2013; Liu and Shafer, 2006).  Here, we have shown that the 
protease mutations A71T, I13V and L63P contributed to the reduced 
susceptibility observed for viruses derived from patients 2 and 4.  In addition, 
we demonstrate that introduction of these changes to the assay reference strain 
confers small reductions in susceptibility, of up to 3-fold.  Our data indicate that 
the presence of a combination of minor resistance mutations and 
polymorphisms in protease is able to convey reduced susceptibility to PIs, in the 
absence of major PI resistance mutations.  To our knowledge, only one study 
examining the role of these three protease mutations in the absence of other 
minor resistance mutations in protease on PI susceptibility in vitro has been 
carried out (Kempf et al., 2001).  The study reported a small FC EC50 to LPV 
when the three mutations were found together (0.8 fold), but did not examine 
the effect on susceptibility to the three other PIs studied here (APV, ATV and 
TPV). In addition, two studies have been carried out that demonstrate a role of 
these three protease mutations in an increased rate of PI resistance 
development during passage in vitro in the presence of drug (Lisovsky et al., 
2010; Vergne et al., 2006).  In vivo, a number of studies have reported an 
association between these protease mutations and reduced rates of virological 
response in patients when present in baseline sequences (Baxter et al., 2006; 
Johnson et al., 2005; Marcelin et al., 2007; Pellegrin et al., 2006; Pellegrin et al., 
2008).   
These amino acid changes are not uncommon within PI-naïve subtype B 
viruses, with I13V present in 14%, L63P present in 57% and A71T present in 
6% (Rhee et al., 2003).  In addition, each of these is present at an increased 
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frequency in PI-experienced viruses in comparison to PI-naïve viruses: I13V in 
25%, L63P in 78% and A71T in 10%.  L63P was also identified as one of the 
amino acid changes present at higher frequency in viruses from patients failing 
ATV therapy in comparison to those from PI-naïve patients in a UK cohort as 
described below, providing evidence for a role in PI resistance (Dolling et al. 
2013).  However our modeling data show that amino acids 13, 63 and 71 are 
not located near the active site of the protease enzyme, so the exact 
mechanism by which they affect PI susceptibility is unknown.  It is possible that 
these amino acid changes induce a conformational change in protease that 
results in reduced affinity of protease for the drug and/or a higher affinity for the 
natural Gag substrate.  Taken together, these data indicate that the precise 
mechanisms of development of resistance to PIs and the role of protease 
polymorphisms remain to be fully determined.   
The most significant reduction in PI susceptibility and the greatest effect on PI 
susceptibility of reversion of the minor mutations and protease polymorphisms 
was observed for ATV.  This led us to further investigate the role of protease 
polymorphisms in ATV susceptibility and resistance.  To date, studies have 
mainly concentrated on the development of major mutations as a marker for 
changes in susceptibility, but it has been shown that major resistance mutations 
are rarely found in patients failing ATV therapy, in both PI-naïve patients and 
those with prior PI exposure (Scherrer et al., 2012).  It has been assumed that 
treatment failure in the absence of resistance mutations is a consequence of 
poor adherence, but we hypothesised that reduced susceptibility in the absence 
of major resistance mutations could also contribute to treatment failure, for 
example conferred by combinations of minor mutations and polymorphisms in 
protease.  To further investigate, a collaboration was established with the UK 
HIV Drug Resistance Database to establish whether there was any variation in 
the frequency of amino acids within protease between ATV-naïve patients and 
those failing on ATV-based therapy (Dolling et al., 2013b).  The study utilised 
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the UK National HIV Resistance Database, which contains all genotypic 
resistance tests carried out by public labs in the UK coupled with clinical 
information from the UK Collaborative HIV Cohort (CHIC), to compare two 
groups of patients: those who had experienced virological failure on ATV based 
therapy and a PI-naïve control group.  The study reported that only six of the 
322 resistance tests included contained major PI resistance mutations.  In 
addition, the study reported multiple novel mutations associated with treatment 
failure including L19T, K43T, L63P/V, K70Q, V77I and L89I/T/V, providing 
further evidence that the exact genetic determinants of ATV susceptibility 
remain to be fully defined.   
In conclusion, we demonstrate significant variation in PI susceptibility using a 
single replication-cycle phenotypic assay encompassing full-length Gag-
protease from subtype B HIV-1 viruses derived from treatment-naïve patients.  
We show that protease can confer significant reductions in susceptibility in the 
absence of major protease mutations, an effect that is particularly pronounced 
for ATV.  Furthermore, this reduction in susceptibility would not be captured by 
traditional genotyping methods and partnership with its co-evolved Gag in 
phenotypic assays is necessary to measure the full effect on PI susceptibility.  
Further research is required to fully elucidate the role of minor resistance 
mutations and polymorphisms in protease on PI susceptibility and to confirm the 
clinical significance of these findings. 
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5 Investigation of the genotypic and phenotypic 
correlates of virological failure in treatment-naïve 
patients receiving LPV/r monotherapy  
5.1 Introduction 
Although efficacious, long-term HAART treatment entails both a high financial 
cost and a risk of significant side-effects, making exploration of alternative 
treatment regimens prudent.  Simplification strategies have been investigated in 
an effort to reduce the number of antiretroviral drugs required as part of 
treatment regimens without compromising treatment efficacy.  To date two main 
mechanisms of treatment simplification have been explored: firstly the removal 
of one or more ART drugs from patients with a suppressed viral load on HAART 
(Arribas et al., 2010; Gilks et al., 2012) and secondly by initiating treatment-
naïve patients on just one ART drug (Delfraissy et al., 2008).  Early clinical trials 
have shown that reverse transcriptase inhibitors cannot be used successfully as 
monotherapy, although they are used in certain situations including the 
prevention of mother-to-child transmission in the developing world (Guay et al. 
1999).  However, PIs are a potent class of inhibitors and to date a number of 
trials have been carried out to examine their efficacy when used as 
monotherapy  
5.1.1 Previous PI simplification clinical trials  
The first PI simplification trials conducted in the 1990s investigated the use of 
the first generation of PIs NFV, SQV and IDV (Havlir et al., 1998; Reijers et al., 
1998).  The ADAM study recruited ART-naïve patients and started with an 
induction therapy comprising d4T, NFV, 3TC and SQV, before a randomised 
switch to maintenance therapy after 26 weeks of either d4T and NFV, SQV and 
NFV, or continuation on the induction therapy.  This study was discontinued 
after interim analyses due to inferiority of the d4T/NFV and SQV/NFV arms 
  
193 
 
 
(Reijers et al., 1998).  A second study recruited patients with suppressed viral 
load <200 copies/ml on IDV, 3TC and AZT before randomisation to either a 
continuation of triple therapy, IDV monotherapy or AZT and 3TC dual therapy, 
with 106, 103 and 107 patients randomised to each arm respectively.  This trial 
reported 23% patients experiencing virological failure in both the IDV 
monotherapy and AZT/3TC dual therapy arms, compared to only 4% in the 
triple therapy arm (Havlir et al., 1998).  These early trials showed significant 
inferiority of PI simplification strategies with the early PIs in comparison to triple 
therapy.     
5.1.1.1 ATV monotherapy trials      
Several clinical trials to examine the efficacy of ATV/r monotherapy have been 
carried out, but to date they have included small numbers of patients, between 
15 and 36.  The first study recruited 36 patients with suppressed viral loads on a 
PI-containing regimen.  Patients were switched to an ATV/r-containing regimen 
and after 6 weeks the NRTIs were removed from the regimen, leaving patients 
with ATV/r monotherapy.  After 24 weeks, 91% patients had maintained 
virological suppression.  Three patients failed on PI monotherapy, but none had 
major resistance mutations and 2/3 had low or undetectable ATV/r levels in the 
blood at the time of treatment failure (Swindells et al., 2006).  Another small, 
single-centre trial aimed to recruit 30 patients but was discontinued at only 15, 
when 5 patients experienced virological failure.  However, none of the patients 
failing monotherapy had any major PI resistance mutations (Karlstrom et al., 
2007).  A third recruited 34 patients with suppressed viral loads, whose therapy 
was simplified to monotherapy.  Thirty of the 34 patients maintained virological 
suppression and none of the 4 patients failing therapy had a major PI resistance 
mutation (Wilkin et al., 2009). The ATARITMO trial recruited 30 patients with 
suppressed viral loads on HAART and patients were swapped to receive only 
ATV/r monotherapy.  The trial showed good efficacy, however there was 
evidence of ongoing viral replication in the CSF and semen despite suppression 
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in the plasma (Vernazza et al., 2007).  A larger ATV/r monotherapy trial –
MODAt - has enrolled 342 patients and is currently ongoing (Castagna et al., 
2013).     
5.1.1.2 DRV/r monotherapy trials 
Several large clinical trials showing the efficacy of DRV/r monotherapy have 
been reported to date.  The MONET trial took place in Spain and included 256 
patients with viral loads <50 copies/ml.  Patients were randomised to DRV/r 
monotherapy (n=127) or the DRV/r based triple therapy arm with two NRTIs 
(n=129).  The trial reported non-inferiority of the monotherapy arm, with 86.2% 
and 87.8% maintaining viral suppression at week 48 for the monotherapy and 
triple therapy arms respectively (Arribas et al., 2010).  Of those failing therapy, 
only one patient in each treatment arm developed major PI resistance 
mutations.  The MONOI-ANRS 136 trial recruited 225 patients with viral loads 
<400 copies/ml, and randomised them to DRV/r monotherapy arm or DRV/r 
based triple therapy.  Virological suppression of 99% and 94% was seen in the 
triple therapy and monotherapy arms, respectively.  Of the three patients who 
failed, none had developed any major PI resistance mutations (Katlama et al., 
2010b).  Another DRV/r monotherapy trial is currently underway in the UK, the 
PIVOT trial.  It includes several sub-studies to investigate the penetration of 
DRV/r into the CNS.  
5.1.1.3 LPV/r monotherapy trials  
Currently, LPV/r is the only PI available in most of the developing world 
particularly sub-Saharan Africa, so investigation of its efficacy as monotherapy 
is particularly important.  The Only Kaletra (OK) trial involved 21 patients who 
had been virologically suppressed for at least 6 months before trial enrollment.  
At trial end, 14/21 patients remained suppressed and 5 experienced virological 
rebound.  However, no major PI resistance mutations were present in these 
patients and suppression was achieved with the addition of two NRTIs (Pulido 
et al., 2008).  The SARA study was another LPV/r monotherapy study that was 
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conducted as a sub-study of the DART trial.  The DART trial took place in 
Uganda and Zimbabwe and aimed to establish whether ARV could be 
successfully introduced in the absence of viral load and CD4 count monitoring.  
Patients on second-line therapy in DART were recruited to the SARA study and 
randomised to continue therapy (CT) or simplify therapy to PI monotherapy.  At 
entry to the SARA study, patients had already received ARV for a mean 4.4 
years and only 77% had a suppressed viral load, <50 copies/ml.  After 24 
weeks, in those patients who had suppressed viral loads at entry, CT was 
superior to monotherapy with 85% and 66% of patients with viral load <50 
copies/ml, respectively.  Genotypic resistance testing carried out in 12 patients 
failing therapy identified major PI resistance mutations in two patients, I54V in 
one patient and both M46IM and V82AV in the second (Gilks et al., 2012).     
5.1.2 The MONARK trial 
The MONARK trial investigated the efficacy of boosted lopinavir (LPV/r) 
monotherapy in comparison to LPV/r-containing HAART in treatment-naïve 
patients.  In total, 83 patients were randomised to the LPV/r monotherapy arm, 
with 53 patients in the HAART control arm who received LPV/r with AZT and 
3TC.  Patients in the monotherapy arm were followed for up to 96 weeks, with 
CD4+ T cell counts and viral load monitoring carried out.  Primary endpoints 
were defined as proportion of individuals achieving a virological response – a 
viral load of <400 copies/ml after 24 weeks and <50 copies/ml after 48 weeks.  
The MONARK trial was undertaken in France, Spain and Poland with the 
proportion of subtypes as follows: 68% subtype B, 16% CRF02_AG, and 16% 
other subtypes and recombinants (A, CRF01_AE, C and G). 
The trial reported inferiority of LPV/r monotherapy in comparison to the LPV/r-
containing HAART regimen after 48 weeks, with virological response achieved 
in 64% and 75% of patients respectively (P = 0.19) (Delfraissy et al., 2008).  A 
significant proportion of patients randomised to the LPV/r monotherapy arm 
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experienced virological failure (23/83), defined as viral load >400 copies/ml from 
week 24 or viral load >50 copies/ml by week 48 (Delfraissy et al., 2008).  By 
week 96, 23/83 patients had experienced virological failure (a viral load >50 
copies/ml) (Ghosn et al., 2010).  Of patients experiencing failure in the LPV/r 
monotherapy arm, genotypic resistance testing identified major PI resistance 
mutations in only 5, with none occurring in the triple therapy arm.  Phenotypic PI 
susceptibility testing was performed for patients failing with major PI resistance 
mutations utilising the Monogram Phenosense Assay.  This showed a mean 
increase of 2.2 fold-difference in LPV/r EC50 in viruses at the time of treatment 
failure in comparison to baseline viruses from the same patient (Delaugerre et 
al., 2009).  However, as previously discussed the Phenosense assay does not 
include full-length Gag from the patient virus and our data have shown the 
importance of its inclusion when determining phenotypic susceptibility 
accurately (see chapters 3 and 4, Gupta et al., 2010; Parry et al., 2009).  
Flandre et al. (2009) reported a number of prognostic factors associated with 
virological response in the MONARK trial including a lower baseline viral load 
and viral subtype.  87% of patients infected with subtype B virus achieved 
virological response in comparison to 65% of those infected with non-B viruses, 
although the significance of this is complicated by the finding that patients 
infected with non-B subtype viruses reported missing more doses that those 
infected with subtype B viruses.  Analysis of the amino acid sequences at the 
Gag cleavage sites of viruses from all patients in the PI monotherapy arm 
reported CSMs in 81/82 patients at baseline including Gag changes K463R, 
I437V, L449F and P453L.  Furthermore, Gag changes V484G/I/P/S and 
S451G/N/R were associated with virological failure and success, respectively 
(Ghosn et al., 2011).  Comparison of viral sequences at baseline and failure 
showed the development of additional CSMs at failure in 11/23 patients and 
conversely reversions to wild-type in 9/23 patients.  Thus, in the patients failing 
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therapy without major PI resistance mutations the exact determinants of 
treatment failure remain unknown.     
Recent studies have provided evidence for the role of Gag in the determination 
of PI susceptibility, with amino acid changes located outside the Gag cleavage 
sites reported to affect PI susceptibility and correlate with treatment failure and 
PI exposure (Aoki et al., 2009; Gatanaga et al., 2002; Parry et al., 2011).  In 
addition, the inclusion of full-length patient-derived Gag alongside its co-evolved 
protease in in vitro phenotypic assays has been shown to affect PI susceptibility 
in both treatment-naïve and treatment-experienced patients (Gupta et al., 2010; 
Jinnopat et al., 2009; Parry et al., 2009).  In chapters 3 and 4 of this study, we 
have shown variation in susceptibility to PIs in the absence of previously 
reported resistance mutations when full-length Gag-protease from the test virus 
was included in phenotypic assays.  We have provided evidence that both Gag 
and protease can contribute to this variation in susceptibility.  Thus, this study 
sought to investigate the determinants of treatment failure in the MONARK trial 
by studying co-evolved, full-length Gag-protease both genotypically and 
phenotypically from patient viruses at baseline and time of treatment failure.   
Chapter aims: 
1) Amplify full-length Gag-protease from paired plasma samples taken at 
baseline and at the time of treatment failure from patients in the LPV/r 
monotherapy arm of the MONARK trial  
2) Perform clonal analysis of full-length Gag-protease of viruses derived 
from each time point for each patient to identify amino acid changes 
previously reported to be involved in or associated with PI resistance 
3) Use bioinformatic methods to examine sequences for evidence of 
positive selection and evolution. 
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4) Examine the PI susceptibility and single-round infectivity of 
representative viral variants from each patient at baseline and failure 
time points.  
 
5.2 Results 
5.2.1 Clinical and virological information of patients experiencing 
virological failure on LPV/r monotherapy, selected for this study. 
We had access to paired baseline and failure samples from 23 patients 
experiencing virological failure on LPV/r monotherapy up to week 96 of the 
MONARK trial.  Full-length Gag-protease from both baseline and failure plasma 
samples was successfully amplified from five of these patients by performing 
RNA extraction, DNA synthesis and nested PCR as previously described (see 
materials and methods section).  These patients formed the basis of this study 
(figure 5.1) and their clinical and virological information including viral load, 
subtype and time of treatment failure is shown in table 5.1.  These data show 
that the patients selected for this study were representative of all those enrolled 
in the trial. Patients randomised to the LPV/r monotherapy arm were infected 
with the following subtypes: 68% B, 16% CRF02_AG, 2% A, 4% G and 10% 
other subtypes (Ghosn et al., 2011).  The five patients detailed here were 
infected with three subtypes, two with B, two with CRF02_AG and one with G, 
as determined by the REGA subtyping tool (de Oliveira et al., 2005).  The 
patients’ viral loads at time of failure ranged between 342 and 25,300 RNA 
copies/ml.  In addition, the five patients experienced virological failure at 
different times spanning the length of the trial – ranging from week 24 (failure to 
achieve the primary endpoint of viral load <400 copies/ml by week 24) to week 
96 (the total length of trial follow up), as shown in table 5.1 and figure 5.2.   
Therapy adherence data from compliance assessments carried out at nine time 
points and LPV trough concentrations measured in the blood plasma at three 
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time points, are presented in table 5.2 and figure 5.2, respectively.  Analysis of 
adherence data and LPV trough concentrations at the time of treatment failure, 
when available, enabled an assessment of the potential contribution of 
suboptimal plasma drug concentrations to treatment failure.  For this study, 
LPV/r trough concentrations below 3,000 ng/ml were considered suboptimal 
(Solas et al. 2004). 
Table 5.1. Clinical and virological information for the five patients included 
in this study. 
Patient 
Number 
Subtype 
Screen VL 
(copies/ml) 
Failure time  
(weeks) 
Fail VL 
(copies/ml) 
1403 (KON) CRF02_AG 44,600 24 24,000 
3204 (HG) B 23,800 40 603 
1404 (DIO) CRF02_AG 166,000 42 1080 
4201 (SO) G 79,500 48 342 
508   (SP) B 37,800 96 25,300 
 
Table 5.2. Self-reported adherence to trial medication by week. 
Patient #  
Adherence report from compliance assessment (by 
week) 
4  8  12  16  20  24  32  40  48  
1403 (KON)  0 0  0  0  -  1 -  -  -  
3204 (HG)  0  0  0  0  0  0  0  0  1  
1404 (DIO)  0  0  0  0  1  0  0  1  1  
4201 (SO)  0  0  0  0  0  1  0  0  1  
508   (SP)  0  0  0  0  1  0  0  0  0  
Table shows the self-reported adherence of each patient, as assessed by compliance 
evaluation at each study visit. Input was either reported as no doses of therapy missed 
(0) or at least one dose missed (1). For some patients, data are missing (-)   
  
200 
 
 
 
Figure 5.1. Selection criteria for patients included in this study. The 
patients included in the study are shown, with the reasons stated for those that 
experienced virologic failure on LPV/r monotherapy, but were excluded. 
*As defined by trial primary endpoints. a As detected by clinical testing during 
the trial and investigated by Delfraissy et al., 2008. b Patients with a subtype 
present at low frequency in the MONARK trial (A1 and CRF01_AE) or VL < 200 
copies/ml at failure were excluded. C Viral load < 200 copies/ml, below limit of 
detection for our PCR. 
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Figure 5.2. LPV trough concentrations and time to treatment failure for 
each patient included in this study. The plasma LPV trough concentrations 
(ng/ml) at intervals since the start of therapy (measured in weeks) are shown, 
with assessments performed at weeks 4, 24 and 48 after treatment initiation. 
LPV concentrations are shown for each of the five patients experiencing 
virological failure included in this study and the time of virological failure is 
represented by the symbols and arrows below the X axis. The minimum 
therapeutic dose is considered to be 3000 ng/ml, hence at least 3 patients 
exhibited sub-optimal LPV drug concentrations in their plasma, particularly at 
week 24.  
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5.2.2 Clonal analysis of Gag-protease from patients experiencing 
treatment failure 
Clonal analysis of viral variants from each patient at each time point was 
performed to identify amino acid mutations in Gag or protease that have been 
previously described to affect PI susceptibility. In addition, comparison of 
sequences at baseline and failure could enable the identification of mutations 
associated with PI exposure. Following amplification of full-length Gag-protease 
by cDNA synthesis and nested PCR, the PCR product was cloned into the 
pGEM vector and transformed into JM109 competent cells. Colony PCR to 
identify clones containing full-length Gag-protease was performed, colonies 
were cultured and plasmid DNA purified and sequenced. To represent the 
quasispecies within a patient at each time point, sequence analysis of at least 
10 clonal variants for each sample was performed. Viral variants were 
numbered 1-10 for each sample, and the sequences labelled S (screening 
sample at baseline) or F (failure time point sample). Protease sequences were 
submitted to the Stanford HIVdb Resistance Algorithm for analysis and 
compared to the IAS list of Resistance Mutations (Johnson et al., 2013; Liu and 
Shafer, 2006). The results of the protease analysis are shown in table 5.3. Gag 
sequences were compared to table 1.2 containing the mutations in Gag 
previously reported to be associated with PI resistance and/or PI exposure, both 
in vitro and in vivo (see appendix). The transframe-protease changes D5N, L9P, 
K12E and N55S/D/V/E were also considered, but they were present at such 
high frequency in these patients that no correlation with phenotype was possible 
and hence they were not considered further (McKinnon et al., 2011).  
Patients #1403 (KON) and #1404 (DIO) were both infected with CRF02_AG 
viruses and patient #4201 with a subtype G virus. Viruses from these patients at 
both time points shared a number of Gag mutations and protease 
polymorphisms, although differences between the patients were present. In 
particular Gag mutations E12K and R76K were present in viral variants from all 
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three patients at both time points, along with Y79F which was present in only a 
few viral variants from each patient. Of note, Y79F appeared at time of 
treatment failure correlating with PI exposure, in failure variants 6 and 9 from 
patient #1403 (KON). Significant amino acid variation was present in the p2/NC 
Gag cleavage site – in particular amino acid positions 370-376. V370A was 
present in viral variants from both time points in patients #1404 (DIO) and 
#4201 (SO) and T371Q in variants from patient #1404 (DIO). A deletion of 
position 373 was present in viruses from patients #1403 (KON) and #1404 
(DIO), and in variants from patient #4201 (SO) the S373A mutation was 
present. In patients #1403 (KON) and #4201 (SO), baseline variants contained 
amino acids A and T at position 374, but only T was present at treatment failure.  
There was also a change at this position in patient #1404 (DIO) to N. Viral 
variants derived from patient #1403 (KON) contained two additional previously 
reported mutations – T375N and I376V. Of interest I376V was present in the 
viral variants from patient #1403 (KON) at baseline, but had reverted to 
consensus amino acid by the time of treatment failure in variants 1, 2 and 6.  
Previously described mutations in the p1/p6 cleavage site were also present 
with L449P in variants from both time points for patients #1403 (KON) and 
#1404 (DIO), and S451N in patient #4201 (SO).   
Of particular importance, the V82A major PI resistance mutation was detected 
in patient #1403 (KON) in failure variant 6 which had not been detected by 
previous genotypic resistance testing performed as part of clinical care during 
the trial. Viral variants derived from both screening and failure samples for 
patient #1404 (DIO) contained the A71T minor resistance mutation that was 
analysed phenotypically in chapter 4. No PI resistance mutations were present 
in viral variants derived from patients #1403 (KON), #1404 (DIO) and #4201 
(SO) at either time point, however the subtype CRF02_AG and G viruses 
contained a number of protease polymorphisms. Changes K20I, M36I and 
H69K were present in viral variants from all three patients, of which K20I and 
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M36I have previously been associated with PI exposure and treatment failure 
(Baxter et al., 2006; Bertoli et al., 2006; Descamps et al., 2009). Changes at 
position 13 and 89 of protease were present in viral variants from all three 
patients. In addition, the R41K polymorphism was present in variants from 
patients #1404 (DIO) and #4201 (SO). Each of the protease polymorphisms 
present represent consensus amino acids in recombinant CRF02_AG and 
subtype G viruses (Kuiken et al., 2012).  
Whilst a number of changes present in variants from patient #1403 (KON) 
correlated with PI exposure (Gag Y79F and protease V82A), none of the 
changes present in Gag and protease in viral variants from patients #4201 (SO) 
and #1404 (DIO) correlated fully with PI exposure.   
Patients #3204 (HG) and #508 (SP) were infected with subtype B viruses. The 
R380K mutation was present in viral variants from both patients at both time 
points, and the S451N p1/p6 CSM was present in a minority of viral variants 
from both patients. For patient #508 (SP), the presence of these two changes 
only in variants from the failure sample correlates with their development 
following PI exposure. As observed for the recombinant CRF02_AG and 
subtype G viruses, variation in the p2/NC cleavage site of the subtype B viruses 
was present with changes at position 370 to A in patient #508 (SP) variants and 
L in those from patient #3204 (HG). In addition, viral variants from patient #3204 
(HG) contained the previously reported T375N and a minority of screening 
variants contained S373P and I376V. Of note, these previously described 
mutations at positions 373 and 376 were not present at treatment failure and 
hence do not correlate with PI exposure. This is also true for the PTAP 
duplication present as a mixture at baseline but not present in the failure 
variants of patient #3204 (HG). Conversely, the T81A change does appear at 
time of treatment failure in all variants from patient #3204 (HG).   
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The protease polymorphism L63P, which was phenotypically examined in 
chapter 4 of this thesis, was present in viral variants derived from both patients 
#3204 (HG) and #508 (SP) at both time points. In addition, viral variants from 
both patients contained V771I and I93L changes in protease. Of note, patient 
#3204 (HG) had the M36I polymorphism present in all failure variants, and the 
mutation has previously been associated with PI resistance when present with 
other changes in subtype B viruses (Baxter et al., 2006).   
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Table 5.3. Drug resistance mutations and polymorphisms present in 
protease of patient-derived viruses. 
Patient  Protease Inhibitor 
Resistance mutations+ 
Protease polymorphisms+ 
Major Minor 
#1403 
(KON) 
V82A 
(F6) 
 I13V, K14R, G16E, K20I, 
E35D, M36I, H69K, K70R, 
L89M 
#508 
(SP) 
  T31I (F1), N37S, P39Q, 
S47N (S2), Q49L (S5), I62V, 
L63P, V77I, I93L 
#1404 
(DIO) 
 A71T I13A, K20I, M36I, R41K, 
I64V (S1,2,3,4,6,7,9), H69K, 
I72M (F1-10), L89I, I93M 
#3204 
(HG) 
  E35D, M36I (F1-10), N37S 
(S1,2,3,4,5,7,8,10), L63P, 
I72V, V77I, I93L 
#4201 
(SO) 
  I13V, K14R, K20I, E35Q, 
M36I, R41K, G52R (S8), 
R57K, Q61N, Q61D (S7), 
I64M (S1,2,3,4,5,6,8,9,10), 
C67E, H69K, I72V (S2,4,6), 
V82I, L89M 
Protease sequences were assessed for resistance mutations and polymorphisms using 
the Stanford Resistance algorithm. Major and minor resistance mutations are shown, 
along with any polymorphisms in comparison with a group M consensus sequence. 
Changes reported are present in all viral variants from a patient, except where specific 
variants are shown in brackets after the change.   
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5.2.3  Positive selection analyses  
The viral variants from each patient were subjected to selective pressure testing 
to identify evidence of positive selection as a result of PI exposure using various 
methods available on www.datamonkey.org (Delport et al., 2010). All viral 
variants from a single patient, derived from both screening and failure samples, 
were aligned in MEGA software using the ClustalW algorithm and nucleotides 
1450-1 removed to ensure Gag and protease were in a single reading frame.  
Aligned nucleotide sequences were submitted to datamonkey in FASTA format.  
To test for genome wide evidence of selection the PARRIS method (Scheffler et 
al., 2006) was used and for identification of particular sites under 
diversifying/purifying selection the FUBAR method (as discussed by 
Kosakovsky Pond and Frost, 2005) was selected.       
The PARRIS method detected evidence of genome-wide positive selection at P 
< 0.1 in patients #3204 (HG), #508 (SP) and #1404 (DIO). No evidence of 
positive selection was reported in alignments for patients #1403 (KON) and 
#4201 (SO). The sites identified by the FUBAR analysis as undergoing positive 
selection within each patient are shown in table 5.4, along with the amino acid 
present at that position in each of the viral variants. In patient #1404 (DIO), no 
sites were identified as undergoing positive selection, but in the remaining 
patients at least one amino acid position was identified. For two patients, #1404 
(KON) and #508 (SP), none of the amino acid changes identified by the 
analysis correlated with PI exposure. For example for patient #1404 (KON) at 
position 109 the N/K mix was present in variants from both baseline and failure 
time points, indicating that selection at this amino acid position as a result of PI 
exposure was unlikely.   
Most of the amino acid positions identified by the analysis in patient #4201 (SO) 
contained a mixture of amino acids in the screening variants but at failure a 
single amino acid was present in all variants. For example position 75 was an 
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I/L mix at baseline, but at failure all viral variants contained L. At position 418 
viral variants were R/Q mix at baseline, but at failure all variants contained K.   
In viral variants derived from patient #3204 (HG) two amino acid positions of 
particular interest were identified by the positive selection analysis – position 12 
of Gag and 36 of protease. The E12K mutation in Gag has been previously 
reported following in vitro PI exposure, and in this patient a mixture of K and Q 
was present in baseline variants but K was present in 9/10 failure variants (Aoki 
et al., 2009). Protease mutation M36I appeared in all variants from this patient 
at time of treatment failure, but was not present at baseline. M36I has been 
previously associated with PI resistance in subtype B viruses, and in particular 
to the PI TPV/r (Baxter et al., 2006).    
Of particular note, a significant number of the amino acid positions identified by 
positive selection analyses were located within the MA subunit of Gag – position 
75 and 91 in patient #4201 (SO), 15 and 55 in patient #508 (SP) and positions 
12, 63 and 70 for patient #3204 (HG).   
 
Table 5.4. Positively selected sites in Gag and protease (next page). Full-
length Gag-protease sequences from all viral variants isolated at baseline and 
failure for each patient were used. Positive selection analysis was performed 
using the FUBAR method available on the Datamonkey website tool. Positively 
selected sites are shown, along with the amino acid residue present in each 
viral variant at that site. Positively selected sites are numbered according to the 
patient sequence, with the HXB2 numbering shown in brackets where different.  
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Patient 
# 
Patient 
Initials 
Positively 
selected 
site+ 
Screening Variants Failure Variants 
1 2 3 4 5 6 7 8 9 10 1 2 3 4 5 6 7 8 9 10 
1403 KON 
28 Q Q Q Q Q Q Q Q Q Q R R Q Q R R Q Q R R 
34 L L L L L L L L L L I I I L I L L L L I 
109 N N N N K K N N K N N N N K K N N K K K 
1404 DIO None                      
4201 SO 
75 L I I L L I L I I L L L L L L L L L L L 
91 R K K R R K R R K R R R R R R R R R R R 
107  I I I R R R R I I I I I I I I I I I I I 
215  I L I I I I L I I I L L L L L L L L L L 
418 R R Q R R R Q Q Q R K K K K K K K K K K 
508 SP 
15 Q Q Q Q R Q Q Q Q Q K K T Q T Q Q S T Q 
55 I I G G E G A A G A D D A A A I A A A D 
121 D D D D G G G D D G G G G G G D G G G D 
312 D D D D D D E E E D E E D D D D D D D D 
403 K R K K K K K R K K K K K K K K R R K K 
480 D D N N D D D D N D D D D N D D D D D N 
3204 HG 
12 K Q K K Q Q K K K K K Q K K K K K K K K 
63 Q H H Q H H Q Q H Q Q Q Q Q Q Q Q Q Q Q 
70 T A A T A A T T A T T T T T T T T T T T 
81 A T T T T T T T T T A A A A A A A A A A 
313 (310) Q Q Q Q Q Q Q Q P Q S Q S S S S S S S S 
378 (376) I I V I I I V I V V V I V V V V V V V V 
pro 36 M M M M M M M M M M I I I I I I I I I I 
Table 5.4. Positively selected sites in Gag and protease (legend on previous page) 
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5.2.4 Phylogenetic and genetic distance analysis 
In order to further study the evolution of the viral variants within each patient, 
phylogenetic analysis was performed. Nucleotide sequences from both baseline 
and time of treatment failure were included for each patient. Alignment was 
performed in MEGA using the ClustalW algorithm and imported into the PHYLIP 
program for phylogeny construction using the Maximum Likelihood method 
under the GTR model of nucleotide substitution. In addition, ancestral 
reconstruction was performed using HyPhy software and inferred nucleotide 
sequences for each node used to identify amino acid changes correlating with 
treatment failure (Figure 5.3). Mean pairwise genetic distances (MPWGD) 
between the amino acid sequences of the viral variants were calculated in 
MEGA to compare genetic diversity at screening and time of treatment failure.  
Figure 5.3 shows a maximum-likelihood tree constructed using all Gag-protease 
variants from both baseline and failure time points from each of the five patients 
studied here, with the confidence of the tree tested using 500 bootstrap 
replications. The amino acid changes correlating with treatment failure and the 
node from which they were identified is shown. Figure 5.4 and 5.5 show 
maximum-likelihood trees constructed using only the gag sequence and the 
protease sequence of each clonal variant, respectively. These trees enabled an 
examination of the relationship between the baseline and failure viral variants 
from each of the patients. In each tree, the sequences from each patient formed 
a monophyletic cluster confirming that no contamination between patient 
samples had occurred. As expected, the viruses grouped by subtype, with 
subtype B variants from patients #508 (SP) and #3204 (HG) forming a distinct 
cluster, subtype CRF02_AG viruses from patients #1404 and #1403 (DIO and 
KON) forming another with the subtype G viruses from patient #4201 (SO) 
being more closely related to the CRF02_AGs than the Bs. The branches 
separating the interpatient sequences were strongly supported with 100% 
bootstrap support values.  
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For phylogeny derived from Gag-protease, the screening and failure variants 
grouped separately on the tree for four patients; #1404, #1403, #4201 and 
#3204. The emergence of genetically distinct variants at failure indicated 
ongoing evolution of the viruses during PI monotherapy. For these patients, 
amino acid changes were identified using ancestral reconstruction that correlate 
with PI exposure and treatment failure. Mutations in Gag were identified in all 
four patients and changes in protease identified in #4201 (position 64) and #5-8 
(M36I). The majority of positions identified by the ancestral site reconstruction 
are located in Gag, indicating that PI pressure results in the development of 
changes within Gag. However, for one patient #508 the baseline and failure 
viral variants were not phylogenetically distinct, indicating the re-emergence of 
genetically similar viruses at failure. The bootstrap values were low for the 
nodes between the branches within a single patient, but this is likely due to the 
close relatedness of the variants derived from a single patient. However in three 
patients, the branch lengths for the failure variants were much shorter than 
those for screening variants – patients #1404, #4201 and #3204. This indicated 
that viral diversity was reduced at time of treatment failure in comparison to 
baseline.   
The emergence of genetically distinct viruses at failure is also supported by 
phylogeny based on Gag only, figure 5.4, and protease only, figure 5.5. In both 
trees separation of viruses at baseline and failure was present for patients 
#4201, #1404 and #3204.  
The MPWGD values, showed that overall genetic diversity was significantly 
reduced at time of treatment failure in comparison to baseline (P = 0.0345, 
unpaired t test). In patients #1404 (DIO), #4201 (SO) and #3204 (HG) 
significant reductions in MPWGD were present at failure in comparison to 
baseline, from 0.014 to 0.001, 0.009 to 0.002 and 0.019 to 0.001 amino acid 
substitutions per site for baseline and failure time points, respectively.  
However, for patients #1403 (KON) and #508 (SP) no significant change in 
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diversity at baseline and failure was present. MPWGD values at baseline and 
failure were 0.007 and 0.009 for #1403 (KON) and 0.011 and 0.010 for #508 
(SP).  
We also investigated the relationship between genetic diversity and viral load.  
Correlation analyses of both factors including both failure and baseline samples 
showed no correlation between viral load and MPWGD, indicating that the 
difference in MPWGD is not an artefact of reduced viral load at failure (R = 
0.132).   
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Figure 5.3. (Title and figure on next page) 
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Figure 5.3.  Maximum-likelihood phylogeny of Gag-protease viral variants from 
baseline and failure time points. A maximum-likelihood tree constructed under the 
GTR model of nucleotide substitution in PhyML using an alignment of all variants from 
baseline and failure time points from five patients. Variants from each patient are 
represented colour, the screening variants by triangles and those from failure with 
circles. Nodes supported by >75% bootstrapping (at least 350/500) are marked by an 
asterisk(*). The tree shows the emergence of genetically distinct variants at failure, 
indicating ongoing replication during PI exposure in four of five patients. In a fifth 
patient, the re-emergence similar variants at the time of failure is in-keeping with poor 
adherence. Mutations correlating with treatment failure are marked at the node at 
which they were identified from the most recent common ancestor, inferred using 
ancestral reconstruction using HyPhy software.  
 
 
 
 
 
 
 
 
Figure 5.4. Maximum Likelihood phylogeny of full-length Gag from five patients 
at baseline and time of treatment failure, derived by clonal analysis. A maximum-
likelihood tree constructed under the GTR model of nucleotide substitution in PhyML 
using an alignment of all variants from baseline and failure time points from five 
patients. Variants from each patient are represented colour, the screening variants by 
triangles and those from failure with circles. As for the tree based on Gag-protease, 
there is evidence for the emergence of genetically distinct viruses at the time of 
treatment failure for a number of patients (4201, 1404 and 3204). 
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Figure 5.4. Maximum Likelihood phylogeny of full-length Gag from five patients 
at baseline and time of treatment failure, derived by clonal analysis. (Legend on 
previous page). 
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Figure 5.5. Maximum Likelihood phylogeny of the protease gene from five 
patients at baseline and time of treatment failure, derived by clonal analysis. 
Trees were derived using the same method as in figure 5.3 and 5.4. As for tree 5.4 
based on Gag, there is evidence for the emergence of genetically distinct viruses at the 
time of treatment failure for three patients (4201, 1404 and 3204)
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5.2.5 Phenotypic PI susceptibility and single-round infectivity of Gag-
protease derived from patients receiving LPV/r monotherapy  
To elucidate the mechanisms contributing to treatment failure in the absence of 
known PI resistance mutations, we determined the phenotypic PI susceptibility 
and single-round infectivity in comparison to reference strain p8.9NSX+ for viral 
variants representative of each patient sample at baseline and failure.  
Approximately six viral variants were chosen for each patient from both baseline 
and failure time points. At each time point the viral variant most similar to the 
consensus amino acid sequence was selected, defined as the variant with the 
least number of non-conserved amino acid changes from the consensus 
sequence when an identical variant was not present. Additional viral variants 
were selected based on the presence or absence of amino acids of interest 
identified in the genotypic analyses. Full-length gag-protease from the selected 
variants was cloned from the pGEM intermediate vector into the reference strain 
p8.9NSX+, using the NotI and XhoI restriction sites. The phenotypic 
susceptibility to the PIs ATV, DRV, LPV and SQV, and the single-round 
infectivity were determined for each variant using single-cycle assays, as 
previously described (see materials and methods).   
For patient #1403 (KON) seven viral variants in total were subjected to 
phenotypic testing, two derived from the baseline sample (S1, S5) and five from 
the time of treatment failure (F2, F5, F6, F7, F9), as shown in figure 5.6. Of note 
the F5 variant containing the major PI resistance mutation V82A displayed 
significantly reduced susceptibility to LPV of 17-fold. For the remaining variants, 
reduced susceptibility in comparison to the reference strain was observed to 
both ATV and LPV of up to 10 fold-difference in EC50 for S1, F2 and F5. 
However, F6 and F9 displayed susceptibilities similar to the assay reference 
strain to ATV and LPV, with only up to four fold-difference in EC50. Susceptibility 
levels similar to that of the reference strain were observed for all variants from 
patient #1403 (KON) to PIs DRV and SQV. All viral variants displayed reduced 
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single-round infectivity in comparison to the reference strain of between 60% 
and 90% (figure 5.7). Two viral variants in particular displayed further reductions 
to only 30% that of the reference strain, these being F6 and F9. 
A total of seven viral variants were subjected to phenotyping for patient #3204 
(HG), five from baseline (S1, S2, S6, S8, S9) and two from the time of treatment 
failure (F1, F2). Figure 5.6 shows that for this patient, the failure variants 
displayed greater reductions in susceptibility to PIs ATV, DRV and LPV than the 
screening variants. This was most pronounced for PIs ATV and LPV where up 
to 16-fold and 13-fold reduction in susceptibility in comparison to assay 
reference strain was observed, approximately two-fold higher than the reduction 
observed for screening variants of up to 8- and 7-fold, respectively. Reduced 
susceptibility to a lesser extent was observed for DRV, of up to 5-fold difference 
for the failure viral variants. For the PI SQV reduced susceptibility was observed 
for both screening and failure variants of up to 9-fold for S6. Each of the 
variants displayed reduced infectivity of between 40-80% that of the reference 
strain, as shown in figure 5.7.   
Six viral variants in total were tested for patient #1404 (DIO), four from baseline 
(S4, S5, S6, S8) and two from the failure time point (F1, F4). For this patient, 
reduced PI susceptibility to ATV and LPV were observed with the screening 
variants and F1, which displayed similar fold-differences in EC50 values of up to 
11- and 8-fold, respectively, as shown in figure 5.6. Screening variants 
remained susceptible to the PI DRV, although variant F4 displayed a 5-fold 
reduction in DRV susceptibility. Reduced susceptibility to SQV of up to 5-fold 
was observed for screening variants and up to 9-fold for failure variants.  Each 
of the viral variants displayed a reduced single-round infectivity in comparison to 
the assay reference strain. Figure 5.7 shows that the single-round infectivity for 
the screening variants ranged from 30-70%; however, variant F4 displayed a 
pronounced reduction to only 5% that of reference strain.   
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For patient #4201 (SO) five variants in total were analysed phenotypically: four 
variants derived from baseline (S1, S3, S4, S5) and one from failure (F2), as 
shown in figure 5.6. The baseline viral variants S1 and S5 displayed significant 
reductions in susceptibility to a number of PIs, most notably to LPV where at 
least 16-fold reduction in susceptibility in comparison to reference strain was 
observed (figure 5.6). Reduced susceptibility to ATV (up to 11-fold), DRV (up to 
5-fold) and SQV (up to 4-fold) were also observed. This reduction in 
susceptibility was also observed for the viral variant derived from the failure time 
point, F2. The other variants derived from the baseline time point, S3 and S4, 
exhibited less pronounced reductions in susceptibility of 8- and 11-fold to LPV, 
respectively. All variants derived from patient #4201 (SO) exhibited pronounced 
reductions in single-round infectivity in comparison to the reference strain of 14-
22% (figure 5.7).      
For patient #508 (SP), phenotypic susceptibility was measured for six variants 
in total – three each from baseline (S1, S2, S3) and the time of treatment failure 
(F2, F3, F9). Figure 5.6 shows that modest reductions in susceptibility to the PIs 
ATV and SQV were seen of up to 7- and 5.5-fold, respectively. For LPV, most 
viral variants remained susceptible with up to 4-fold reduction in EC50 in 
comparison to assay reference strain. In addition, viral variants were fully 
susceptible to the PI DRV. Viral variants isolated from patient #508 (SP) 
displayed similar RCs to the reference strain, ranging from 80-120% (figure 
5.7).   
For each patient the fold-difference in EC50 values of the viral variants most 
similar to consensus at baseline and failure were compared using t tests. In 
each case there were no statistically supported differences in susceptibility at 
baseline and treatment failure within a patient. However, the trend was towards 
reduced susceptibility at failure in comparison to baseline – in particular for 
patient #3204 (HG). Comparison of LPV susceptibility of HG variants S9 and F1 
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by t-test returned a P value of 0.068. Analysis for each patient using EC90 data 
showed the same pattern as observed for the EC50 data, as shown in figure 5.9.   
  
221 
 
 
  
222 
 
 
  
223 
 
 
Table 5.5. Summary of clinical and virological information and data for each patient (legend on next page) 
 
 
 
 
 
 
 
 
 
 
  
Patient Subtype 
VL 
Failure 
MPWGD 
at failure 
Mean LPV susceptibility 
Mutations correlating with treatment 
failure 
Baseline Failure 
#1403 
(KON) 
CRF02_AG 24,000 0.009 9.28 8.39 Gag Y79F, V186I, A375T, E452K, 
protease V82A 
#3204 
(HG) 
B 603 0.001 5.43 11.48 Gag E12K, T81A, Q311S, M317I, 
I376V, D432N, D470N, protease M36I 
#1404 
(DIO) 
CRF02_AG 1080 0.002 8.53 8.74 Gag H144Y 
#4201 
(SO) 
G 342 0.001 13.11 16.1 Gag P255S, A339P, R461C, protease 
M64L 
#508 
(SP) 
B 25,300 0.010 2.86 2.66 Gag R380K and S451N (each in one 
variant) 
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Table 5.5. Summary of clinical and virological information and data for 
each patient. A summary of the data generated in this chapter is shown in this table. 
MPWGD was calculated in MEGA 4.0 software using alignments of all viral variants 
from a each patient. LPV susceptibility was measured using VSV-g pseudotyped 
virions derived from patient Gag-protease in a single replication-cycle phenotypic 
susceptibility assay. The mean LPV susceptibility was calculated from the susceptibility 
data of all viral variants tested from the patient at either the baseline or failure time 
points. Mutations identified by ancestral site reconstruction, performed using a 
maximum parsimony approach, positive selection analysis and analysis of alignments 
by eye as correlating with treatment failure are shown. 
5.3 Discussion  
Here we report the first detailed analysis of the determinants of treatment failure 
in a PI monotherapy clinical trial, as summarised in table 5.5. The MONARK 
clinical trial offered an opportunity to examine the effects of PI monotherapy in 
previously treatment and PI-naïve patients, as opposed to other PI 
monotherapy trials which concentrated on the simplification of regimens for 
patients with a suppressed viral load on HAART. To date, phenotypic analysis 
using the commercial Phenosense assay had only been performed on viruses 
derived from patients experiencing virological failure in the LPV/r monotherapy 
arm of the MONARK trial exhibiting major PI resistance mutations (Delaugerre 
et al., 2009). This analysis showed only a mean 2.2-fold increase in EC50 at 
treatment failure in comparison to baseline. A second study has examined the 
Gag cleavage sites from all patients, but neither of these studies conclusively 
identified the determinants of treatment failure (Flandre et al., 2009). Given the 
evidence for the importance of the inclusion of full-length Gag alongside its co-
evolved protease in phenotypic assays, we set out to examine whether testing 
phenotypic PI susceptibility of full-length Gag-protease from patients failing 
therapy in the absence of PI resistance mutations could shed light on the 
causes of treatment failure. The paired nature of these samples, one taken 
before treatment and one at time of treatment failure, enabled a comparison of 
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PI susceptibility, single-round infectivity and amino acid sequence of viruses 
from a single patient before and after PI monotherapy. 
As with the other subtype B viruses we have studied in chapters 3 and 4, here 
we have observed significant variation in PI susceptibility to PIs ATV and LPV of 
subtype B, CRF02_AG and G PI-naïve viruses derived from baseline time 
points when full-length Gag-protease is included in a single-cycle phenotypic 
assay. In total, full-length Gag-protease of numerous viral variants from 5 
patients were tested, two infected with subtype B, two with CRF02_AG and one 
with subtype G viruses. This showed reduced susceptibility of up to 17-fold to 
the PIs ATV and LPV. To date, no other study has examined the PI 
susceptibility of subtype CRF02_AG and G viruses using an assay which 
encompasses full-length Gag-protease. However, these data are in keeping 
with other studies and our own data, in chapters 3 and 4, demonstrating 
significant PI variation in PI susceptibility of full-length Gag-protease of other 
viral subtypes (Gupta et al., 2010; Jinnopat et al., 2009; Parry et al., 2009).   
Our data provide evidence for a number of factors that separately or in 
combination contribute to treatment failure amongst patients in the MONARK 
LPV/r monotherapy trial. The first of these was suboptimal LPV/r trough 
concentrations in the plasma and the data from the trial indicate that 3/5 
patients had LPV/r trough concentrations below the 3,000 ng/ml considered the 
minimum effective therapeutic LPV concentration for at least one of the three 
time points where drug levels were measured. Previous analysis has shown 
that the mean LPV/r trough concentrations for patients who succeeded on 
monotherapy were 6466 ng/ml at week 4, 4518 ng/ml at week 24 and 5149 
ng/ml at week 48 (Flandre et al., 2009). At weeks 4 and 24 of the trial in 
particular, the five patients failing monotherapy included in this study had lower 
LPV/r levels than these values. In addition, each of the patients reported 
missing at least one dose during the course of the trial but as compliance 
assessment did not quantify the number of doses missed it was not possible to 
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gauge the percentage adherence for each patient. For example ‘1’ could 
indicate a single missed dose or no drug taken at all in the previous 4-8 weeks.  
Although studies on the minimum adherence required to suppress viral 
replication successfully during LPV/r monotherapy have not been performed, 
studies examining LPV/r based HAART have shown that reduction to 90-95% 
adherence does not significantly increase the risk of treatment failure (King et 
al., 2005; Shuter et al., 2007). However, as only one active agent is present 
during PI monotherapy in comparison to three for HAART it is likely that this 
may be more sensitive to poor adherence than HAART regimens.  
Data from two patients in particular, #1403 (KON) and #508 (SP), indicated the 
significant contribution of poor adherence and/or suboptimal LPV trough 
concentrations to subsequent LPV/r monotherapy failure. Patient #1403 (KON) 
experienced therapy failure at the earliest possible point in the trial – failure to 
achieve the primary endpoint of a viral load <400 copies/ml by week 24 – with a 
high viral load of 24,000 copies/ml. Very low levels of LPV were present at time 
of treatment failure, with only 75 ng/ml LPV in plasma when 3,000 ng/ml is 
considered the minimum effective therapeutic level in plasma. Thus, we cannot 
exclude the possibility that the V82A mutation was present at low frequency at 
baseline but was not detected by clonal analysis. Given that at failure V82A did 
not dominate the viral variants, being present in only 1/10 clones, it seems 
unlikely that outgrowth of this pre-existing resistant variant caused treatment 
failure. However, a recent study reported PI resistance mutations at low 
frequency using ultra-deep sequencing in a minority of patients failing PI-based 
HAART that were not identified by Sanger sequencing (9/36 patients) 
(Lataillade et al., 2012). Next generation sequencing would aid this, as 
discussed in section 7.3.3, although the clinical significance of low level viral 
variants remains unknown (Lataillade et al., 2010).   
Patient #508 (SP) also appears to have experienced treatment failure primarily 
due to poor adherence. The viral variants from this patient were the most 
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susceptible of all five failure patients at both baseline and time of treatment 
failure, with only up to 4-fold reduction in PI susceptibility to LPV. Treatment 
failure occurred with a high viral load of 25,300 RNA copies/ml after full viral 
suppression for 96 weeks. Up to 48 weeks, when drug adherence monitoring 
was performed, LPV trough concentrations were above or around the 3,000 
ng/ml minimum and reported adherence was relatively good. In addition, there 
was no evidence of positive selection using the PARRIS method and amino 
acids identified by FUBAR as undergoing positive selection did not correlate 
with PI exposure. Phylogenetic analysis demonstrated that the variants present 
at failure were closely related to those at screening indicating the re-emergence 
of the baseline viruses without viral evolution during the 96 weeks on therapy. 
Taken together, there is no evidence for any other reason for failure than a slip 
in adherence towards the end of trial and other studies have shown significant 
reductions in adherence over time (Parienti et al., 2013).  
This study also provides evidence for a second factor in LPV/r monotherapy 
failure – the development of reduced PI susceptibility over the course of 
treatment in the absence of major PI resistance mutations in protease. Data 
from one patient in particular, #3204 (HG), provided evidence that reduced PI 
susceptibility developed over the course of LPV/r monotherapy in the absence 
of known PI resistance mutations and that this may have contributed to the 
subsequent treatment failure. Patient #3204 (HG) experienced therapy failure at 
week 40 despite demonstrating adequate LPV trough concentrations and 
reporting good adherence. Screening variants displayed reduced PI 
susceptibilities of up to 9-fold to ATV and LPV, but reduced PI susceptibilities of 
up to 16- and 13-fold were observed for ATV and LPV, respectively, for variants 
derived from the time of treatment failure.   
Positive selection analysis using the PARRIS model provided evidence of 
evolution of the virus under PI pressure and a number of amino acid positions 
undergoing positive selection in both Gag and protease were identified, 
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including E12K and M36I. In addition, ancestral reconstruction identified four 
amino acid chnages correlating with PI exposure and treatment failure: Gag 
311, 317, 376 and protease 36. Several of these mutations that have been 
previously described in relation to PI resistance – 376 in Gag and M36I in 
protease – hence they may have contributed to the reduced PI susceptibility 
observed at treatment failure.  Recent studies have shown an association 
between M36I and ATV exposure and virological failure on LPV/r containing 
regimens (Dolling et al., 2013b; Santos et al., 2012). In addition, our data in 
chapter 4 have demonstrated that the presence of polymorphisms can confer 
reduced PI susceptibility in the absence of major resistance mutations. 
However, molecular modelling demonstrates that residue 36 is not located near 
the protease active site, so the mechanism by which it may affect PI 
susceptibility remains unknown, figure 5.9. E12K has been previously described 
as being associated with exposure to PI in vitro and shown to affect PI 
susceptibility and single-round infectivity when present in combination with other 
changes (Aoki et al., 2009).  
In addition to E12K, a number of other changes at positions previously 
described to be involved in PI resistance are present at treatment failure within 
the MA subunit of Gag – E62D and T81A. Positive selection analyses 
additionally identified mutations at two other positions within MA, 63 and 70. 
Our data from chapter 3 showed that the N terminus of Gag, a region 
encompassing MA and the N terminus of CA, can confer reduced PI 
susceptibility and we hypothesise that changes in this region within patient 
#3204 (HG) are contributing to the reduced PI susceptibility observed and 
hence LPV/r monotherapy failure. Future work should investigate which of these 
changes directly affect susceptibility, and whether they are required in 
combination or can have an effect when present singly. In addition, the 
mechanism by which these mutations affect PI susceptibility should be 
explored, as discussed in chapter 7.  
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Whilst drug levels and the development of reduced susceptibility played a role 
in treatment failure in these patients, our data do provide evidence for a third 
factor in failure on LPV/r monotherapy; the contribution of reduced PI 
susceptibility conferred by full-length Gag-protease of viral variants at baseline.  
Data for one patient in particular, #4201 (SO), provided evidence that a 
significant reduction in PI susceptibility at baseline may contribute to treatment 
failure. The baseline variants for this patient displayed up to 16-fold reduction in 
susceptibility to LPV that was also present at treatment failure. This reduction in 
PI susceptibility was the same as was observed for variant F6 of patient #1403 
(KON) which contained the V82A major PI resistance mutation. Patient #4201 
(SO) failed at week 48 of the clinical trial, at which time a good LPV trough 
concentration was present in the plasma and self-reported adherence was good 
at most appointments. Positive selection analysis did not provide evidence of 
evolution during PI monotherapy, although phylogenetic analysis did show the 
emergence of a genetically distinct virus at treatment failure. Ancestral 
reconstruction identified a number of amino acid positions correlating with 
treatment failure: Gag positions 215, 255, 315, 437 and protease 64. None of 
these amino acid positions have been previously described and as the PI 
susceptibility is unchanged between baseline and failure variants, they do not 
appear to have contributed to treatment failure. Molecular modelling 
demonstrates that residue 64 is not located near the active site of the enzyme, 
so the mechanism by which it may affect PI susceptibility remains unknown, 
figure 5.9. Given that virological failure occurred with acceptable LPV/r plasma 
concentrations and with a low viral load, this indicates that the reduced PI 
susceptibility present at baseline may have enabled ongoing viral replication in 
the presence of PI monotherapy. The role of reduced PI susceptibility in 
treatment failure is further explored in chapter 6 of this thesis.     
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Figure 5.9. Location of residues 36 and 64 in the structure of the protease 
protein. Residues 36 and 64 were identified by ancestral site reconstruction as 
evolving under PI exposure, each in a single patient experiencing therapy failure on the 
MONARK trial. The location of these residues was mapped using PyMol software and 
the 3ELI protease structure from the RBSC PDB. Neither residue is located near the 
active site of the enzyme.  
 
The use of phylogenetic analysis to study the evolution of the viruses within 
each patient also provides useful insight into the mechanisms of treatment 
failure in the PI monotherapy trial. In four patients #1403 (KON), #3204(HG), 
#1404 (DIO) and #4201 (SO), the failure variants are phylogenetically distinct 
from the screening variants indicating the presence of a genetic bottleneck 
resulting in the selection of one or a few variants at treatment failure. This 
provides evidence for the selection of a minority population at failure as a 
consequence of drug selective pressure and indicates the involvement of 
genetic determinants. This suggest the existence of genetic determinants 
enabling the emergence of variants under PI pressure, as identified by positive 
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selection analysis and ancestral reconstruction. Conversely, the failure variants 
from patient #508 (SP) are not phylogenetically distinct from the screening 
variants. This supports the hypothesis that poor adherence likely caused this 
patient to experience virological failure as there is no evidence of a genetic 
bottleneck before the emergence of virus at treatment failure.   
Whilst the use of positive selection analysis is very informative in the study of 
the evolution of Gag-protease in these patient-derived viruses, the interpretation 
of the data are limited. As the viral loads at time of treatment failure were low for 
three of the five patients in comparison to screening, it is possible that some of 
the amino acids identified may be a result of reduced diversity and not truly 
undergoing positive selection. It is difficult to determine if this is the case, but a 
number of the amino acid positions identified here have been previously 
described in the literature as associated with PI resistance or exposure. Future 
work to examine whether these amino acid changes affect PI susceptibility 
directly will help to inform whether they are truly undergoing positive selection 
under PI-pressure.    
We conclude that a number of factors, both virological and therapeutic, 
contributed to these patients experiencing virological failure on LPV/r 
monotherapy. Whilst suboptimal drug levels were obviously a contributing factor 
for therapy failure in some of these patients, either due to poor adherence or 
other biological factors, this study provides evidence that variation in PI 
susceptibility also contributed to treatment failure. This finding is novel, and of 
particular importance as it may explain PI therapy failure in the absence of 
major PI resistance mutations. Our data here, in particular for patient #3204 
(HG), provide evidence that reduced PI susceptibility can develop in response 
to PI therapy in the absence of major PI resistance mutations, contributing to 
subsequent treatment failure. We also provide evidence that reduced 
susceptibility at baseline, particularly in patient #4201 (SO), may have 
contributed to subsequent therapy failure. 
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6 Genotypic and phenotypic comparison between 
patients achieving a sustained virological response 
and those experiencing virological failure on LPV/r 
monotherapy 
6.1 Introduction 
In chapter 5 we examined the determinants of therapy failure in five patients 
experiencing virological failure on LPV/r monotherapy as part of the MONARK 
clinical trial. MONARK was a randomized control trial to compare the efficacy of 
LPV/r monotherapy in comparison to LPV/r based HAART. After 48 weeks, 
inferiority of the LPV/r monotherapy regimen was reported with 23/83 (24%) 
patients experiencing therapy failure in the monotherapy treatment arm 
(Delfraissy et al., 2008). Major PI resistance mutations were present in only 
5/23 patients and examination of Gag cleavage site mutations did not fully 
explain the determinants of treatment failure in the remaining patients 
(Delaugerre et al., 2009; Ghosn et al., 2011). In chapter 5 we investigated full-
length Gag-protease from paired samples in patients who experienced 
virological failure on LPV/r monotherapy, one sample from baseline and one 
from the time of therapy failure. We examined full-length Gag-protease 
genotypically and phenotypically in the context of clinical information and our 
data provided evidence for a number of factors that contributed to virological 
failure. We presented evidence for a role of suboptimal LPV trough 
concentrations, most likely due to poor adherence. In addition, we showed the 
development of reduced PI susceptibility during PI exposure in the absence of 
major resistance mutations in one of our study patients that may have 
contributed to therapy failure (patient #3204 (HG)).      
Reduced PI susceptibility of baseline viral variants from a number of the failure 
patients was also observed (see chapter 5). Full-length Gag-protease from one 
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patient in particular, patient #4201 (SO), demonstrated significant levels of 
reduced baseline PI susceptibility, indicating that reduced PI susceptibility at 
baseline may have contributed to virological failure on LPV/r monotherapy. In 
viral variants from patient #4201 (SO), reduced susceptibility of up to 17-fold to 
LPV was observed, which was the same reduction conferred by the V82A major 
mutation in patient #1403 (KON). This was a potentially important observation, 
hence further investigation of the potential correlation between reduced PI 
susceptibility at baseline and subsequent therapy failure was required. 
In order to determine the clinical significance of the reduced PI susceptibility 
observed at baseline in some patients who went on to experience therapy 
failure, baseline samples from patients who achieved a sustained virological 
response were obtained. The PI susceptibility and single-round infectivity of 
baseline viral variants from the two groups of patients were measured and 
compared. In this analysis, we use the term ‘non-controller’ for patients 
experiencing virological failure in the LPV/r monotherapy arm and ‘controllers’ 
for the patients who had a sustained virological response.     
Chapter aims: 
1) Amplify full-length Gag-protease from baseline samples of controller 
patients, matched to the non-controller patients described in chapter 5 
2) Genotypic analysis for the presence of amino acid positions previously 
described to be associated with PI exposure or resistance in viruses 
derived from controller patients 
3) Determine PI susceptibility and single-round infectivity of representative 
viral variants from each controller patient 
4) Compare the PI susceptibility and single-round infectivity of baseline 
variants from non-controller and controller patients  
  
234 
 
 
5) Use statistical modeling to determine factors associated with treatment 
outcome in the MONARK patients included in this study 
6.2 Results 
6.2.1 Clinical and virological information for controller patients selected 
for analysis 
Controller patients were selected by matching to the non-controller patients 
included in chapter 5 using the following baseline criteria: viral subtype > viral 
load > CD4 count. Virological and clinical information for the five non-controller 
and eight controller patients is presented in table 6.1. Statistical analysis 
demonstrated no significant differences in viral load or CD4+ T cell count 
between the non-controller and controller patients.   
Table 6.1. Clinical and virological information for patients studied.   
Treatment 
Outcome  
Patient 
number  
Subtype  Viral Load 
(copies/ml)  
CD4+ T cell 
count 
(cells/ml)  
Non-
Controller 
(Failure)  
508 (SP)  B  37800  250 
3204 (HG)  B  23800  318 
1403 (KON)  CRF02_AG  44600  262 
1404 (DIO)  CRF02_AG  166000  326 
4201 (SO)  G  79500  168 
Controller 
(Success)  
2112 (WA)  B  78800  331 
909 (TH)  B  16200  249 
509 (MBF)  B  40800  422 
110 (FRD)  CRF02_AG  25600  237 
4003 (MD)  CRF02_AG  29000  235 
515 (MF)  CRF02_AG  67500  144 
1702 (BOY)  CRF02_AG  50500  211 
4202 (LR)  G  36500  341 
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6.2.2 Clonal analysis of Gag-protease from controller patients 
Full-length gag-protease was amplified from the baseline plasma samples using 
the same method as used for the non-controller patients. Viral RNA was 
manually extracted from the plasma and cDNA synthesis and nested PCR 
performed. PCR products were cloned into pGEM and subjected to clonal 
sequencing analysis as for the non-controller patients, with approximately 10 
clones sequenced for each patient. Clonal nucleotide sequences were aligned 
in MEGA using the ClustalW algorithm. Protease sequences were analysed for 
PI resistance mutations using the Stanford HIVdb (Liu and Shafer, 2006) and 
comparison to the IAS List of Drug Resistance Mutations (Johnson et al., 2013).  
The results of these analyses are presented in table 6.2. The clonal Gag amino 
acid sequences were compared to the table of Gag mutations previously 
reported to be associated with PI resistance or exposure (table 1.2). The 
changes present in Gag for each patient are presented in the appendix and 
discussed below.   
Within Gag, the E12K mutation was present in all recombinant CRF02_AG and 
subtype G viruses. Position 62, at which G is consensus amino acid, was 
particularly variable and G was only present in viruses from one patient #909 
(TH), with viral variants from the other patients containing E, S, L or V. Gag 
mutations previously reported by studies in our laboratory were also present in 
several patients, R76K in patients #4003 (MD), #909 (TH), #4202 (LR), #509 
(MBF) and #515 (MF) and Y79F in patients #4003 (MD), #909 (TH), #4202 (LR) 
and #1702 (BOY) (Parry et al., 2011). The p2/NC cleavage site was variable in 
the subtype CRF02_AG and G viruses with changes at positions 373, 374 375 
and 376. In particular, T375N was present in patients #110 (FRD), #4003 (MD) 
and #1702 (BOY) and T375A in patient #515 (MF). The other cleavage site at 
which variation was present was the p1/p6 site, with the L449P change present 
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in patients #110 (FRD), #4003 (MD), #909 (TH) and #4202 (LR), and with 
patient #515 (MF) containing an L449V change. In addition, the S451N 
mutation was present in viruses from patients #4003 (MD), #4202 (LR) and 
#515 (MF).   
Neither major nor minor PI resistance mutations were identified in the viral 
variants derived from any of the patients, although a number of polymorphisms 
were identified by the Stanford HIVdb present in all subtype CRF02_AG and G 
viruses, these being I13V, K20I and L89M. K20I, predicted to confer low level 
resistance to NFV only, was identified in all subtype CRF02_AG and G viruses, 
those from patients #110 (FRD), #4003 (MD), #515 (MF), #1702 (BOY) and 
#4202 (LR) (Vermeiren et al., 2007). In addition, R41K was present in viruses 
from patients #110 (FRD), #4003 (MD), #515 (MF), #4202 (LR) and one 
subtype B infected patient #509 (MBF). However, each of these amino acid 
changes are considered the consensus in subtype CRF02_AG and G viruses 
(Kuiken et al. 2012).   
Amino acid position 63 of protease was polymorphic in the majority of patients 
regardless of virus subtype, with amino acid P present in viruses from patients 
#110 (FRD), #2112 (WA), #509 (MBF) (as a mixture with S and T) and #1702 
(BOY). Viruses from patient #909 (TH) contained an L63S change and from 
patient #515 (MF) L63V/M. Position 69 was also highly polymorphic with amino 
acid K present in patients #110 (FRD), #4003 (MD), #1702 (BOY) and #515 
(MF), and Q in patient #2112 (WA).    
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Table 6.2. Protease polymorphisms in viruses derived from non-controller 
patients.   
Patient Protease Polymorphism 
#110 (FRD) I13V, K14R, K20I, M36I, P39L, R41K, L63P, H69K, L89M 
#2112 (WA) T12A (v4)†, L33V, N37Y, I62V, L63P, I64L, H69Q 
#4003 (MD) I13V, K20I, M36I, R41K, H69K, K70R, L89M 
#4202 (LR) 
I13V, K14R, K20I, D25N (v8 & v10), E35Q, M36I, N37D, R41K, 
G48R (v8 & v10), G49E (v5), C67E, K70R, V82I, L89M, Q92H 
#909 (TH) 
L10I, E35D, M36I, R57K (except v5), D60E (except v5), I62V, 
L63S, I64V, K70T, V77I (except v5), I72T (v5), I93L 
#509 (MBF) 
P39S (v2,6,9,10), R41K (v1,3,4,5,7,8), L63P (v1,2,6,7,9,10), 
L63S (v3,4), L63T (v5,8), I64V (v.2), V77I 
#1702 (BOY) 
I13V, K14R (v2,4,5,7,9), I15V, K20I, M36I, I62V (v4), L63P, 
G68E, E68D (v10), H69K, L70R, L89M 
#515 (MF) 
L10V (v.1,2,3,8), T12K (v5), I13V, K14R (v1,2,3,7,8,10), K14Q 
(v4,5,6,9), I15V, Q18K, Q18R (v2), L19I (v4,5,6,8), K20I, M36I, 
N37D, R41K, L63V (v1,3,4,5,6,8), L63M (v2,7,9,10), I64M, 
C67S, H69K, K70R (v10), L89M 
Protease sequences were assessed for resistance mutations and polymorphisms using 
the Stanford Resistance algorithm. Major and minor resistance mutations are shown, 
along with any polymorphisms in comparison with a group M consensus sequence. 
Changes reported are present in all viral variants from a patient, except where specific 
variants are shown in brackets after the change.   
 
6.2.3 PI susceptibility and single-round infectivity of viral variants 
derived from controller patients 
The PI susceptibility and single-round infectivity of viral variants derived from 
controller patients was measured, with between one and three viral variants 
from each patient selected for phenotyping. From each patient one viral variant 
identical, or most similar to, the consensus amino acid sequence was selected, 
along with one or two others containing amino acid changes of interest, where 
applicable. Full-length gag-protease from the selected variants was cloned from 
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the pGEM intermediate vector into the reference strain p8.9NSX+, using the 
NotI and XhoI restriction sites. The PI susceptibility to four PIs, ATV, DRV, LPV 
and SQV, and the infectivity were determined using single-cycle phenotypic 
assays.   
The PI susceptibilities of each of the controller patient viral variants subjected to 
phenotyping are shown in figure 6.1. Significant variation in the PI 
susceptibilities of viral variants derived from different patients was observed, 
with reduced PI susceptibility of viral variants derived from some patients to the 
PIs ATV and LPV. Variants from all patients appeared fully susceptible to both 
DRV and SQV, with fold-difference EC50 values of less than three-fold. To the 
PI ATV, significant reductions in susceptibility of up to 9-fold were observed for 
viral variants from patients #110 (FRD) and #4003 (MD). Intermediate 
reductions in ATV susceptibility of between 5- and 7-fold were shown for viral 
variants from patients #1702 (BOY), #909 (TH) and #4202 (LR). Variants from 
three patients did not display significant reductions in PI susceptibility to ATV, 
with only up to four-fold difference in EC50, #2112 (WA), #515 (MF) and #509 
(MBF). For LPV, variants derived from three patients displayed significant 
reductions in PI susceptibility of up to 9-fold, #110 (FRD), #4003 (MD) and 
#4202 (LR). Conversely, the remaining patients did not display significant 
reductions in PI susceptibility of higher than four-fold.   
The infectivity of each of the viral variants derived from the controller patients 
was determined using a single-cycle infectivity assay, as shown in figure 6.2.  
The infectivity of variants from each patient were not significantly different from 
that of the assay reference strain ranging from 65-115%.   
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Figure 6.1. Limited variation in PI susceptibility of baseline viral variants from 
controller patients. Full-length Gag-protease was amplified from baseline plasma 
samples for 8 controller patients (a-h) and cloned into p8.9NSX+. VSV-g pseudotyped 
viruses encoding luciferase were produced by co-transfection in 293T cells. PI 
susceptibility of pseudovirions derived from each patient was determined using a single 
replication-cycle drug susceptibility assay as measured by luciferase activity. Data 
displayed are fold difference in EC50 values in comparison to that of the assay 
reference strain, p8.9NSX+, for each of six PIs: APV, ATV, DRV, LPV, SQV and TPV. 
Viruses for which the raw EC50 values were statistically different from assay reference 
strain using unpaired t-tests (P < 0.05) are denoted with an asterisk(*). Error bars 
represent the standard error of the mean of two independent experiments performed in 
duplicate. The dashed line shows the previously reported cut off for a significant 
reduction in susceptibility of greater than four-fold in comparison with the assay 
reference strain (Gong et al., 2004).  
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Figure 6.2. Single-round infectivity of baseline viral variants from controller 
patients. The single-round infectivity of pseudovirions produced from co-transfection of 
293T cells was determined by titration of viruses using a single-cycle of infection. 
Luciferase activity was measured using SteadyGlo and expressed as a fold difference 
in comparison with that of the assay reference strain, p8.9NSX+. The single-round 
infectivity of consensus baseline viral variants from 8 controller patients is shown, with 
each patient represented by a different colour. Error bars are standard error of the 
means of two independent experiments, each performed in duplicate. 
 
6.2.4 Association between PI susceptibility at baseline and therapy 
failure  
Having determined the PI susceptibility of viral variants derived from non-
controller patients (chapter 5) and controller patients, comparison of the two 
patient groups was performed. This would enable the identification of any 
correlation between baseline PI susceptibility and subsequent treatment 
outcome. The susceptibility of baseline viral variants derived from patients in 
both treatment outcome groups for all four PIs is displayed in figure 6.3.   
The viral variants derived from non-controller patients showed reductions in 
susceptibility to PIs ATV, LPV and SQV in comparison to those who achieved a 
sustained virological response. No viral variants from controller patients 
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displayed fold-difference EC50 values above 10 to LPV, but 4/18 non-controller 
patient variants displayed reduced LPV susceptibility above 10-fold difference in 
EC50 in comparison to assay reference strain. There was no evidence of 
reduced SQV susceptibility in any viral variants derived from controller patients.  
8/12 controller viral variants displayed below 2-fold reductions in EC50 and all 
variants conferred less than 4-fold reductions in SQV susceptibility.  
Conversely, 11/18 viral variants from non-controllers demonstrated reduced 
SQV susceptibility of above 4-fold in EC50 and one variant displayed a 10-fold 
reduction.   
For the PI ATV, 7/12 controller viral variants and only 5/18 variants from non-
controller patents displayed fold-difference in EC50 values < 6. Controller patient 
variants displayed up to 9-fold reductions in EC50 whereas variants derived from 
non-controllers displayed up to an 11-fold reduction in ATV susceptibility. 9/18 
non-controller viral variants displayed approximately 8-fold reductions in ATV 
susceptibility. For the PI DRV, none of the viral variants displayed significant 
reductions in PI susceptibility.   
Despite these observations, reduced PI susceptibility was not significantly 
associated with treatment failure using Mann-Whitney U rank sum tests at the P 
= 0.05 significance level (ATV P = 0.08, DRV P = 0.46 , LPV P = 0.31, SQV P = 
0.31).   
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Figure 6.3. Comparison of PI susceptibility of viral variants from non-controller 
and controller patients shows a trend towards greater reductions in 
susceptibility for non-controllers. The phenotypic susceptibility of VSV-g 
pseudotype viruses derived at baseline from 8 controller and 5 non-controller patients 
was determined measuring luciferase activity. Susceptibility to four PIs was measured: 
(a) ATV, (b) DRV, (c) LPV and (d) SQV, data are expressed as a fold-difference in 
comparison to p8.9NSX+. The mean and standard deviation for each treatment 
outcome group are shown. The difference in susceptibility between controller and non-
controllers was not statistically significant for any PI (p = 0.05, unpaired T test).  
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6.2.5 Reduced single-round infectivity was associated with sustained 
virological response 
The single-round infectivity of the consensus viral variants for each controller 
and non-controller patient compared to the assay reference strain are shown in 
figure 6.4. Significant variation in single-round infectivity between non-controller 
and controller derived variants was present, with non-controller variants 
displaying significantly lower values compared to controllers. Of the five variants 
from non-controllers, three demonstrated infectivity values around 60% and a 
fourth a value of just 20% that of assay reference strain. The fifth displayed 90% 
that of the assay reference strain. Only 2/8 variants from controller patients 
demonstrated values below 90% that of reference strain, with the other patients 
displaying values between 90 and 100%. These differences were statistically 
supported when the mean single-round infectivity of variants from non-
controllers at 60.4%± 25.3% was compared to that of the controllers 
90.6%±16.8% (P = 0.0078, unpaired t test). In addition, lower single-round 
infectivity was significantly associated with treatment failure in a Mann-Whitney 
U rank sum test using mean of within individual log-fold differences (P = 0.04).   
  
244 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.4. Reduced single-round infectivity at baseline correlates with treatment 
failure. The single-round infectivity of pseudovirions produced from co-transfection of 
293T cells was determined by titration of viruses using a single-cycle of infection. 
Luciferase activity was measured using SteadyGlo and expressed as a fold difference 
in comparison with that of the assay reference strain, p8.9NSX+. The single-round 
infectivity of consensus baseline viral variants from 8 controller patients and 5 non-
controller patients is shown. Mean and standard error for each treatment outcome 
group is shown. The relative infectivity of controllers was significantly different at the 
p>0.05 significance level (p=0.0078, unpaired t test). In addition, lower single-round 
infectivity was significantly associated with treatment failure in a Mann-Whitney U rank 
sum test using mean of within individual log-fold differences (P = 0.04). 
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6.2.6 Exploration of genetic correlates of reduced PI susceptibility 
Having shown a correlation between reduced PI susceptibility at baseline and 
treatment failure, investigation of the genetic determinants of reduced PI 
susceptibility and hence treatment failure was performed. Subtype specific 
alignments containing the viral variants subject to phenotypic analysis were 
generated using MEGA. Each alignment was searched for genetic changes 
correlating with treatment outcome, defined as being present in all non-
controller variants and not in any controller variants. 
Alignment of the subtype B controller and non-controller consensus viral 
variants revealed a total of 78 amino acids in Gag that were variable between 
patients out of 498 amino acids in total, and 3 indels of at least three amino 
acids (see appendix figure 2). Of these, variation at three amino acid positions 
correlated with virological failure: 34, 93 and 490 (HXB2 position #473). At 
position 34, L was present in non-controllers and I in controllers. For positions 
93, E was present in non-controllers and D in controllers. At position 473 amino 
acid P correlated with treatment failure, and S with virological suppression. 
Within protease 16 variable positions were present for subtype B viruses, but 
none of these correlated with treatment outcome. 
Alignment of consensus viral variants from non-controller and controller patients 
infected with the recombinant CRF02_AG viruses revealed the presence of 97 
variable amino acids in Gag. Of these, only position 287 (HXB2 position #286) 
correlated with treatment outcome – with R present in patients #1403 (KON) 
and #1404 (DIO) and K in controller patients. Within protease 19 amino acids 
were variable, but none correlated with treatment outcome. Analyses were also 
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performed with only one non-controller patient #1404 (DIO), as patient #1403 
(KON) was thought to fail primarily due to poor adherence (see chapter 5). In 
this analysis, 8 amino acid positions in Gag correlated with treatment outcome – 
75, 164, 166, 192, 225, 235, 287 and 327. In addition, three polymorphisms 
were present only in protease of patient #1404 (DIO): 71T, 89I and 93M.    
Alignment of the subtype G consensus viral variants from the non-controller 
(#4201, SO) and controller (#4202, LR) patients revealed 42 variable amino 
acids in Gag and two indels of at least two amino acids. In addition, five variable 
positions in protease were present – 37, 57, 61, 64 and 70. As only one non-
controller and one controller subtype G patient were included, filtering based on 
treatment outcome was not possible. However, one of these Gag positions, 93, 
was identified as correlating with treatment outcome in both subtype G and 
subtype B viruses. At this position, E correlated with treatment failure and D 
with virological suppression.   
6.3 Discussion 
Here we report a correlation between PI susceptibility and infectivity of VSV-G 
pseudotyped viruses in a single-round of infection, with reduced PI susceptibility 
and single-round infectivity at baseline associated with subsequent virological 
failure on LPV/r monotherapy. The variation in PI susceptibility observed in PI-
naïve viruses is in keeping with other studies and our own data in chapters 3, 4 
and 5 using single replication-cycle assays encompassing full-length co-evolved 
Gag-protease (Gupta et al., 2010; Jinnopat et al., 2009). Studies using 
commercial phenotypic assays have not reported the same degree of variation 
in PI susceptibilities of PI-naïve viruses as described here, but these did not 
include full-length co-evolved Gag from the patient viruses (Parkin et al., 2004; 
Vergne et al., 2006). Given the data showing that the inclusion of co-evolved 
Gag affects the PI susceptibility of protease, the inclusion of full-length patient-
derived Gag-protease was prudent and justified (Gupta et al., 2010; Parry et al., 
2009; chapter 3). 
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Our data provide the first evidence that reduced PI susceptibility and reduced 
single-round infectivity of patient-derived Gag-protease in the absence of major 
resistance mutations correlate with treatment failure on LPV/r monotherapy. 
This is a potentially clinically significant finding, as it indicates that screening at 
baseline may enable a prediction of patients who are suitable for these 
simplification strategies. However, we have been unable to elucidate the 
genetic correlates of reduced susceptibility, single-round infectivity and hence 
treatment failure.  
Subtype-specific genotypic analysis identified a number of amino acid changes 
in Gag and protease that were only present in non-controller patient viruses, 
correlating with treatment outcome, these being 34, 93, 287 and 473 of Gag 
and 16 in protease. However, the small number of viruses in this study limited 
the confidence with which these can be associated with therapy outcome. Given 
the significant levels of variability in Gag between patients infected with the 
same subtype, it is possible that the amino acid positions are associated with 
treatment failure solely by chance. However, position 93 in Gag was identified in 
the separate analyses for both subtype B and G analyses with the amino acid E 
correlating with therapy failure. This amino acid position in Gag has not 
previously been associated with PI exposure or resistance, so further 
investigation of its role in PI susceptibility would be prudent (table 1.2).  
Additionally, it is located within the MA subunit of Gag, a region shown to confer 
reduced PI susceptibility in subtype B molecular clones (chapter 3) and in an 
extensively PI-experienced subtype B virus (Parry et al. 2009).      
Whilst our data indicate that reduced baseline susceptibility may be associated 
with treatment failure, four of the five non-controller patients did initially achieve 
virological suppression to a viral load below 400 copies/ml on LPV/r 
monotherapy by week 24, before experiencing virological failure after 40 weeks 
of the trial. As virological suppression was initially achieved, the reduced PI 
susceptibility present at baseline in these patients was not sufficient to prevent 
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the PI from initially suppressing viral replication. However, in each of the non-
controller patients examined, suboptimal LPV trough concentrations were 
present and compliance assessments reported missed doses for at least one 
time point. We hypothesise that the reduced PI susceptibility present in the 
baseline viral variants from non-controller patients reduces the tolerance to 
suboptimal adherence, thus rendering these patients more likely to experience 
virological failure when adherence is not optimal. This is supported by the 
comparison of the EC90 for each viral variants with the LPV trough 
concentrations. For example, for screening variants from patient SO the EC90 
was 65 ng/mL and the LPV concentration 121 ng/mL, indicating that small 
levels of viral replication would be possible.   
Although studies on the minimum adherence required to suppress viral 
replication successfully during LPV/r monotherapy have not been performed, 
those examining LPV/r based HAART have shown that reduction to 90-95% 
adherence does not significantly increase the risk of treatment failure (King et 
al., 2005; Shuter et al., 2007). However, as only one active agent is present 
during PI monotherapy it is likely that this regimen may be more sensitive to 
poor adherence compared to HAART regimens. This is supported by data from 
the OK LPV/r monotherapy trial showing that the addition of two NRTIs enables 
virological suppression in patients experiencing virological failure on PI 
monotherapy in the absence of major resistance mutations (Pulido et al., 2008).  
It is possible that patients with viruses demonstrating reduced PI susceptibility 
at baseline may be better suited to HAART, which is likely to be more forgiving 
of reduced adherence, as three active agents are present. Alternatively, 
identification of these patients before treatment initiation would enable 
interventions to increase adherence and reduce this risk of failure, such as 
additional adherence counseling. 
In conclusion, we report an association between reduced PI susceptibility and 
single-round infectivity at baseline and subsequent virological failure on LPV/r 
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monotherapy in patients enrolled in the MONARK trial. This is a potentially 
important finding as it indicates that it may be possible to predict treatment 
outcome on LPV/r monotherapy from baseline PI phenotyping. We hypothesise 
that reduced baseline PI susceptibility renders patients more vulnerable to 
virological rebound when their adherence is not optimal.  Extension of this study 
to include more patients is warranted.    
 
 
 
 
 
 
  
250 
 
 
7 Final discussion and future work 
7.1 Final discussion 
HIV causes a significant global burden, with an estimated 35.3 million HIV 
positive individuals and 1.6 million AIDS related deaths worldwide in 2012 
(WHO, 2013). However, the introduction of HAART to treat HIV has greatly 
improved the prognosis of HIV-infected individuals. An optimal treatment 
regimen will result in a decrease in viral load to ‘undetectable’ levels (< 50 
copies/ml) together with an increase in patient CD4+ T cell count. In recent 
years, efforts and funds to ensure worldwide access to antiretrovirals have been 
stepped up and by the end of 2011, approximately 8 million patients were 
receiving ART.      
Although HAART has greatly improved the prognosis of HIV positive individuals, 
virological failure and the development of resistance remains a significant 
problem. Philips et al. (2007) estimated that after 10 years of HAART treatment, 
9.2% of patients will have developed resistance to all three drugs included, and 
that the risk of death within 5 years of the development of resistance is 10.6% 
(Phillips et al., 2007). PIs are a potent class of inhibitors and it has been 
reported that use of a PI as the third drug in HAART leads to significantly fewer 
patients experiencing virological failure than HAART using an NNRTI as the 
third agent (Gupta et al., 2008). Nonetheless, therapy failure during treatment 
with PIs remains a significant issue. Virological failure in patients receiving PI-
based therapy often occurs in the absence of major PI resistance mutations in 
protease and hence the exact determinants of treatment failure on PIs remain 
largely unknown. This is particularly important as the number of patients 
receiving PIs in the developing world increases, where traditional laboratory 
monitoring including regular viral load testing and CD4+ T cell counts cannot 
always be performed (Mugyenyi et al., 2010).    
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Resistance to PIs primarily occurs via the accumulation of resistance mutations 
in protease. Major mutations reduce the affinity of the protease to the PI, but 
also reduce the affinity of protease to the Gag substrate, hence they cause 
reduced viral fitness (Condra et al., 1995; Zennou et al., 1998). Minor mutations 
occur within protease and Gag to compensate for the reduced fitness conferred 
by the major resistance mutations (Croteau et al., 1997). However, recent 
studies have shown that mutations in Gag can directly contribute to PI 
resistance in mechanisms independent of the compensation of reduced RC 
conferred by the resistance protease (Dam et al., 2009; Jinnopat et al., 2009; 
Nijhuis et al., 2007b; Parry et al., 2011). It has also been demonstrated that 
inclusion of co-evolved Gag alongside its cognate protease in phenotypic 
assays can directly affect PI susceptibility (Gupta et al., 2010; Parry et al., 
2009). Given the increasing use of PIs, mainly ATV and LPV, in second line 
therapies in the developing world an understanding of the exact mechanism and 
determinants of treatment failure and virological resistance is vital.   
Given the mounting evidence for a role of Gag in PI susceptibility, we 
hypothesised that PI-naïve Gag may contain polymorphisms that can affect PI 
susceptibility. In addition, given the extensive evidence for the co-evolution of 
Gag and protease, a detailed investigation of phenotypic susceptibility of co-
evolved Gag-protease was required (as reviewed by Fun et al., 2012). This 
thesis has investigated the determinants of PI susceptibility utilising a single-
cycle phenotypic assay, with the aim of answering two main questions. The first 
was whether natural amino acid sequence variation present in full-length Gag-
protease of PI-naïve subtype B HIV viruses can confer variation in PI 
susceptibility. To date, no assessment of variation in phenotypic PI susceptibility 
between different PI-naïve subtype B viruses has been performed using assays 
encompassing full-length Gag alongside its co-evolved protease.  The second 
objective was to investigate whether variation in PI susceptibility of full-length 
Gag-protease may have contributed to treatment failure in the PI monotherapy 
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arm of the MONARK clinical trial.  Our study was the first to perform such a 
detailed virological analysis of patients failing PI monotherapy, and in particular, 
no previous studies have utilised phenotypic assays encompassing full-length 
co-evolved Gag.   
We have shown significant variation in PI susceptibility of full-length Gag-
protease from PI-naïve viruses of subtypes B, CRF02_AG and G, for both 
molecular clones and viruses derived directly from patients. Reduced 
susceptibility of up to 17-fold in EC50 in comparison to assay reference strain to 
the PIs ATV and LPV was observed. Reduced susceptibility was consistently 
observed to four of the six PIs tested: APV, ATV, LPV and TPV. This is a novel 
finding and the first demonstration of variation in susceptibility of PI-naïve, 
subtype B, CRF02_AG and G viruses using an assay encompassing full-length, 
co-evolved Gag-protease. These data are in keeping with other reports based 
on full-length Gag-protease of viruses of other subtypes and those from PI-
experienced patients (Gupta et al., 2010; Jinnopat et al., 2009; Parry et al., 
2009). Other studies based on large numbers of viruses assessing variation in 
PI susceptibility have not reported such a range, but these utilised commercial 
assays in which only protease from the test virus was included alongside 
reference strain Gag (Parkin et al., 2004; Vergne et al., 2006). We provide 
further evidence of the importance of the inclusion of co-evolved Gag alongside 
protease in phenotypic PI susceptibility assays. However, the limited number of 
samples included in our study means that further and more extensive research 
to confirm our findings in a wider panel of viruses is required.   
Our second main finding is that variation in PI susceptibility can be 
independently conferred by the N terminus of Gag, specifically MA and N 
terminus of CA. Our data show the involvement of changes distant from the 
Gag cleavage sites in reduced susceptibility – positions 30 and 102 of Gag.  
This is one of a handful of reports that have provided evidence for the 
importance of changes outside the cleavage sites within the N terminus of Gag 
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in affecting PI susceptibility, but ours is the first to demonstrate the role of 
changes in MA in PI-naïve viruses. Of these reports, Parry et al (2011) 
demonstrated that changes within MA could directly affect PI susceptibility in a 
PI-experienced subtype B virus, specifically changes at positions 76, 79 and 81.  
The second report was a PI-naïve subtype CRF01_AE virus, in which position 
165 of Gag located in CA was shown to affect PI susceptibility (Jinnopat et al., 
2009; Kameoka et al., 2010). Positive selection analysis and correlation 
between genotypic and phenotypic data amongst non-controller patients in the 
MONARK trial identified a number of amino acid positions within MA that were 
associated with PI exposure and reduced susceptibility, providing further 
evidence for the role of MA in PI susceptibility. Overall, our data show the direct 
involvement of the MA subunit of Gag in PI susceptibility and we conclude that 
further investigation of the role of MA in PI resistance and therapy failure is 
required.     
We have shown that significant reductions in PI susceptibility can be conferred 
by protease in the absence of major PI resistance mutations, with up to 13-fold 
reduction in EC50 observed for the PI ATV. Furthermore, this study provides 
evidence that minor resistance mutations and polymorphisms present in 
combination can confer reduced PI susceptibility. Data for three amino acid 
positions in protease are presented here, namely 13, 63 and 71, but we 
hypothesise the involvement of other changes that when present in combination 
confer reduced PI susceptibility. These data are in keeping with that of other 
studies which have shown that PI polymorphisms affect PI susceptibility and 
fitness, including at amino acid positions 10, 20, 33 and 71 (Nijhuis et al., 1999; 
Vermeiren et al., 2007). A number of reports have also shown as association 
between the presence of protease polymorphisms and poorer treatment 
outcomes (Kempf et al., 2001; Pellegrin et al., 2006; Vora et al., 2006). In 
addition, the study performed using the UK HIV Drug Resistance Database 
identified a number of other protease changes that are present at higher 
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frequencies in patients failing ATV therapy than in PI-naïve patients (Dolling et 
al., 2013b). Further research to fully elucidate the role of protease 
polymorphisms in PI resistance is required, particularly as the roll-out of HAART 
to areas of the world where non-B subtypes are most prevalent occurs.      
Of particular interest was the difference in the independent role of Gag and 
protease in PI susceptibility in molecular clones (chapter 3) and patient-derived 
viruses (chapter 4). Our data show that Gag solely conferred the reduced 
susceptibility observed in molecular clones YU2 and JRFL, but that protease 
solely conferred the reduced susceptibility observed in the patient-derived 
viruses. The exact reason for this difference is unknown, although another study 
that included both molecular clones and patient viruses did not report a 
difference in the role of Gag and protease (Gupta et al., 2010). It is possible that 
the relatively small number of viruses included in this study could account for 
this difference. The fact that the two molecular clones in which Gag conferred 
reduced susceptibility were not subjected to extensive in vitro passage, YU2 
and JRFL, appears to discount the hypothesis that adaptation to tissue culture 
during the generation of the molecular clones may explain the difference in the 
role of Gag in comparison with patient-derived viruses (Collman et al., 1992; 
Hahn et al., 1984). Another possible explanation is that the effect of Gag on PI 
susceptibility is only present in viruses derived from the CNS, as YU2 and JRFL 
were both isolated from the brain. Adaptations in Gag could occur to favour viral 
replication in the brain that by chance also affect the susceptibilities of these 
viruses to PIs. Further investigation is required to elucidate the clinical 
relevance of these findings, in particular the study of other molecular clones 
derived from brain tissue. Given the concern of ongoing viral replication in the 
brain during PI therapy and the question of the penetration of PIs into the CNS, 
this could be of potential importance (Valero et al., 2014).      
Here, we have performed the first detailed virological analysis of full-length 
Gag-protease in patients experiencing virological failure on PI monotherapy.  
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We have shown that reduced PI susceptibility of full-length Gag-protease in the 
absence of major resistance mutations contributed to treatment failure in at 
least some of the patients studied in the MONARK trial by two main 
mechanisms. Firstly, reduced PI susceptibility at baseline may render the 
patient more likely to experience subsequent virological failure and secondly 
reduced PI susceptibility developed during therapy in the absence of major 
resistance mutations. We hypothesise that reduced PI susceptibility alone did 
not cause treatment failure, but coupled with suboptimal adherence led to 
ongoing viral replication in these patients. This is supported by the findings of 
another report, in which escalation of these patients onto HAART lead to 
successful viral suppression (Pulido et al., 2008). If confirmed by studies of 
larger groups of patients, this would offer an explanation for the causes of 
treatment failure in other patients on PI monotherapy who fail without major PI 
resistance mutations (Gilks et al., 2012; Pulido et al., 2008).  
To date, PI monotherapy trials have largely been performed in the developed 
world in patients closely monitored with regular laboratory testing including 
CD4+ T cell counts and viral loads (Arribas et al., 2010; Castagna et al., 2013; 
Delfraissy et al., 2008; Pulido et al., 2008). All of these trials have reported very 
low rates of failure with PI resistance mutations which would compromise future 
treatment options (Arribas et al., 2010; Delaugerre et al., 2009; Pulido et al., 
2008). Given that the vast majority of those requiring treatment are in the 
developing world, in particular sub-Saharan Africa where laboratory testing is 
not routinely performed, it is important to understand the utility of PI 
monotherapy in this setting. Recent data from the ERNEST trial have shown 
that in the absence of viral load testing, 18% of patients on LPV/r monotherapy 
developed major resistance mutations after 96 weeks of therapy in comparison 
to just 2% on LPV/r based HAART (Paton et al. 2013). In many parts of Africa, 
only two lines of treatment are available and LPV-based HAART forms the 
second, and final, option for patients experiencing failure on first line regimens.  
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Our data, along with other studies, indicate that PI monotherapy may have a 
place in treatment of patients with fully-susceptible viruses at baseline, good 
adherence and close virological monitoring. In these patients the reduced 
financial cost, pill-burden and side-effects merit the consideration of PI 
monotherapy as a treatment option, especially given that it is unlikely to 
compromise future treatment by the development of major PI resistance 
mutations. However, PI monotherapy appears to have limited utility in sub-
Saharan Africa where there is little to no viral load or resistance testing and 
LPV/r is the final treatment option for many patients.     
7.2 Study limitations 
This study had a number of limitations, as imposed by the methods used to 
perform the analysis. Although the single-cycle phenotypic assay used to 
measure PI susceptibility has a number of advantages justifying its selection, it 
also imposes limitations on the interpretation of our data. The phenotypic assay 
was carried out at containment level 2, as opposed to multiple-cycle assays 
performed with replication-competent viruses which require containment level 3 
facilities. In addition, it has been reported that single-cycle assays have 
increased sensitivity and reproducibility over multiple-cycle ones, although they 
are further removed from the conditions in vivo. Another important advantage is 
that single-cycle assays offer no opportunity for evolution and selection under 
tissue culture conditions unlike multiple-cycle assays (Petropoulos et al., 2000). 
The assay used in this study and its modified versions have been used in a 
series of published studies, so the assay has already undergone peer-review 
(Gupta et al., 2010; Koning et al., 2013; Martin et al., 2012; Parry et al., 2009). 
The assay has also been subjected to extensive measures of variation, as well 
as the additional confirmations performed here (Gupta et al., 2010). This assay 
also controlled for variation in infectivity and transfection efficiency between 
viruses as each EC50 value was normalised using a no-drug control luciferase 
reading for each virus. 
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Whilst the assay offers important advantages over similar multiple-cycle assays, 
it also has limitations. A previous study has shown that the results of single-
cycle and multiple-cycle assays are not always concordant (Dykes et al., 2010).  
The most important limitation is the use of pseudoviruses with a VSV-G 
envelope glycoprotein, as opposed to an HIV envelope. A recent study has 
demonstrated the PIs block viral entry and that this block is only observed when 
an HIV-1 envelope is used and is not found when VSV-g and MLV pseudotyped 
viruses are used (Rabi et al. 2013). Our data indicate the role of MA in PI 
susceptibility, and given that MA interacts with HIV Env for the incorporation of 
Env in the assembling virion and the correct positioning of Env in the mature 
plasma membrane, it is important to confirm our data in the future using an 
assay system with HIV Env (as discussed in 7.3.1). In addition, VSV-g enters 
cells using a different pathway than native HIV virions, which could affect 
downstream pathways such as the transport of the capsid across the 
cytoplasm, uncoating and nuclear entry, which have been shown to be affected 
by the presence of PI (Muller et al. 2009).  
The assay reference strain, p8.9NSX+, is derived from molecular clone HXB2 
up to the SpeI site in Gag and from NL4-3 from the SpeI site onwards to the end 
of Pol. However, both HXB2 and NL4-3 displayed reduced susceptibility in 
comparison to the reference strain to APV, indicating that p8.9NSX+ may 
exhibit hypersusceptibility to the PI APV. This does not significantly limit the 
interpretation of our data as all fold-difference values were derived using the 
same reference strain so susceptibility and single-round infectivity values for 
each virus were directly comparable. In addition, as this reference strain has 
been used in other published studies with this assay system, direct 
comparisons to these viruses can also be performed (Gupta et al. 2010; Parry 
et al. 2009). Whilst the use of p8.9NSX+ does not enable direct comparison 
with other assays using different reference strain, it is similar to the reference 
strains used in commercial phenotypic assays Antivirogram and Phenosense, 
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that use HXB2 and NL4-3, respectively. In particular, clinical cut-offs derived for 
other assays cannot be directly applied to our assay. The lack of clinical cut-offs 
for this assay is an obvious limitation, but their derivation would require 
phenotyping of thousands of patient derived viruses (Winters et al., 2009).  
Another disadvantage of this assay is the use of luciferase activity as a marker 
for infectivity. The luciferase activity measurement is affected by factors other 
than the percentage of cells infected, in particular the reading is altered by cells 
infected multiple times. Conversely, the use of a GFP reporter measured by 
FACS would have enabled the determination of the percentage of cells infected.  
The single-round infectivity assay used here offers similar advantages as the 
phenotypic susceptibility assay in that it is single-cycle and hence carried out in 
containment level 2 laboratories. However, as p24 quantification occurs after 
virion assembly this assay will not capture any differences in viral fitness 
conferred during virion production – including transcription/translation of viral 
genes, virion assembly and budding. Gag has been shown to drive the process 
of virion assembly and in particular amino acid changes surrounding position 30 
of Gag have been shown to affect targeting to the plasma membrane (Ono and 
Freed, 2004). The single-round infectivity assays performed without p24 
adjustment for the MONARK study enabled capturing of all life cycle stages, but 
do not control for variation in transfection efficiency. In the future, different 
methods to measure fitness over multiple-cycles of replication could be used 
such as competition assays to compare the fitness of each of the molecular 
clones.   
Use of clonal analysis limited the representation of the quasispecies within 
patients for both the PI-naïve subtype B viruses and the patients from the 
MONARK trial. This method has a number of limitations as it is laborious and 
time consuming, and is vulnerable to recombination events during the PCR 
step. As recombination between viral genomes cannot be ruled out, linkage of 
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mutations cannot be inferred from sequences generated by clonal analysis.  
Sequencing of just ten variants from each time point limited the depth to which 
variation was examined and may not have detected low level variants which 
could have had differing PI susceptibilities. Different experimental methods to 
overcome these issues are discussed below (section 7.3.3).    
7.3 Future work 
7.3.1 Variation in PI susceptibility of subtype B molecular clones  
We have shown that the N terminus of Gag conferred variation in PI 
susceptibility observed for full-length Gag-protease of some subtype B 
molecular clones in our pseudotyped virus assay. In the future, we need to 
confirm that this effect is also present with full-length virus given the interactions 
that take place between HIV Env and the MA subunit of Gag. Our data 
demonstrated the involvement of two novel changes in Gag in PI susceptibility – 
K30R and D102E. In addition, examining the role of positions 30 and 102 in the 
susceptibility of full-length viruses with HIV Env is important, given that PIs have 
been shown to affect entry and that this is dependent on the interaction 
between MA and Env. One finding of interest was the introduction of these two 
changes into the reference strain prevented the production of infection 
pseudovirus. Further investigation of this finding, in particular whether the 
changes would also cause a loss of infectivity when present singly, and the life 
cycle stage at which this block occurred would be of interest. It is possible that 
these experiments could help elucidate how PIs block infectivity as well as the 
role of these two changes in PI resistance.  
Whilst the identification of changes K30R and D102E is of interest,  they did not 
fully account for the reduced PI susceptibility observed and the remaining 
genetic determinants were unknown. Further work to identify these would 
concentrate on the amino acid changes present within the N terminus of Gag, 
but these are different in the two molecular clones studied, YU2 and JRFL. The 
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unique changes from consensus B sequence in the N terminus of Gag were 
T53S, Q69K, R76T, V94I, N109T, K112M and V159I for JRFL and G10A, 
K28Q, N47D and R91K for YU2. Further site-directed mutagenesis and PI 
susceptibility assays could explore the role of these changes in PI susceptibility.  
Given the small effect on PI susceptibility of the changes at positions 30 and 
102, it is likely that a number of these changes in combination account for the 
reduced susceptibility observed for gagN in each molecular clone.   
The other main way in which this study could be extended is further 
investigation of the mechanisms by which the reduced PI susceptibility of Gag-
protease in conferred. We have already performed preliminary experiments 
here using electron microscopy techniques which showed that for molecular 
clone JRFL, pseudovirion maturation is not significantly affected by the 
presence of the EC90 of ATV. Conversely the maturation of p8.9NSX+ and YU2 
is inhibited by ~50%. Examination of the chimeric pseudovirions (MCgag, 
MCpro, MCgagN and MCgagC) using EM would enable confirmation that the 
difference in maturation was in fact conferred by the N terminus of molecular 
clone Gag as was assumed here, given that the N terminus of Gag solely 
conferred the change in PI susceptibility. Further experiments using the same 
EM methods, but with more concentrations of PI would be beneficial. In addition 
the inclusion of more molecular clones in the analysis, in particular one of 89.6 
or SF2 in which both Gag and protease contributed to the reduced PI 
susceptibility observed, would shed further light on the role of the N terminus of 
Gag.   
To understand the determinants of the variation in PI susceptibility between 
different viruses, western blotting to monitor Gag cleavage could be used. 
Western blots would show whether the proportion of Gag cleaved varies 
between the different viruses and if these differences are small this may not be 
obvious in the proportion of mature virions. Whilst western blotting was 
attempted during the course of this study, a method sensitive enough for use 
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with pseudovirus in cell media proved technically challenging and could not be 
developed in time. As an alternative, the cleavage of radio-labelled Gag-Pol 
protein by wild-type protease could be examined, as in previous studies (Pettit 
et al., 2005). A quantitative examination of the Gag cleavage products present 
at various time points (12, 24 and 48 hours post-transfection), and at varying 
concentrations of ATV would be required. This could provide additional 
evidence as to whether a difference in the rates of Gag cleavage between the 
different molecular clones and reference strain is present and whether the 
proportion of pseudovirions achieving maturation is affected. In addition, 
comparison of the efficiency of Gag cleavage at each site between each 
molecular clone could be performed using an enzymatic cleavage assay. Van 
Maarseveen et al. (2012) described a method involving the synthesis of 
peptides mimicking each of the Gag cleavage sites, which were cleaved by 
wild-type protease enzyme under controlled conditions.  Cleavage products 
were identified and quantified using HPLC (high-performance liquid 
chromatography) which would enable a comparison of cleavage efficiencies 
between molecular clones and the reference strain (van Maarseveen et al., 
2012).  
At the concentration of ATV used here for EM, viral infectivity was reduced by 
90% but no difference in maturation was present for JRFL, indicating that this 
reduced infectivity must be conferred at another stage of the life cycle. A recent 
study has examined the effect of PIs on the efficiency of each life cycle step and 
in particular has shown that PIs significantly block cellular entry (Rabi et al. 
2013). Another study has examined the effect and mechanisms of varying 
concentrations of the PI LPV on viral infectivity. This reported that incompletely 
cleaved Gag, and in particular a lack of full release of the CA subunit, exerts a 
strongly trans-dominant, negative effect on viral infectivity. The authors 
hypothesised that within a virion which appears mature morphologically, the 
presence of relatively small amounts of incompletely cleaved CA in the viral 
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core lead to incorrect uncoating post-entry, preventing the formation of the 
reverse transcriptase complex (Muller et al., 2009). Hence, it is possible that a 
difference in the efficiency of viral uncoating in the presence of PI may 
contribute to the different PI susceptibilities of the JRFL, YU2 and p8.9NSX+. In 
addition, mutations at positions 89 and 90 of Gag have been shown to affect 
infectivity by the inhibition of interactions with host factors cyclophilin A and 
Nup358, necessary for entry and uncoating steps (Schaller et al., 2011).   
This efficiency of various viral life cycle stages including reverse transcription, 
nuclear entry and integration could be tested using qPCR based assays and 
compared between the molecular clones and p8.9NSX+ (Butler et al., 2001; 
Mbisa et al., 2009). This assay can distinguish early, intermediate and late RT 
products as well as products present following nuclear import, LTR circles and 
integrated cDNA, by the design of primers targeting the regions present 
exclusively at each stage. For example primers-probe sets covering the U5-R-
U3 regions to target early RT products as this region is only present during 
minus DNA strand synthesis following the first DNA strand jump. For the 
purposes of this study, comparison of the amount of early and late RT products, 
and integrated cDNA (performed using primers targeting the R-U5 of HIV and 
the Alu repeats present throughout the human genome) would enable the 
identification of reduced efficiency of reverse transcription and integration. If 
required, qPCR to distinguish a surrogate marker of nuclear import (LTR circles) 
and integrated cDNA could also be performed.  
7.3.2 Variation in PI susceptibility of subtype B, patient-derived PI-naïve 
viruses 
This study examined the variability in PI susceptibility of PI-naïve subtype B 
viruses derived directly from patient viruses. A major limitation was that only 
four patients were included, but the MONARK study detailed in chapter 5 also 
included an additional five patients infected with subtype B viruses. These data 
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from the MONARK patients support the findings of the PI-naïve patients from 
PHE, with both demonstrating variation in PI susceptibility in particular to the 
PIs ATV and LPV. Unfortunately, clinical information was not available for the 
PHE patients as this would have been useful in determining the treatment 
outcomes for any who subsequently received PI containing regimens.   
In this study, we have shown variation in PI susceptibility conferred by protease 
in the absence of major resistance mutations. Whilst we were able to identify 
three polymorphisms that contributed to this reduced susceptibility – I13V, L63P 
and A71T – they did not fully account for the reduction in susceptibility.  
Experiments to determine the other genetic determinants are important, as a 
change affecting PI susceptibility may also confer resistance. As proposed for 
the identification of further Gag amino acid changes in section 7.3.1, site-
directed mutagenesis and PI susceptibility experiments could shed light on the 
role of the other protease polymorphisms present in each of the two patients: 
I15V, P39E, D60E, I72V, V77I and I93L in patient 2 and K14R, E35D, N37T, 
R41K and I62V in patient 4. The same methods could be used to determine 
whether any of the changes identified at higher frequency in patients failing ATV 
using the UK HIV Drug Resistance Database have a direct effect on PI 
susceptibility, either separately or in combination (Dolling et al., 2013b).  
In the future, work to identify the mechanisms by which protease 
polymorphisms affect PI susceptibility should be carried out. Computer 
modelling performed here has shown that the three polymorphisms analysed 
phenotypically were not located near the substrate binding cleft so are unlikely 
to directly affect the binding of the PI to the protease enzyme, but further 
experiments could be performed. The efficiency of the protease enzyme from 
each patient virus and from the reference strain could be measured using a 
previously described assay involving the cleavage of chromogenic substrates 
by protease proteins produced in E. coli (Velazquez-Campoy et al., 2001). This 
assay could also be used to further investigate the effect of the polymorphisms 
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identified in collaboration with the UK HIV Drug Resistance Database (Dolling et 
al., 2013b).  
There is evidence that some of the protease polymorphisms studied 
phenotypically may affect the pathways to resistance to PIs (Lisovsky et al., 
2010; Vergne et al., 2006). In the future, in vitro passage experiments with 
replication-competent viruses to examine the evolution of resistance to ATV 
should be performed. To date, only one study has described in vitro passage in 
the presence of ATV and the authors only described the data from one 
experimental repeat (Gong et al., 2000). In vitro passage with ATV could be 
performed using methods that have been previously described (Patick et al., 
1995). Viruses containing the polymorphisms analysed phenotypically in 
combination, I13V, L63P and A71T, could be included which would show 
whether they affect the development of other resistance mutations. In addition 
the novel protease mutations present at higher frequency in patients failing ATV 
therapy could also be examined in this way (Dolling et al., 2013b). It would be 
particularly interesting to passage a number of different subtype B viruses from 
different patients with ATV and see whether any of these novel protease 
mutations described here appear over time.      
7.3.3 Determinants of treatment failure in LPV/r monotherapy arm of the 
MONARK trial  
This study examined 13 patients in total; 5 non-controllers who subsequently 
experienced treatment failure and 8 controllers who achieved a sustained 
virological response. This study could have been improved by the inclusion of 
more patients, but the sensitivity of the PCR methods employed limited the 
number of failure samples with low viral loads from which Gag-protease could 
be amplified. Another study has described a PCR that resulted in amplification 
from a diverse range of subtypes and from viral loads down to 500 copies/ml 
(Van Laethem et al., 2006). However, in 13/23 non-controller patients the viral 
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load at treatment failure was below 500 copies/ml. The reverse primer used for 
cDNA synthesis in this study was taken from this publication, KVL065, but in our 
hands the method described by Van Laethem et al. (2006) was less sensitive 
than our existing one. Plans are in place to extend the study so that the is a 1:1 
ratio of non-controllers to controllers.   
The small number of patients was further complicated by the fact that patients 
were infected with viruses of different subtypes with three subtypes represented 
here: subtype B, CRF02_AG and subtype G. The genotypic and phenotypic 
differences between the viruses of different subtypes further complicated the 
analysis of our data. For example, M36I in protease and E12K in Gag have 
been described to affect PI susceptibility in subtype B viruses, but are 
consensus amino acids in subtypes CRF02_AG and G (Aoki et al., 2009; Baxter 
et al., 2006). In the future, further statistical analyses including Mann Whitney U 
Rank Sum tests and conditional logistic regression will be performed. This will 
test whether any factors are significantly associated with treatment outcome, for 
example virus subtype or LPV susceptibility.   
As well as an expansion of the number of patients, a more detailed study of the 
patient viruses already characterised is important. In particular, whilst the 
ancestral site reconstruction has identified changes that correlate with PI 
exposure and therapy failure, we have not directly shown the effect of particular 
mutations on PI susceptibility, as in chapters 3 and 4. Sites correlating with 
treatment failure were identified in patients #1403 (KON – 3 sites), #4210 (SO – 
4 sites) and #3204 (HG – 7 changes). Site-directed mutagenesis techniques 
could be used to revert these mutations to consensus B sequence in the patient 
vectors and introduce these changes into the reference strain. Further PI 
susceptibility assays could then be used to determine their exact role in PI 
susceptibility, and hence the potential role in treatment failure.  
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Another of the limitations of our study was the use of clonal analysis to examine 
the quasispecies within a patient. Other PCR and sequencing techniques could 
be used in the future which would enable sequencing to a greater depth and the 
linkage of mutations on a single viral genome. Single Genome Analysis (SGA), 
a terminal dilution PCR assay that results in the amplification of a PCR product 
from a single RNA genome, could be used (Palmer et al., 2005). A SGA assay 
covering full-length pol is already in use in our lab and a SGA assay covering 
Gag has been previously described and could be implemented (McKinnon et 
al., 2011). This would offer an important advantage over the existing method as 
linkage between mutations on a single viral genome could be shown and the 
frequency of recombination would be greatly reduced.   
Next generation sequencing of certain patient samples would provide insight, in 
particular those from patient #1403 (KON) which would shed light on the 
development of the V82A mutation at failure, as discussed in section 5.3. In 
particular the frequency of resistance mutations or other amino acid changes of 
interest within the viral quasispecies could be determined with greater accuracy.  
Certain next generation sequencing assays are now able to detect resistance 
mutations present in as low as 1% of viral variants, although the exact effect of 
low level viral variants on treatment outcome is yet to be determined (Lataillade 
et al., 2010).   
It would be interesting to examine other PI monotherapy studies to further 
explore the utility of PI monotherapy, in particular those including patients with 
other subtypes and those using different PIs. Of particular interest would be the 
more recent studies performed with DRV/r monotherapy, a more potent PI than 
LPV with a high genetic barrier to resistance, and trials performed in the 
absence of close virological monitoring. In the future, the use of ancestral site 
reconstruction as will help to identify novel mutations that occur under PI 
pressure that could may contribute to treatment failure.  
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7.4 Final comments 
Here, we have investigated the determinants of PI susceptibility utilising a 
phenotypic PI susceptibility assay encompassing full-length, co-evolved Gag-
protease from the virus of interest.  We have demonstrated significant variation 
in PI susceptibility in PI-naïve viruses of subtypes B, CRF02_AG and G, 
showing the direct role of Gag and protease independently in this variation.  We 
have shown evidence for the contribution of variation in susceptibility of Gag-
protease in the absence of major protease resistance mutations to treatment 
failure on PI monotherapy, an important and novel finding.  Our data further 
support the importance of considering Gag and protease together when 
investigating PI susceptibility.  
    
 
  
268 
 
 
7.4.1.1 Reference List 
Abdool,K.Q., Abdool Karim,S.S., Frohlich,J.A., Grobler,A.C., Baxter,C., Mansoor,L.E., 
Kharsany,A.B., Sibeko,S., Mlisana,K.P., Omar,Z., Gengiah,T.N., Maarschalk,S., Arulappan,N., 
Mlotshwa,M., Morris,L., and Taylor,D. (2010). Effectiveness and safety of tenofovir gel, an 
antiretroviral microbicide, for the prevention of HIV infection in women. Science 329, 1168-1174. 
Adamson,C.S., Ablan,S.D., Boeras,I., Goila-Gaur,R., Soheilian,F., Nagashima,K., Li,F., 
Salzwedel,K., Sakalian,M., Wild,C.T., and Freed,E.O. (2006). In vitro resistance to the human 
immunodeficiency virus type 1 maturation inhibitor PA-457 (Bevirimat). J. Virol. 80, 10957-
10971. 
Adamson,C.S., Waki,K., Ablan,S.D., Salzwedel,K., and Freed,E.O. (2009). Impact of human 
immunodeficiency virus type 1 resistance to protease inhibitors on evolution of resistance to the 
maturation inhibitor bevirimat (PA-457). J. Virol. 83, 4884-4894. 
Ait-Khaled,M., Rakik,A., Griffin,P., Stone,C., Richards,N., Thomas,D., Falloon,J., and Tisdale,M. 
(2003). HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 
weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving 
abacavir/efavirenz/amprenavir in the CNA2007 study. Antivir. Ther. 8, 111-120. 
Amico,P., Aran,C., and Avila,C. (2010). HIV Spending as a Share of Total Health Expenditure: 
An Analysis of Regional Variation in a Multi-Country Study. PLoS One 5, e12997. 
Aoki,M., Venzon,D.J., Koh,Y., Aoki-Ogata,H., Miyakawa,T., Yoshimura,K., Maeda,K., and 
Mitsuya,H. (2009). Non-cleavage site gag mutations in amprenavir-resistant human 
immunodeficiency virus type 1 (HIV-1) predispose HIV-1 to rapid acquisition of amprenavir 
resistance but delay development of resistance to other protease inhibitors. J. Virol. 83, 3059-
3068. 
Arien,K.K., Vanham,G., and Arts,E.J. (2007). Is HIV-1 evolving to a less virulent form in 
humans? Nat. Rev. Microbiol. 5, 141-151. 
Arribas,J.R., Horban,A., Gerstoft,J., Fatkenheuer,G., Nelson,M., Clumeck,N., Pulido,F., Hill,A., 
van,D.Y., Stark,T., and Moecklinghoff,C. (2010). The MONET trial: darunavir/ritonavir with or 
without nucleoside analogues, for patients with HIV RNA below 50 copies/ml. AIDS 24, 223-
230. 
Arts,E.J. and Hazuda,D.J. (2012). HIV-1 antiretroviral drug therapy. Cold Spring Harb. Perspect. 
Med 2, a007161. 
Asaoka,K., Ikeda,K., Hishinuma,T., Horie-Inoue,K., Takeda,S., and Inoue,S. (2005). A retrovirus 
restriction factor TRIM5alpha is transcriptionally regulated by interferons. Biochem. Biophys. 
Res. Commun. 338, 1950-1956. 
Bacheler,L., Jeffrey,S., Hanna,G., D'Aquila,R., Wallace,L., Logue,K., Cordova,B., Hertogs,K., 
Larder,B., Buckery,R., Baker,D., Gallagher,K., Scarnati,H., Tritch,R., and Rizzo,C. (2001). 
Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing 
nonnucleoside reverse transcriptase inhibitor therapy. J. Virol. 75, 4999-5008. 
Bailey,H., Townsend,C., Cortina-Borja,M., and Thorne,C. (2011). Insufficient antiretroviral 
therapy in pregnancy: missed opportunities for prevention of mother-to-child transmission of HIV 
in Europe. Antivir. Ther. 16, 895-903. 
  
269 
 
 
Baldauf,H.M., Pan,X., Erikson,E., Schmidt,S., Daddacha,W., Burggraf,M., Schenkova,K., 
Ambiel,I., Wabnitz,G., Gramberg,T., Panitz,S., Flory,E., Landau,N.R., Sertel,S., Rutsch,F., 
Lasitschka,F., Kim,B., Konig,R., Fackler,O.T., and Keppler,O.T. (2012). SAMHD1 restricts HIV-
1 infection in resting CD4(+) T cells. Nat. Med 18, 1682-1687. 
Bally,F., Martinez,R., Peters,S., Sudre,P., and Telenti,A. (2000). Polymorphism of HIV type 1 
gag p7/p1 and p1/p6 cleavage sites: clinical significance and implications for resistance to 
protease inhibitors. AIDS Res. Hum. Retroviruses 16, 1209-1213. 
Barber,T.J., Harrison,L., Asboe,D., Williams,I., Kirk,S., Gilson,R., Bansi,L., Pillay,D., and 
Dunn,D. (2012). Frequency and patterns of protease gene resistance mutations in HIV-infected 
patients treated with lopinavir/ritonavir as their first protease inhibitor. J. Antimicrob. Chemother. 
67, 995-1000. 
Barbour,J.D., Hecht,F.M., Wrin,T., Liegler,T.J., Ramstead,C.A., Busch,M.P., Segal,M.R., 
Petropoulos,C.J., and Grant,R.M. (2004). Persistence of primary drug resistance among 
recently HIV-1 infected adults. AIDS 18, 1683-1689. 
Barre-Sinoussi,F., Chermann,J.C., Rey,F., Nugeyre,M.T., Chamaret,S., Gruest,J., Dauguet,C., 
Axler-Blin,C., Vezinet-Brun,F., Rouzioux,C., Rozenbaum,W., and Montagnier,L. (1983). 
Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency 
syndrome (AIDS). Science 220, 868-871. 
Baxter,J.D., Schapiro,J.M., Boucher,C.A., Kohlbrenner,V.M., Hall,D.B., Scherer,J.R., and 
Mayers,D.L. (2006). Genotypic changes in human immunodeficiency virus type 1 protease 
associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir. 
J. Virol. 80, 10794-10801. 
Berkhout,B. and Jeang,K.T. (1992). Functional roles for the TATA promoter and enhancers in 
basal and Tat-induced expression of the human immunodeficiency virus type 1 long terminal 
repeat. J. Virol. 66, 139-149. 
Berman,H.M., Westbrook,J., Feng,Z., Gilliland,G., Bhat,T.N., Weissig,H., Shindyalov,I.N., and 
Bourne,P.E. (2000). The Protein Data Bank. Nucleic Acids Res. 28, 235-242. 
Bertoli, A., Santoro, M, Lorenzini, P, Ceccherini-Silberstein, F, Lazzarin, A., Di Perri, G, 
Esposito, D, Caramello, P, Cargme, A, Cargnel, A, Narciso, P, Rizzrdini, G, Filice, G, Minoli, L, 
Carosi, G, Antinori, A, and Perno, C. F. Different patterns of mutations involved in tghe 
genotypic resistance score for atazanavir versus atazanavir unboosted in multiplying fialing 
patients. HIVDRW2006 . 2006.  
Ref Type: Abstract 
Bishop,K.N., Verma,M., Kim,E.Y., Wolinsky,S.M., and Malim,M.H. (2008). APOBEC3G inhibits 
elongation of HIV-1 reverse transcripts. PLoS. Pathog. 4, e1000231. 
Bour,S., Geleziunas,R., and Wainberg,M.A. (1995). The human immunodeficiency virus type 1 
(HIV-1) CD4 receptor and its central role in promotion of HIV-1 infection. Microbiol. Rev. 59, 63-
93. 
Boyd,M.A., Siangphoe,U., Ruxrungtham,K., Duncombe,C.J., Stek,M., Lange,J.M., Cooper,D.A., 
and Phanuphak,P. (2005). Indinavir/ritonavir 800/100 mg bid and efavirenz 600 mg qd in 
patients failing treatment with combination nucleoside reverse transcriptase inhibitors: 96-week 
outcomes of HIV-NAT 009. HIV. Med 6, 410-420. 
  
270 
 
 
Brennan,C.A., Bodelle,P., Coffey,R., Devare,S.G., Golden,A., Hackett,J., Jr., Harris,B., 
Holzmayer,V., Luk,K.C., Schochetman,G., Swanson,P., Yamaguchi,J., Vallari,A., Ndembi,N., 
Ngansop,C., Makamche,F., Mbanya,D., Gurtler,L.G., Zekeng,L., and Kaptue,L. (2008). The 
prevalence of diverse HIV-1 strains was stable in Cameroonian blood donors from 1996 to 
2004. J. Acquir. Immune. Defic. Syndr. 49, 432-439. 
Brenner,B.G., Routy,J.P., Petrella,M., Moisi,D., Oliveira,M., Detorio,M., Spira,B., Essabag,V., 
Conway,B., Lalonde,R., Sekaly,R.P., and Wainberg,M.A. (2002). Persistence and fitness of 
multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection. J. Virol. 
76, 1753-1761. 
Briggs,J.A. and Krausslich,H.G. (2011). The molecular architecture of HIV. J. Mol. Biol 410, 
491-500. 
Bukrinskaya,A.G. (2004). HIV-1 assembly and maturation. Arch. Virol. 149, 1067-1082. 
Burns,J.C., Friedmann,T., Driever,W., Burrascano,M., and Yee,J.K. (1993) Vesicular stomatitis 
virus G glycoprotein pseudotyped retroviral vectors: Concentration to very high titer and efficient 
gene transfer into mammalian and nonmammalian cells. Proc. Natl. Aca. Sci. 90,8033-8037. 
Butler,S.L., Hansen,M.S., and Bushman,F.D. (2001). A quantitative assay for HIV DNA 
integration in vivo. Nat. Med. 7, 631-634. 
Buzon,M.J., Massanella,M., Llibre,J.M., Esteve,A., Dahl,V., Puetas,M.C., Gatell,J.M., 
Domingo,P., Paredes,R., Sharkey,M., Palmer,S., Stevenson,M., Clotet,B., Blanco,J., and 
Martinez-Picado,J. (2010). Nat Med. 16, 460-465. 
Callebaut,C., Stray,K., Tsai,L., Xu,L., Lee,W., and Cihlar,T. (2007). In vitro HIV-1 resistance 
selection to GS8374, a novel phosphonate protease inhibitor: comparison with lopinavir, 
atazanavir and darunavir. Antivir. Ther. 12, S18. 
Carrillo,A., Stewart,K.D., Sham,H.L., Norbeck,D.W., Kohlbrenner,W.E., Leonard,J.M., 
Kempf,D.J., and Molla,A. (1998). In vitro selection and characterization of human 
immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease 
inhibitor. J. Virol. 72, 7532-7541. 
Castagna,A., Spagnuolo,V., Galli,L., Vinci,C., Nozza,S., and Carini,E. (2013). 48 weeks 
outcomes of atazanavir/ritonavir monotherapy as maintenance strategy in HIV-1 treated 
subjects with viral suppression: interim analysis results of the MODAt Study. EACS 2013.  
Chatterji,U., Bobardt,M.D., Gaskill,P., Sheeter,D., Fox,H., and Gallay,P.A. (2006). Trim5alpha 
accelerates degradation of cytosolic capsid associated with productive HIV-1 entry. J. Biol 
Chem. 281, 37025-37033. 
Chen,P., Hubner,W., Spinelli,M.A., and Chen,B.K. (2007). Predominant mode of human 
immunodeficiency virus transfer between T cells is mediated by sustained Env-dependent 
neutralization-resistant virological synapses. J. Virol. 81, 12582-12595. 
Chin-Hong,P.V., Deeks,S.G., Liegler,T., Hagos,E., Krone,M.R., Grant,R.M., and Martin,J.N. 
(2005). High-risk sexual behavior in adults with genotypically proven antiretroviral-resistant HIV 
infection. J. Acquir. Immune. Defic. Syndr. 40, 463-471. 
  
271 
 
 
Chojnacki,J., Staudt,T., Glass,B., Bingen,P., Engelhardt,J., Anders,M., Schneider,J., Muller,B., 
Hell,S.W., and Krausslich,H.G. (2012). Maturation-dependent HIV-1 surface protein 
redistribution revealed by fluorescence nanoscopy. 338, 524-8. 
Christ,F., and Debyser,Z. (2013). The LEDGF/p75 integrase interaction, a novel target for anti-
HIV therapy. Virology. 435, 102-9.  
Cihlar,T. and Ray,A.S. (2010). Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 
25 years after zidovudine. Antiviral Res. 85, 39-58. 
Clavel,F. and Mammano,F. (2010). Role of Gag in HIV Resistance to Protease Inhibitors. 
Viruses. 2, 1411-1426. 
Coffin,J.M., Hughes,S.H., and Varmus,H.E. (1997). Retroviruses. Cold Spring Harbor 
Laboratory Press). 
Cohen,M.S., Chen,Y.Q., McCauley,M., Gamble,T., Hosseinipour,M.C., Kumarasamy,N., 
Hakim,J.G., Kumwenda,J., Grinsztejn,B., Pilotto,J.H., Godbole,S.V., Mehendale,S., 
Chariyalertsak,S., Santos,B.R., Mayer,K.H., Hoffman,I.F., Eshleman,S.H., Piwowar-Manning,E., 
Wang,L., Makhema,J., Mills,L.A., de,B.G., Sanne,I., Eron,J., Gallant,J., Havlir,D., Swindells,S., 
Ribaudo,H., Elharrar,V., Burns,D., Taha,T.E., Nielsen-Saines,K., Celentano,D., Essex,M., and 
Fleming,T.R. (2011). Prevention of HIV-1 infection with early antiretroviral therapy. N. Engl. J. 
Med 365, 493-505. 
Collins,J.R., Burt,S.K., and Erickson,J.W. (1995). Activated dynamics of flap opening in HIV-1 
protease. Adv. Exp. Med Biol 362, 455-460. 
Collman,R., Balliet,J.W., Gregory,S.A., Friedman,H., Kolson,D.L., Nathanson,N., and 
Srinivasan,A. (1992). An infectious molecular clone of an unusual macrophage-tropic and highly 
cytopathic strain of human immunodeficiency virus type 1. J. Virol. 66, 7517-7521. 
Colonno,R., Rose,R., McLaren,C., Thiry,A., Parkin,N., and Friborg,J. (2004). Identification of 
I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected 
patients receiving ATV-containing regimens. J. Infect. Dis. 189, 1802-1810. 
Colonno,R.J., Thiry,A., Limoli,K., and Parkin,N. (2003). Activities of atazanavir (BMS-232632) 
against a large panel of human immunodeficiency virus type 1 clinical isolates resistant to one 
or more approved protease inhibitors. Antimicrob. Agents Chemother. 47, 1324-1333. 
Condra,J.H., Holder,D.J., Schleif,W.A., Blahy,O.M., Danovich,R.M., Gabryelski,L.J., 
Graham,D.J., Laird,D., Quintero,J.C., Rhodes,A., Robbins,H.L., Roth,E., Shivaprakash,M., 
Yang,T., Chodakewitz,J.A., Deutsch,P.J., Leavitt,R.Y., Massari,F.E., Mellors,J.W., Squires,K.E., 
Steigbigel,R.T., Teppler,H., and Emini,E.A. (1996). Genetic correlates of in vivo viral resistance 
to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J. Virol. 70, 8270-8276. 
Condra,J.H., Schleif,W.A., Blahy,O.M., Gabryelski,L.J., Graham,D.J., Quintero,J.C., Rhodes,A., 
Robbins,H.L., Roth,E., and Shivaprakash,M. (1995). In vivo emergence of HIV-1 variants 
resistant to multiple protease inhibitors. Nature 374, 569-571. 
Cote,H.C., Brumme,Z.L., and Harrigan,P.R. (2001). Human immunodeficiency virus type 1 
protease cleavage site mutations associated with protease inhibitor cross-resistance selected 
by indinavir, ritonavir, and/or saquinavir. J. Virol. 75, 589-594. 
  
272 
 
 
Coutsoudis,A., Pillay,K., Spooner,E., Kuhn,L., and Coovadia,H.M. (1999). Influence of infant-
feeding patterns on early mother-to-child transmission of HIV-1 in Durban, South Africa: a 
prospective cohort study. South African Vitamin A Study Group. Lancet 354, 471-476. 
Craig,J.C., Duncan,I.B., Hockley,D., Grief,C., Roberts,N.A., and Mills,J.S. (1991). Antiviral 
properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase. 
Antiviral Res. 16, 295-305. 
Craigie,R., and Bushman,F.D. (2012). HIV DNA Integration. Cold Spring Harb Perspect Med. 2, 
a006890. 
Croteau,G., Doyon,L., Thibeault,D., McKercher,G., Pilote,L., and Lamarre,D. (1997). Impaired 
fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease 
inhibitors. J. Virol. 71, 1089-1096. 
Dam,E., Quercia,R., Glass,B., Descamps,D., Launay,O., Duval,X., Krausslich,H.G., Hance,A.J., 
and Clavel,F. (2009). Gag mutations strongly contribute to HIV-1 resistance to protease 
inhibitors in highly drug-experienced patients besides compensating for fitness loss. PLoS. 
Pathog. 5, e1000345. 
Daniels,S.I., Davis,D.A., Soule,E.E., Stahl,S.J., Tebbs,I.R., Wingfield,P., and Yarchoan,R. 
(2010). The initial step in human immunodeficiency virus type 1 GagProPol processing can be 
regulated by reversible oxidation. PLoS. One. 5, e13595. 
Davis,M.R., Jiang,J., Zhou,J., Freed,E.O., and Aiken,C. (2006). A mutation in the human 
immunodeficiency virus type 1 Gag protein destabilizes the interaction of the envelope protein 
subunits gp120 and gp41. J Virol. 80, 2405-17. 
Davis,D.A., Soule,E.E., Davidoff,K.S., Daniels,S.I., Naiman,N.E., and Yarchoan,R. (2012). 
Activity of human immunodeficiency virus type 1 protease inhibitors against the initial 
autocleavage in Gag-Pol polyprotein processing. Antimicrob. Agents Chemother. 56, 3620-
3628. 
de Bethune,M.P. (2010). Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their 
discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 
years (1989-2009). Antiviral Res. 85, 75-90. 
de Oliveira,T., Deforche,K., Cassol,S., Salminen,M., Paraskevis,D., Seebregts,C., Snoeck,J., 
van Rensburg,E.J., Wensing,A.M., van de Vijver,D.A., Boucher,C.A., Camacho,R., and 
Vandamme,A.M. (2005). An automated genotyping system for analysis of HIV-1 and other 
microbial sequences. Bioinformatics. 21, 3797-3800. 
De,M.S., Vangeneugden,T., Van,B.B., De,P.E., van,M.H., Picchio,G., Lefebvre,E., and de 
Bethune,M.P. (2008). Resistance profile of darunavir: combined 24-week results from the 
POWER trials. AIDS Res. Hum. Retroviruses 24, 379-388. 
Delaugerre,C., Flandre,P., Chaix,M.L., Ghosn,J., Raffi,F., Dellamonica,P., Jaeger,H., 
Shurmann,D., Cohen-Codar,I., Van,P.N., Norton,M., Taburet,A.M., Delfraissy,J.F., and 
Rouzioux,C. (2009). Protease inhibitor resistance analysis in the MONARK trial comparing first-
line lopinavir-ritonavir monotherapy to lopinavir-ritonavir plus zidovudine and lamivudine triple 
therapy. Antimicrob. Agents Chemother. 53, 2934-2939. 
  
273 
 
 
Delelis,O., Carayon,K., Saib,A., Deprez,E., and Mouscadet,J.F. (2008). Integrase and 
integration: biochemical activities of HIV-1 integrase. Retrovirology. 5, 114. 
Delfraissy,J.F., Flandre,P., Delaugerre,C., Ghosn,J., Horban,A., Girard,P.M., Norton,M., 
Rouzioux,C., Taburet,A.M., Cohen-Codar,I., Van,P.N., and Chauvin,J.P. (2008). 
Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-
infected patients. AIDS 22, 385-393. 
Delport,W., Poon,A.F., Frost,S.D., and Kosakovsky Pond,S.L. (2010). Datamonkey 2010: a 
suite of phylogenetic analysis tools for evolutionary biology. Bioinformatics. 26, 2455-2457. 
Demaison,C., Parsley,K., Brouns,G., Scherr,M., Battmer,K., Kinnon,C., Grez,M., and 
Thrasher,A.J. (2002). High-level transduction and gene expression in hematopoietic 
repopulating cells using a human immunodeficiency [correction of imunodeficiency] virus type 1-
based lentiviral vector containing an internal spleen focus forming virus promoter. Hum. Gene 
Ther. 13, 803-813. 
Derdowski,A., Ding,L., and Spearman,P. (2004). A novel fluorescence resonance energy 
transfer assay demonstrates that the human immunodeficiency virus type 1 Pr55Gag I domain 
mediates Gag-Gag interactions. J. Virol. 78, 1230-1242. 
Descamps,D., Lambert-Niclot,S., Marcelin,A.G., Peytavin,G., Roquebert,B., Katlama,C., 
Yeni,P., Felices,M., Calvez,V., and Brun-Vezinet,F. (2009). Mutations associated with 
virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced 
patients. J. Antimicrob. Chemother. 63, 585-592. 
Devereux,H.L., Emery,V.C., Johnson,M.A., and Loveday,C. (2001). Replicative fitness in vivo of 
HIV-1 variants with multiple drug resistance-associated mutations. J. Med Virol. 65, 218-224. 
Diaz-Griffero,F., Li,X., Javanbakht,H., Song,B., Welikala,S., Stremlau,M., and Sodroski,J. 
(2006). Rapid turnover and polyubiquitylation of the retroviral restriction factor TRIM5. Virology 
349, 300-315. 
Didigu,C.A. and Doms,R.W. (2012). Novel approaches to inhibit HIV entry. Viruses. 4, 309-324. 
Dierynck,I., De,W.M., Gustin,E., Keuleers,I., Vandersmissen,J., Hallenberger,S., and Hertogs,K. 
(2007). Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain 
the potent antiviral activity and high genetic barrier. J. Virol. 81, 13845-13851. 
Dixon,S., McDonald,S., and Roberts,J. (2013). AIDS and economic growth in Africa: a panel 
data analysis. J Int Dev 13, 411-426. 
Dolling, D. I., Dunn, D., and The UK Collaborative Group on HIV Resistance. The increasing 
genetic diversity of HIV-1 in the UK, 2002-2010.  2013a.  
Ref Type: Unpublished Work 
Dolling,D.I., Dunn,D.T., Sutherland,K.A., Pillay,D., Mbisa,J.L., Parry,C.M., Post,F.A., 
Sabin,C.A., and Cane,P.A. (2013b). Low frequency of genotypic resistance in HIV-1-infected 
patients failing an atazanavir-containing regimen: a clinical cohort study. J. Antimicrob. 
Chemother. 
Doms,R.W. and Peiper,S.C. (1997). Unwelcomed guests with master keys: how HIV uses 
chemokine receptors for cellular entry. Virology 235, 179-190. 
  
274 
 
 
Doyon,L., Croteau,G., Thibeault,D., Poulin,F., Pilote,L., and Lamarre,D. (1996). Second locus 
involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J. Virol. 70, 
3763-3769. 
Doyon,L., Tremblay,S., Bourgon,L., Wardrop,E., and Cordingley,M.G. (2005). Selection and 
characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor 
tipranavir. Antiviral Res. 68, 27-35. 
Dragic,T., Trkola,A., Thompson,D.A., Cormier,E.G., Kajumo,F.A., Maxwell,E., Lin,S.W., 
Ying,W., Smith,S.O., Sakmar,T.P., and Moore,J.P. (2000). A binding pocket for a small 
molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc. Natl. Acad. 
Sci. U. S. A 97, 5639-5644. 
Dykes,C., Fox,K., Lloyd,A., Chiulli,M., Morse,E., and Demeter,L.M. (2001). Impact of clinical 
reverse transcriptase sequences on the replication capacity of HIV-1 drug-resistant mutants. 
Virology 285, 193-203. 
Dykes,C., Wu,H., Sims,M., Holden-Wiltse,J., and Demeter,L.M. (2010). Human 
immunodeficiency virus type 1 protease inhibitor drug-resistant mutants give discordant results 
when compared in single-cycle and multiple-cycle fitness assays. J. Clin. Microbiol. 48, 4035-
4043. 
Engelman,A., and Cherepanov,P. (2012). The structural biology of HIV-1: mechanistic and 
therapeutic insights. 10, 279-890. 
Espeseth,A.S., Felock,P., Wolfe,A., Witmer,M., Grobler,J., Anthony,N., Egbertson,M., 
Melamed,J.Y., Young,S., Hamill,T., Cole,J.L., and Hazuda,D.J. (2000). HIV-1 integrase 
inhibitors that compete with the target DNA substrate define a unique strand transfer 
conformation for integrase. Proc. Natl. Acad. Sci. U. S. A 97, 11244-11249. 
Fassati,A. (2012). Multiple roles of the capsid protein in the early steps of HIV-1 infection. Virus 
Res. 170, 15-24. 
Fisher,R.D., Chung,H.Y., Zhai,Q., Robinson,H., Sundquist,W.I., and Hill,C.P. (2007). Structural 
and biochemical studies of ALIX/AIP1 and its role in retrovirus budding. Cell 128, 841-852. 
Flandre,P., Delaugerre,C., Ghosn,J., Chaix,M.L., Horban,A., Girard,P.M., Gladysz,A., Cohen-
Codar,I., Van,P.N., Taburet,A.M., Rouzioux,C., and Delfraissy,J.F. (2009). Prognostic factors for 
virological response in antiretroviral therapy-naive patients in the MONARK Trial randomized to 
ritonavir-boosted lopinavir alone. Antivir. Ther. 14, 93-97. 
Fletcher,C.V. (2003). Enfuvirtide, a new drug for HIV infection. Lancet 361, 1577-1578. 
Franke,E.K., Yuan,H.E., and Luban,J. (1994). Specific incorporation of cyclophilin A into HIV-1 
virions. Nature 372, 359-362. 
Fransen,S., Gupta,S., Danovich,R., Hazuda,D., Miller,M., Witmer,M., Petropoulos,C.J., and 
Huang,W. (2009). Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is 
conferred via multiple nonoverlapping genetic pathways. J. Virol. 83, 11440-11446. 
Fun,A., Wensing,A.M., Verheyen,J., and Nijhuis,M. (2012). Human Immunodeficiency Virus 
Gag and protease: partners in resistance. Retrovirology. 9, 63. 
  
275 
 
 
Gamble,T.R., Vajdos,F.F., Yoo,S., Worthylake,D.K., Houseweart,M., Sundquist,W.I., and 
Hill,C.P. (1996). Crystal structure of human cyclophilin A bound to the amino-terminal domain of 
HIV-1 capsid. Cell 87, 1285-1294. 
Ganser-Pornillos,B.K., Yeager,M., and Sundquist,W.I. (2008). The structural biology of HIV 
assembly. Curr. Opin. Struct. Biol. 18, 203-217. 
Garrus,J.E., von Schwelder,U.K., Pornillos,O.W., Morham,S.G., Zavitz,K.H., Wang,H.E., 
Wettstein,D.A., Stray,K.M., Cote,M., Rich,R.L., Myszka,D.G., and Sundquist,W.I. (2001). 
Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding. Cell. 107, 55-
65. 
Gatanaga,H., Suzuki,Y., Tsang,H., Yoshimura,K., Kavlick,M.F., Nagashima,K., Gorelick,R.J., 
Mardy,S., Tang,C., Summers,M.F., and Mitsuya,H. (2002). Amino acid substitutions in Gag 
protein at non-cleavage sites are indispensable for the development of a high multitude of HIV-1 
resistance against protease inhibitors. J. Biol. Chem. 277, 5952-5961. 
Geijtenbeek,T.B., Kwon,D.S., Torensma,R., van Vliet,S.J., van Duijnhoven,G.C., Middel,J., 
Cornelissen,I.L., Nottet,H.S., Kewalramani,V.N., Littman,D.R., Figdor,C.G., and van,K.Y. 
(2000). DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of 
T cells. Cell 100, 587-597. 
Gheysen,D., Jacobs,E., de,F.F., Thiriart,C., Francotte,M., Thines,D., and De,W.M. (1989). 
Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant 
baculovirus-infected insect cells. Cell 59, 103-112. 
Ghosn,J., Delaugerre,C., Flandre,P., Galimand,J., Cohen-Codar,I., Raffi,F., Delfraissy,J.F., 
Rouzioux,C., and Chaix,M.L. (2011). Polymorphism in Gag gene cleavage sites of HIV-1 non-B 
subtype and virological outcome of a first-line lopinavir/ritonavir single drug regimen. PLoS. 
One. 6, e24798. 
Ghosn,J., Flandre,P., Cohen-Codar,I., Girard,P.M., Chaix,M.L., Raffi,F., Dellamonica,P., 
Ngovan,P., Norton,M., and Delfraissy,J.F. (2010). Long-term (96-week) follow-up of 
antiretroviral-naive HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in 
the MONARK trial. HIV. Med 11, 137-142. 
Gianotti,N. and Lazzarin,A. (2005). Sequencing antiretroviral drugs for long-lasting suppression 
of HIV replication. New Microbiol. 28, 281-297. 
Gilks,C.F., Walker,A.S., Dunn,D.T., Gibb,D.M., Kikaire,B., Reid,A., Musana,H., Mambule,I., 
Kasirye,R., Robertson,V., Ssali,F., Spyer,M., Pillay,D., Yirrell,D., and Kaleebu,P. (2012). 
Lopinavir/ritonavir monotherapy after 24 weeks of second-line antiretroviral therapy in Africa: a 
randomized controlled trial (SARA). Antivir. Ther. 17, 1363-1373. 
Goldstone,D.C., Ennis-Adeniran,V., Hedden,J.J., Groom,H.C., Rice,G.I., Christodoulou,E., 
Walker,P.A., Kelly,G., Haire,L.F., Yap,M.W., de Carvalho,L.P., Stoye,J.P., Crow,Y.J., 
Taylor,I.A., and Webb,M. (2011). HIV-1 restriction factor SAMHD1 is a deoxynucleoside 
triphosphate triphosphohydrolase. Nature 480, 379-382. 
Gong,Y.F., Robinson,B.S., Rose,R.E., Deminie,C., Spicer,T.P., Stock,D., Colonno,R.J., and 
Lin,P.F. (2000). In vitro resistance profile of the human immunodeficiency virus type 1 protease 
inhibitor BMS-232632. Antimicrob. Agents Chemother. 44, 2319-2326. 
  
276 
 
 
Gottlinger,H.G., Dorfman,T., Sodroski,J.G., and Haseltine,W.A. (1991). Effects of mutations 
affecting the p6 gag protein on human immunodeficiency virus particle release. Proc Natl Acad 
Sci USA. 88, 3095-9.  
Grobler,J.A., Stillmock,K., Hu,B., Witmer,M., Felock,P., Espeseth,A.S., Wolfe,A., Egbertson,M., 
Bourgeois,M., Melamed,J., Wai,J.S., Young,S., Vacca,J., and Hazuda,D.J. (2002). Diketo acid 
inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of 
phosphotransferase enzymes. Proc. Natl. Acad. Sci. U. S. A 99, 6661-6666. 
Guay,L.A., Musoke,P., Fleming,T., Bagenda,D., Allen,M., Nakabiito,C., Sherman,J., Bakaki,P., 
Ducar,C., Deseyve,M., Emel,L., Mirochnick,M., Fowler,M.G., Mofenson,L., Miotti,P., Dransfield,
K., Bray,D., Mmiro,F., and Jackson,J.B. (1999). Intrapartum and neonatal single-dose 
nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in 
Kampala, Uganda: HIVNET 012 randomised trial. Lancet 354, 795-802. 
Guenzel,C.A., Herate,C., and Benichou,S. (2014). HIV-1 Vpr-a still “enigmatic multitasker”. 
Front Microbiol. 5, 127. 
Guindon,S., Dufayard,J.F., Lefort,V., Anisimova,M., Hordijk,W., and Gascuel,O. (2010). New 
algorithms and methods to estimate maximum-likelihood phylogenies: assessing the 
performance of PhyML 3.0. Syst. Biol 59, 307-321. 
Gulick,R.M., Mellors,J.W., Havlir,D., Eron,J.J., Gonzalez,C., McMahon,D., Richman,D.D., 
Valentine,F.T., Jonas,L., Meibohm,A., Emini,E.A., and Chodakewitz,J.A. (1997). Treatment with 
indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and 
prior antiretroviral therapy. N. Engl. J. Med 337, 734-739. 
Gupta,R., Hill,A., Sawyer,A.W., and Pillay,D. (2008). Emergence of drug resistance in HIV type 
1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic 
review of clinical trials. Clin. Infect. Dis. 47, 712-722. 
Gupta,R.K., Hue,S., Schaller,T., Verschoor,E., Pillay,D., and Towers,G.J. (2009). Mutation of a 
single residue renders human tetherin resistant to HIV-1 Vpu-mediated depletion. PLoS. 
Pathog. 5, e1000443. 
Gupta,R.K., Mlcochova,P., Pelchen-Matthews,A., Petit,S.J., Mattiuzzo,G., Pillay,D., 
Takeuchi,Y., Marsh,M., and Towers,G.J. (2009). Simian immunodeficiency virus envelope 
glycoprotein counteracts tetherin/BST-2?CD317 by intracellular sequestration. Proc Natl Acad 
Sci USA. 106, 20889-94. 
Gupta,R.K., Kohli,A., McCormick,A.L., Towers,G.J., Pillay,D., and Parry,C.M. (2010). Full-length 
HIV-1 Gag determines protease inhibitor susceptibility within in-vitro assays. AIDS 24, 1651-
1655. 
Hahn,B.H., Shaw,G.M., Arya,S.K., Popovic,M., Gallo,R.C., and Wong-Staal,F. (1984). 
Molecular cloning and characterization of the HTLV-III virus associated with AIDS. Nature 312, 
166-169. 
Hare,S., Gupta,S.S., Valkov,E., Engelman,A., and Cherepanov,P. (2010). Retroviral intasome 
assembly and inhibition of DNA strand transfer. Nature. 464, 232-6.  
Havlir,D.V., Marschner,I.C., Hirsch,M.S., Collier,A.C., Tebas,P., Bassett,R.L., Ioannidis,J.P., 
Holohan,M.K., Leavitt,R., Boone,G., and Richman,D.D. (1998). Maintenance antiretroviral 
  
277 
 
 
therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy. 
AIDS Clinical Trials Group Study 343 Team. N. Engl. J. Med 339, 1261-1268. 
He,Y., Xiao,Y., Song,H., Liang,Q., Ju,D., Chen,X., Lu,H., Jing,W., Jiang,S., and Zhang,L. 
(2008). Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor. J. Biol Chem. 283, 
11126-11134. 
Health Protection Agency. HIV in the United Kingdom: 2012 Report .  2012.  
Ref Type: Report 
Heider,D., Verheyen,J., and Hoffmann,D. (2010). Predicting Bevirimat resistance of HIV-1 from 
genotype. BMC. Bioinformatics. 11, 37. 
Hertogs,K., de Bethune,M.P., Miller,V., Ivens,T., Schel,P., Van,C.A., Van Den Eynde,C., 
Van,G., V, Azijn,H., Van,H.M., Peeters,F., Staszewski,S., Conant,M., Bloor,S., Kemp,S., 
Larder,B., and Pauwels,R. (1998). A rapid method for simultaneous detection of phenotypic 
resistance to inhibitors of protease and reverse transcriptase in recombinant human 
immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. 
Antimicrob. Agents Chemother. 42, 269-276. 
Hicks,C.B., Cahn,P., Cooper,D.A., Walmsley,S.L., Katlama,C., Clotet,B., Lazzarin,A., 
Johnson,M.A., Neubacher,D., Mayers,D., and Valdez,H. (2006). Durable efficacy of tipranavir-
ritonavir in combination with an optimised background regimen of antiretroviral drugs for 
treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of 
Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an 
analysis of combined data from two randomised open-label trials. Lancet 368, 466-475. 
Hijazi,K., Wang,Y., Scala,C., Jeffs,S., Longstaff,C., Stieh,D., Haggarty,B., Vanham,G., 
Schols,D., Balzarini,J., Jones,I.M,., Hoxie,J., Shattock,R., and Kelly,C.G. (2011). PLoS One. 
DC_SIGN increases the affinity of HIV-1 envelope glycoprotein interaction with CD4. 6, e28307. 
Hilditch,L., and Towers,G.J. (2014). A model for cofactor use during HIV-1 reverse transcription 
and nuclear entry. Curr Opin Virol. 4, 32-6.  
Hodcroft,E., Hadfield,J.D., Fearnhill,E., Philips,A., Dunn,D., O’Shea,S., Leigh Brown,A.J., UK 
HIV Drug Resistance Database, UK CHIC Study. (2014). Contribution of viral genotype to 
plasma viral set-point in HIV infection. PLoS Pathog. 10, e1004112.  
Hu,C., Saenz,D.T., Fadel,H.J., Walker,W., Peretz,M., and Poeschla,E.M. (2012). The HIV-1 
central polypurine tract functions as a second line of defense against APOBEC3G/F. J. Virol. 
84, 11981-93 
Hu,W.S. and Hughes,S.H. (2012). HIV-1 reverse transcription. Cold Spring Harb Perspect Med. 
2, a006882 
Ibe,S., Yokomaku,Y., Shiino,T., Tanaka,R., Hattori,J., Fujisaki,S., Iwatani,Y., Mamiya,N., 
Utsumi,M., Kato,S., Hamaguchi,M., and Sugiura,W. (2010). HIV-2 CRF01_AB: first circulating 
recombinant form of HIV-2. J. Acquir. Immune. Defic. Syndr. 54, 241-247. 
Iglesias,C., Ringeard,M., Di Nunzio,F., Fernandez,J., Guadin,R., Souque,P., Charneau,P., and 
Arhel,N. (2011). Residual HIV-1 DNA Flap-independent nuclear import of cPPT/CTS double 
mutant viruses does not support spreading infection. Retrovirology, 8, 92. 
  
278 
 
 
Jacobsen,H., Haenggi,M., Ott,M., Duncan,I.B., Andreoni,M., Vella,S., and Mous,J. (1996). 
Reduced sensitivity to saquinavir: an update on genotyping from phase I/II trials. Antiviral Res. 
29, 95-97. 
Jayaweera,D. and Dilanchian,P. (2012). New therapeutic landscape of NNRTIs for treatment of 
HIV: a look at recent data. Expert. Opin. Pharmacother. 13, 2601-2612. 
Jinnopat,P., Isarangkura-na-ayuthaya,P., Utachee,P., Kitagawa,Y., de Silva,U.C., 
Siripanyaphinyo,U., Kameoka,Y., Tokunaga,K., Sawanpanyalert,P., Ikuta,K., Auwanit,W., and 
Kameoka,M. (2009). Impact of amino acid variations in Gag and protease of HIV type 1 
CRF01_AE strains on drug susceptibility of virus to protease inhibitors. J. Acquir. Immune. 
Defic. Syndr. 52, 320-328. 
Johnson,M., Grinsztejn,B., Rodriguez,C., Coco,J., DeJesus,E., Lazzarin,A., Lichtenstein,K., 
Rightmire,A., Sankoh,S., and Wilber,R. (2005). Atazanavir plus ritonavir or saquinavir, and 
lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS 19, 685-694. 
Johnson,V.A., Calvez,V., Gunthard,H.F., Paredes,R., Pillay,D., Shafer,R., Wensing,A.M., and 
Richman,D.D. (2011). 2011 update of the drug resistance mutations in HIV-1. Top. Antivir. Med 
19, 156-164. 
Johnson,V.A., Calvez,V., Gunthard,H.F., Paredes,R., Pillay,D., Shafer,R.W., Wensing,A.M., and 
Richman,D.D. (2013). Update of the drug resistance mutations in HIV-1: March 2013. Top. 
Antivir. Med 21, 6-14. 
Johnston,E., Winters,M.A., Rhee,S.Y., Merigan,T.C., Schiffer,C.A., and Shafer,R.W. (2004). 
Association of a novel human immunodeficiency virus type 1 protease substrate cleft mutation, 
L23I, with protease inhibitor therapy and in vitro drug resistance. Antimicrob. Agents 
Chemother. 48, 4864-4868. 
Jolly,C., Kashefi,K., Hollinshead,M., and Sattentau,Q.J. (2004). HIV-1 cell to cell transfer across 
an Env-induced, actin-dependent synapse. J. Exp. Med 199, 283-293. 
Kagan,R.M., Shenderovich,M.D., Heseltine,P.N., and Ramnarayan,K. (2005). Structural 
analysis of an HIV-1 protease I47A mutant resistant to the protease inhibitor lopinavir. Protein 
Sci. 14, 1870-1878. 
Kameoka,M., Isarangkura-na-ayuthaya,P., Kameoka,Y., Sapsutthipas,S., Soonthornsata,B., 
Nakamura,S., Tokunaga,K., Sawanpanyalert,P., Ikuta,K., and Auwanit,W. (2010). The role of 
lysine residue at amino acid position 165 of human immunodeficiency virus type 1 CRF01_AE 
Gag in reducing viral drug susceptibility to protease inhibitors. Virology 405, 129-138. 
Karlstrom,O., Josephson,F., and Sonnerborg,A. (2007). Early virologic rebound in a pilot trial of 
ritonavir-boosted atazanavir as maintenance monotherapy. J. Acquir. Immune. Defic. Syndr. 44, 
417-422. 
Karn,J., and Stoltzfus,C.M. (2012). Transcription and posttranscriptional regulation of HIV-1 
gene expression. Cold Spring Harb Perspect Med. 2, a006919. 
Katlama,C., Clotet,B., Mills,A., Trottier,B., Molina,J.M., Grinsztejn,B., Towner,W., Haubrich,R., 
Nijs,S., Vingerhoets,J., Woodfall,B., and Witek,J. (2010a). Efficacy and safety of etravirine at 
week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 
trials. Antivir. Ther. 15, 1045-1052. 
  
279 
 
 
Katlama,C., Esposito,R., Gatell,J.M., Goffard,J.C., Grinsztejn,B., Pozniak,A., Rockstroh,J., 
Stoehr,A., Vetter,N., Yeni,P., Parys,W., and Vangeneugden,T. (2007). Efficacy and safety of 
TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS 
21, 395-402. 
Katlama,C., Valantin,M.A., Algarte-Genin,M., Duvivier,C., Lambert-Niclot,S., Girard,P.M., 
Molina,J.M., Hoen,B., Pakianather,S., Peytavin,G., Marcelin,A.G., and Flandre,P. (2010b). 
Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral 
suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136. AIDS 24, 2365-
2374. 
Keller,P.W., Adamson,C.S., Heymann,J.B., Freed,E.O., and Steven,A.C. (2011). HIV-1 
maturation inhibitor bevirimat stabilizes the immature Gag lattice. J. Virol. 85, 1420-1428. 
Kempf,D.J., Isaacson,J.D., King,M.S., Brun,S.C., Xu,Y., Real,K., Bernstein,B.M., Japour,A.J., 
Sun,E., and Rode,R.A. (2001). Identification of genotypic changes in human immunodeficiency 
virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among 
viral isolates from protease inhibitor-experienced patients. J. Virol. 75, 7462-7469. 
Kempf,D.J., Marsh,K.C., Denissen,J.F., McDonald,E., Vasavanonda,S., Flentge,C.A., 
Green,B.E., Fino,L., Park,C.H., Kong,X.P., and . (1995). ABT-538 is a potent inhibitor of human 
immunodeficiency virus protease and has high oral bioavailability in humans. Proc. Natl. Acad. 
Sci. U. S. A 92, 2484-2488. 
King,M.S., Brun,S.C., and Kempf,D.J. (2005). Relationship between adherence and the 
development of resistance in antiretroviral-naive, HIV-1-infected patients receiving 
lopinavir/ritonavir or nelfinavir. J. Infect. Dis. 191, 2046-2052. 
King,N.M., Prabu-Jeyabalan,M., Bandaranayake,R.M., Nalam,M.N., Nalivaika,E.A., Ozen,A., 
Haliloglu,T., Yilmaz,N.K., and Schiffer,C.A. (2012). Extreme entropy-enthalpy compensation in a 
drug-resistant variant of HIV-1 protease. ACS Chem. Biol 7, 1536-1546. 
Kitahata,M.M., Gange,S.J., Abraham,A.G., Merriman,B., Saag,M.S., Justice,A.C., Hogg,R.S., 
Deeks,S.G., Eron,J.J., Brooks,J.T., Rourke,S.B., Gill,M.J., Bosch,R.J., Martin,J.N., Klein,M.B., 
Jacobson,L.P., Rodriguez,B., Sterling,T.R., Kirk,G.D., Napravnik,S., Rachlis,A.R., 
Calzavara,L.M., Horberg,M.A., Silverberg,M.J., Gebo,K.A., Goedert,J.J., Benson,C.A., 
Collier,A.C., Van Rompaey,S.E., Crane,H.M., McKaig,R.G., Lau,B., Freeman,A.M., and 
Moore,R.D. (2009). Effect of early versus deferred antiretroviral therapy for HIV on survival. N. 
Engl. J. Med 360, 1815-1826. 
Koh,Y., Amano,M., Towata,T., Danish,M., Leshchenko-Yashchuk,S., Das,D., Nakayama,M., 
Tojo,Y., Ghosh,A.K., and Mitsuya,H. (2010). In vitro selection of highly darunavir-resistant and 
replication-competent HIV-1 variants by using a mixture of clinical HIV-1 isolates resistant to 
multiple conventional protease inhibitors. J. Virol. 84, 11961-11969. 
Kohlstaedt,L.A., Wang,J., Friedman,J.M., Rice,P.A., and Steitz,T.A. (1992). Crystal structure at 
3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256, 1783-
1790. 
Komarova,N.L., Anghelina,D., Voznesensky,I., Trinite,B., Levy,D.N., and Wodarz,D. (2013). 
Relative contribution of free-virus and synaptic transmission to the spread of HIV-1 through 
target cell populations. Biol Lett. 9, 20121049. 
  
280 
 
 
Koning,F.A., Castro,H., Dunn,D., Tilston,P., Cane,P.A., and Mbisa,J.L. (2013). Subtype-specific 
differences in the development of accessory mutations associated with high-level resistance to 
HIV-1 nucleoside reverse transcriptase inhibitors. J. Antimicrob. Chemother. 68, 1220-1236. 
Korber,B., Muldoon,M., Theiler,J., Gao,F., Gupta,R., Lapedes,A., Hahn,B.H., Wolinsky,S., and 
Bhattacharya,T. (2000). Timing the ancestor of the HIV-1 pandemic strains. Science 288, 1789-
1796. 
Kosakovsky Pond,S.L. and Frost,S.D. (2005). Not so different after all: a comparison of 
methods for detecting amino acid sites under selection. Mol. Biol Evol. 22, 1208-1222. 
Koyanagi,Y., Miles,S., Mitsuyasu,R.T., Merrill,J.E., Vinters,H.V., and Chen,I.S. (1987). Dual 
infection of the central nervous system by AIDS viruses with distinct cellular tropisms. Science 
236, 819-822. 
Krausslich,H.G., Ingraham,R.H., Skoog,M.T., Wimmer,E., Pallai,P.V., and Carter,C.A. (1989). 
Activity of purified biosynthetic proteinase of human immunodeficiency virus on natural 
substrates and synthetic peptides. Proc. Natl. Acad. Sci. U. S. A 86, 807-811. 
Kuiken,C., Foley,B., Leitner,T., Apetrei,C., Hahn,B., Mizrachi,I., Mullins,J., Rambaut,A., 
Wolinsky,S., and Korber,B. (2012). HIV Sequence Compendium. Theoretical Biology and 
Biophysics Group, Los Alamos National Laboratory). 
Kutluay,S.B., and Bieniasz,P.D. (2010). Analysis of the initiating events in HIV-1 particle 
assembly and genome packaging. PLoS Pathog. 6, e1001200. 
Kuzembayeva,M., Dilley,K., Sardo,L., and Hu,W.S. (2014) Life of psi: how full-length HIV-1 
RNAs become packaged genomes in viral particles. Virology. 454-455, 362-70. 
Lahouassa,H., Daddacha,W., Hofmann,H., Ayinde,D., Logue,E.C., Dragin,L., Bloch,N., 
Maudet,C., Bertrand,M., Graberg,T., Pancino,G., Priet,S., Canard,B., Laguette,N., 
Benkirane,M., Transy,C., Landau,N.R., Kim,B., and Margotting-Goguet,F. (2012). SAMHD1 
restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular 
pool of deoxynucleoside triphosphates. Nat Immunol. 12, 223-8. 
Lambert-Niclot,S., Masquelier,B., Cohen,C., I, Soulie,C., Delaugerre,C., Morand-Joubert,L., 
Charpentier,C., Ferre,V., Plantier,J.C., Montes,B., Carret,S., Perrot,V., Peytavin,G., 
Costagliola,D., Calvez,V., and Marcelin,A.G. (2012). Impact of lopinavir/ritonavir use on 
antiretroviral resistance in recent clinical practice. J. Antimicrob. Chemother. 67, 2487-2493. 
Landi,A., Iannucci,V., Nuffel,A.V., Meuwissen,P., and Verhasselt,B. (2011). One protein to rule 
them all: modulation of cell surface receptors and molecules by HIV Nef. Curr HIV Res. 9, 496-
504. 
Larrouy,L., Chazallon,C., Landman,R., Capitant,C., Peytavin,G., Collin,G., Charpentier,C., 
Storto,A., Pialoux,G., Katlama,C., Girard,P.M., Yeni,P., Aboulker,J.P., Brun-Vezinet,F., and 
Descamps,D. (2010). Gag Mutations Can Impact Virological Response to Dual Boosted 
Protease Inhibitor Combinations in Antiretroviral Naive HIV Infected Patients (2 IP - ANRS 127 
trial). Antimicrob. Agents Chemother. 
Larrouy,L., Lambert-Niclot,S., Charpentier,C., Fourati,S., Visseaux,B., Soulie,C., Wirden,M., 
Katlama,C., Yeni,P., Brun-Vezinet,F., Calvez,V., Marcelin,A.G., and Descamps,D. (2011). 
  
281 
 
 
Positive impact of HIV-1 gag cleavage site mutations on the virological response to darunavir 
boosted with ritonavir. Antimicrob. Agents Chemother. 55, 1754-1757. 
Lataillade,M., Chiarella,J., Yang,R., DeGrosky,M., Uy,J., Seekins,D., Simen,B., St,J.E., 
Moreno,E., and Kozal,M. (2012). Virologic failures on initial boosted-PI regimen infrequently 
possess low-level variants with major PI resistance mutations by ultra-deep sequencing. PLoS. 
One. 7, e30118. 
Lataillade,M., Chiarella,J., Yang,R., Schnittman,S., Wirtz,V., Uy,J., Seekins,D., Krystal,M., 
Mancini,M., McGrath,D., Simen,B., Egholm,M., and Kozal,M. (2010). Prevalence and clinical 
significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-naive 
subjects in the CASTLE study. PLoS. One. 5, e10952. 
Latinovic,O., Kuruppu,J., Davis,C., Le,N., and Heredia,A. (2009). Pharmacotherapy of HIV-1 
Infection: Focus on CCR5 Antagonist Maraviroc. Clin. Med Ther. 1, 1497-1510. 
Lehmann,M., Nikolic,D.S., and Piguet,V. (2011). How HIV-1 takes advantage of the 
cytoskeleton during replication and cell-to-cell transmission. Viruses. 3, 1757-76. 
Li,Y., Kappes,J.C., Conway,J.A., Price,R.W., Shaw,G.M., and Hahn,B.H. (1991). Molecular 
characterization of human immunodeficiency virus type 1 cloned directly from uncultured human 
brain tissue: identification of replication-competent and -defective viral genomes. J. Virol. 65, 
3973-3985. 
Liao,F., Alkhatib,G., Peden,K.W., Sharma,G., Berger,E.A., and Farber,J.M. (1997). STRL33, A 
novel chemokine receptor-like protein, functions as a fusion cofactor for both macrophage-tropic 
and T cell line-tropic HIV-1. J. Exp. Med 185, 2015-2023. 
Lisovsky,I., Schader,S.M., Martinez-Cajas,J.L., Oliveira,M., Moisi,D., and Wainberg,M.A. 
(2010). HIV-1 protease codon 36 polymorphisms and differential development of resistance to 
nelfinavir, lopinavir, and atazanavir in different HIV-1 subtypes. Antimicrob. Agents Chemother. 
54, 2878-2885. 
Little,S.J., Holte,S., Routy,J.P., Daar,E.S., Markowitz,M., Collier,A.C., Koup,R.A., Mellors,J.W., 
Connick,E., Conway,B., Kilby,M., Wang,L., Whitcomb,J.M., Hellmann,N.S., and Richman,D.D. 
(2002). Antiretroviral-drug resistance among patients recently infected with HIV. N. Engl. J. Med 
347, 385-394. 
Liu,T.F. and Shafer,R.W. (2006). Web resources for HIV type 1 genotypic-resistance test 
interpretation. Clin. Infect. Dis. 42, 1608-1618. 
London HIV Consortium. Summary of ARV prescribing in London updated October 2011b.  
2012. Ref Type: Online Source 
 
Louis,J.M., Zhang,Y., Sayer,J.M., Wang,Y.F., Harrison,R.W., and Weber,I.T. (2011). The L76V 
drug resistance mutation decreases the dimer stability and rate of autoprocessing of HIV-1 
protease by reducing internal hydrophobic contacts. Biochemistry 50, 4786-4795. 
Luca,A. (2006). The impact of resistance on viral fitness and its clinical implications. In Antiviral 
Resistance in Clinical Practice, A.M.Geretti, ed. Mediscipt). 
Maddison,D.R., and Maddison,W.P. (2001). McClade. Sinauer Assoc. Sunderland, MA. 
  
282 
 
 
Maguire,M.F., Guinea,R., Griffin,P., Macmanus,S., Elston,R.C., Wolfram,J., Richards,N., 
Hanlon,M.H., Porter,D.J., Wrin,T., Parkin,N., Tisdale,M., Furfine,E., Petropoulos,C., 
Snowden,B.W., and Kleim,J.P. (2002). Changes in human immunodeficiency virus type 1 Gag 
at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of 
sensitivity to amprenavir and improved viral fitness in vitro. J. Virol. 76, 7398-7406. 
Malet,I., Roquebert,B., Dalban,C., Wirden,M., Amellal,B., Agher,R., Simon,A., Katlama,C., 
Costagliola,D., Calvez,V., and Marcelin,A.G. (2007). Association of Gag cleavage sites to 
protease mutations and to virological response in HIV-1 treated patients. J. Infect. 54, 367-374. 
Malim,M.H., and Bieniasz,P.D. (2012). HIV restriction factors and mechanisms of evasion. Cold 
Spring Harb Perspect Med. 2, a006940.  
Mammano,F., Ohagen,A., Hoglund,S., and Gottlinger,H.G. (1994). Role of the major homology 
region of human immunodeficiency virus type 1 in virion morphogenesis. J. Virol. 68, 4927-
4936. 
Mammano,F., Petit,C., and Clavel,F. (1998). Resistance-associated loss of viral fitness in 
human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in 
protease inhibitor-treated patients. J. Virol. 72, 7632-7637. 
Marcelin,A.G., Flandre,P., de,M.C., Roquebert,B., Peytavin,G., Valer,L., Wirden,M., Abbas,S., 
Katlama,C., Soriano,V., and Calvez,V. (2007). Clinical validation of saquinavir/ritonavir 
genotypic resistance score in protease-inhibitor-experienced patients. Antivir. Ther. 12, 247-
252. 
Martin,N., Welsch,S., Jolly,C., Briggs,J.A., Vaux,D., and Sattentau,Q.J. (2010). Virological 
synapse-mediated spread of human immunodeficiency virus type 1 between T cells is sensitive 
to entry inhibition. J. Virol. 84, 3516-3527. 
Martin, S. A., Cane, P. A, Pillay, D, and Mbisa, J. L. The emergence of HIV-1 integrase mutation 
Y143G upon re-initiation of raltegravir-containing therapy confers high-level resistance to 
raltegravir and improved viral fitness. Antivir.Ther. 17 Suppl 1. 2012.  
Ref Type: Abstract 
Martin-Serrano,J., Zang,T., and Bieniasz,P.D. (2001). HIV-1 and Ebola virus encode small 
peptide motifs that recruit Tsg101 to sites of particle assembly to facilitate egress. Nat. Med 7, 
1313-1319. 
Martin-Serrano,J., and Neil,S.J. (2011). Host factors involved in retroviral budding and release. 
Nat Rev Microbiol. 9, 519-31. 
Martinez-Picado,J., Savara,A.V., Sutton,L., and D'Aquila,R.T. (1999). Replicative fitness of 
protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J. Virol. 73, 3744-
3752. 
Mbisa,J.L., Delviks-Frankenberry,K.A., Thomas,J.A., Gorelick,R.J., and Pathak,V.K. (2009). 
Real-Time PCR Analysis of HIV-1 Replication Post-entry Events. In HIV Protocols, V.R.Prasad 
and G.V.Kalpana, eds. Humana Press), pp. 55-72. 
Mbisa,J.L., Martin,S.A., and Cane,P.A. (2011). Patterns of resistance development with 
integrase inhibitors in HIV. Infect. Drug Resist. 4, 65-76.  
  
283 
 
 
McKinnon,J.E., Delgado,R., Pulido,F., Shao,W., Arribas,J.R., and Mellors,J.W. (2011). Single 
genome sequencing of HIV-1 gag and protease resistance mutations at virologic failure during 
the OK04 trial of simplified versus standard maintenance therapy. Antivir. Ther. 16, 725-732. 
Mellors,J.W., Kingsley,L.A., Rinaldo,C.R., Jr., Todd,J.A., Hoo,B.S., Kokka,R.P., and Gupta,P. 
(1995). Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann. 
Intern. Med 122, 573-579. 
Meng,B. and Lever,A.M. (2013). Wrapping up the bad news: HIV assembly and release. 
Retrovirology. 10, 5. 
Menzo,S., Monachetti,A., Balotta,C., Corvasce,S., Rusconi,S., Paolucci,S., Baldanti,F., 
Bagnarelli,P., and Clementi,M. (2003). Processivity and drug-dependence of HIV-1 protease: 
determinants of viral fitness in variants resistant to protease inhibitors. AIDS 17, 663-671. 
Meynard,J.L., Vray,M., Morand-Joubert,L., Race,E., Descamps,D., Peytavin,G., Matheron,S., 
Lamotte,C., Guiramand,S., Costagliola,D., Brun-Vezinet,F., Clavel,F., and Girard,P.M. (2002). 
Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment 
failure: a randomized trial. AIDS 16, 727-736. 
Mills,A.M., Nelson,M., Jayaweera,D., Ruxrungtham,K., Cassetti,I., Girard,P.M., Workman,C., 
Dierynck,I., Sekar,V., Abeele,C.V., and Lavreys,L. (2009). Once-daily darunavir/ritonavir vs. 
lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS 23, 1679-
1688. 
Molina,J.M., Andrade-Villanueva,J., Echevarria,J., Chetchotisakd,P., Corral,J., David,N., 
Moyle,G., Mancini,M., Percival,L., Yang,R., Thiry,A., and McGrath,D. (2008). Once-daily 
atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and 
emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy 
and safety results of the CASTLE study. Lancet 372, 646-655. 
Molla,A., Korneyeva,M., Gao,Q., Vasavanonda,S., Schipper,P.J., Mo,H.M., Markowitz,M., 
Chernyavskiy,T., Niu,P., Lyons,N., Hsu,A., Granneman,G.R., Ho,D.D., Boucher,C.A., 
Leonard,J.M., Norbeck,D.W., and Kempf,D.J. (1996). Ordered accumulation of mutations in HIV 
protease confers resistance to ritonavir. Nat. Med. 2, 760-766. 
Moore,M.D. and Hu,W.S. (2009). HIV-1 RNA dimerization: It takes two to tango. AIDS Rev. 11, 
91-102. 
Moulard,M. and Decroly,E. (2000). Maturation of HIV envelope glycoprotein precursors by 
cellular endoproteases. Biochim. Biophys. Acta 1469, 121-132. 
Mugyenyi,P., Walker,A.S., Hakim,J., Munderi,P., Gibb,D.M., Kityo,C., Reid,A., Grosskurth,H., 
Darbyshire,J.H., Ssali,F., Bray,D., Katabira,E., Babiker,A.G., Gilks,C.F., Grosskurth,H., 
Munderi,P., Kabuye,G., Nsibambi,D., Kasirye,R., Zalwango,E., Nakazibwe,M., Kikaire,B., 
Nassuna,G., Massa,R., Fadhiru,K., Namyalo,M., Zalwango,A., Generous,L., Khauka,P., 
Rutikarayo,N., Nakahima,W., Mugisha,A., Todd,J., Levin,J., Muyingo,S., Ruberantwari,A., 
Kaleebu,P., Yirrell,D., Ndembi,N., Lyagoba,F., Hughes,P., Aber,M., Lara,A.M., Foster,S., 
Amurwon,J., Wakholi,B.N., Whitworth,J., Wangati,K., Amuron,B., Kajungu,D., Nakiyingi,J., 
Omony,W., Fadhiru,K., Nsibambi,D., Khauka,P., Mugyenyi,P., Kityo,C., Ssali,F., Tumukunde,D., 
Otim,T., Kabanda,J., Musana,H., Akao,J., Kyomugisha,H., Byamukama,A., Sabiiti,J., 
Komugyena,J., Wavamunno,P., Mukiibi,S., Drasiku,A., Byaruhanga,R., Labeja,O., Katundu,P., 
Tugume,S., Awio,P., Namazzi,A., Bakeinyaga,G.T., Katabira,H., Abaine,D., Tukamushaba,J., 
  
284 
 
 
Anywar,W., Ojiambo,W., Angweng,E., Murungi,S., Haguma,W., Atwiine,S., Kigozi,J., 
Namale,L., Mukose,A., Mulindwa,G., Atwiine,D., Muhwezi,A., Nimwesiga,E., Barungi,G., 
Takubwa,J., Murungi,S., Mwebesa,D., Kagina,G., Mulindwa,M., Ahimbisibwe,F., Mwesigwa,P., 
Akuma,S., Zawedde,C., Nyiraguhirwa,D., Tumusiime,C., Bagaya,L., Namara,W., Kigozi,J., 
Karungi,J., Kankunda,R., Enzama,R., Latif,A., Hakim,J., Robertson,V., Reid,A., Chidziva,E., 
Bulaya-Tembo,R., Musoro,G., Taziwa,F., Chimbetete,C., Chakonza,L., Mawora,A., Muvirimi,C., 
Tinago,G., Svovanapasis,P., Simango,M., Chirema,O., Machingura,J., Mutsai,S., Phiri,M., 
Bafana,T., Chirara,M., Muchabaiwa,L., Muzambi,M., Mutowo,J., Chivhunga,T., Chigwedere,E., 
Pascoe,M., Warambwa,C., Zengeza,E., Mapinge,F., Makota,S., Jamu,A., Ngorima,N., 
Chirairo,H., Chitsungo,S., Chimanzi,J., Maweni,C., Warara,R., Matongo,M., Mudzingwa,S., 
Jangano,M., Moyo,K., Vere,L., Mdege,N., Machingura,I., Katabira,E., Ronald,A., Kambungu,A., 
Lutwama,F., Mambule,I., Nanfuka,A., Walusimbi,J., Nabankema,E., Nalumenya,R., Namuli,T., 
Kulume,R., Namata,I., Nyachwo,L., Florence,A., Kusiima,A., Lubwama,E., Nairuba,R., 
Oketta,F., Buluma,E., Waita,R., Ojiambo,H., Sadik,F., Wanyama,J., Nabongo,P., Oyugi,J., 
Sematala,F., Muganzi,A., Twijukye,C., Byakwaga,H., Ochai,R., Muhweezi,D., Coutinho,A., 
Etukoit,B., Gilks,C., Boocock,K., Puddephatt,C., Grundy,C., Bohannon,J., Winogron,D., 
Gibb,D.M., Burke,A., Bray,D., Babiker,A., Walker,A.S., Wilkes,H., Rauchenberger,M., 
Sheehan,S., Spencer-Drake,C., Taylor,K., Spyer,M., Ferrier,A., Naidoo,B., Dunn,D., Goodall,R., 
Darbyshire,J.H., Peto,L., Nanfuka,R., Mufuka-Kapuya,C., Kaleebu,P., Pillay,D., Robertson,V., 
Yirrell,D., Tugume,S., Chirara,M., Katundu,P., Ndembi,N., Lyagoba,F., Dunn,D., Goodall,R., 
McCormick,A., Lara,A.M., Foster,S., Amurwon,J., Wakholi,B.N., Kigozi,J., Muchabaiwa,L., 
Muzambi,M., Weller,I., Babiker,A., Bahendeka,S., Bassett,M., Wapakhabulo,A.C., 
Darbyshire,J.H., Gazzard,B., Gilks,C., Grosskurth,H., Hakim,J., Latif,A., Mapuchere,C., 
Mugurungi,O., Mugyenyi,P., Burke,C., Jones,S., Newland,C., Pearce,G., Rahim,S., Rooney,J., 
Smith,M., and Snowden,W. (2010). Routine versus clinically driven laboratory monitoring of HIV 
antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet 375, 123-131. 
Muller,B., Anders,M., Akiyama,H., Welsch,S., Glass,B., Nikovics,K., Clavel,F., Tervo,H.M., 
Keppler,O.T., and Krausslich,H.G. (2009). HIV-1 Gag processing intermediates trans-
dominantly interfere with HIV-1 infectivity. J. Biol. Chem. 284, 29692-29703. 
Muriaux,D., Mirro,J., Harvin,D., and Rein,A. (2001). RNA is a structural element in retrovirus 
particles. Proc. Natl. Acad. Sci. U. S. A 98, 5246-5251. 
Myint,L., Matsuda,M., Matsuda,Z., Yokomaku,Y., Chiba,T., Okano,A., Yamada,K., and 
Sugiura,W. (2004). Gag non-cleavage site mutations contribute to full recovery of viral fitness in 
protease inhibitor-resistant human immunodeficiency virus type 1. Antimicrob. Agents 
Chemother. 48, 444-452. 
Naldini,L., Blomer,U., Gallay,P., Ory,D., Mulligan,R., Gage,F.H., Verma,I.M., and Trono,D. 
(1996). In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. 
Science 272, 263-267. 
Neil,S.J.D, Zang,T., and Bieniasz,P.D. (2008). Tetherin inhibits retrovirus release and is 
antagonized by HIV-1 Vpu. Nature. 451, 425-431. 
Neil,S. and Bieniasz,P. (2009). Human immunodeficiency virus, restriction factors, and 
interferon. J. Interferon Cytokine Res. 29, 569-580. 
Nijhuis,M., Schuurman,R., de,J.D., Erickson,J., Gustchina,E., Albert,J., Schipper,P., Gulnik,S., 
and Boucher,C.A. (1999). Increased fitness of drug resistant HIV-1 protease as a result of 
acquisition of compensatory mutations during suboptimal therapy. AIDS 13, 2349-2359. 
  
285 
 
 
Nijhuis,M., van Maarseveen,N.M., and Boucher,C.A. (2007a). HIV protease resistance and viral 
fitness. Curr. Opin. HIV. AIDS 2, 108-115. 
Nijhuis,M., van Maarseveen,N.M., Lastere,S., Schipper,P., Coakley,E., Glass,B., Rovenska,M., 
de,J.D., Chappey,C., Goedegebuure,I.W., Heilek-Snyder,G., Dulude,D., Cammack,N., Brakier-
Gingras,L., Konvalinka,J., Parkin,N., Krausslich,H.G., Brun-Vezinet,F., and Boucher,C.A. 
(2007b). A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism. PLoS. 
Med. 4, e36. 
Notermans,D.W., Goudsmit,J., Danner,S.A., de,W.F., Perelson,A.S., and Mittler,J. (1998). Rate 
of HIV-1 decline following antiretroviral therapy is related to viral load at baseline and drug 
regimen. AIDS 12, 1483-1490. 
Onafuwa-Nuga,A. and Telesnitsky,A. (2009). The remarkable frequency of human 
immunodeficiency virus type 1 genetic recombination. Microbiol. Mol. Biol Rev. 73, 451-80, 
Table. 
Ono,A. (2010). HIV-1 assembly at the plasma membrane. Vaccine 28 Suppl 2, B55-B59. 
Ono,A., Ablan,S.D., Lockett,S.J., Nagashima,K., and Freed,E.O. (2004). Phosphatidylinositol 
(4,5) bisphosphate regulates HIV-1 Gag targeting to the plasma membrane. Proc. Natl. Acad. 
Sci. U. S. A 101, 14889-14894. 
Ono,A. and Freed,E.O. (2004). Cell-type-dependent targeting of human immunodeficiency virus 
type 1 assembly to the plasma membrane and the multivesicular body. J. Virol. 78, 1552-1563. 
Ott,D.E. (2009). Purification of HIV-1 virions by subtilisin in digestion or CD45 immunoaffinity 
depletion for biochemical studies. Methods Mol Biol. 485, 15-25.  
Palmer,S., Kearney,M., Maldarelli,F., Halvas,E.K., Bixby,C.J., Bazmi,H., Rock,D., Falloon,J., 
Davey,R.T., Jr., Dewar,R.L., Metcalf,J.A., Hammer,S., Mellors,J.W., and Coffin,J.M. (2005). 
Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-
experienced patients are missed by standard genotype analysis. J. Clin. Microbiol. 43, 406-413. 
Pao,D., Andrady,U., Clarke,J., Dean,G., Drake,S., Fisher,M., Green,T., Kumar,S., Murphy,M., 
Tang,A., Taylor,S., White,D., Underhill,G., Pillay,D., and Cane,P. (2004). Long-term persistence 
of primary genotypic resistance after HIV-1 seroconversion. J. Acquir. Immune. Defic. Syndr. 
37, 1570-1573. 
Parienti,J.J., Barrail-Tran,A., Duval,X., Nembot,G., Descamps,D., Vigan,M., Vrijens,B., 
Panhard,X., Taburet,A.M., Mentre,F., and Goujard,C. (2013). Adherence profiles and 
therapeutic responses of treatment-naive HIV-infected patients starting boosted atazanavir-
based therapy in the ANRS 134-COPHAR 3 trial. Antimicrob. Agents Chemother. 57, 2265-
2271. 
Parkin,N.T., Hellmann,N.S., Whitcomb,J.M., Kiss,L., Chappey,C., and Petropoulos,C.J. (2004). 
Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1. 
Antimicrob. Agents Chemother. 48, 437-443. 
Parry,C.M., Kohli,A., Boinett,C.J., Towers,G.J., McCormick,A.L., and Pillay,D. (2009). Gag 
determinants of fitness and drug susceptibility in protease inhibitor-resistant human 
immunodeficiency virus type 1. J. Virol. 83, 9094-9101. 
  
286 
 
 
Parry,C.M., Kolli,M., Myers,R.E., Cane,P.A., Schiffer,C., and Pillay,D. (2011). Three residues in 
HIV-1 matrix contribute to protease inhibitor susceptibility and replication capacity. Antimicrob. 
Agents Chemother. 55, 1106-1113. 
Partaledis,J.A., Yamaguchi,K., Tisdale,M., Blair,E.E., Falcione,C., Maschera,B., Myers,R.E., 
Pazhanisamy,S., Futer,O., Cullinan,A.B., and . (1995). In vitro selection and characterization of 
human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to 
hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease. J. Virol. 69, 5228-5235. 
Patick,A.K., Rose,R., Greytok,J., Bechtold,C.M., Hermsmeier,M.A., Chen,P.T., Barrish,J.C., 
Zahler,R., Colonno,R.J., and Lin,P.F. (1995). Characterization of a human immunodeficiency 
virus type 1 variant with reduced sensitivity to an aminodiol protease inhibitor. J. Virol. 69, 2148-
2152. 
Paton,N., Kityo,C., Hoppe,A., Hakim,J., van Oosterhout,J., Siika,A., Mwaba,P., 
Kambugu,A.,Easterbrook,P., Boles,J., Walker,S., Mugyenyi,P., EARNEST Trial Group. (2013). 
A pragmatic randomised controlled strategy trial of three second-line treatment options for use 
in public health rollout programme settings: the Europe-Africa Research Network for Evaluation 
of Second-line Therapy (EARNEST) Trial. 7
th
  IAS Conference. Abstract WELBB02.    
Pellegrin,I., Breilh,D., Montestruc,F., Caumont,A., Garrigue,I., Morlat,P., Le,C.C., Saux,M.C., 
Fleury,H.J., and Pellegrin,J.L. (2002). Virologic response to nelfinavir-based regimens: 
pharmacokinetics and drug resistance mutations (VIRAPHAR study). AIDS 16, 1331-1340. 
Pellegrin,I., Breilh,D., Ragnaud,J.M., Boucher,S., Neau,D., Fleury,H., Schrive,M.H., Saux,M.C., 
Pellegrin,J.L., Lazaro,E., and Vray,M. (2006). Virological responses to atazanavir-ritonavir-
based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar 
study). Antivir. Ther. 11, 421-429. 
Pellegrin,I., Wittkop,L., Joubert,L.M., Neau,D., Bollens,D., Bonarek,M., Girard,P.M., Fleury,H., 
Winters,B., Saux,M.C., Pellegrin,J.L., Thiebaut,R., and Breilh,D. (2008). Virological response to 
darunavir/ritonavir-based regimens in antiretroviral-experienced patients (PREDIZISTA study). 
Antivir. Ther. 13, 271-279. 
Perez Valero,I., Gonzalez-Baeza,A., and Montest Ramirez,M.L. (2014). Central nervous system 
penetration and effectiveness of darunavir/ritonavir monotherapy. AIDS Rev. 16, 101-8 
Perno,C.F., Cozzi-Lepri,A., Balotta,C., Forbici,F., Violin,M., Bertoli,A., Facchi,G., Pezzotti,P., 
Cadeo,G., Tositti,G., Pasquinucci,S., Pauluzzi,S., Scalzini,A., Salassa,B., Vincenti,A., 
Phillips,A.N., Dianzani,F., Appice,A., Angarano,G., Monno,L., Ippolito,G., Moroni,M., and d' 
Arminio,M.A. (2001). Secondary mutations in the protease region of human immunodeficiency 
virus and virologic failure in drug-naive patients treated with protease inhibitor-based therapy. J. 
Infect. Dis. 184, 983-991. 
Petropoulos,C.J., Parkin,N.T., Limoli,K.L., Lie,Y.S., Wrin,T., Huang,W., Tian,H., Smith,D., 
Winslow,G.A., Capon,D.J., and Whitcomb,J.M. (2000). A novel phenotypic drug susceptibility 
assay for human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 44, 920-928. 
Pettit,S.C., Henderson,G.J., Schiffer,C.A., and Swanstrom,R. (2002). Replacement of the P1 
amino acid of human immunodeficiency virus type 1 Gag processing sites can inhibit or 
enhance the rate of cleavage by the viral protease. J. Virol. 76, 10226-10233. 
  
287 
 
 
Pettit,S.C., Lindquist,J.N., Kaplan,A.H., and Swanstrom,R. (2005). Processing sites in the 
human immunodeficiency virus type 1 (HIV-1) Gag-Pro-Pol precursor are cleaved by the viral 
protease at different rates. Retrovirology. 2, 66. 
Pettit,S.C., Moody,M.D., Wehbie,R.S., Kaplan,A.H., Nantermet,P.V., Klein,C.A., and 
Swanstrom,R. (1994). The p2 domain of human immunodeficiency virus type 1 Gag regulates 
sequential proteolytic processing and is required to produce fully infectious virions. J. Virol. 68, 
8017-8027. 
Pettit,S.C., Simsic,J., Loeb,D.D., Everitt,L., Hutchison,C.A., III, and Swanstrom,R. (1991). 
Analysis of retroviral protease cleavage sites reveals two types of cleavage sites and the 
structural requirements of the P1 amino acid. J. Biol Chem. 266, 14539-14547. 
Phillips,A.N., Leen,C., Wilson,A., Anderson,J., Dunn,D., Schwenk,A., Orkin,C., Hill,T., 
Fisher,M., Walsh,J., Pillay,D., Bansi,L., Gazzard,B., Easterbrook,P., Gilson,R., Johnson,M., and 
Sabin,C.A. (2007). Risk of extensive virological failure to the three original antiretroviral drug 
classes over long-term follow-up from the start of therapy in patients with HIV infection: an 
observational cohort study. Lancet 370, 1923-1928. 
Plantier,J.C., Leoz,M., Dickerson,J.E., De,O.F., Cordonnier,F., Lemee,V., Damond,F., 
Robertson,D.L., and Simon,F. (2009). A new human immunodeficiency virus derived from 
gorillas. Nat. Med 15, 871-872. 
Pornillos,O., Ganser-Pornillos,B.K., and Yeager,M. (2011). Atomic-level modelling of the HIV 
capsid. Nature 469, 424-427. 
Prabu-Jeyabalan,M., Nalivaika,E., and Schiffer,C.A. (2002). Substrate shape determines 
specificity of recognition for HIV-1 protease: analysis of crystal structures of six substrate 
complexes. Structure. 10, 369-381. 
Prabu-Jeyabalan,M., Nalivaika,E.A., King,N.M., and Schiffer,C.A. (2003). Viability of a drug-
resistant human immunodeficiency virus type 1 protease variant: structural insights for better 
antiviral therapy. J. Virol. 77, 1306-1315. 
Prabu-Jeyabalan,M., Nalivaika,E.A., King,N.M., and Schiffer,C.A. (2004). Structural basis for 
coevolution of a human immunodeficiency virus type 1 nucleocapsid-p1 cleavage site with a 
V82A drug-resistant mutation in viral protease. J. Virol. 78, 12446-12454. 
Price,M.N., Dehal,P.S., and Arkin,A.P. (2010). FastTree 2 – Approximately Maximum-Likelihood 
trees for large alignments. PLoS One, 5, e9490.  
Pulido,F., Delgado,R., Perez-Valero,I., Gonzalez-Garcia,J., Miralles,P., Arranz,A., Hernando,A., 
and Arribas,J.R. (2008). Long-term (4 years) efficacy of lopinavir/ritonavir monotherapy for 
maintenance of HIV suppression. J. Antimicrob. Chemother. 61, 1359-1361. 
Qari,S.H., Respess,R., Weinstock,H., Beltrami,E.M., Hertogs,K., Larder,B.A., Petropoulos,C.J., 
Hellmann,N., and Heneine,W. (2002). Comparative analysis of two commercial phenotypic 
assays for drug susceptibility testing of human immunodeficiency virus type 1. J. Clin. Microbiol. 
40, 31-35. 
Quinones-Mateu,M. and Arts,E.J. (2001). HIV-1 Fitness: Implications for Drug Resistance, 
Disease Progression, and Global Epidemic Evolution. Theoretical Biology and Biophysics 
Group, Los Alamos National Library), pp. 134-170. 
  
288 
 
 
Rabi,S.A., Laird,G.M., Durand,C.M., Laskey,S., Shan,L., Bailey,J.R., Chioma,S., Moore,R.D., 
and Siliciano,R. (2013). Multi-step inhibition explains HIV-1 protease inhibitor 
pharmacodynamics and resistance.  J Clin Invest.123, 3848–3860. 
Rasaiyaah,J., Tan,C.P., Fletcher,A.J., Price,A.J., Blondeau,C., Hilditch,L., Jacques,D.A., 
Selwood,D.L., James,L.C., Noursadeghi,M., and Towers,G.J. (2013). HIV-1 evades innate 
immune recognition through specific cofactor recruitment. 503, 402-5.  
Ray,N., Blackburn,L.A., and Doms,R.W. (2009). HR-2 mutations in human immunodeficiency 
virus type 1 gp41 restore fusion kinetics delayed by HR-1 mutations that cause clinical 
resistance to enfuvirtide. J. Virol. 83, 2989-2995. 
Reijers,M.H., Weverling,G.J., Jurriaans,S., Wit,F.W., Weigel,H.M., Ten Kate,R.W., Mulder,J.W., 
Frissen,P.H., van,L.R., Reiss,P., Schuitemaker,H., de,W.F., and Lange,J.M. (1998). 
Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: 
Amsterdam Duration of Antiretroviral Medication (ADAM) study. Lancet 352, 185-190. 
Rhee,S.Y., Gonzales,M.J., Kantor,R., Betts,B.J., Ravela,J., and Shafer,R.W. (2003). Human 
immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids 
Res. 31, 298-303. 
Rhee,S.Y., Taylor,J., Wadhera,G., Ben-Hur,A., Brutlag,D.L., and Shafer,R.W. (2006). Genotypic 
predictors of human immunodeficiency virus type 1 drug resistance. Proc. Natl. Acad. Sci. U. S. 
A 103, 17355-17360. 
Riddler,S.A., Haubrich,R., DiRienzo,A.G., Peeples,L., Powderly,W.G., Klingman,K.L., 
Garren,K.W., George,T., Rooney,J.F., Brizz,B., Lalloo,U.G., Murphy,R.L., Swindells,S., 
Havlir,D., and Mellors,J.W. (2008). Class-sparing regimens for initial treatment of HIV-1 
infection. N. Engl. J. Med 358, 2095-2106. 
Rodriguez-French,A., Boghossian,J., Gray,G.E., Nadler,J.P., Quinones,A.R., Sepulveda,G.E., 
Millard,J.M., and Wannamaker,P.G. (2004). The NEAT study: a 48-week open-label study to 
compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral 
therapy-naive HIV-1-infected patients. J. Acquir. Immune. Defic. Syndr. 35, 22-32. 
Saag,M.S., Tebas,P., Sension,M., Conant,M., Myers,R., Chapman,S.K., Anderson,R., and 
Clendeninn,N. (2001). Randomized, double-blind comparison of two nelfinavir doses plus 
nucleosides in HIV-infected patients (Agouron study 511). AIDS 15, 1971-1978. 
Sadler,B.M., Gillotin,C., Lou,Y., and Stein,D.S. (2001). Pharmacokinetic and pharmacodynamic 
study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral 
dosing. Antimicrob. Agents Chemother. 45, 30-37. 
Santos,J.R., Llibre,J.M., Imaz,A., Domingo,P., Iribarren,J.A., Marino,A., Miralles,C., 
Galindo,M.J., Ornelas,A., Moreno,S., Schapiro,J.M., and Clotet,B. (2012). Mutations in the 
protease gene associated with virological failure to lopinavir/ritonavir-containing regimens. J. 
Antimicrob. Chemother. 67, 1462-1469. 
Sarafianos,S.G., Marchand,B., Das,K., Himmel,D.M., Parniak,M.A., Hughes,S.H., and Arnold,E. 
(2009). Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of 
polymerization and inhibition. J. Mol. Biol. 385, 693-713. 
  
289 
 
 
Sato,M., Motomura,T., Aramaki,H., Matsuda,T., Yamashita,M., Ito,Y., Kawakami,H., 
Matsuzaki,Y., Watanabe,W., Yamataka,K., Ikeda,S., Kodama,E., Matsuoka,M., and Shinkai,H. 
(2006). Novel HIV-1 integrase inhibitors derived from quinolone antibiotics. J. Med Chem. 49, 
1506-1508. 
Sauter,D., Schindler,M., Specht,A., Landford,W.N., Munch,J., Kim,K.A., Votteler,J., Schubert,U., 
Bibollet-Ruche,F., Keele,B.F., Takehisa,J., Ogando,Y., Ochsenbauer,C., Kappes,J.C., 
Ayouba,A., Peeters,M., Learn,G.H., Shaw,G., Sharp,P.M., Bieniasz,P., Hahn,B.H., 
Hatziioannou,T., and Kirchhoff,F. (2009). Tetherin-driven adaptation of Vpu and Nef function 
and the evolution of pandemic and nonpandemic HIV-1 strains. Cell Host. Microbe 6, 409-421. 
Sauter,D., (2014). Counteraction of the multifunctional restriction factor tetherin. Front Microbiol. 
5, 163.  
Schaller,T., Ocwieja,K.E., Rasaiyaah,J., Price,A.J., Brady,T.L., Roth,S.L., Hue,S., Fletcher,A.J., 
Lee,K., Kewalramani,V.N., Noursadeghi,M., Jenner,R.G., James,L.C., Bushman,F.D., and 
Towers,G.J. (2011). HIV-1 Capsid-Cyclophilin Interactions Determine Nuclear Import Pathway, 
Integration Targeting and Replication Efficiency. PLoS. Pathog. 7, e1002439. 
Schapiro,J.M., Winters,M.A., Stewart,F., Efron,B., Norris,J., Kozal,M.J., and Merigan,T.C. 
(1996). The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected 
patients. Ann. Intern. Med 124, 1039-1050. 
Scheffler,K., Martin,D.P., and Seoighe,C. (2006). Robust inference of positive selection from 
recombining coding sequences. Bioinformatics. 22, 2493-2499. 
Scherrer,A.U., Ledergerber,B., von,W., V, Boni,J., Yerly,S., Klimkait,T., Cellerai,C., Furrer,H., 
Calmy,A., Cavassini,M., Elzi,L., Vernazza,P.L., Bernasconi,E., and Gunthard,H.F. (2012). Minor 
protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 
subtype B infected patients. PLoS. One. 7, e37983. 
Schinazi,R.F., Lloyd,R.M., Jr., Nguyen,M.H., Cannon,D.L., McMillan,A., Ilksoy,N., Chu,C.K., 
Liotta,D.C., Bazmi,H.Z., and Mellors,J.W. (1993). Characterization of human immunodeficiency 
viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob. Agents Chemother. 37, 875-
881. 
Schroder,A.R., Shinn,P., Chen,H., Berry,C., Ecker,J.R., and Bushman,F. (2002). HIV-1 
integration in the human genome favors active genes and local hotspots. Cell 110, 521-529. 
Shafer,R.W. (2006). Rationale and uses of a public HIV drug-resistance database. J. Infect. Dis. 
194 Suppl 1, S51-S58. 
Sharova,N., Wu,Y., Zhu,X., Stranska,R., Kaushik,R., Sharkey,M., and Stevenson,M. (2008). 
Primate lentiviral Vpx commandeers DDB1 to counteract a macrophage restriction. PLoS 
Pathog. 4, e1000057.  
Sheehy,A.M., Gaddis,N.C., and Malim,M.H. (2003). The antiretroviral enzyme APOBEC3G is 
degraded by the proteasome in response to HIV-1 Vif. Nat. Med 9, 1404-1407. 
Shibata,J., Sugiura,W., Ode,H., Iwatani,Y., Sato,H., Tsang,H., Matsuda,M., Hasegawa,N., 
Ren,F., and Tanaka,H. (2011). Within-host co-evolution of Gag P453L and protease 
D30N/N88D demonstrates virological advantage in a highly protease inhibitor-exposed HIV-1 
case. Antiviral Res. 90, 33-41. 
  
290 
 
 
Shimura,K. and Kodama,E.N. (2009). Elvitegravir: a new HIV integrase inhibitor. Antivir. Chem. 
Chemother. 20, 79-85. 
Shuter,J., Sarlo,J.A., Kanmaz,T.J., Rode,R.A., and Zingman,B.S. (2007). HIV-infected patients 
receiving lopinavir/ritonavir-based antiretroviral therapy achieve high rates of virologic 
suppression despite adherence rates less than 95%. J. Acquir. Immune. Defic. Syndr. 45, 4-8. 
Sigal,A., Kim,J.T., Balazs,A.B., Dekel,E., Mayo,A., Milo,R., and Baltimore,D. (2011). Cell-to-cell 
spread of HIV permits ongoing replication despite antiretroviral therapy. Nature 477, 95-98. 
Simm,M., Shahabuddin,M., Chao,W., Allan,J.S., and Volsky,D.J. (1995). Aberrant Gag protein 
composition of a human immunodeficiency virus type 1 vif mutant produced in primary 
lymphocytes. J. Virol. 69, 4582-4586. 
Sloan,R.D., and Wainberg,M.A. (2011). The role of unintegrated DNA in HIV Infections. 
Retrovirology. 8, 52. 
Smith,D.M., May,S.J., Tweeten,S., Drumright,L., Pacold,M.E., Kosakovsky Pond,S.L., 
Pesano,R.L., Lie,Y.S., Richman,D.D., Frost,S.D., Woelk,C.H., and Little,S.J. (2009). A public 
health model for the molecular surveillance of HIV transmission in San Diego, California. AIDS 
23, 225-232. 
Smith,S.M. (2004). HIV CTL escape: at what cost? Retrovirology. 1, 8. 
Solas,C., Poizot-Martin,I., Drogoul,M.P., Ravaux,I., Dhiver,C., Lafeuillade,A., Allegre,T., 
Mokhtari,M., Moreau,J., Lepeu,G., Petit,N., Durand,A., and Lacarelle,B. (2004) Therapeutic 
drug monitoring of lopinavir/ritonavir given alone or with a non-nucleoside reverse transcriptase 
inhibitor. Br. J. Clin. Pharacol. 57, 436-40.  
Stein,D.S., Fish,D.G., Bilello,J.A., Preston,S.L., Martineau,G.L., and Drusano,G.L. (1996). A 24-
week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir). AIDS 10, 
485-492. 
Stoltzfus,C.M. (2009). Chapter 1. Regulation of HIV-1 alternative RNA splicing and its role in 
virus replication. Adv. Virus Res. 74, 1-40. 
Stremlau,M., Owens,C.M., Perron,M.J., Kiessling,M., Autissier,P., and Sodroski,J. (2004). The 
cytoplasmic body component TRI 
M5alpha restricts HIV-1 infection in Old World monkeys. Nature 427, 848-853. 
Sundquist,W.I. and Krausslich,H.G. (2012). HIV-1 assembly, budding, and maturation. Cold 
Spring Harb. Perspect. Med 2, a006924. 
Swain,A.L., Miller,M.M., Green,J., Rich,D.H., Schneider,J., Kent,S.B., and Wlodawer,A. (1990). 
X-ray crystallographic structure of a complex between a synthetic protease of human 
immunodeficiency virus 1 and a substrate-based hydroxyethylamine inhibitor. Proc. Natl. Acad. 
Sci. U. S. A 87, 8805-8809. 
Swindells,S., DiRienzo,A.G., Wilkin,T., Fletcher,C.V., Margolis,D.M., Thal,G.D., Godfrey,C., 
Bastow,B., Ray,M.G., Wang,H., Coombs,R.W., McKinnon,J., and Mellors,J.W. (2006). Regimen 
simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained 
virologic suppression. JAMA 296, 806-814. 
  
291 
 
 
Tamura,K., Peterson,D., Peterson,N., Stecher,G., Nei,M., and Kumar,S. (2011). MEGA5: 
molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and 
maximum parsimony methods. Mol. Biol Evol. 28, 2731-2739. 
Tantillo,C., Ding,J., Jacobo-Molina,A., Nanni,R.G., Boyer,P.L., Hughes,S.H., Pauwels,R., 
Andries,K., Janssen,P.A., and Arnold,E. (1994). Locations of anti-AIDS drug binding sites and 
resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. 
Implications for mechanisms of drug inhibition and resistance. J. Mol. Biol 243, 369-387. 
Tilton,J.C. and Doms,R.W. (2010). Entry inhibitors in the treatment of HIV-1 infection. Antiviral 
Res. 85, 91-100. 
Tisdale,M., Myers,R.E., Maschera,B., Parry,N.R., Oliver,N.M., and Blair,E.D. (1995). Cross-
resistance analysis of human immunodeficiency virus type 1 variants individually selected for 
resistance to five different protease inhibitors. Antimicrob. Agents Chemother. 39, 1704-1710. 
Titanji,B.K., Aasa-Chapman,M., Pillay,D., and Jolly,C. (2013). Protease inhibitors effectively 
block cell-to-cell spread of HIV-1 between T cells. Retrovirology. 10, 161.  
Towers,G.J. (2007). The control of viral infection by tripartite motif proteins and cyclophilin A. 
Retrovirology. 4, 40. 
Tsibris,A.M. and Hirsch,M.S. (2010). Antiretroviral therapy in the clinic. J. Virol. 84, 5458-5464. 
Turner, B.G. and Summers, M.F. (1999) Structural biology of HIV. J. Mol. Biol. 285, 1-32. 
Turner,S.R., Strohbach,J.W., Tommasi,R.A., Aristoff,P.A., Johnson,P.D., Skulnick,H.I., 
Dolak,L.A., Seest,E.P., Tomich,P.K., Bohanon,M.J., Horng,M.M., Lynn,J.C., Chong,K.T., 
Hinshaw,R.R., Watenpaugh,K.D., Janakiraman,M.N., and Thaisrivongs,S. (1998). Tipranavir 
(PNU-140690): a potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-
dihydro-4-hydroxy-2-pyrone sulfonamide class. J. Med Chem. 41, 3467-3476. 
Vallari,A., Bodelle,P., Ngansop,C., Makamche,F., Ndembi,N., Mbanya,D., Kaptue,L., 
Gurtler,L.G., McArthur,C.P., Devare,S.G., and Brennan,C.A. (2010). Four new HIV-1 group N 
isolates from Cameroon: Prevalence continues to be low. AIDS Res. Hum. Retroviruses 26, 
109-115. 
Vallari,A., Holzmayer,V., Harris,B., Yamaguchi,J., Ngansop,C., Makamche,F., Mbanya,D., 
Kaptue,L., Ndembi,N., Gurtler,L., Devare,S., and Brennan,C.A. (2011). Confirmation of putative 
HIV-1 group P in Cameroon. J. Virol. 85, 1403-1407. 
van Heeswijk,R.P., Veldkamp,A., Mulder,J.W., Meenhorst,P.L., Lange,J.M., Beijnen,J.H., and 
Hoetelmans,R.M. (2001). Combination of protease inhibitors for the treatment of HIV-1-infected 
patients: a review of pharmacokinetics and clinical experience. Antivir. Ther. 6, 201-229. 
Van Heuverswyn,F., Li,Y., Neel,C., Bailes,E., Keele,B.F., Liu,W., Loul,S., Butel,C., Liegeois,F., 
Bienvenue,Y., Ngolle,E.M., Sharp,P.M., Shaw,G.M., Delaporte,E., Hahn,B.H., and Peeters,M. 
(2006). Human immunodeficiency viruses: SIV infection in wild gorillas. Nature 444, 164. 
Van Laethem,K., Schrooten,Y., Dedecker,S., Van,H.L., Deforche,K., Van,W.E., Van,R.M., and 
Vandamme,A.M. (2006). A genotypic assay for the amplification and sequencing of gag and 
protease from diverse human immunodeficiency virus type 1 group M subtypes. J. Virol. 
Methods 132, 181-186. 
  
292 
 
 
van Maarseveen,N.M., Andersson,D., Lepsik,M., Fun,A., Schipper,P.J., de,J.D., Boucher,C.A., 
and Nijhuis,M. (2012). Modulation of HIV-1 Gag NC/p1 cleavage efficiency affects protease 
inhibitor resistance and viral replicative capacity. Retrovirology. 9, 29. 
van Maarseveen,N.M., de,J.D., Boucher,C.A., and Nijhuis,M. (2006). An increase in viral 
replicative capacity drives the evolution of protease inhibitor-resistant human immunodeficiency 
virus type 1 in the absence of drugs. J. Acquir. Immune. Defic. Syndr. 42, 162-168. 
van Opijnen,T., de,R.A., Boerlijst,M.C., and Berkhout,B. (2007). Adaptation of HIV-1 depends 
on the host-cell environment. PLoS. One. 2, e271. 
Velazquez-Campoy,A., Todd,M.J., Vega,S., and Freire,E. (2001). Catalytic efficiency and vitality 
of HIV-1 proteases from African viral subtypes. Proc. Natl. Acad. Sci. U. S. A 98, 6062-6067. 
Vercauteren,J., Wensing,A.M., van de Vijver,D.A., Albert,J., Balotta,C., Hamouda,O., 
Kucherer,C., Struck,D., Schmit,J.C., Asjo,B., Bruckova,M., Camacho,R.J., Clotet,B., 
Coughlan,S., Grossman,Z., Horban,A., Korn,K., Kostrikis,L., Nielsen,C., Paraskevis,D., 
Poljak,M., Puchhammer-Stockl,E., Riva,C., Ruiz,L., Salminen,M., Schuurman,R., 
Sonnerborg,A., Stanekova,D., Stanojevic,M., Vandamme,A.M., and Boucher,C.A. (2009). 
Transmission of drug-resistant HIV-1 is stabilizing in Europe. J. Infect. Dis. 200, 1503-1508. 
Vergne,L., Stuyver,L., Van,H.M., Butel,C., Delaporte,E., and Peeters,M. (2006). Natural 
polymorphism in protease and reverse transcriptase genes and in vitro antiretroviral drug 
susceptibilities of non-B HIV-1 strains from treatment-naive patients. J. Clin. Virol. 36, 43-49. 
Verheyen,J., Litau,E., Sing,T., Daumer,M., Balduin,M., Oette,M., Fatkenheuer,G., 
Rockstroh,J.K., Schuldenzucker,U., Hoffmann,D., Pfister,H., and Kaiser,R. (2006). 
Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and 
therapy-experienced patients. Antivir. Ther. 11, 879-887. 
Verheyen,J., Verhofstede,C., Knops,E., Vandekerckhove,L., Fun,A., Brunen,D., Dauwe,K., 
Wensing,A.M., Pfister,H., Kaiser,R., and Nijhuis,M. (2010). High prevalence of bevirimat 
resistance mutations in protease inhibitor-resistant HIV isolates. AIDS 24, 669-673. 
Vermeiren,H., Van,C.E., Alen,P., Bacheler,L., Picchio,G., and Lecocq,P. (2007). Prediction of 
HIV-1 drug susceptibility phenotype from the viral genotype using linear regression modeling. J. 
Virol. Methods 145, 47-55. 
Vernazza,P., Daneel,S., Schiffer,V., Decosterd,L., Fierz,W., Klimkait,T., Hoffmann,M., and 
Hirschel,B. (2007). The role of compartment penetration in PI-monotherapy: the Atazanavir-
Ritonavir Monomaintenance (ATARITMO) Trial. AIDS 21, 1309-1315. 
Vora,S., Marcelin,A.G., Gunthard,H.F., Flandre,P., Hirsch,H.H., Masquelier,B., Zinkernagel,A., 
Peytavin,G., Calvez,V., Perrin,L., and Yerly,S. (2006). Clinical validation of atazanavir/ritonavir 
genotypic resistance score in protease inhibitor-experienced patients. AIDS 20, 35-40. 
Wain,L.V., Bailes,E., Bibollet-Ruche,F., Decker,J.M., Kelle,B.F., Van Heuverswyn,F., Li,Y., 
Takehisa,J., Ngole,E.M., Shaw,G.M,. Peeters,M., Hahn,B.H., and Sharp,P.M. (2007). 
Adaptation of HIV-1 to its human host. Mol Biol Evol. 24, 1853-60.  
Wainberg,M.A. and Albert,J. (2010). Can the further clinical development of bevirimat be 
justified? AIDS 24, 773-774. 
  
293 
 
 
Wainberg,M.A., Miller,M.D., Quan,Y., Salomon,H., Mulato,A.S., Lamy,P.D., Margot,N.A., 
Anton,K.E., and Cherrington,J.M. (1999). In vitro selection and characterization of HIV-1 with 
reduced susceptibility to PMPA. Antivir. Ther. 4, 87-94. 
Walmsley,S., Bernstein,B., King,M., Arribas,J., Beall,G., Ruane,P., Johnson,M., Johnson,D., 
Lalonde,R., Japour,A., Brun,S., and Sun,E. (2002). Lopinavir-ritonavir versus nelfinavir for the 
initial treatment of HIV infection. N. Engl. J. Med 346, 2039-2046. 
Walmsley,S.L., Becker,M.I., Zhang,M., Humar,A., and Harrigan,P.R. (2001). Predictors of 
virological response in HIV-infected patients to salvage antiretroviral therapy that includes 
nelfinavir. Antivir. Ther. 6, 47-54. 
Wei,X., Decker,J.M., Liu,H., Zhang,Z., Arani,R.B., Kilby,J.M., Saag,M.S., Wu,X., Shaw,G.M., 
and Kappes,J.C. (2002). Emergence of resistant human immunodeficiency virus type 1 in 
patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46, 
1896-1905. 
Wensing,A.M., van Maarseveen,N.M., and Nijhuis,M. (2010). Fifteen years of HIV Protease 
Inhibitors: raising the barrier to resistance. Antiviral Res. 85, 59-74. 
Westby,M., Lewis,M., Whitcomb,J., Youle,M., Pozniak,A.L., James,I.T., Jenkins,T.M., 
Perros,M., and van der Ryst,E. (2006). Emergence of CXCR4-using human immunodeficiency 
virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the 
CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J. Virol. 80, 
4909-4920. 
Westby,M., Smith-Burchnell,C., Mori,J., Lewis,M., Mosley,M., Stockdale,M., Dorr,P., 
Ciaramella,G., and Perros,M. (2007). Reduced maximal inhibition in phenotypic susceptibility 
assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-
bound receptor for entry. J. Virol. 81, 2359-2371. 
WHO. Progress Report 2011: Global HIV/AIDS response.  2011.  
Ref Type: Report 
WHO: Core epidemiological slides; HIV/AIDS estimates. 2013. 
Wilen,C.B,, Tilton,J.C., and Doms,R.W. (2012). HIV: cell binding and entry. Cold Spring Harb 
Perspect Med. 2, a006866. 
Wilkin,T.J., McKinnon,J.E., DiRienzo,A.G., Mollan,K., Fletcher,C.V., Margolis,D.M., Bastow,B., 
Thal,G., Woodward,W., Godfrey,C., Wiegand,A., Maldarelli,F., Palmer,S., Coffin,J.M., 
Mellors,J.W., and Swindells,S. (2009). Regimen simplification to atazanavir-ritonavir alone as 
maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes. J. Infect. Dis. 
199, 866-871. 
Williams,I., Churchill,D., Anderson,J., Boffito,M., Bower,M., Cairns,G., Cwynarski,K., 
Edwards,S., Fidler,S., Fisher,M., Freedman,A., Geretti,A.M., Gilleece,Y., Horne,R., Johnson,M., 
Khoo,S., Leen,C., Marshall,N., Nelson,M., Orkin,C., Paton,N., Phillips,A., Post,F., Pozniak,A., 
Sabin,C., Trevelion,R., Ustianowski,A., Walsh,J., Waters,L., Wilkins,E., Winston,A., and 
Youle,M. (2012). British HIV Association guidelines for the treatment of HIV-1-positive adults 
with antiretroviral therapy 2012. HIV. Med 13 Suppl 2, 1-85. 
  
294 
 
 
Winters,B., Van,C.E., Van der Borght,K., Lecocq,P., Villacian,J., and Bacheler,L. (2009). 
Clinical cut-offs for HIV-1 phenotypic resistance estimates: update based on recent pivotal 
clinical trial data and a revised approach to viral mixtures. J. Virol. Methods 162, 101-108. 
World Health Organisation. Consolidated guidelines on the use of antiretroviral drugs for 
treating and preventing HIV infection.  2013.  
Ref Type: Report 
Wright,E., Temperton,N.J., Marston,D.A., McElhinney,L.M., Fooks,A.R., and Weiss,R.A. (2008). 
Investigating antibody neutralization of lyssaviruses using lentiviral pseudotypes: a cross-
species comparison. J. Gen. Virol. 89, 2204-2213. 
Wu,J., Matunis,M.J., Kraemer,D., Blobel,G., and Coutavas,E. (1995). Nup358, a cytoplasmically 
exposed nucleoporin with peptide repeats, Ran-GTP binding sites, zinc fingers, a cyclophilin A 
homologous domain, and a leucine-rich region. J. Biol Chem. 270, 14209-14213. 
Wyatt,R., Kwong,P.D., Desjardins,E., Sweet,R.W., Robinson,J., Hendrickson,W.A., and 
Sodroski,J.G. (1998). The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 
393, 705-711. 
Yamashita,M., and Emerman,M., (2006). Retroviral infection of non-dividing cells: old and new 
perspectives. 344, 88-93.  
Yates,P.J., Hazen,R., St,C.M., Boone,L., Tisdale,M., and Elston,R.C. (2006). In vitro 
development of resistance to human immunodeficiency virus protease inhibitor GW640385. 
Antimicrob. Agents Chemother. 50, 1092-1095. 
Zennou,V., Mammano,F., Paulous,S., Mathez,D., and Clavel,F. (1998). Loss of viral fitness 
associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus 
type 1 variants selected for resistance to protease inhibitors in vivo. J. Virol. 72, 3300-3306. 
Zhai,Q., Landesman,M.B., Chung,H.Y., Dierkers,A., Jeffries,C.M., Trewhella,J., Hill,C.P., and 
Sundquist,W.I. (2011). Activation of the retroviral budding factor ALIX. J. Virol. 85, 9222-9226. 
Zhang,Y.M., Imamichi,H., Imamichi,T., Lane,H.C., Falloon,J., Vasudevachari,M.B., and 
Salzman,N.P. (1997). Drug resistance during indinavir therapy is caused by mutations in the 
protease gene and in its Gag substrate cleavage sites. J. Virol. 71, 6662-6670. 
  
  
295 
 
 
Appendix: 
 
  
296 
 
 
patient HG   MGARASILSG GKLDKWEKIR LRPGGKKQYK LKHLVWASRE LERFAVNPGL  
patient SP     ......V..P .E..Q..... .......K.R .......... ..........  
patient FRD         ......V... ....A..... .......K.R .......... .....L....  
patient MD          ......V... ....S..... .......K.R .......... .....L....  
patient BOY         ........T. ....Q..... .......... .......... .....I....  
patient MF          ......V... ....S..... .......K.. .......... .....L....  
 
patient HG       LESSEGCRQI LEHLQPSLKA GSEELRSLFN TVATLYCVHQ NIEVRDTKEA  
patient SP          ..T.I..... ..Q.....QT ........Y. ....I..... K...K.....  
patient FRD         ..TT...Q.L M.Q..SA..T ........Y. .I...W.... R..IK.....  
patient MD          ..TA...Q.. M.Q..SA.GT .....K.... .....W...R R.DIK.....  
patient BOY         ..TA...Q.. ..Q..ST..T .....K.... .I...W.... K.DI......  
patient MF          ..NA...Q.V M.QF.ST..T .....K..Y. .......... R...K.....  
 
patient HG        LDKIEEEQNK SRKKAQQAAA AADTGNRSQV SQNYPIVQNH QGQMVHQALS  
patient SP        .......... .K.......? -?....SN.. .........L ........I.  
patient FRD     V..V..I.D. ..Q.T..... .-TAATG.-S .........A ....T..SM.  
patient MD     ...V..V... .KQ....... ?---?TG.-S ...F.....A ....T..SM.  
patient BOY       ...V..A.K. .KQ.T..... ?--?ATG.-. .........A .......PM.  
patient MF     ......I.K. ..QQT..... .-TGSSN... ......M..A ....TY....  
 
patient HG     PRTLNAWVKV VEEKAFSPEV IPMFSALSEG ATPQDLNTML NTVGGHQAAM  
patient SP     .......... I......... .......... .......... ..........  
patient FRD     .......... I......... .......... .......M.. .I........  
patient MD     .......... I......... .......... .......M.. .I........  
patient BOY     .......... I......... ....T..... .......M.. .I........  
patient MF     .......... .......... .......A.. .P.H...... ..........  
 
patient HG     QILKEAINEE AAEWDRLHPV QAGPVAPGQL REPRGSDIAG TTSTLQEQIG  
patient SP     .M...T.... .......... H...I....M .......... ..........  
patient FRD     .M..DT.... ......V... H...IP...M .......... ..........  
patient MD     .M..DT.... ......V... H...IP...M .......... ...N......  
patient BOY     .M..D..... ......T... H...IP...M .......... ..........  
patient MF     .M..DT.... ......Q..Q ....LP.... .......... .........R  
 
patient HG     WMTHNPPIPV GEIYKRWIII GLNKIVRMYS PTSILDIKQG PKEPFRDYVD  
patient SP      ...N...... .........L .......... .V.....R.. ..........  
patient FRD         ...S...... ........VL .......... .......... ..........  
patient MD      ...S...... ........VL .......... .......... ..........  
patient BOY  ...S...V.. ........VL .......... .V........ ..........  
patient MF  ...ST..V.. .........L .......... .V........ ..........  
 
patient HG     RFYKTLRAEQ ATPEVKNWMT ETLLVQNANP DCKTILKALG PGASLEEMMT  
patient SP  .......... .SQD...... .......... .......... .A.T......  
patient FRD  ..F....... ..Q....... .......... ...A..R... ...T......  
patient MD  ..F....... ..Q....... .......... ...S..R... ...T......  
patient BOY  ..F....... ..Q....... ....I..... ...S..R... ...T......  
patient MF  ..F.I..... ..Q....... .......... .......... .A.T......  
 
patient HG     ACQGVGGPAH KARVLAEAMS QLTNS?*R?? DAERQF*EPK KDG*VLQLWQ  
patient SP  ........S. .......... .A.S.?YH?? ......Q.S. ..S..F....  
patient FRD  ........G. .......... .V?-TDQC?? .......R?? ENNK.F....  
patient MD  ........G. .......... .V?-TVQH?? .......G?? ETNKMF....  
patient BOY  S.......S. .......... .A?ATVQHSN .....L.G?? ENNK.F....  
patient MF  ........G. .......... .T.GMAAA?N .......G.. .KY..F....  
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patient HG  RRAHSQKL*G T*EKGLLEMW KGGTPNERLH *ETG*FFRED LAFPQGEARE  
patient SP  ..P.....Q. S......... .RRA.....Y ....Q..... ..........  
patient FRD  ..TS....Q. SQ.E...... E.R......Y .K.......N ...Q.....K  
patient MD  ..TP.K..Q. P......... E.R......Y .........N ...Q.....K  
patient BOY  ..TP..E.Q. .......... ..R.S..... .........N ...Q.....K  
patient MF  G.TS....Q. P.K.....V. ....S..... GK.......N ...Q.R....  
 
patient HG  FSSEQTRANS PTRANSPTSR ELQVWGRDNN SPSEAGADRS ?--?TVS??S  
patient SP  .......... ..?-----?. .......... .........Q ?--?...SF.  
patient FRD  ......GT?- ----?..... ..WDG....- PLP..RTKGQ ?--?.I.SFN  
patient MD  .....IGT?- ----?..... ..WD??...- LL...RTEGQ GGQG.I.SFN  
patient BOY  .......TKT R.?-?..... DPGDG...S- LL....TGGQ ?--?.I.SL.  
patient MF  .....A..?- ----?..SCG DPR.RR..S- LLP.T..EGE ?--?VI.??G  
 
patient HG  FPQITLWQRP LVTIKIGGQL KEALLDTGAD DTVLEDMNLP GRWKPKMIGG  
patient SP  .......... .......... .......... .....E.S.Q ..........  
patient FRD  .......... ...VR..... I......... .....EI..L .K........  
patient MD  .......... ...V...... I......... .....EI... .K........  
patient BOY  .......... ...VRV.... I......... .....EI... ..........  
patient MF  .......... ..KVQV..KI I......... .....EID.. .K........  
 
patient HG  IGGFIKVRQY DQIPIEICGH KAVGTVLIGP TPVNIIGRNL LTQLGCTLNF  
patient SP  .......... ..V....... ..I....... .......... ..........  
patient FRD  .......... .........K ..I....V.. .........M ...I......  
patient MD  .......... ...LL....K R.I....V.. .........M ...I......  
patient BOY  .......... ........EK R.I....V.. .........M ...I......  
patient MF  .......... ...MM..S.K ..I....V.. .........M ...I......  
 
 
 
 
 
Appendix Figure 2. Alignment of Gag-protease consensus viral variants subjected to 
phenotyping from patients infected with subtype B viruses experiencing therapy failure 
(HG and SP) and achieving virologic suppression (FRD, MD, BOY, MF). In total, 78 
variant amino acids are present in Gag and 16 in protease. Of these, three amino acid 
residues correlated with treatment outcome – Gag 34, 93 and 490 (HXB2 position 
473).  
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Appendix Table S1.  Amino acid positions within Gag previously associated with 
PI resistance or exposure that demonstrate intra-patient variability within patient 
#1403 (KON). 
 Viral variants from patient #1403 (KON) 
Amino 
Acid 
Change 
Screening Failure 
1 2 3 4 5 6 7 8 9 1
0 
1 2 3 4 5 6 7 8 9 1
0 
Y79F Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y F Y Y F Y 
M200I M M M M M M M M M M M M M M M M M M V M 
A374P/
S 
A A A A T A A A T A T T T T T T T T T T 
I376V V V V V V V V V V V I I V V V I V V V V 
Q474L P P P P Q P P P Q P P P P P P P P P P P 
 
Appendix Table S2. Amino acid positions within Gag previously associated with 
PI resistance or exposure that demonstrate intra-patient variability within patient 
#508 (SP). 
 Viral variants from patient #508 (SP) 
Reported 
Mutation 
  Screening Failure 
1 2 3 4 5 6 7 8 9 10 1 2 3 4 5 6 7 8 9 10 
V128A V V V V V V A V V V V V V V V V V V V V 
V370A/M A V A A A A A V A A A A A A A A A A A A 
T375N/S T T T T T T T T T T T T T T T T T A T T 
R380K R R R R R R R R R R R K R R R R R R R R 
S451N S S S S S S S S S S S S N S S S S S S S 
 
Appendix Table S3. Amino acid positions within Gag previously associated with 
PI resistance or exposure that demonstrate intra-patient variability within patient 
#1404 (DIO). 
 Viral variants from patient #1404 (DIO) 
Reported 
Mutation 
Screening Failure 
1 2 3 4 5 6 7 8 9 10 1 2 3 4 5 6 7 8 9 10 
Y79F Y Y Y F Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
E428G E E E E K E E E E E E E E E E E E E E E 
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Appendix Table S4. Amino acid positions within Gag previously associated with 
PI resistance or exposure that demonstrate intra-patient variability within patient 
#4201 (SO) 
 
 
Appendix Table S5. Amino acid positions within Gag previously associated with 
PI resistance or exposure that demonstrate intra-patient variability within patient 
(HG). 
  
Reported 
Mutation 
Viral variants from patient #3204 (HG) 
Screening Failure 
1 2 3 4 5 6 7 8 9 10 1 2 3 4 5 6 7 8 9 10 
E12K K Q K K K Q Q K K K K Q K K K K K K K K 
R76K R R R R K R R R R R R R R R R R R R R R 
T81A A T T T T T T T T T A A A A A A A A A A 
H219Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q K 
S373P P P S S P S P S P S S P S S S S S S S S 
I376V I I V V I I I V I V I I I I I I I I I I 
I389T M M T T M T M T M T T M T T T T T T T T 
S451N S N S S N S N S S N S S S S S S S S S S 
 
 
 Viral variants from patient #4201 (SO) 
Reported 
Mutation 
Screening Failure 
1 2 3 4 5 6 7 8 9 1
0 
1 2 3 4 5 6 7 8 9 1
0 
G62R K N N N N N N N N K K K K K K K K K K K 
L75R L I I L L I L I I L L L L L L L L L L L 
Y79F Y F F F F F F F F Y Y Y Y Y Y Y Y Y Y Y 
A374P/S T A T A T A T T T T T T T T T T T T T T 
G381S S G G G S G G G G S G G G G G G G G G G 
